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Abstract 
 
Both uveal and cutaneous metastatic melanoma remain incurable, largely due to the 
deregulation of signalling networks that facilitate drug resistance and tumour dissemination 
for which CXCR4-CXCL12 chemotaxis, MAPK signalling and angiogenesis play key roles. While 
hyper-activating mutations in MAPK signalling promote tumour survival/drug resistance, 
CXCR4-CXCL12 chemotaxis and angiogenesis, promote melanoma migration. Known 
individually to drive melanoma escape from the localised microenvironment, how these 
pathways interact remains largely undefined. The principle aim of the present study was thus 
to define the role and crosstalk of CXCR4-CXCL12, MAPK and VEGFR2 signalling in uveal and 
cutaneous melanoma, to inform on more efficacious targeted approaches to prevent 
metastasis. 
Results revealed increased CXCR4 expression as a putative prognostic biomarker for AJCC 
stage II cutaneous melanomas, while CXCL12 expression within the epidermis likely prevents 
metastasis. Additionally, CXCL12 secretion by melanomas was associated with autocrine 
CXCR4-CXCL12 signalling and MAPK activation. VEGFR2 was expressed by primary melanomas 
and associated with cutaneous metastasis to lymph nodes, with VEGF treatment promoting 
melanoma cell migration. Analysis of CXCR4-CXCL12-mediated chemotaxis demonstrated 
enhanced migration of melanoma cells towards CXCL12, either recombinant of derived from 
primary dermal fibroblast supernatants, the effect of which was inhibited by both the MEK 
inhibitor, trametinib, and the VEGFR2 inhibitor, pazopanib. Interestingly, the concurrent 
increase in autophagy observed in response to trametinib, prevented by co-treatment of 
uveal/cutaneous melanoma cells with chloroquine, suggest the efficacy of MEK inhibition may 
be potentiated with dual inhibition of pro-survival autophagy. 
Given that both CXCR4-CXCL12 and VEGF-VEGFR2 signalling activate MAPK pathway, and 
alone promote melanoma migration. Results demonstrated combined trametinib and 
pazopanib, potentiated both inhibition of uveal and cutaneous melanoma cell viability as well 
as CXCR4-CXCL12-mediated migration. Collectively these studies confirm the intimate 
relationship between CXCR4-CXCL12/VEGFR2/MAPK signalling, highlighting potential novel 
combinational approaches through which to prevent melanoma survival and migration. 
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1.1 Melanogenesis: From Melanocyte to Melanoma 
1.1.1 Melanocyte Origin, Differentiation and Function 
Melanocytes, our pigment producing cells within the skin reside dispersed along the dermal 
to epidermal border, surrounded by fibroblasts within the dermis, and keratinocytes in the 
epidermis. Originating from undifferentiated and un-pigmented precursor melanoblasts in the 
neural crest during the early stages of embryonic development, which migrate dorsolaterally 
and invade the ectoderm, differentiated melanocytes migrate to different destinations 
including the skin epidermis and the iris or choroid of the eye (Figure 1.1) (Bertolotto, 2013). 
 
Figure 1.1 Overview of Melanocyte Development and Distribution Within the Skin. 
Melanocytes are derived from the neural crest melanoblasts where transcription factors and signalling 
molecules such as microphthalmia associated transcription factor (MITF), paired domain and 
homeodomain containing transcription factor (Pax3), and the sry related transcription factor Sox10 
determine cell commitment to a melanocytic fate (Thomas and Erickson, 2008). Melanoblasts 
differentiate into pigmented cells and migrate to the epidermis where they synthesise melanin from 
tyrosine within their melanosomes. Melanosomes are then transferred to neighbouring keratinocytes 
through their protruding dendrites, offering vital UV protection to the skin. Image taken from 
(Bertolotto, 2013). 
 
Melanocytes in the epidermis interact through their many dendrites with up to 30-40 
keratinocytes, and transfer matured melanosomes by excocytosis and cytophagocytosis to 
Introduction 
4 
 
keratinocytes (Park et al., 2009). Melanosomes containing the pigmented melanin of which 
there are two forms eumelanin and pheomelanin, are then positioned over the keratinocyte 
cell nucleus to prevent DNA damage and genomic instability induced by UV radiation, by 
absorbing and scattering the radiation, converting it into the less genotoxic energy source, 
heat (Tsatmali et al., 2002; Lin and Fisher, 2007; Park et al., 2009). 
Although both cutaneous and uveal melanocytes are derived from the neural crest and 
synthesise both eumelanin and pheomelanin pigments, they differ substantially in terms of 
their interactions and stimulatory effects. Unlike epidermal melanocytes, uveal melanocytes 
do not transfer melanin to any other cell types (Hu, 2000). Furthermore, epidermal 
melanocytes respond to both endogenous an exogenous stimulation, with the ability to adapt 
to such stimuli, whereas uveal melanocytes remain unaffected and hence changes in iris 
pigmentation are very rare (Imesch PD et al., 1997). These differences may illustrate the 
discord between these two cell types, or highlight the very different microenvironment of 
uveal melanocytes in the eye compared to cutaneous melanocytes in our skin.  
Melanogenesis describes the process by which the pigmented polymer melanin, is produced 
by melanocytes, which acts as a vital natural photo-protection that augments the 
accumulation of DNA damage leading to skin aging and malignant transformation. The process 
of melanogenesis is multifaceted and is tightly regulated by multiple genetic factors, and 
cellular signalling pathways, that respond to both endogenous and exogenous stimulation. 
Interestingly, uveal melanocytes do not respond to stimulation by α-MSH or 
adrenocorticotropic hormone, strong stimulators of cutaneous melanogenesis, which is 
thought to be attributable to the lack of MC1R receptors present on uveal melanocytes (Li et 
al., 2006). 
The greatest activator of melanogenesis is exposure to UV radiation (UVR), and although 
melanocytes are specialised to protect against and repair UV induced DNA damage, not 
everyone’s skin acts alike, with constitutional differences in skin photo type and regulation of 
melanogenesis increasing an individual’s risk of developing melanoma. Interestingly it is 
proposed that the increased incidence of melanomas in fair skinned individuals may be due 
to germline mutations in the MCR1 gene that causes disruption in the key cAMP, Protein 
Kinase A, CREB melanogenesis pathway increasing risk of melanoma 2-4 fold (Kennedy et al., 
2001). Individuals with this skin photo type have propensity to produce mainly pheomelanin, 
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which has weaker UV protective properties than eumelanin (Marrot et al., 1999). Recently the 
direct genotoxic effects of UV radiation on melanocytes have been demonstrated by the 
identification of UVB-induced cyclobutane pyrimidine dimers and 6-pyrimidine photoproducts 
in DNA that result in C to T or G to A transitions, and activating mutations in melanoma genes 
(De Fabo et al., 2004; Hodis et al., 2012b). UVA and B have also been shown to indirectly 
trigger DNA mutations via the generation of oxidative stress (Filipe et al., 2013). Therefore, 
effective DNA damage prevention by melanogenesis and DNA repair mechanisms is essential 
to prevent genomic instability and UV-induced melanocytic transformation.  
1.1.2 Melanomagenesis  
Cutaneous melanoma arises from the malignant transformation of melanocytes derived from 
normal skin or a pre-existing melanocytic naevi. DNA damage can be induced by both 
endogenous (e.g ROS production) and exogenous (e.g UV radiation) sources, initiating 
tumourigenesis of melanocytes, a result of genetic or epigenetic changes in genes that control 
critical cellular processes such as proliferation, apoptosis, senescence and DNA repair 
(Bertolotto, 2013). 
 
Figure 1.2 Benign Naevi Development into a Melanoma 
A benign naevus (mole) (http://www.melanoma.net.au/Melanoma/melanoma.htm) or dysplastic 
naevi (http://www.cancerresearchuk.org) or a melanoma (Melanoma Diagnostic Centre). Adapted 
from (McKee, 2013). 
 
In line with the multistep process of carcinogenesis, a stepwise model for melanoma 
progression has been proposed, whereby genetic mutations cause disruption of critical 
cellular processes regulating melanocyte proliferation and survival leading to a pre-malignant 
melanoma, with benign naevi (common mole) or dysplastic naevi formation (Figure 1.2) (Chin 
et al., 1998). 
The consecutive acquisition of further genetic mutations, promotes tumour progression to in 
situ disease with the melanoma expanding radially within the epidermis (radial growth phase), 
before breaching the basement membrane and vertically invading within the dermis (vertical 
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growth phase). This invasive disease may further progress to metastatic disease if the 
melanoma is able to invade microvasculature and lymphatics of the dermis, allowing spread 
to lymph nodes and other organs (Figure 1.3).  
Recently studies have further defined the succession of genetic alterations during melanoma 
progression demonstrating the evolutionary paths of melanoma subtypes (Maressa C. Criscito 
et al., 2016). The following section will discuss the most prevalent and key molecular events 
in melanoma initiation and progression by germline and sporadically formed mutations but is 
not exhaustive. 
 
Figure 1.3 Melanoma Progression 
Melanocytes within the basal layer of the epidermis proliferate forming naevi of which some become 
dysplastic. Radial growth phase proceeds and the melanoma spreads horizontally within the epidermis. 
Vertical growth phase the melanoma breaches the basement membrane and invades the dermis. 
Infiltration into lymphatics or blood vessels precedes metastatic spread to lymph nodes and distant 
organs. Adapted from (Abbasi et al., 2004). 
 
A seminal study of the evolution of melanoma, suggests that the acquisition of melanocytic 
naevi is primarily induced by oncogenic mutations causing hyperactivation of the MAPK 
signalling pathway (as discussed in section 1.2.3). Unequivocally, benign naevi have been 
found to possess B-RAFV600E mutations in 85% of cases, suggesting that B-RAFV600E is the major 
initiating event (Shain et al., 2015). It is therefore proposed that an activating point mutation 
in N-Ras, B-RAF, GNAQ and GNA11 in a mutually exclusive manner, is the driving event for the 
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development of melanocytic naevi in both cutaneous and uveal melanoma (Pollock et al., 
2003; Van Raamsdonk et al., 2009b). 
However, given the large spectrum of mutations in melanoma, distinguishing between driver 
and passenger events has been a difficult process that large genetic sequencing studies have 
aimed to uncover. TERT (human telomerase reverse transcriptase) promoter mutations, result 
in increased TERT expression and a concomitant increase in telomerase activity that can 
promote tumourigenesis by overcoming replicative senescence executed by telomere 
shortening  (Chiba et al., 2015). Recent studies have identified TERT promoter mutations as 
the earliest secondary mutations frequently identified with B-RAF or N-Ras mutations in 77% 
of “likely benign” intermediate melanocytic tumours, suggesting that neither are sufficient for 
malignant transformation (Lian CG and Murphy GF, 2016). 
Additional early, but not initiating molecular events in naevi include the epigenetic 
modification of ALK (anaplastic lymphoma kinase) and biallelic loss of BAP-1 (BRCA-1 
associated protein). The novel isoform of ALK present in 11% of melanomas,  is initiated from 
a de novo alternative transcription initiation (ATI) site in ALK intron 19, and translates a kinase 
domain of ALK without the extracellular or transmembrane regions resulting in constitutively 
activation of MAPK, AKT, and STAT3 signalling (Wiesner et al., 2015). BAP-1 is a tumour 
suppressor gene that encodes a histone deubiquitinase, involved in cell cycle progression, 
growth and DNA repair (Machida et al., 2009b; Eletr and Wilkinson, 2011). Although biallic 
loss of BAP-1 is common in early stages of uveal melanoma progression and associated with 
GNAQ/11 mutations and a worse prognosis (Kalirai et al., 2014), the cutaneous counterpart 
presents with B-RAF or N-Ras mutations and is found in a distinct epithelioid low risk 
intermediate naevi (Wiesner et al., 2012; Yeh et al., 2014).  
As naevi progress to melanomas in situ and invasive melanomas, chromosome and copy 
number aberration become frequent, reflecting the ongoing genomic instability. Biallelic 
inactivation of CDKN2A has been found to be an exclusive signature of invasive melanomas 
and present in up to 50% of all tumours (Bennett, 2008; Lian CG and Murphy GF, 2016), with 
further mutations in SWI/SNF chromatin remodelling genes associated with the development 
of invasive melanomas (Lian CG and Murphy GF, 2016). 
Introduction 
8 
 
At later stages of tumour progression, tumour evolution becomes more heterogeneous in 
terms of genomic alterations, with Phosphatase and tensin homologue deleted on 
chromosome 10 (PTEN) and TP53 tumour suppressor loss characteristic of advanced primary 
melanomas (Lian CG and Murphy GF, 2016). PTEN is reported to be deleted in 37% of 
cutaneous melanomas but not in naevi, allowing cells to bypass senescence via negative 
regulation of the PI3K/AKT pathway (Stahl et al., 2004; Bertolotto, 2013), while the nuclear 
transcription factor P53, is functionally defective in 90% of advanced melanomas (Vogelstein 
et al., 2000; Lu et al., 2013). 
1.2 Cutaneous Melanoma 
1.2.1 Cutaneous Melanoma: Risk Factors, Staging and Prognosis 
Cutaneous melanoma is one of the most aggressive and therapeutically challenging forms of 
skin cancer, with a continually growing world-wide incidence that affects individuals from all 
ethnicities, socioeconomic groups, geographic locations and stages of life. In the UK alone, 
15.9 cases per 100,000 men and 16.5 cases per 100,000 women were reported in 2014 and 
metastatic melanoma continues to increase more than any other malignancy in the last 40 
years (Cancer Research U.K www.cancerresearchuk.org, 2014). 
Undoubtedly the greatest environmental risk factor contributing to melanoma development 
is UV exposure, with sun exposure both cumulative and chronic, and sun burn episodes, 
positively correlating with melanoma incidence (Gandini et al., 2005; Chang et al., 2010; 
Russak and Rigel, 2012). Host susceptibility to UVR-induced risk of melanoma is also 
associated with individuals with fair skin and hair complexion, light coloured eyes, freckles and 
a tendency to burn, as well as geographical location (Elwood et al., 1990; Bishop et al., 2002). 
Unsurprisingly due to its location with a high UV index, and a predominantly Caucasian 
population Australia has the highest rate of melanoma, 12 fold the average world-wide rate 
(Thompson et al., 2005; National Cancer Institute, 2013). In support of the role of UVR 
exposure in melanomagenesis, many studies have now linked sun bed use with the 
development of melanoma (Westerdahl et al., 2000; Ting et al., 2007; Russak and Rigel, 2012). 
Further, increased molecular insight into mechanisms mediating melanomagenesis 
additionally reveals UVR-induced mutations in TP53 accelerate mutant B-RAF driven 
melanoma (Viros et al., 2014). As well as environmental factors, the risk of developing 
melanoma encompasses genetic factors. These may include a previous family history of 
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melanoma, increasing melanoma  risk 3-8 fold, also linked to the number of relatives affected, 
and suggestive of heritable risk factors (Hemminki et al., 2003; Amundadottir et al., 2004; 
Florell et al., 2005). Genome wide association studies have also highlighted mutations in high 
risk melanoma loci that are often found within families in an autosomal dominant pattern 
(Eggermont et al., 2014), including mutations in the CDKN2A gene observed in up to 40% of 
hereditary cases of melanoma (Tsao et al., 2012). The presence of multiple or large congenital 
naevi is also a risk factor (Green A et al., 1985), where giant congenital naevi over 20cm in 
diameter can increase lifetime melanoma risk by up to 10% (Arneja and Gosain, 2007). 
Although appreciation of risk factors for the development of melanoma may assist disease 
prevention, many individuals nevertheless develop melanoma, at which point clinical disease 
staging provides vital information on likely outcome as well as informing treatment 
stratification. In 2009 the American Joint Committee on cancer (AJCC) Melanoma Staging 
Committee lead by Charles Balch incorporated data from worldwide institutions analysing 
over 30,000 patients to develop what is now considered the most comprehensive evidence 
based and widely used staging system for cutaneous melanoma, currently in its 7th version 
(Balch et al., 2009a). 
The AJCC staging system is based on TNM (tumour node metastasis) cancer staging, that takes 
into account both tumour depth (Breslow thickness) as well as the degree of tumour spread 
to lymph nodes ‘N’ or distant sites of metastasis ‘M’ (Table 1.1). Breslow thickness forms the 
basis of the tumour ‘T category’ where thin melanomas with a breslow thickness < 1mm (T1) 
have a good prognosis and 5-year survival rates of 95%, whereas tumours with breslow 
thickness >4mm, fall into the T4 category with a considerably worse prognosis (Balch et al., 
2009a) (Table 1.1). Additionally, the presence of tumour ulceration and mitosis is incorporated 
into the ‘T’ categorisation. Ulceration defined as the loss of epidermal integrity overlying 
resected melanomas is one of the worst prognostic indicators (Balch et al., 2009b) although a 
tumour defined by a higher T category in absence of ulceration may have a similar poor 
prognosis (Balch et al., 1980; Grande Sarpa et al., 2006; Balch et al., 2009a). Mitotic rate, has 
been shown also to be a strong predictor of prognosis in thin melanomas where mitosis under 
or over 1mm determines T1a or T1b staging respectively (Balch et al., 2009a). Mitotic rate, has 
been shown also to be a strong predictor of prognosis in thin melanomas where mitosis under 
or over 1mm determines T1a or T1b staging respectively (Balch et al., 2009a). 
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Classification Thickness Ulceration/Mitoses 
T0 (in situ) N/A N/A 
T1  1mm 
a. without ulceration and mitosis <1mm2 b. with 
ulceration or mitoses  1mm2 
T2 1.01-2mm a. without ulceration b. with ulceration 
T3 2.01-4mm a. without ulceration b. with ulceration 
T4 >4mm a. without ulceration b. with ulceration 
Classification Number of Metastatic nodes Nodal metastatic Burden 
N0 0 N/A 
N1 1 a. micrometastasis b. macrometastasis 
N2 2-3 
a. micrometastasis b. macrometastasis c. in transit 
metastases, without metastatic nodes 
N3 
4+ metastatic nodes, or in 
transit metastases 
N/A 
Classification Site Serum LDH 
M0 No distant metastases N/A 
M1a 
Distant skin, subcutaneous or 
nodal metastases 
Normal 
M1b Lung metastases Normal 
M1c 
All other visceral metastases 
Any distant metastases 
Normal 
Elevated 
Table 1.1 Tumour Node Metastasis (TNM) Staging in Melanoma  
The greatest prognostic factor influencing reduced overall survival for melanoma is the 
presence or number of lymph node metastasis (Gershenwald et al., 1999; Scolyer et al., 2008) 
with the ‘N’ category denoting the number of regional nodal metastatic sites, and the final ‘M’ 
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category, defining the region of metastasis and the presence of normal or elevated LDH levels 
(used to stratify M1 stage melanomas into a, b or c category, Table 1.1) 
AJCC 
Stage 
TNM Stage Disease Characteristics 
5 year 
Survival (%) 
0 Tumour in situ Confined to epidermis 100 
IA T1a Tumour  1mm, level II/II, without ulceration 95 
IB TIb-T2a 
Tumour  1mm, level IV/VI, or with ulceration, or 
tumour1.01-2mm without ulceration 
89-91 
IIA 
 
T2b-T3a 
Tumour1.01-2mm with ulceration, or tumour 2.01-4mm 
without ulceration 
77-79 
IIB T3b-T4a 
Tumour 2.01-4mm with ulceration, or >4mm without 
ulceration 
63-67 
IIC T4b Tumour >4mm with ulceration 45 
IIIA T1-4a N1a/N2a Any thickness without ulceration and 1-3 pos LN 63-70 
IIIB 
T1-4b N1a/N2a 
T1-4b N1b/N2b/N2c 
Any thickness with ulceration and 1-3 LN or any 
thickness and 4+ LN or in transit metastasis 
46-59 
IIIC 
T1-4b 
N1/N2b/N2c/N3 
Any thickness with ulceration and 1-3 LN or any 
thickness and 4+ LN or in transit metastasis 
24-29 
IV 
T-Any, N-Any 
M1a/1b/1c 
Any distant metastasis regardless of thickness or LN 
status 
7-19 
Table 1.2 AJCC Staging in Cutaneous Melanoma and 5 year Survival 
The AJCC staging in cutaneous melanoma and 5-year survival. Adapted from (Balch et al., 2009a). ‘LN’ 
lymph node, ‘a’ = micrometastases, ‘b’ = macrometastases, ‘c’ = in-transit metastases without 
metastatic lymph nodes. 
 
Overall, patients diagnosed with AJCC stage Ia melanomas (breslow thickness  1mm, no 
ulceration and mitotic count 1mm2), are usually cured by surgical excision with a resulting 5 
year survival of 95% (Table 1.2) (Balch et al., 2009a). However, for those patients with AJCC 
stage IV melanomas, 5 year survival falls to <20 % (Table 1.2) (Green et al., 2012), emphasising 
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the acute need for novel biomarkers able to predict disease progression as well as more 
effective precision based treatment strategies for metastatic disease. 
1.2.2 Current Biomarkers 
Although AJCC staging provides a useful means of melanoma classification guiding to a certain 
extent treatment strategy, it is unable however, to predict the risk of disease progression for 
early stage, seemingly low risk melanomas. Despite the introduction of sentinel node biopsy 
to AJCC staging to improve accuracy of prognostication, 15% of patients with thin melanomas 
(1mm) with a negative sentinel node still metastasise and die (Gimotty et al., 2004). Similarly 
62% of patients with a positive sentinel node do not progress to distant metastasis (van der 
Ploeg et al., 2011; Morton et al., 2014), highlighting shortfalls in current prognostication. 
Additional biomarkers have therefore been considered including clinico-pathological factors 
such as anatomical location (Garbe et al., 1995), the presence of infiltrating lymphocytes 
(Azimi et al., 2012), and specific histological tumour subtypes (Ettl et al., 2014). In addition 
biological markers of cellular processes critical to tumour metastasis including markers of 
tumour proliferation such as Ki67 (Gimotty et al., 2005), survivin (Schramm and Mann, 2011), 
P16/INK4A (Schramm and Mann, 2011), B-RAF activating mutations (Nagore et al., 2014) and 
TERT promoter mutations (Griewank et al., 2014), have all been used to aid the prediction of 
melanoma survival. 
Markers of tissue invasion such as cell adhesion molecules CEACAM and MCAM (Rothberg et 
al., 2009), or regulators of epithelial-mesenchymal transition such as Twist transcription factor 
(Zhang et al., 2014) maybe predictive of melanoma progression as well as markers of 
immunocompetence, where the presence of programmed death receptor-1 (PD-1) (Cooper et 
al., 2014), and T-regulatory cell marker forkhead P3 (FOXP3) (Mohos et al., 2013) are 
associated with worse prognosis. Further, markers of angiogenesis and lymphangiogenesis 
such as tumour micro-vessel density and peri-tumoural lymphatic density have also been used 
to predict prognosis and disease free survival respectively (Pastushenko et al., 2014a). 
However, to date, no single biomarker or combinational marker has added to the current AJCC 
staging system, with most potential candidates only tested within a single cohort, without 
adherence to REMARK criteria, performed with inappropriate analytical methods, and without 
validation across populations to authenticate prognostic clinical value (Rowe and 
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Khosrotehrani, 2016). Hence there is still an urgent need for fully validated prognostic 
biomarkers in both cutaneous and uveal melanomas. 
1.2.3 MAPK Signalling Activation and Therapeutic Targets 
Early excision of cutaneous melanoma can be curative for 90% of patients with early stage 
primary lesions, however, there is currently no effective therapeutic modality for the 
treatment of advanced metastatic disease. Once established, the intrinsic or acquired 
resistance of metastatic melanoma to current strategies results in 5 year survival rates of less 
than 20%, thus emphasising the urgent need for novel treatments with sustained clinical 
benefit (Altekruse S.F et al., 2010).  
Molecular genetics have eluted distinct patterns of common mutational changes within 
signalling pathways and cell cycle events that can drive tumourigenesis of melanocytes, 
providing the first opportunity of targeted therapy. Perhaps the best defined of these 
deregulating cell signalling mechanisms in melanoma, is the Ras-RAF-MEK-ERK signalling 
pathway. Mutations within the Ras signalling network are particularly important in melanoma 
as signalling cascades to both the mitogen activated protein kinase (MAPK) and 
phosphatidylinositide 3-kinases  (PI3K) pathways (Hocker et al., 2008). Ras is a small GTPase 
protein that transmits signals from extracellular growth factors by conversion into an active 
GTP bound formation mediated by receptor tyrosine kinases. Mutated oncogenic forms of Ras 
include N-Ras, K-Ras and H-Ras of which N-Ras is most commonly mutated in 15-20% of all 
melanomas resulting in the constitutive activation of downstream MAPK signalling 
independent of external stimuli (Downward, 2003; Dumaz et al., 2006). However drugs 
selectively targeting Ras, have not come to fruition with most therapeutic efforts alternatively 
concentrated on downstream elements of the MAPK pathway, fuelled by the seminal 
identification of a gain of function mutation in B-RAF present in up to 90% of all melanomas 
(Davies et al., 2002b) (Figure 1.4). 
RAF is an intermediary kinase for which 3 members A-RAF, B-RAF and C-RAF are 
phosphorylated by active Ras. Activated RAF subsequently participates in the MAPK signalling 
cascade by phosphorylating MEK 1/2 MAP-kinase which consequently phosphorylates ERK 1/2 
mitogen activated kinases, leading to the activation of fos and jun transcription factors with 
pleiotypic effects (Platz et al., 2008). Of more than 50 known mutations discovered in B-RAF, 
80% of those in melanoma, contain a miss-sense substitution of thymine to adenine, resulting 
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in a valine to glutamic acid substitution at codon 600 (V600E) (Davies et al., 2002b; Garnett 
and Marais, 2004). This results in, increased B-RAF kinase activity, enhanced proliferation, and 
the increased likelihood of melanocyte transformation (Davies et al., 2002b). 
 
Figure 1.4 Signalling Events Mediating Melanomagenesis and Targeted Therapeutic 
Strategies 
In normal melanocytes the Ras-RAF-MEK-ERK signalling pathway is tightly regulated to promote 
growth, proliferation and cell survival. However, in melanoma the Ras signalling pathway often 
harbours mutations that are central to melanoma development. Of the most prolific is B-RAF V600E 
mutant that causes oncogenic constitutive signalling and cell transformation. Vemurafenib is a small 
molecule inhibitor that has been shown to cause death of B-RAF mutant cells. Adapted from (Luke and 
Hodi, 2012). 
 
Interestingly B-RAF V600E mutations are observed in over 80% of benign naevi (Dankort et al., 
2009), suggesting mutant B-RAF alone is insufficient to induce oncogenic transformation and 
that additional mutagenic events are required (Michaloglou et al., 2005). Nevertheless the 
fact that mutant B-RAF promotes anchorage independent growth (Smalley, 2009), melanocyte 
survival (Cartlidge et al., 2008), invasion and metastasis (Sharma et al., 2005; Klein and Aplin, 
2009; Arozarena et al., 2011) as well as tumour escape from immune surveillance (Kono et al., 
2006; Sumimoto et al., 2006) confirms the potential for targeting B-RAF in melanoma 
Introduction 
15 
 
therapeutically, and hence has pathed the way for an influx of drugs specifically targeting B-
RAF V600E into clinical trials (Figure 1.4). 
In fact the B-RAF V600E small molecule inhibitor vemurafenib, that prevents signal 
transduction between B-RAF and MEK has yielded the greatest response rates in patients with 
metastatic melanomas harbouring mutant B-RAF V600E compared to any other drug in the 
last 20 years, increasing progression free survival by up to 6 months compared to single agent 
dacarbazine (Flaherty et al., 2010; Chapman et al., 2011). Unfortunately, however, the 
response to vemurafenib is short lived with the development of acquired resistance observed 
in the majority of patients after 6 month or so, and hence impairing any improvement in long 
term survival for patients with malignant melanoma (Flaherty et al., 2010; Chapman et al., 
2011) (Figure 1.5). 
Some melanomas are intrinsically resistant to vemurafinib from the onset, with mechanisms 
of resistance proposed to include an increase in cyclin D1 expression resulting in deregulation 
of cell cycle machinery, as well as a switch or diversion in signalling through A or C-RAF causing 
the reinstatement of MAPK signalling (Figure 1.5) (Montagut et al., 2008; Smalley et al., 2008; 
Villanueva et al., 2010).  Intrinsic resistance may also be mediated by loss of the PTEN tumour 
suppressor gene, seen in over 10% of melanomas and leading to a compensatory increase in 
AKT signalling (Boisvert-Adamo and Aplin, 2008; Paraiso et al., 2011). 
Alternatively acquired resistance to vemurafenib may result from the emergence of secondary 
mutations in B-RAF preventing vemurafenib binding to its target site (Whittaker et al., 2010), 
or the advance of a B-RAF variant lacking a Ras binding site (p61B-RAFV600E) enabling increased 
dimerization with A-RAF and C-RAF and the potentiation of drug-induced resistance 
(Poulikakos et al., 2011; Shi et al., 2012). Furthermore the amplification of B-RAF itself or C-
RAF may also enhance resistance increasing downstream signalling (Poulikakos et al., 2011; 
Shi et al., 2012). Vemurafenib-mediated inhibition of MAPK signalling may also be abrogated 
by acquired upstream activating mutations in N-Ras leading to C-RAF-dependant activation of 
MEK-ERK signalling (Johannessen et al., 2010; Nazarian et al., 2010), or downstream mutations 
in MEK1/2 (MEK1C1251) (Nazarian et al., 2010). Finally the activation or upregulation of other 
receptor tyrosine kinase receptor signalling pathways in response to vemurafenib  treatment 
including, joint IGF1Rβ and PDGFRβ signalling via the PI3K/AKT pathway, may result in a 
reduction of cell dependence on active ERK signalling (Nazarian et al., 2010; Villanueva et al., 
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2010; Wagle et al., 2011). Increased activation of the MEK by either its direct activator COT 
serine/threonine protein kinase or via MET activation by stromal secreted hepatocyte growth 
factor (Straussman et al., 2012), can mediate RAF-Independent MEK signalling and hence can 
also offer a mode of resistance to B-RAF specific inhibition (Johannessen et al., 2010) (Figure 
1.5). 
 
Figure 1.5 Possible Mechanisms of Vemurafenib Resistance. 
Resistance to Vemurafenib may be mediated by reactivation of MAPK signalling via (1) Mutations in 
upstream Ras, (2) C-RAF or COT over expression increasing MEK/ERK activation, (3) activating 
mutations in MEK or (4) Non MAPK growth pathways such as insulin-like growth factor receptor or 
Platelet derived growth factor receptors promoting growth, proliferation and survival of melanocytes 
independent of MAPK signalling. Modified from (Luke and Hodi, 2012). 
 
Dabrafenib a newer B-RAF inhibitor has yielded similar increases in progression free survival 
and response rates as vemurafenib, with remarkable efficiency in intracranial metastases and 
with a slightly more favourable toxicity profile (Falchook et al.; Long et al., 2012), and hence 
its use was therefore FDA approved for the treatment of unresectable melanoma harbouring 
B-RAF mutation in 2013. 
Additional concern for the use of B-RAF specific inhibition is for melanomas that do not 
harbour a B-RAF V600E mutation, but which display paradoxical activation of MAPK in 
response, possibly accounting for the acquisition of new carcinomas and melanomas with B-
RAF inhibition (Poulikakos et al., 2010; Robert et al., 2011; Su et al., 2012). To tackle this 
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problem intra and inter MAPK pathway inhibitors are being evaluated to overcome these 
issues. 
Collectively research highlights the dependence of melanoma on hyperactive MAPK signalling, 
and hence supports the targeting of MEK 1/2 as a promising alternative therapeutic strategy, 
applicable therefore not only to patients harbouring B-RAF mutant melanomas, but also for 
those with N-Ras mutant or indeed N-Ras/B-RAF mutant melanomas. MEK is a particularly 
attractive target given that, activation of RAF becomes amplified at MEK1/2 due to its much 
greater abundance in cells (Gray et al., 2001), the fact that MEK1/2 is rarely mutated, and 
finally by its downstream convergence for both mutant Ras and RAF (McCubrey et al., 2007). 
To this aim, small molecule inhibitors to MEK, including trametinib (GSK 1120212) have been 
developed. In vivo pre-clinical data demonstrated the complete abrogation of tumour growth 
in B-RAF mutant xenografts in response to MEK-specific inhibition, providing proof of concept 
for the use of single-agent trametinib and in combination with new generation B-RAF specific 
inhibitors (Solit et al., 2006; InfanteJR et al., 2010; Gilmartin et al., 2011). 
As a single agent in a phase III trials of trametinib demonstrated improved progression free 
survival and overall survival, resulting in FDA approval in 2013 and the use of trametinib as 
first line treatment for unresectable B-RAF mutated melanoma (Flaherty et al., 2012c). 
Likewise as with B-RAF inhibition, some individuals displayed resistance to MEK inhibition 
mediated via mechanisms disrupting ERK1/2 negative feedback loops, overexpression of 
cyclin D1, increased wnt or PKA signalling and amplification of Ras and RAF family members 
to name but a few (Little et al., 2012). In a bid to overcome resistance gained by either B-RAF 
or MEK inhibitor alone subsequent approaches were taken to target both mutant B-RAF and 
MEK as a strategy to abrogate reactivation of MAPK signalling. Phase I/II trials demonstrated 
impressive results with improved patient free survival to 10 months with the combination of 
trametinib and dabrafenib compared to 5.6 months with dabrafenib alone, leading to the 
rapid approval of combinational therapy in 2014 (Flaherty et al., 2012b). Subsequent phase III 
trials have further confirmed improved progression free survival and overall responses with 
combined MEK and B-RAF inhibition, and hence is now the standard of care for patients with 
metastatic melanoma bearing either mutant B-RAF V600E or V600K (Robert et al., 2015). 
A promising new area in melanoma therapeutics includes immunotherapy, which targets the 
patient’s defective immune responses to melanoma. The cytotoxic T lymphocyte associated 
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antigen (CTLA-4) down regulates T cell activation and promotes immune tolerance of 
melanoma cells. To counteract this, trials of a monoclonal antibody to CTLA-4, ipilimumab to 
promote T cell activation and the reinstatement of anti-tumour immunity have been initiated 
(Fong and Small, 2008). A phase III trial of ipilimumab demonstrated increased overall survival 
by 3.6 months compared to gp100 vaccine alone (Hodi et al., 2010), which has led to its 
adoption into clinical practice. Programmed cell death receptor 1 (PDCD1) and its ligand 
CD274 are similarly immunotherapy targets in melanoma, with engagement of the ligand to 
the receptor resulting in the downregulation of T cell activation. Re-stimulation of the immune 
system by anti-PDCD1 antibodies nivolumab and lambrolizumab has proven to be superior to 
ipilimumab with responses in up to 50% of individuals and outstanding survival rates of 66% 
at 1 year compared to only 25% with systemic chemotherapies (Hamid et al., 2013; Mario 
Sznol et al., 2013). A newer anti-PD-1 monoclonal antibody Pembrolizumab, was FDA 
approved in 2014 for advanced melanoma and demonstrates impressive 1 year survival as a 
monotherapy, at 74.1% compared to 58.2% with ipilimumab (Robert et al., 2015). Collectively 
these data thus suggest that immunomodulatory therapy is likely to make a great impact in 
the future treatment of advanced stage melanomas with other emerging strategies including 
toll-like receptor activation by imiquimod, adoptive T-cell therapy and oncolytic viral therapy. 
Activating mutations or amplification of KIT have been reported in 39% of mucosal and 36% 
of acral melanomas, suggesting that in certain melanoma phenotypes targeting KIT maybe 
advantageous (Curtin et al., 2006). The KIT inhibitor nilotinib and imatinib have shown efficacy 
in phase 2 trials of advanced melanoma trials and further trials with these inhibitors compared 
to systemic chemotherapies are ongoing (Guo et al., 2011a; Carvajal et al., 2015). 
Epigenetic modulations are implicated in melanoma pathogenesis, and may include 
methylation of promoter regions, histone modification, and chromatin remodelling providing 
possible new therapeutic targets (Lee et al., 2014), with early phase trials of decitabine a DNA-
methyltransferase inhibitor and vorinostat a histone deacetylase inhibitor currently under 
way (Tang et al., 2016). 
In an era of personalised and precision based medicine, clearly it will be important to define 
which deregulated signalling mechanisms are best targeted within individual patients with 
cutaneous metastatic melanoma as well as their cross talk in order to optimally define the 
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best therapeutic approach and how to circumvent the development of acquired drug 
resistance. 
1.3 Uveal melanoma 
1.3.1 Uveal Melanoma Characteristics and Prognosis 
Uveal melanoma is the most common primary intraocular cancer in adults accounting for 5% 
of all melanomas. Uveal melanoma originates from neural crest derived melanocytes of the 
uveal tract and arises in 90% of cases, from the choroid where tumours are dome shaped and 
acquire a typical mushroom shape once rupturing the Bruch’s membrane (Figure 1.6). 7% of 
uveal melanomas arise in the ciliary body, with 3% in the iris (Damato, 2006). Unlike cutaneous 
melanoma, the incidence of uveal melanoma has remained relatively constant and is still rare 
in the UK, affecting only 6 per million individuals (Singh et al., 2005; Coupland et al., 2013). 
Although uveal melanomas may occur at any age usual presentation is around 50-60 years of 
age with a slight preponderance for larger tumours in males (Frenkel et al., 2009). Risk factors 
for uveal melanoma development include light skin and eye colour, red or blonde hair, and 
inability to tan (Weis et al., 2006). However, unlike cutaneous melanoma there is no firm 
evidence to suggest a linkage to UV exposure and only a few reported cases of Mendelian 
inheritance (Damato, 2012). Choroid naevi are relatively frequent in Caucasians and undergo 
malignant transformation at a very slow rate, however giant choroid naevi (over 10mm) are 
more likely to transform with 18% transforming into melanomas within 10 years (Li et al., 
2010). 
50% of uveal melanomas metastasise, almost exclusively by a haematogenous route, due to 
lack of lymphatic drainage to the ocular interior, and resulting in liver metastasis in 95% of 
cases (Buzzacco et al., 2012). Once metastasis to the liver occurs this is unvaryingly fatal with 
a median survival of only 4-5 month and 1 year survival rates less than 15% (Lamba et al., 
2009; Besaratinia and Pfeifer, 2011). On the other hand, extrahepatic metastasis to the lung, 
bone or skin are less common and are associated with a slightly longer median survival of 19-
18 months (Bedikian, 2006). 
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Figure 1.6 Uveal Melanoma.  
A and B.) example of a fundus microscope examination used to detect the presence of ocular tumours. 
C.) and D.) uveal melanoma with both pigmented and non-pigmented halves. E.) histological staining 
of a uveal melanoma with an epithelioid cell type and F.) histological staining of a spindle cell type 
uveal melanoma with melanin pigmentation. Taken from (Lim et al., 2014). 
 
The inability to predict the timescale to metastasis development makes prognostication of 
uveal melanoma challenging. Staging is largely based on the 2010 updated criteria by the AJCC 
criteria, which similarly to cutaneous melanoma, is based on the tumour, node, metastasis 
(TNM) staging model for anatomical staging (Figure 1.7), with prognosis determined according 
to primary tumour size, thickness, ciliary body involvement and extraocular spread (Damato, 
2012). Based on the fact that larger tumours are more likely to metastasise, basal tumour 
diameter is the most widely used prognostic indicator within AJCC staging, with, relative ease 
of detection making this the most clinically useful factor (Shields et al., 2009).  
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Figure 1.7 AJCC Staging in Uveal Melanoma.  
A.) Determination of T stage by tumour thickness and basal diameter. B.) Survival curve of uveal 
melanomas at all AJCC stages. Taken from (Harbour, 2012; Kivela and Kujala, 2013). 
 
The only histopathological feature that is incorporated into the AJCC staging is cell type; with 
tumours recorded as being of spindle cell phenotype, mixed cell (spindle and epithelioid) or 
solely of epithelioid phenotype, and for which spindle cell morphology is associated with a 
more favourable prognosis (S.B. Edge et al., 2010). Other histopathological features that 
correlate with worse prognosis include the presence of extravascular closed loops and high 
mitotic count (Damato et al., 2011). Prognosis ranges from a 5 year survival of 96% for patients 
with AJCC stage I uveal melanomas to just 3% survival for patients with stage IV tumours, 
further highlighting the aggressive nature of metastatic disease (Kujala et al., 2013). 
Genetic prognostication is thought to surpass histological prognostication for uveal 
melanoma, with loss of one copy of chromosome 3 has been the strongest prognostic 
indicator to date with metastasis and metastatic death almost exclusive in these individuals 
(Sisley K et al., 1992; Tschentscher et al., 2000). 
1.3.2 MAPK Signalling Activation, Genetic Alterations and Therapeutic Targets 
The constitutive activation of the MAPK/ERK pathway is a common event in both uveal and 
cutaneous melanomas, leading to cell cycle progression and autonomous cell proliferation 
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(Denhardt, 1996). Interestingly, and in contrast to cutaneous melanoma, uveal melanoma 
lacks mutations in the typical oncogenes commonly mutated in cutaneous disease, with 
mutations in B-RAF, N-Ras and KIT extremely rare (Landreville et al., 2008; Hofmann et al., 
2009). The driving force of MAPK hyper-activation in uveal melanoma however, is the 
existence of somatic mutations in the guanine nucleotide-binding protein G(q) subunit 
(GNAQ) or guanine nucleotide-binding protein subunit alpha-11 (GNA11) (Figure 1.8), present 
in 83% of primary uveal melanomas and 90% of metastatic uveal melanomas (Van Raamsdonk 
et al., 2010). GNAQ and GNA11 encode members of the q class of heterotrimeric G-protein α 
subunits, with mutations in either the Gαq or Gα11 subunits preventing intrinsic GTPase 
activity required to maintain the protein in its inactive configuration and enabling constitutive 
G-protein activation (Harbour, 2012). G-protein activation leads to downstream signalling 
events including hyper-activation of phospholipase C and MAPK signalling driving 
tumorigenesis. The GNAQ mutation has 5 known variants arising at codon 209 where a 
glutamine is substituted at this point, with GNAQQ209L or GNAQQ209P most common (Van 
Raamsdonk et al., 2009b). Mutations at the same codon 209 in GNA11 may also occur with 
both GNAQ or GNA11 mutations at codon 183 additionally observed, albeit less commonly, 
but in each case are mutually exclusive events (Van Raamsdonk et al., 2010). GNAQ or GNA11 
mutations are also present in naevi and in uveal melanomas at all stages, so it is likely these 
are also early events in uveal melanoma pathogenesis, but which may not be entirely 
necessary for malignant transformation (Van Raamsdonk et al., 2009a; Van Raamsdonk et al., 
2009b). In addition to hyper-activation of MEK, mutant GNAQ/11 may also lead to the 
downstream activation of the yes-associated protein (YAP), which is the major effector of the 
Hippo tumour suppressor pathway, reported to be essential for the transduction of oncogenic 
activity and promotion of growth of GNAQ/11 mutated uveal melanomas (Yu et al., 2014). 
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Figure 1.8 Constitutive Activation of MAPK Signalling in Uveal and Cutaneous Melanoma 
GNAQ/11 or B-RAF/N-Ras mutations present in uveal or cutaneous melanomas results in the hyper-
activation of Ras-RAF-MEK-ERK signalling that leads to enhanced tumour proliferation and survival. 
Figure illustrated by Barnaby Pathy Bsc project dissertation, Newcastle University. 
 
In the majority of uveal melanomas the tumour suppressor proteins retinoblastoma (Rb) and 
p53 are dysfunctional and associated with poorer prognosis, although mutations in the 
cognate genes are very rare (Coupland et al., 1998; Brantley Jr and Harbour, 2000). Rb is 
inactivated in 65% of uveal melanomas, mediated by the over expression of cyclin D1 or less 
frequently by hyper-methylation of the promoter CDKN2A (Coupland et al., 1998; Brantley 
and Harbour, 2000; Coupland et al., 2000; van der Velden et al., 2001), while p53 is likely 
supressed by overexpression of MDM2, also a common feature of uveal melanomas (Brantley 
Jr and Harbour, 2000; Coupland et al., 2000).  
Studies have also demonstrated the constitutive activation of PI3K/AKT pathway signalling is 
associated with a poorer prognosis in uveal melanoma (Saraiva et al., 2005). Furthermore, loss 
of heterozygosity within the PTEN tumour suppressor locus can arise in 76% of primary uveal 
melanomas leading to increased aneuploidy and poor prognosis (Abdel-Rahman MH et al., 
2006; Ehlers et al., 2008).  
In addition to oncogenic changes in signalling pathways, uveal melanoma hosts some unique 
chromosomal alterations likely specific to tumour progression, and distinct from those 
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observed in cutaneous melanoma. As adhered to above, the most common chromosomal 
alterations include loss on 1p,3,6q, and 9p with a gain at 1q, 6p and 8q (Harbour, 2012). 
Chromosome 3 monosomy or partial loss is the strongest prognostic indicator to date and is 
associated with metastasis and a striking reduction in 5 year survival from 100 to 50% 
(Bornfeld et al., 1996). Interestingly, chromosome 3 is home to the BRCA1-associated protein-
1 (BAP-1) tumour suppressor gene. The BAP-1 gene encodes an ubiquitin carboxy-terminal 
hydrolase that binds to BRCA1 forming a tumour suppressor complex  among other roles in 
cell cycle regulation, transcription and histone ubiquination (Machida et al., 2009a; 
Scheuermann et al., 2010; Laurent et al., 2011). The loss of one copy of BAP-1 mediated by 
monosomy of chromosome 3 or mutations in the other BAP-1 gene is observed in almost 50 
% of uveal melanomas, suggesting a recessive ‘two hit’ scenario that results in the loss of cell 
differentiation and the emergence of stem-like features promoting uveal melanoma 
dissemination into a metastatic phenotype (Matatall et al., 2013). The amplification of the 
long arm of chromosome 8 that occurs in 40% of uveal melanomas also correlates with 
reduced survival  and metastasis (Sisley et al., 1997) . Conversely a 6p gain in a third of uveal 
melanomas is associated with a much better prognosis compared to chromosome 3 loss with 
each event tending to be mutually exclusive (White et al., 1998).  
Gene expression profiling has enabled researchers to understand not only the pathobiology 
of uveal melanoma but also provide prognostic information about two classes of tumour that 
differ markedly in their metastatic potential (Onken et al., 2004). In both cases early molecular 
initiating events are thought to be GNAQ/11 mutations in normal uveal melanocytes, with 
progressing tumours dividing into two distinct classes (Figure 1.9). Class 1 tumours remain 
differentiated resembling uveal melanocytes or naevi, often have a 6p and 8q gain, less 
aneuploidy  with less than 5% of tumours going on to metastasise (Chang et al., 2008). Class 2 
uveal melanomas on the other hand, have a 90% risk of metastasis are dedifferentiated 
resembling primitive neural or ectodermal stem cells (Chang et al., 2008). Class 2 tumours 
have chromosomal abnormalities, commonly chromosome 3 loss and/or amplification of 8q, 
with 84% harbouring inactivating mutations in BAP-1, and suggesting biallelic loss of BAP-1 
maybe a key step in uveal melanoma progression (Harbour et al., 2010). Loss of BAP-1 has 
more recently been shown to be predictive of death from metastasis post enucleation, 
emphasising the importance of this chromosomal aberration in prognostication (van Essen et 
al., 2014). Although BAP-1 mutations have been noted in cutaneous melanoma, these are 
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however, not thought that they play such an important role in disease progression, as they do 
in uveal melanoma (Wiesner et al., 2011). 
 
Figure 1.9 Molecular Events in Uveal Melanoma Progression. 
Gene expression profiling has identified the early events in uveal melanoma progression. The earliest 
events are thought to be activating mutations in GNAQ or 11 that triggers MAPK signalling and entry 
into a senescent state such as that of a nevus tumour. It is thought that from a naevi uveal melanomas 
can progress down one of two molecular pathways. 10% of uveal melanomas are Class 1 tumours that 
gain 6p and 8q with low risk of metastasis. Most uveal melanomas however acquire BAP-1 mutations 
and loss of chromosome 3 falling into the class 2 tumours where they also commonly exhibit 1p and 8p 
loss and gain of 8q and almost exclusively metastasise. Taken from (Harbour, 2012). 
 
Treatment options for primary uveal melanoma include the radical treatment of enucleation 
for advanced large local disease, with exoresection with plaque brachytherapy or 
radiotherapy for medium size tumours, or an conservative approach of plaque brachytherapy, 
photodynamic therapy, or external ionizing radiation for more cosmetically pleasing results 
and increased chance of saving vision in smaller tumours (Damato, 2010; Spagnolo et al., 
2012). Interestingly both radical and conservative treatments show similar impact on survival 
and metastatic development. Despite successful treatment of the primary tumour, and 
advances in systemic chemotherapies, there are still however, no effective systemic therapies 
for uveal melanoma with many clinical trials of differing chemotherapeutics failing to 
demonstrate any effective response and at best only improving median survival just under 10 
months in a handful of individuals (Bedikian et al., 2003; Kivelä et al., 2003; Schmittel et al., 
2005; O'Neill et al., 2006; Schmittel et al., 2006; Bedikian et al., 2008; Homsi et al., 2010). 
Compared to other agents some positive responses has been observed with fortemustine and 
although limited, this remains the standard agent for the treatment of uveal melanoma in 
Europe (J C Becker et al., 2002; Pons et al., 2011; Patricia Rusa Pereira et al., 2013). Although 
only few individuals with liver metastasis are eligible for liver resection this may prolong 
survival (Hsueh et al., 2004), and hence Loco-regional treatments have been developed to 
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target the liver metastasis including radiofrequency ablation, hepatic intra-arterial 
chemotherapy, immunoemobilisation, chemoembolization and hepatic arterial perfusion 
(Sato, 2010). 
Given the aggressive and resistant nature of metastatic uveal melanoma to systemic therapies 
and targeted treatment for liver metastasis, it is clear that there is an urgent need for more 
effective precision based therapies. In this context, there is increasing interest in the potential 
for new generation MEK specific inhibitors as a targeted therapeutic strategy for 
GNAQ/GNA11 mutant uveal melanomas. A multicentre randomised phase II clinical trial of the 
MEK inhibitor selumetinib (AZD6244) compared to single agent temozolomide, in 101 uveal 
melanoma patients has revealed promising preliminary outcomes, with observations of 
increased progression free survival to 15.9 weeks following treatment with selumetinib 
compared to 11.8 weeks with temozolomide (Carvajal et al., 2014). 
Other targeting options may include inhibition of the PI3K/AKT pathway, targeting at the level 
of AKT or mTOR, or possibly targeting BAP-1 mutation/loss. Furthermore, given recent 
discoveries that mutant GNAQ/11 mediated activation of YAP, verteporfin a YAP 
transcriptional activity inhibitor has already been FDA approved for macular degeneration, 
but which also shows promising ability to inhibit uveal melanoma tumour growth, and may 
thus also represent a therapeutic target in uveal melanoma (Feng et al., 2014; Yu et al., 2014). 
As in cutaneous melanoma, the use of immunotherapy in the treatment of uveal melanoma 
is gaining considerable clinical interest, with the initiation of trails of ipilimumab (anti-CTLA-
4). However, although phase III trials of ipilimumab have demonstrated improved survival for 
cutaneous metastatic melanoma (Hodi et al., 2010), such results were not reflected in trials 
for metastatic uveal melanoma (Zimmer et al., 2015). Although to date, studies of the 
potential efficacy for PD-1 blockade in metastatic uveal melanoma are limited, interestingly, 
a single centre trial of 7 patients with pembrolizumab (humanised monoclonal antibody to PD-
1) reported increased progression free survival in 2 patients (Kottschade et al., 2016), 
suggesting this may also be a viable future therapeutic strategy for uveal melanoma. 
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1.4 Melanoma Metastasis  
1.4.1 The Metastatic Cascade 
Cancer metastasis is one of the main clinical parameters that determines prognosis in all forms 
of cancer, typically associated with resistance to treatment, high risk of relapse and lower 
survival rates (Valastyan and Weinberg, 2011). Metastasis is a biological multistep process or 
cascade that describes the propagation of cancer cells from the primary tumour, to distant 
sites in the periphery where they form micro metastasis and eventual secondary tumours 
(Figure 1.10). 
 
Figure 1.10 Metastatic Cascade 
The metastatic cascade (0.) A distant site of metastasis being formed from a pre-metastatic niche. (1.) 
Primary melanoma cells undergo epithelial to mesenchymal transition to acquire an invasive 
phenotype. (2.) Metastatic melanoma cells migrate through the basement membrane aided by 
secretion of metalloproteinases to degrade and remodel the extracellular matrix. (3a) A single 
metastatic cancer cells invades local tissue or (3b.) a group of metastatic cells invade together into the 
extracellular matrix. (4.) New blood vessels are formed by angiogenesis supplying the primary tumour 
allowing cancer cells to intravast through endothelial cells lining the blood vessels into general 
circulation. Alternatively, angiotropic tumour cells that do not invade the vasculature undergo 
EMT/pericyte mimicry and migrate along the blood vessel without entering it towards a secondary 
metastatic site (5.) Once detached cancer cells must avoid death by anoikis being transported through 
circulation. Location of metastasis is often determined by cancer cell migration driven by chemokine 
gradients secreted from the target organ. (6.) The cancer cells attach to capillary endothelial cells and 
extravast into the tissue. (7.) The cancer cell may remain dormant for years but may gain further ability 
to remodel the extracellular matrix and induce angiogenesis to support the formation of a 
micrometastasis and a secondary tumour. Taken from (Geiger and Peeper, 2009). 
 
Metastatic cascade events start in the primary tumour with underlying events often described 
as ‘epithelial to mesenchymal’ (EMT) in nature, and are a prerequisite to melanoma 
metastasis. EMT is characterised firstly by loss of cell–cell adhesion via the suppression of E-
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Cadherin and gain of N-Cadherin expression on the cell surface. EMT is often induced by 
transforming growth factor β, Wnt, NOTCH, hedgehog and NFκb signalling pathways, in 
concert with Ras signalling and under the influence of factors within the tumour 
microenvironment (Oft et al., 1996; Huber et al., 2005). Such changes allow escape of 
melanoma cells from tight linkage with adjacent keratinocytes in the epidermis, facilitating 
invasion and new interaction with stromal cells, including fibroblasts and other cancer cells in 
the immediate tumour microenvironment (Haass NK et al., 2004). Cancer cell metastatic 
potential is not only determined by its own phenotype but is also greatly influenced by the 
tumour microenvironment, which comprises many cell types including; cancer associated 
fibroblasts and immune cells. Together these cells have the potential to shape cancer cell 
behaviour by providing oncogenic signalling stimuli, growth factors, cytokines, chemokines 
and pro or anti-angiogenic factors, in addition to generating an inflammatory or 
immunosuppressive environment promoting cancer cell immune evasion (Spano et al., 2012). 
Next in the metastatic cascade universal to all cancers, cells invade through endothelial cell 
basement membranes lining blood or lymphatic vessels in a process called intravasation 
(Figure 1.10). Intravasation allows for the transport of cancer cells away from the primary 
tumour site. Once the cancer cell has migrated through the basement membrane and no 
longer adheres to the extracellular matrix via integrins, metastasis maybe prevented by 
induction of cell death by anoikis (Geiger and Peeper, 2009). Cancer cells must acquire the 
ability to prevent anoikis induced death which may occur at many stages of the metastatic 
cascade (Zhu et al., 2001). Circulating tumour cells then travel via blood or lymph adhering to 
the vascular endothelium at the site of metastasis. In the extravasation process the cancer cell 
crosses from circulation over the endothelium, and extracellular matrix of the targeted tissue. 
The location of the site of metastasis is dependent on adhesion and chemokine ligands and 
receptors expressed by the cancer cell and endothelium (Felding-Habermann et al., 2001). 
Finally once the cancer cells have transendothelially migrated into the tissue the process of 
micro metastasis establishes a peripheral niche of cancer cells, which in favourable 
microenvironmental conditions, often after a period of dormancy may form a secondary 
tumour completing the metastatic cascade (Bustelo, 2012).  
More recently, a new paradigm has emerged in the field of melanoma metastasis namely 
‘Extravascular Migratory Metastasis’ (EVMM) an alternative mechanism by which melanoma 
cells disseminate from the primary tumour, to sites of metastasis without intravasation into 
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blood vessels (Lugassy et al., 2014). EVMM describes the process in which tumour cells from 
the advancing front of the primary tumour adhere to abluminal vasculature and migrate in a 
crawling fashion along the external surfaces of the vasculature to metastatic sites without 
entering any vascular channels. Studies of these ‘angiotropic’ melanoma cells suggests they 
express EMT and mesenchymal stem cell associated genes and have migratory properties 
mirroring what is seen in embryonic development where neural crest cells travel along 
external surfaces (Lugassy et al., 2013a; Lugassy et al., 2013b). The angiotropic melanoma cells 
occupy a pericyte location on blood vessels, upregulating the pericyte receptor displaying 
‘pericyte mimicry’ (Lugassy et al., 2013b). Angiotropism has been demonstrated in several 
studies to be a prognostic factor in melanoma spread both locally and to distant metastasis 
(Van Es et al., 2008; Wilmott et al., 2012). This phenomenon of angiotropism and EVMM 
therefore should be considered an alternative mechanism in the metastatic cascade, 
alongside the widely excepted mechanism of cancer cell intravasation in to blood vessels.  
Although the general events and mechanisms by which cancer cells facilitate metastasis is 
shared by most forms of cancer, there are some ways by which uveal melanoma and 
cutaneous melanomas differ in their metastatic spread. The first difference owes to the 
contrasting anatomical location of the melanomas. Cutaneous melanomas must undergo 
epithelial to mesenchymal transition and invade the skins basement membrane for 
progression, whereas uveal melanoma has no such requirement in the uveal layer of the eye 
(Onken et al., 2006). Secondly the absence of lymphatic structures in the eye large enough to 
allow cell passage, means that cutaneous melanoma may spread by both lymphatic’s and 
haematogenously to secondary sites including the lymph nodes, skin, lung, liver, small 
intestine, brain and bone, whereas uveal melanoma may only disseminate haematogenously 
with greatest propensity to metastasise to the liver and rarely to the lung, bone or skin (Yücel 
et al., 2009). 
Why most uveal melanomas metastasise to the liver is unknown, but recently it has become 
clearer that many factors may influence the favouritism of uveal melanoma seeding in the 
liver. The presence of the chemokine receptor CXCR4 and c-Met on the surface of uveal 
melanoma cells are thought to promote uveal melanoma migration to the liver, as the liver 
secrets the respective ligands CXCL12 chemokine and hepatocyte growth factor (HGF). Uveal 
melanoma cells forming small micro metastasis of only a few cells are thought to lie dormant 
within the liver for years before metastatic progression is triggered and the metastasis 
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enlarges and macro metastasises are formed (Ossowski and Aguirre-Ghiso, 2010). It is likely 
that the microenvironment within the liver also plays a key role in determining the progression 
of uveal melanoma metastasis. Stromagenesis occurs in the liver, and involves the activation 
of hepatic stellate cells and the production of extracellular matrix components such as 
collagens, that provide a scaffold for the development of blood vessels during angiogenesis, 
supporting increases in tumour burden (Vidal-Vanaclocha, 2008). Pigment epithelium-derived 
factor (PEDF) is a factor that is secreted from hepatocytes and is a potent inhibitor of 
stromagenesis and angiogenesis. PEDF may be inhibited by hypoxia and degraded by 
metalloproteinases MMP-2/9 which are often secreted from tumour cells, suggesting that 
hypoxic tumour microenvironments can downregulate PEDF and induce a more favourable 
metastatic microenvironment (He et al., 2015). It is thought that the ratio of VEGF:PEDF may 
be key to the angiogenic switch in uveal melanoma liver micro metastases. Uveal melanoma 
cells have been found to express PEDF and overexpression can decrease uveal melanoma 
tumour growth and liver metastasis (Lattier et al., 2013). Similarly using a mouse model of 
uveal melanoma, PEDF-null mice were found to have an increased number of metastases, 
enhanced hepatic stellate cell activity, collagen III production, and greater microvessel 
density, compared to control PEDF producing mice (Lattier et al., 2013). Taken as a whole this 
study illustrates a hypothesis where under normal homeostasis hepatocytes secrete PEDF that 
inhibits angiogenesis. However, in the hypoxic environment of a liver micro metastasis where 
VEGF and MMP’s are produced by tumour cells, PEDF is degraded leading to hepatocyte 
activation, increased production of stroma and blood vessels, leading to metastatic 
progression. This indicates that PEDF may control angiogenesis and stromagenesis in uveal 
melanoma liver metastases and maybe a key regulator of rapid metastatic advancement. 
1.5 The CXCR4-CXCR7-CXCL12 Chemokine Axis 
1.5.1 The Chemokine System and Cancer: CXCR4 
Chemotaxis refers to the process in which cells direct their movement in reaction to a chemical 
stimulus, and in general in response to chemo-attractant chemokines, a group of small 
secreted proteins which act together with their cell surface receptors to control the migration 
of cells during normal processes of immune regulation, tissue maintenance or developmental 
processes. Cancer cells however, acquire the ability to subvert the chemokine system, such 
that these molecules and their receptors become important regulators of cell movement in 
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and out of the tumour microenvironment and hence are major players in the process of 
metastasis. 
 
Figure 1.11 Chemokine Receptor Signalling Pathways Promoting Cell Migration, Growth and 
Survival. 
The G-protein coupled cell surface chemokine receptors belong to class A rhodopsin-like G protein 
coupled seven transmembrane spanning cell surface receptors which homo or heterodimerise on ligand 
binding (Mellado et al., 2001). The dimerised receptor is then internalised via clatherin, dynamin 
dependant or a caveolin dependant routes differential to individual receptors (Kiefer and Siekmann, 
2011). Intracellular signalling is propagated by the release of GDP from the G proteins Gα subunit 
allowing for the association with GTP and allosteric changes in the receptor allowing for signal 
transduction. For the cell to migrate the cell must become polarised with accumulation of PI-3 Kinases, 
Rho GTPases, Rac and Cdc42 at the leading edge causing actin reorganisation, within the trailing edge 
PTEN phosphatase counteracting PI3 Kinase activity allowing for tail retraction (Balkwill, 2012). Further 
downstream signalling pathways include activation of many MAPK pathways including RAS and AKT, 
promoting cell growth, survival and proliferation. The internalised receptor may be degraded or 
recycled back to the cell surface which is dependent on the particular chemokine allowing for 
chemokines to alter the level of receptor expression on the cell (Kiefer and Siekmann, 2011). Taken from 
(O'Hayre et al., 2008). 
 
Chemokines are the largest cytokine superfamily comprising 48 small secreted protein ligands 
that act with their 20 or so cognate G-protein coupled cell surface receptors to activate 
downstream signalling and activation of effectors such as MAPK, PI3K, AKT signalling, integrin 
activation, increased cell adhesion, and polarization of the actin skeleton, resulting in 
directional sensing and cell migration along chemokine gradients (Figure 1.11) (Kaibuchi et al., 
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1999; Serrador et al., 1999; Bajetto et al., 2001; Balkwill, 2012). The chemokine system 
therefore generates ‘cellular highways’ in our bodies by which any cells expressing chemokine 
receptors can home to specific locations in the body to the source of chemokine ligand 
secretion (Zlotnik et al., 2011). 
The chemokine system can be divided into 4 subsets based on their chemokine expression 
patterns and functional roles (Figure 1.12). Homeostatic chemokines are constitutively 
expressed by certain tissues and cells, and are involved in development and normal human 
physiology.  Inflammatory chemokines are induced during inflammation and are involved in 
coordination of immune responses, with viral chemokines enabling pathogens to modulate 
immune responses against them, with atypical chemokines acting as decoys to negatively 
regulate chemokine availability. 
 
Figure 1.12 The Chemokine System.  
The chemokine system is made up of the 4 chemokine receptor groups broadly determined by their 
physiological function and their constitutive ligands. Inflammatory chemokine receptors dominate 
immune responses. Homeostatic chemokine receptors, regulate cell migration during developmental 
processes. Viral chemokine receptors coordinate the immune response during pathogenic responses 
(Seet and McFadden, 2002). Atypical chemokine receptors are often termed ‘decoy’ receptors as they 
dampen chemokine responses by being non responsive in nature (Balkwill, 2012). Taken from (Balkwill, 
2012). 
 
Given cancers evolutionary ability to hijack normal cellular controlled processes for its own 
propagation and the pivotal role of chemokines in tissue homeostasis and cell migration, it is 
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not surprising therefore that the chemokine system plays an integral part in cancer 
progression and metastasis. 
Deregulation of molecular mechanisms in the pathogenesis of cancer results in the 
upregulation of chemokine receptor expression, the most common being CXCR4 which is 
overexpressed in over 20 different cancers including cutaneous and uveal melanoma (Scala et 
al., 2007; Kim et al., 2008). Chemokine receptor expression by cancer cells not only has 
profound effects on the cells ability to migrate, but engagement also leads to internal cell 
signalling that may increase the cells resistance to apoptosis and enhance its proliferation, 
induced in particular by chemokine receptor mediated activation of downstream MAP/ERK 
signalling , demonstrated in many cancers including melanoma (Balkwill, 2004). Anti-apoptotic 
protection has also been seen by chemokine activation of PI3K pathways (Murakami et al., 
2003). 80% of melanoma death mediated by FAS ligand activation can be prevented by prior 
exposure to CCL27 highlighting the ability of chemokines to prevent apoptosis and also aid 
immune evasion (Murakami et al., 2003).  
Although oncogenic changes may be responsible for chemokine receptor up regulation, the 
tumour microenvironment and hypoxia may also play a role. In breast cancer VEGF and 
oestradiol can up regulate CXCR4 expression in an autocrine manner (Bachelder et al., 2002; 
Hall and Korach, 2003). Furthermore, studies in uveal melanoma have shown that both CXCR4 
and  VEGF expression correlates with liver metastasis, which likewise suggests that chemokine 
receptor expression and metastasis is influenced by VEGF with intercalating pathways (Franco 
et al., 2010). Additionally, hypoxic conditions such as those in the tumour microenvironment 
have also been shown to cause CXCR4 upregulation, reinforcing the pivotal role of the tumour 
microenvironment in tumour metastasis (Evemie Schutyser et al., 2007).  
Cunningly, cancer cells often express both the chemokine and its receptor creating autocrine 
loops aiding its survival and progression (Balkwill, 2012). Although it is often presumed that 
autocrine chemokine secretion would have to be reduced at later stages of progression to 
allow directional metastasis, interestingly autocrine mediated secretion of chemokines may 
provide a means through which to facilitate tumour migration and invasion in the absence of 
a strong paracrine chemokine secreting source. It has been shown that under the influence of 
interstitial fluid flow, autocrine secretion of chemokines can cause cell migration in the 
direction of flow, a term conned ‘autologous chemotaxis’. It is hypothesised that interstitial 
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flow alters the concentration of the cancer cell secreted chemokine to create a gradient that 
allows the cell to become polarised and directionally migrate, a concept that has been 
demonstrated in many cancers (Shields et al., 2007; Shah et al., 2015). 
It has long been hypothesised that the immune system has the potential to recognise and 
destroy cancer cells or hinder tumour progression. The amount and type of chemokine 
produced by the tumour can profoundly determine the constituents of inflammation in the 
tumour microenvironment, making a cancer chemokine profile either detrimental or 
beneficial to tumour evolution (Viola et al., 2012)(Figure 1.13). 
 
Figure 1.13 The Role of Tumour Associated Macrophages in Tumour Progression  
Chemokines CCL2 and CCL5 are secreted by tumour cells and recruit monocytes to the tumour 
microenvironment. Here the tumour cells have ability to polarise monocyte differentiation into M1 or 
M2 macrophages, with opposing effects on tumour progression. M1 macrophages secrete IL-12 that 
stimulates a cytotoxic cancer eradicating response. M2 macrophages on the other hand secrete many 
cytokines and chemokines supporting tumour progression. Of note CXCL12 in melanoma supports 
tumour growth, and VEGF secretion promotes angiogenesis. TGF-β, IL-10 and chemokines CCL17, 18 
and 22 secreted by tumours promote immune tolerance promoting the invasion and metastasis of 
melanoma. Adapted from (Fukuda K et al., 2012). 
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Tumour secretion of chemokines including CXCL9,10, or 11 induces innate and adaptive 
immune responses by attracting CXCR3 positive Natural Killer cells, and CD4+/CD8+ tumour 
infiltrating lymphocytes to the microenvironment, which correlates with both better 
prognosis and anti-tumour responses (Villegas et al., 2002; Pan et al., 2006). Pro-inflammatory 
chemokines CCL3, CCL4 and CCL5 also recruit CCR5 expressing immune cells with anti-tumour 
activity (Viola et al., 2012). 
However the majority of infiltrating immune cells are tumour associated macrophages (TAMs) 
also named kuppfer cells if resident in the liver, and are attracted by CCL2 and CCL5 produced 
by both tumour and stromal cells (Figure 1.13)(Talmadge, 2011). Classically activated 
macrophages with a M1 phenotype respond to Th1 helper T cell responses exerting pro-
inflammatory activity and anti-tumoural effects via secretion of reactive oxidative species 
(Kiefer and Siekmann, 2011). Conversely, macrophage colony-stimulating factor (MCSF-1) and 
IL-10 secreted by tumour cells may induce differentiation of monocytes towards M2 
macrophages which appear exclusively in growing tumours, and by suppressing the adaptive 
immune response are equipped to generate a pro-tumorigenic microenvironment (Hagemann 
et al., 2006; Qian and Pollard, 2010). M2 macrophages themselves also secrete chemokines, 
that attract Th2 and T regulatory cells devoid of anti-tumoural cytotoxic action (Balkwill, 
2012). 
In addition to shaping the nature of the inflammatory infiltrate, the chemokine system can 
also directly or indirectly contribute to tumour angiogenesis. Chemokines can promote 
tumour angiogenesis by acting on endothelial cells surrounding the tumour expressing 
chemokine receptors. Chemokines that contain a conserved ELR amino acid motif (ELR+), such 
as CXCL5 and CXCL8 are pro-angiogenic and stimulate CXCR1/CXCR2 receptors on local 
endothelial cells inducing survival and proliferation required for the induction of angiogenesis. 
Although CXCL12 is a chemokine without a conserved ELR amino acid motif (ELR-) which 
typically promotes angiostasis, it nevertheless has potent angiogenic properties and acts on 
CXCR4 receptors on endothelial cells synergistically with VEGF inducing proliferation and cell 
migration (Kryczek et al., 2005). In contrast, Interferon-y induces the expression of CXC 
chemokines lacking the ELR motif and in contrast is highly anti-angiogenic, inhibiting 
endothelial cell proliferation, or secretion of VEGF and FGF (Strieter et al., 1995; Romagnani 
et al., 2001). Due to the opposing effects of ELR+ and ELR- chemokines it is hypothesised that 
angiogenesis may in part be determined by the balance between ELR+ and ELR- chemokine 
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secretion and consequently affects patient outcome (Allavena et al., 2011) (Figure 1.14). 
Indirectly, the chemokine system may further contribute to angiogenesis by the recruitment 
of leukocytes, TAMs, myeloid-derived suppressor cells, dendritic cells to the tumour site that 
release pro-angiogenic factors further contributing to the microenvironment (Lewis and 
Pollard, 2006; Mantovani et al., 2006; Sozzani et al., 2007). 
 
Figure 1.14 The Differing Tumour Outcomes Determined by Chemokine Regulation of 
Angiogenesis.  
Angiogenesis is a result of an imbalance of chemokines favouring overexpression of ELR+ CXC pro-
inflammatory chemokines with lack of ELR- CXC anti-inflammatory chemokines. Low chemokine 
secretion by the tumour may restrict tumour growth. Excessive ELR- CXC chemokines induces 
inflammation and angiostasis where as excessive ELR+ chemokine secretion tips the angiogenic balance 
towards neovascularization and tumour growth. Adapted from (Coussens and Werb, 2002). 
 
However, cancers greatest manipulation of the chemokine system is the up-regulation of 
chemokine receptors enabling tumour migration, a pre-requisite for metastasis. Tumour cells 
preferentially metastasise to specific regions, a concept first coined by Stephen Paget, based 
on his observations that breast cancer preferentially spreads to the liver but not the spleen 
(Paget, 1889). This idea of cancer organ specific metastasis has developed into the ‘seed and 
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soil hypothesis’ which theorises that the destination of metastasis is determined by the cancer 
cell itself (seed) and development of secondary metastasis, also determined by environmental 
conditions at the metastatic site (soil) (Fidler, 2003). One explanation for the ‘seed and soil’ 
hypothesis may lie with the ability of cancer to manipulate the chemokine system, as 
chemokine receptor expression on tumour cells and chemokine gradients generated from 
specific organs may define the organ specific destination of the tumour and the preferential 
site of metastasis. CXCL12, is secreted by lymph nodes, bone marrow, liver and lungs under 
normal physiological processes to attract haematopoietic cells (Nagasawa T, 2000). However 
the upregulation of CXCR4 by melanoma cells generates an attraction towards peak CXCL12 
secreting sites, unsurprisingly the common sites of metastasis (Furusato et al., 2010). More 
recently studies indicate the expression of CXCL12 by liver myofibroblasts promotes the 
migration of CXCR4 tumour cells to the liver and this may be inhibited by use of the CXCR4 
inhibitor AMD-11070 (O'Boyle et al., 2013). 
Given the multifaceted role chemokines play in cancer cell progression, immune evasion, 
angiogenesis and migration, CXCR4 expression may represent a powerful independent 
biomarker in melanoma, in particular given the correlation of high expression in primary 
cutaneous melanomas with tumour ulceration, increased Breslow tumour thickness, and a 
worse prognosis (Longo-Imedio et al., 2005; Scala et al., 2005; Tucci et al., 2007). Further, 
CXCR4 expression in liver metastatic cutaneous melanoma tumours correlates with reduced 
patient survival (Joseph Kim et al., 2006). Interestingly, increased CXCR4 expression in uveal 
melanomas correlates with an epithelioid phenotype, a prognostic indicator of metastasis 
(Scala et al., 2007). Furthermore, CXCR4 expression, both in vitro and in vivo, predisposes the 
migration of uveal melanoma cells towards CXCL12 which may be inhibited by both CXCR4 
inhibitors and RNAi mediated knockdown (Di Cesare et al., 2007a; Li et al., 2008; Li et al., 
2009). Studies therefore suggest that as in cutaneous melanoma, CXCR4 expression in uveal 
melanoma maybe a bad prognostic feature and that uveal melanoma may use the 
CXCR4/CXCL12 chemotaxis axis to mediate organ specific homing to the liver. Although, 
additional factors have been implicated in the preferential homing of uveal melanoma to the 
liver including; hepatocyte growth factor-scatter factor (HGF/SF) (Rusciano D et al., 1993; 
Rusciano et al., 1994; Rusciano et al., 1998), and Insulin like growth factor 1 (IGF-1) secreted 
by the liver (Bakalian et al., 2008), targeting the CXCR4-CXCL12 chemokine axis may 
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nevertheless represent a viable therapeutic strategy through which to prevent the metastasis 
of cutaneous or uveal melanoma. 
1.5.2 CXCR7 
The activation of CXCR4 receptor by its cognate ligand CXCL12 results in the activation of ERK 
and AKT controlling multiple downstream cellular effects such as chemotaxis, proliferation, 
survival and adhesion, hence the CXCR4/CXCL12 axis an attractive anti-tumour target. 
However the maintained binding of CXCL12 to cells without CXCR4 expression, coupled with 
the observation of incomplete cessation of cell chemotaxis towards CXCL12 with use of CXCR4 
inhibitors, highlights the possibility of another CXCL12 binding receptor (Burns et al., 2006). 
Recently this receptor has been identified as CXCR7 or RDC-1 a seven transmembrane protein, 
that binds to CXCL12 with 10 times the affinity of CXCR4 (Balabanian et al., 2005). Additionally 
CXCR7 also binds CXCL11 (I-TAC) chemokine but with much lower affinity (Burns et al., 2006). 
Despite having many features of classical G-protein coupled chemokine receptors, CXCR7 has 
a small alteration in the typical chemokine receptor DRYLAIV motif which is essential for 
recruitment and activation of G proteins and subsequent calcium mobilisation (Thelen and 
Thelen, 2008). This lack of G-protein mediated signalling and inability to induce calcium 
mobilization, leads CXCR7 to be regarded as a ‘decoy’ receptor that, ‘scavenges’ (removal) 
monomeric CXCL12 to dampen, inhibit or regulate CXCR4-CXCL12 signalling (Naumann et al., 
2010). Chemotaxis models in zebra fish have demonstrated CXCR7 mediated scavenging of 
CXCL12 from the extracellular space, internalising bound CXCL12, trafficking it to the lysosome 
for degradation, hence generating a chemokine gradient required for a differential CXCR4 
mediated chemotactic response (Boldajipour et al., 2008). The potent ability of CXCR7 to 
modulate circulating chemokine levels, has been further demonstrated in CXCR7 knock out 
mice, as well as by the use of a CXCR7 inhibitor in vivo, where plasma CXCL12 levels increased 
up to 5 fold (Berahovich et al., 2014). CXCR7’s modulation of circulating CXCL12 levels has also 
been shown to effect leucocyte CXCL12 homing, and so may indirectly modulate tumour 
infiltration (Berahovich et al., 2014). 
Chemokine receptors are known to dimerise and oligomerise depending on the expression 
level of the receptors, with CXCR4 and CXCR7 forming both homo- and hetero-dimers with 
equal efficiency (Levoye et al., 2009). CXCR7 has the ability to modulate CXCR4 G-protein 
signalling, with CXCR4-CXCR7 heterodimers found to enhance CXCL12 induced calcium 
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signalling, and delay ERK activation and cell migration compared to CXCR4 signalling alone 
(Sierro et al., 2007). The co-expression of CXCR7 and CXCR4 has been found to reduce the 
ability of CXCR4 to interact with G proteins, suggesting that there is a shift from G-protein to 
β-arrestin signalling in CXCR4-CXCR7 heterodimers, highlighting CXCR7 as a potential 
modulator CXCR4-CXCL12 signalling (Décaillot et al., 2011a). Further, discoveries demonstrate 
that CXCR7 alone can activate the AKT, PKC and MAP-kinase pathway independent of G-
protein signalling, via β-arrestin recruitment in a ligand dependant manner, suggesting CXCR7 
has functions other than that of a decoy receptor, and which may affect cell proliferation and 
survival (Rajagopal et al., 2010).  
 
Figure 1.15 The CXCL12 Signalling Pathway.  
CXCR4 activation by CXCL12 leads to cell survival, proliferation and cell chemotaxis by activation of cell 
signalling through PI3K/AKT, IP3 and MAPK pathways. CXCR7 signals through β arrestin to internalise 
and sink CXCL12, or in some circumstances signals through AKT, PLC/MAPK to promote cell survival, 
proliferation, adhesion and chemotaxis of CXCR4 negative cells (Wang et al., 2008b). 
Heterodimerisation of CXCR4 and CXCR7 is thought to recruit β arrestin and induce conformational 
rearrangements to the CXCR4/G-protein complex abrogating CXCR4 cell signalling. Taken from (Duda 
et al., 2011). 
 
Given the large influence the chemokine system plays in tumourigenesis and metastasis and 
the newly identified biological functions of CXCR7, efforts have been made to elute the role 
of CXCR7 in cancer. CXCR7 is expressed in normal human tissues and commonly restricted to 
vascular endothelial cells of the kidney, heart, brain, lung, thyroid and spleen, however CXCR7 
may be upregulated by many cancer cells including breast, lung, prostate and glioma, 
suggesting an advantageous role in tumorigenesis (Burns et al., 2006; Miao et al., 2007; Wang 
et al., 2008b; Berahovich et al., 2014). In support of this, the tumour suppressor gene, 
hypermethylated in cancer 1 (HIC1) supresses CXCR7 expression, consistent with CXCR7 
upregulation during tumourigenesis (Van Rechem et al., 2009). Further, a role of CXCR7 in 
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cancer growth and survival has been demonstrated in breast cancer, where tumour cells 
overexpressing CXCR7, proliferated more rapidly into larger tumours than control cells, and in 
lung cancer where the use of a CXCR7 inhibitor reduced tumour growth (Décaillot et al., 
2011b; Hernandez et al., 2011). In prostate cancer, CXCR7 is highly expressed and correlates 
with disease aggressiveness, associated with increased cell proliferation, adhesion and 
migration, suggesting CXCR7 expression may be of prognostic value in some cancers (Wang et 
al., 2008b). CXCR7 has also been postulated to have a role in differentiation demonstrated by 
exclusive CXCR7 expression in mature and differentiated glioblastomas or neuroblastomas 
(Hattermann et al., 2010; Liberman et al., 2012). Interestingly, it has been reported that 
melanoblast cell migration is determined by CXCL12-CXCR4 signalling however mature 
melanocytes express both CXCR4 and CXCR7 receptors and migrate, signalling via CXCR7 and 
β-arrestin-MAPK pathways, suggesting a switch between receptor function during 
differentiation (Belmadani et al., 2009; Lee et al., 2013). In general, accumulating evidence 
proposes CXCR7 and CXCR4 may have differential functions where CXCR7 signalling is 
associated with increased cell adhesion and survival and CXCR4 determines cell migration 
enhancing cancer metastasis, although co-expression of both receptors has also 
demonstrated contradictory effects including reduced invasiveness and metastasis (Mazzinghi 
et al., 2008; Levoye et al., 2009; Décaillot et al., 2011a). 
Although there have been no reports of CXCR7 expression by melanoma tumour cells, notably 
CXCR7 is highly expressed by most tumour associated blood vessels including in melanoma 
and hence, proposed as a marker for tumour vasculature (Sánchez-Martín et al., 2011a). 
CXCR7 expression on tumour endothelial cells is upregulated by hypoxia (HIF-1α induction) 
and by factors secreted in the immediate tumour microenvironment, including VEGF and 
CXCL8 (Maksym et al., 2009b). Interestingly, in prostate cancer CXCR7 has been shown to 
increase the secretion of angiogenic factors such as VEGF and IL-8 and its overexpression has 
resulted in higher density of neovessels in tumours (Wang et al., 2008b). It has also been 
demonstrated that CXCR7 expression on endothelial cells results in the redistribution of 
platelet endothelial cell adhesion molecule-1 (PECAM-1) altering endothelial cell barrier 
function, hence effecting vascular homeostasis (Totonchy et al., 2014). Paradoxically, CXCR4-
CXCL12 signalling by endothelial cells has been demonstrated to supress endothelial 
permeability (Kobayashi et al., 2014). Overall this suggests a role of CXCR7 in tumour 
angiogenesis and highlights CXCR7 as a possible anti-angiogenic therapeutic target, however 
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it must be noted that a direct link between CXCR7 expression and stimulation of endothelial 
cell chemotaxis has not yet been established. 
It is likely that the role of CXCR7 in cancer maybe dynamic, differing between tumour types, 
cells within tumours, stages of progression or expression by tumour associated vasculature. It 
is clear the distinct or intercalating roles of CXCR4 and CXCR7 are yet to be established in 
melanoma. Given the potential contribution of the CXCL12-CXCR7 axis to processes that were 
previously thought to be monogamously CXCL12-CXCR4 driven, CXCR7 expression deserves 
some consideration.  
1.5.3 CXCL12 
Chemokines are small 7-12 kDa chemoattractant peptides, that have 4 conserved cysteine 
residues that form 2 disulphide bonds, classified into 4 subfamilies, CXC, CC, CX3C and C, based 
on the arrangement of the first 2 cysteine’s (where X is any amino acid). The CXC chemokine 
ligand CXCL12 also named stromal cell derived factor-1 (SDF-1) or pre-B cell growth 
stimulating factor (PBSF), is constitutively expressed by bone marrow cells, and binds to the 
G-protein coupled chemokine receptors CXCR4, CXCR7 and glycosaminoglycans. CXCL12 is 
expressed by many different tissues and organs including lymph nodes, liver and lungs, 
attracting CXCR4 expressing cells. CXCL12 exists in 2 isoforms generated by alternative splicing 
of the single CXCL12 gene on chromosome 10, generating an 89 amino acid CXCL12α peptide 
or a CXCL12β peptide with 4 additional  amino acids at its carboxy terminal end (Kryczek et al., 
2007). In our bodies CXCL12 exists in a monomer-dimer equilibrium, of which both states have 
been shown to activate CXCR4 (Veldkamp et al., 2005). Interestingly, the half-life of CXCL12 is 
only minutes, as the ligand may be degraded by numerous biological enzymes including matrix 
metallioproteinase-2 (MMP-2) (McQuibban et al., 2001). 
CXCL12 was the first chemokine demonstrated to be critical for development processes, with 
CXCL12/CXCR4 knock out mice having deficient hematopoiesis, cardiogenesis, vascular 
formation and neurogenesis precluding embryonic viability (Nagasawa et al., 1996; Ma et al., 
1998; Tachibana et al., 1998; Zou et al., 1998). CXCL12 is a strong chemoattractant for 
immature hematopoietic stem cells and progenitor cells, and has been shown to be critical for 
their embryonic migration and homing to bone marrow during ontogeny (Ara et al., 2003). 
Importantly CXCL12 also plays a key role in immune cell regulation, promoting B cell precursor 
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proliferation and migration of mature B cells and plasma cells to the bone marrow (Tokoyoda 
et al., 2004).  
Although the physiological function of CXCL12 during development is well established, its role 
within skin is much less well defined. In normal skin CXCL12 is documented to be present in 
the basal layer of epidermis, papillary dermis, small capillary vessels of the sub papillary plexus 
,endothelial layer of blood vessels, pericytes, fibrous sheath of hair follicles, sweat glands, 
mature sebocytes, axons, and small blood vessels in nerve tissue (Pablos et al., 1999; Avniel 
et al., 2006). Keratinocytes and dermal fibroblasts however, are not believed to express 
CXCL12 under normal physiological conditions, but may display increased expression in 
inflamed and wounded skin with dermal fibroblasts additionally reported to secrete CXCL12 
under stress during hypoxia, irradiation and burns (Avniel et al., 2006). It is postulated that 
CXCL12 in injured skin promotes the attraction of immune cells to the damage site including 
epidermal stem cells, encouraging the re-epithelialisation of the epidermis (Guo et al., 2015). 
Further, the CXCL12 gradient generated between the epidermis and dermal skin layers 
promotes epidermal mature Langerhans cells (highly CXCR4 positive) to migrate into the 
dermis for effective antigen presentation in the immune response to injured skin (Ouwehand 
et al., 2008). 
Though it is well established that the secretion of CXCL12 by endothelial cells, fibroblasts, and 
osteoblasts in organs determines the migration and specific metastasis of CXCR4 positive 
cancer cells, the role of CXCL12 in the primary tumours remains poorly understood. Tumoural 
expression of CXCL12 has been documented in a plethora of cancers including prostate, breast 
and pancreatic cancer (Koshiba et al., 2000; Bachelder et al., 2002; Darash-Yahana et al., 
2004). In breast and prostate cancer CXCL12 expression has been strongly correlated with 
lymph and bone marrow metastasis, and for which secretion of CXCL12 by tumour stromal 
fibroblasts is reported to contribute to primary tumour vascularisation or transformation 
(Muller et al., 2001a; Taichman et al., 2002; Orimo et al., 2005). Hypoxia is thought to be a 
common trigger of CXCL12 upregulation by cancer cells, via induction of hypoxia inducible 
factor (HIF-1) of which there are 2 potential binding sites in the promoter region of the CXCL12 
gene. There is evidence that CXCL12 has the ability to transduce tumour cell proliferation 
through activation of AKT and ERK cell signalling pathways in many cancers (Julie and Kenneth, 
2003; Marchesi et al., 2004). Furthermore, CXCL12 has also been reported to regulate tumour 
cell apoptosis through activation of anti-apoptotic pathways, such as activation of NF-κB 
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signalling, or indirectly by activating integrins such as integrin α4, resulting in increased 
tumour cell adherence, and preventing chemotherapy induced death (Helbig et al., 2003; 
Hartmann et al., 2005). Tumoural CXCL12 secretion may also facilitate the escape of tumour 
cells from immune surveillance since CXCL12 is able to recruit CXCR4+CD4+ T regulatory cells 
from the bone marrow (Zou et al., 2004b). However, some beneficial effects of CXCL12 in the 
tumour microenvironment are perceived by the recruitment of CXCR4+ cytotoxic T cells that 
promote tumour immunity (Zhang et al., 2005). The greatest effects of CXCL12 in cancer are 
most frequently demonstrated during the process of metastasis. CXCL12 can encourage the 
dissemination of cancer cells from the primary site or deeper invasion not only by CXCR4-
CXCL12 chemotaxis but through CXCL12 induction of metalloproteases, enzymes that degrade 
the extracellular matrix assisting in the migration of cancer cells (Figure 1.16) (Burger et al., 
2003; Singh et al., 2004). Given that many cancer cells express CXCR4 and upregulate the 
secretion of CXCL12 or have CXCL12 expressed in the tumoural microenvironment, logic 
suggests that the expression of both CXCR4 and CXCL12 would retain tumour cells at the 
primary site. However, CXCL12 isn’t always expressed throughout the whole tumour (Kryczek 
et al., 2007), and tumour cells may nevertheless become sensitised to CXCL12 in the local 
environment, thereby preventing such retention. Another explanation maybe that cancer cells 
may become desensitised to CXCL12 in the local environment. Cancer cells can regulate their 
sensitivity to CXCL12 by modulating their expression of CD26 or dipeptidyl peptidase IV 
(DPPIV) an extracellular peptidase (Kryczek et al., 2007). The absence of CD26 leads to 
increased homing of HSCs towards CXCL12 gradients (increased sensitivity) (Christopherson 
et al., 2004). CD26 is expressed on endothelial cells but is often lost by cancer cells, yet can be 
upregulated in response to hypoxia (Wesley et al., 2004; Wesley et al., 2005). The presence of 
CD26 by tumour cells in response to hypoxia could desensitise them to local CXCL12 thereby 
aiding movement from the CXCL12 rich primary site. Overall, the effects of CXCL12 on tumour 
proliferation, survival, angiogenesis, immunity, and organ specific metastasis suggest that 
CXCL12 in the tumour microenvironment is a detrimental effect and hence maybe a viable 
therapeutic target. 
In the context of melanoma, the role of CXCL12 in tumourigenesis has yet to be fully 
elucidated. The largest immunohistochemical study of CXCL12 expression in 107 primary 
cutaneous melanomas suggested lack the of CXCL12 tumoural expression as a poor prognostic 
indicator (Mitchell et al., 2014). A further small study demonstrated a positive correlation 
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between CXCR4 expression and CXCL12, however this was contradicted by a larger study in 
which no such correlation or any association with CXCL12 expression and tumour B-RAF 
mutational status  was observed (Toyozawa et al., 2012). Moreover, this contradicts the 
findings of an interesting study where the induced expression of mutated B-RAF V600E in wild-
type melanoma cells enhanced the secretion of cytokines IL-1β, IL-6 and IL-8 and MMP-1, and 
in which the derived supernatants promoted the secretion of CXCL12 in dermal fibroblasts, 
suggesting a link between melanoma mutational status and CXCL12 secretion by dermal 
fibroblasts (Whipple and Brinckerhoff, 2014). 
 
Figure 1.16 Effects of CXCR4 and CXCL12 within the Tumour Microenvironment 
Hypoxic areas of solid tumours induce the expression of CXCR4 on tumour cells and CXCL12 secreted 
from fibroblast stimulating tumour progression. CXCL12 stimulates tumour growth by activating CXCR4 
on tumour cells, and angiogenesis by recruiting endothelial progenitor cells to the tumour 
microenvironment. CXCR4 positive tumour cells hijack the CXCR4-CXCL12 migratory path used by 
haematopoietic progenitor cells and travel to CXCL12 secreting sites such as the bone marrow, where 
they invade into tissues forming a secondary metastasis (Burger and Kipps, 2006). 
 
In terms of uveal melanoma, studies of CXCL12 expression are limited with just one study 
reporting expression in 27% of primary tumours, and the expression of the chemokines 
CXCL19 and CXCL21 which bind to CCR7, the predominantly expressed chemokine receptor 
(Dobner et al., 2012). Nevertheless, the eye is likely a CXCL12 rich environment with 
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documented expression of CXCL12 within the retina (Crane et al., 2000; Hasegawa et al., 2008; 
Lai et al., 2008; Otsuka et al., 2010). How such expression may affect uveal melanoma 
tumorigenesis, or the interplay of tumour cells with the stroma within the eye is unknown. 
Given the perceived diverse role of CXCL12 within tumours and the immediate 
microenvironment, a defined role of CXCL12 expression in both cutaneous and uveal 
melanoma progression, or use as a prognostic indicator is not fully established. 
1.6 Angiogenesis and Vascular Endothelial Growth Factor Signalling 
1.6.1 The Role of VEGF and Receptors in Angiogenesis 
Tumour invasion alone aids local tumour spread but angiogenesis is an important prerequisite 
for tumour growth, deeper invasion and distant melanoma metastasis. Angiogenesis is the 
term applied to describe the formation of new blood vessels from existing vessels and is 
essential for oxygen, nutrient and growth factor supply, and for the removal of waste 
metabolic products from the growing tumour, subsequently aiding its metastasis (Hanahan 
and Weinberg, 2011). Briefly angiogenesis involves the induction of vessel sprouting by 
endothelial cell proliferation and migration, with eventual formation into tubular structures 
and maturation of new functional vessels (Figure 1.17) (Hicklin and Ellis, 2005). Although this 
is the traditional ‘sprouting’ mechanism of angiogenesis, in melanoma it is now recognised 
that angiogenesis may occur by additional mechanisms (Pastushenko et al., 2014b). Concisely 
these involve intussusceptive angiogenesis where an interstitial column is inserted into a pre-
existing vessels lumen, vascular co-option where tumour cells migrate along existing vessels, 
mosaic vessels where melanoma cells become part of the vessel walls, vasculogenic mimicry 
where the melanoma cells upregulate endothelium associated genes and form vascular like 
networks, and finally bone marrow derived vasculogenesis where tumour cells recruit 
endothelial progenitors from bone marrow to form vessel walls (Pastushenko et al., 2014b). 
The process of angiogenesis is thought to be regulated by a similar set of oncogenic mutations 
that drive melanoma progression, including abnormal cell signalling of MAPK, PI3K, NFκB 
pathways and generation of reactive oxygen species all of which have been shown to enhance 
the secretion of pro-angiogenic and principally vascular endothelial growth factor (VEGF) 
(Arbiser et al., 1997; Amiri and Richmond, 2005; Pastushenko et al., 2014b).  
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Figure 1.17 Sprouting Angiogenesis 
There are 4 major sequential steps of angiogenesis that turn a vascular sprout from a pre-existing vessel 
into a mature vessel supplying blood. (1) Sprouting: Pro-angiogenic stimuli (e.g VEGF) initiates 
sprouting and induces quiescent endothelial cells to proliferate and migrate. There are two types of 
activated endothelial cells, tip cells that are located at the head of the sprout and are more migratory 
and stalk cells that elongate and proliferate rapidly causing sprouting. In response to angiogenic stimuli 
pericytes detach from the endothelium and migrate through the basement membrane. (2) Tube 
Morphogenesis: After migrating from the original vessel the stalk cells form vacuoles by pinocytosis, 
which conjoin with each other to form an interstitial vessel column. (3) Adaptation: The endothelial 
tubes will then regress or go on to mature into permanent vessels. The decision is mediated by pro-
angiogenic factors. If the pro-angiogenic stimuli are lost the endothelial tubes will dismantle and the 
cells die. Maintained pro-angiogenic and growth factor stimuli the vessel will be sustained. (4) 
Maturation: Endothelial cells cease proliferation and become quiescent once more. Circulatory 
anastomosis provide the new vessel with a blood supply. Tight junctions form and pericytes encase the 
new vessel providing pro-survival signals to maintain homeostasis of the endothelial cells. (Taken from 
(Irvin et al., 2014)). 
 
Angiogenesis is tightly regulated by the opposing balance between pro- and anti-angiogenic 
factors. It is thought that dysregulation in this balance, favouring pro-angiogenesis factors 
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within the tumour microenvironment causes an “angiogenic switch” and the evolution of a 
phenotype characteristic of the metastatic disease (Hanahan and Weinberg, 2011). Pro-
angiogenic regulators include VEGF, basic fibroblast growth factor (bFGF), placental like 
growth factor (PLGF), angioprotein-2, angiogenin, interleukin-8 and endostatin, with VEGF 
signalling a key factor to cancer progression. 
The VEGF family consists of 5 secreted angiogenic and lymphangiogenic glycoprotein ligands 
VEGF A, B, C, D and placental growth factor (PIGF). VEGF A is the most characterised ligand 
and exists in seven pro-angiogenic  isoforms and five anti-angiogenic isoforms as a result of 
alternative RNA splicing, with the VEGF 165 predominantly secreted by cancer cells and 
infiltrating immune cells (Ferrara and Davis-Smyth, 1997). VEGF C and D are synthesised as 
precursor proteins with long N and C terminal pro-peptides that are removed under 
proteolytic cleavage by pro-peptidases to their mature forms. The ligands bind and activate 3 
class III receptor tyrosine kinases with different specifics and functions termed VEGF receptor 
1, 2, 3 (VEGFR1, 2, 3) (Figure 1.18). VEGF binds with greatest affinity to VEGFR1 with nearly 10 
fold greater affinity than to VEGFR2, however the complex has weak tyrosine kinase activity 
with strongest intercellular signalling response mediated by VEGFR2 (Koch and Claesson-
Welsh, 2012). VEGFR1 can also exist as a soluble isoform that can act like a decoy receptor 
sequestering VEGF in the local environment, and so may in part regulate VEGFR signalling 
(Marika J Karkkainen and Petrova, 2000). 
VEGFR2 exists in an immature form located intracellularly within the golgi apparatus and 
translocates to the endoplasmic reticulum where it undergoes N-linked glycosylation in a 
secretory pathway to produce a fully mature form, before transport to the plasma membrane. 
When ligand activates the VEGF receptor the receptor undergoes conformational changes 
that include homo or hetero-dimerisation exposing the tyrosine kinases ATP binding site. 
Trans-autophosphorylation of the tyrosine kinase site generates a docking site for SH2- 
domain adaptor molecules and activation of downstream signalling cascades. Inactivation of 
the receptor is under the strict control and mediated by ubiquitination, followed by receptor 
internalisation, dephosphorylation and degradation by protein tyrosine phosphatases. 
VEGFR2 becomes ubiquitinated after activation and is internalised into early endosomes, 
where it may be recycled back to the plasma membrane or cleaved of its C-terminus before 
trafficking to late endosomes where it will undergo lysosomal processing and terminal 
degradation. Interestingly VEGFR2 is able to continue to transduce cell signalling cascades 
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once internalised until it is committed to either a recycling or degradation pathway (Murdaca 
et al., 2004). VEGF receptor cell signalling may also be modulated in part by the promiscuous 
interactions of VEGF with other receptors including MET receptor or by VEGF mediated 
activation of additional receptors such as neuropilin receptor 2 (Cao et al., 2012; Lu et al., 
2012).  
 
Figure 1.18 Vascular Endothelial Growth Factor Ligands and Receptors 
The five mammalian VEGF ligands have specific receptor binding specificities. VEGF-B and Placental 
growth factor bind exclusively to VEGF receptor 1. VEGF-A binds to both VEGF receptors 1 and 2, and 
can form heterodimers with PGF also activating VEGFR2 (Ellis and Hicklin, 2008b). VEGF-C and D bind 
VEGF receptor 3 and after proteolytic cleave may bind VEGF receptor 2 additionally (Ellis and Hicklin, 
2008b). VEGF signalling can cause many functional changes in endothelial cells. VEGF can promote 
vascular permeability by inducing endothelial fenestrations, opening junctions between adjacent 
endothelial cells and recruitment of vesicovascuolar organelles (Hicklin and Ellis, 2005). Endothelial cell 
proliferation is induced by activation of mitogen activated protein kinases, and cell survival via 
induction of PI3K/AKT, Bcl-2, surviving, XIAP or inhibition of caspases (Hicklin and Ellis, 2005). Migration 
of endothelial cells occurs by activation of FAK, P38 and nitric oxide, with invasion promoted by 
initiation of metalloproteinase secretion (Hicklin and Ellis, 2005). Adapted from (Veena Shankaran, 
2008). 
 
VEGF secreted from cancer cells or host stromal cells mediates angiogenesis in a number of 
different ways through stimulation of its cognate receptors expressed by local endothelial 
cells, lymphatic endothelial cells or haematopoietic cells. A key microenvironmental regulator 
of VEGF expression is oxygen deprivation, that activates the hypoxia inducible factor-1 (HIF-1) 
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(Iliopoulos et al., 1996). In hypoxic conditions such as in the avascular core of solid tumours, 
HIF-1α and HIF-β are not degraded by the ubiquitin proteasome pathway, leading to their 
dimerization and translocation to the VEGF promoter, increasing VEGF transcription as a 
tumour survival mechanism (Iliopoulos et al., 1996).  
One of VEGF’s most prominent angiogenic features is its potent ability to increase local 
microvascular permeability which is thought to be mediated by induction of vesicovascular 
organelles, endothelial fenestrations, or by the opening of inter-endothelial cell junctions 
(Ferrara, 1999; Dvorak, 2002). VEGF further promotes angiogenesis by inducing local 
endothelial cell migration, by inducing genes involved in integrin expression and cell 
cytoskeleton changes aiding cell movement (Dvorak, 2002). The migration of endothelial cells 
through the basement membrane is further aided by the ability of VEGF to induce 
metalloproteinases and serine proteases secretion, important in the degradation process of 
the extracellular matrix (Zachary and Gliki, 2001). Further, an important feature of 
angiogenesis is the promotion of endothelial cell survival and proliferation mediated by VEGF 
dependent activation of key signalling mechanisms including PI3K-Akt signalling, upregulation 
of anti-apoptotic BCL-2 family protein bcl-2, and inhibitors of apoptosis  proteins, survivin and 
XIAP (Zachary and Gliki, 2001). 
In addition to stimulating angiogenesis, VEGF-C and D secreted from cancer cells are thought 
to induce lymphangiogenesis (lymphatic endothelial proliferation), as a way to expand the 
lymphatics and make a more favourable pre-metastatic niche for cancer cell arrival, enhancing 
the likelihood of distant metastasis (Hirakawa et al., 2005; Harrell et al., 2007; Hirakawa et al., 
2007). This maybe particularly evident in melanoma, as high rates of lymphangiogenesis are a 
biomarker for sentinel node metastasis (Dadras et al., 2005). 
In addition to the effect VEGF has on endothelial cells, many more cell types are affected by 
VEGF signalling within the immediate tumour microenvironment. Notably immune cells may 
express VEGF receptors and respond to VEGF, of particular importance are T regulatory cells 
that supress anti-tumour immune responses (Hansen et al., 2012). Macrophages and stromal 
fibroblasts both secrete VEGF and their presence in the tumour microenvironment may 
contribute to angiogenesis (Galdiero et al., 2013). 
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1.6.2 VEGF and Receptor Expression in Melanoma 
As cutaneous and uveal melanomas are highly vascularised cancers, the VEGF ligand and 
receptor axis forms a critical angiogenic pathway. It has been demonstrated that angiogenesis 
is often induced early in melanoma tumour development and in tumours over 1mm3 in size 
require angiogenesis to avoid hypoxia (Folkman, 1971). In cutaneous melanoma increased 
secretion of pro-angiogenic regulators are evident in the serum of patients, and have been 
correlated with shorter progression free survival and lower overall survival (Donnini et al., 
1999; Ugurel et al., 2001; Kurschat et al., 2007; Helfrich et al., 2009). Immunohistochemical 
studies have additionally shown VEGF secretion by 20-70% of primary cutaneous melanomas, 
with expression correlating with transition from radial to vertical growth indicating 
angiogenesis as an essential step of melanoma progression (Erhard H et al., 1997; Potti A et 
al., 2003). 
The clinical progression of uveal melanomas is often slower than for cutaneous melanomas 
with metastasis developing  even 10 years after primary tumour treatment, suggesting a 
period of disease dormancy (el Filali et al., 2010). The rate limiting step in uveal melanoma 
metastasis is often the development of tumour vasculature, so it is possible that the 
angiogenic switch is required for the haematological dissemination and the development of 
metastasis. Needless to say the angiogenic profile of uveal melanoma has therefore attracted 
a lot of attention owing to in part to the capillary rich tissue in which uveal melanoma develops 
(Notting et al., 2006). Studies have demonstrated primary uveal melanomas harbour areas of 
high vascular density and tumour growth within the lumen of tumour associated blood vessels 
correlating with poor prognosis (Foss et al., 1996; Mäkitie et al., 1999; Ly et al., 2010). VEGF-
A levels are also elevated in the serum, aqueous and vitreous humour of the eyes in uveal 
melanoma patients, correlating with patient survival, and tumour size (Sheidow et al., 2000; 
el Filali et al., 2010). Interestingly, two studies have shown that VEGF levels are raised in 
patients only when metastasis develops, and in a murine uveal melanoma model VEGF A 
serum concentrations correlated with metastatic frequency and lower survival, further 
supporting the role of VEGF in the dissemination of metastatic disease (Boyd et al., 2002a; 
Missotten et al., 2006; el Filali et al., 2010; Barak et al., 2011; Crosby et al., 2011a). 
Of equal importance in angiogenesis is VEGF receptor expression. It is well known that VEGF 
stimulates VEGF receptors on tumour endothelium in a paracrine fashion, but more recently 
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accumulating evidence suggests VEGF secretion can also act in an autocrine manner 
stimulating VEGF receptors on the surface of tumour cells themselves (Lacal et al., 2000). 
Microarray tissue studies have additionally revealed the secretion of VEGF and expression of 
all 3 VEGF receptors by melanomas, with greater VEGFR2 expression detected in metastatic 
compared to primary cutaneous melanomas (Mehnert et al., 2010). Cutaneous melanomas 
expressing high levels of VEGFR2 also demonstrate increased propensity to invade, with 
inhibition of VEGFR1 receptors reducing melanoma growth by 90%, thus supporting an 
autocrine role for VEGF signalling, in the promotion of tumour growth and invasion (Pedro 
Miguel Lacal et al., 2005; Frank et al., 2011). In addition studies have shown that tumours may 
use VEGF signalling to promote their survival as evidenced by the secretion of VEGF from VEGF 
receptor expressing tumour cells and the induction of  MAPK dependant survival (Graells et 
al., 2004). Interestingly, a recent paper has also shown that uveal melanoma cell lines not only 
express an active VEGF receptor (VEGF-R2) but they also secrete VEGF-A, postulating that 
uveal melanomas also use autocrine VEGF cell signalling in the same way as cutaneous 
melanomas (Patrick Logan et al., 2013). Collectively these data provide evidence for an 
extended role of VEGF beyond angiogenesis and its contribution to metastatic progression 
and the potentiation of tumour survival, through the induction of MAPK signalling. This 
hypothesis predicts a vicious circle where by aberrant MAPK signalling characteristic of both 
cutaneous and uveal melanoma, drives VEGF secretion which in an autocrine manor, further 
potentiates MAPK hyperactivity, cell proliferation, survival, angiogenesis and metastasis, 
making VEGF signalling both tumour driving and tumour driven. Thus there is a strong 
biological rational for targeted VEGF and VEGFR2 inhibition as a therapeutic strategy for both 
cutaneous and uveal melanomas. 
1.6.3 Anti-angiogenesis Therapy in Melanoma 
Based on the importance of angiogenesis in local and metastatic tumour development, anti-
angiogenic therapies have been trailed in both cutaneous and uveal melanomas. The premise 
for this therapeutic approach is to prevent tumour growth and metastasis by inhibiting new 
blood vessel formation, starving tumours of nutrients, oxygen and growth factors required for 
survival, growth and metastasis. Current therapeutic strategies involve prevention of all 
isoforms of VEGF binding to its receptor by use of monoclonal anti-VEGF antibodies, or 
inhibition of VEGF receptor signalling by use of tyrosine kinase inhibitors (Figure 1.19). So far 
bevacizumab a humanised monoclonal antibody targeting VEGF and tyrosine kinase inhibitors 
Introduction 
52 
 
with selectivity for VEGF receptors sorafenib and sunitinib are U.S.A food and drug 
administration (FDA) approved for clinical use in melanoma. 
Initial studies with Bevacizumab administered as a monotherapy in cutaneous melanoma 
patients, only resulted in disease stabilisation in a quarter of patients, with effects deemed 
only modest, however in combination with cytotoxic chemotherapy, more favourable results 
have been demonstrated (Varker et al., 2007a). Phase II trials of combined bevacizumab, 
carboplatin and paclitaxel have shown a trend for improved survival (Perez et al., 2009). A 
phase III trial of bevacizumab in combination with nanoparticle albumin bound paclitaxel as a 
first line therapy for metastatic cutaneous melanoma demonstrated a 12 month survival rates 
in 83% of patients (P. Boasberg et al., 2009). The apparent improvement in anti-tumour 
activity of cytotoxics in combination with bevacizumab is thought to be due to the reversal of 
the cytotoxics induction of pro-survival VEGF secretion and bevacizumab’s normalisation of 
tumour vasculature from the chaotic hyper-permeable vasculature that often hinders 
cytotoxic drug delivery (Jain, 2001). In the case of uveal melanoma, bevacizumab has also 
shown efficacy to reduce primary tumour size and the number of micro metastasis, in models, 
resulting in current clinical trials of intra-vitreal bevacizumab injections, and a phase II trial in 
combination with temozolomide (Hua Yang et al., 2010; Piperno-Neumann S et al., 2012). In 
addition the decoy VEGF receptor drug aflibercept (VEGF Trap, an antibody with a VEGF-A 
binding domain of VEGFR1 and 2 fused to a Fc domain) has been used in a phase II trial of 
cutaneous and uveal melanoma patients with stage III/VIII inoperable melanoma, in which 4 
months progression free survival was observed in 50% of uveal melanoma patients (Tarhini et 
al., 2011), and further supporting the use of anti-angiogenesis therapies to treat uveal 
melanoma. 
Despite initially promising results targeting VEGF ligand with bevacizumab, this has had no 
effect on improving overall survival for patients with metastatic melanoma, leading to studies 
focusing on targeting VEGF receptors mainly with tyrosine kinase inhibitors. Tyrosine kinase 
inhibitors are a particularly attractive modality for inhibition of VEGF signalling, preventing 
signal transduction of VEGF receptors on tumour blood vessel endothelial membrane and 
tumour cells themselves. While some inhibitors are highly specific others display multiple 
tyrosine kinase specificity affecting numerous signalling pathways concurrently. Sorafenib 
originally developed as a B-RAF inhibitor, selectively inhibits VEGFR2,3 with some specificity 
for platelet derived growth factor receptor. Unfortunately sorafenib has proved of little value 
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for melanoma care either as a monotherapy or in combination with cytotoxics as first or 
second line treatment (Eisen et al., 2006; Hauschild et al., 2009).  
Pazopanib (GSK GW786034) is a novel second generation receptor tyrosine kinase inhibitor 
which targets many angiogenic pathways including VEGF receptors 1, 2, 3, PDGF receptors α 
and β, and c-KIT, demonstrating anti-angiogenic activity in vivo in many types of tumours and 
greater potency than sunitinib or sorafenib, and with fewer serious side effects (Podar et al., 
2006). The additional kinase targets of pazopanib may also afford bonus therapeutic benefits, 
for example through its ability to inhibit PDGF receptors it may have display the additional 
anti-angiogenic function of disassociating pericytes from tumour vascular rendering the 
vascular endothelial cells more sensitive to therapy without the protective cover from 
pericytes (Bergers and Hanahan, 2008). The additional potential for pazopanib to inhibit c-KIT, 
may also be advantageous, given 28% of melanomas that arise from acral, mucosal or 
chronically sun damaged sites exhibit amplification or mutations in KIT receptor tyrosine 
kinase (Becker et al., 2007). Furthermore, pazopanib has been shown to significantly improve 
progression free survival in metastatic renal cell cancer and soft tissue sarcoma culminating in 
its approval as monotherapy in the U.S.A, and its continued presence in many ongoing trials 
for a variety of tumour types and combinations (van der Graaf et al.; Sternberg et al., 2010). 
 
Figure 1.19 The VEGF Receptor and Ligand System and Current Anti-angiogenic Therapeutic 
Strategies. 
Tyrosine kinase inhibitor (TKI). Platelet derived growth factor and receptor (PDGF and PDGFR). Adapted 
from (Nazer et al., 2011). 
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Pazopanib has also recently been identified as having potential clinical value in the treatment 
of melanoma, evidenced by observations of inhibited tumour cell growth in vitro in addition 
to its anti-angiogenic effect (Gril et al., 2011).  
An unbiased combinational drug screen of 108 targeted therapies on 36 melanoma cell lines 
identified specific synergy between VEGFR2/PDGFR inhibitors and B-RAF/MEK inhibitors in B-
RAF mutated cell lines (Friedman et al., 2015). This study demonstrated increased sensitivity 
of PLX4270 (a B-RAF-V600E inhibitor) intrinsically resistant melanoma cell lines to combined 
treatment with cediranib (VEGFR2/PDGFR inhibitor) and PLX4720, an effect that was 
replicated with MEK inhibition both in vitro and in vivo (Friedman et al., 2015). This study also 
reported the elevated expression of VEGFR2 as a predictive marker of poor B-RAF/MEK 
inhibitor response, highlighting possible crosstalk between MAPK cell signalling and VEGFR2 
expression. Additionally other, studies have demonstrated that cutaneous melanoma cell lines 
bearing a B-RAF mutation are more sensitive than N-Ras mutated melanoma cells to 
treatment with pazopanib, with mutational status correlating with anti-angiogenic activity 
(Gril et al., 2011). Moreover, both studies suggest that B-RAF status may affect pazopanib 
sensitivity in melanoma, further highlighting the association between MAPK signalling and 
angiogenesis. Given the cross talk of both VEGF and MAPK signalling pathways in survival, 
growth, angiogenesis and chemotaxis of melanoma, it therefore maybe more applicable to 
modulate VEGF receptor activity with pazopanib in concert with targeting other VEGF 
promoting pathways such as the MAPK signalling by use of the MEK inhibitor trametinib, as a 
more efficient means through which to hamper cutaneous and uveal melanoma at both 
primary and metastatic sites. Nevertheless, such approaches may also require the 
investigation of crosstalk with other cell signalling mechanisms that may impair the efficacy of 
such combined approaches, including autophagy, which is well documented to be induced by 
many drugs to counteract apoptotic signalling. 
1.7 Autophagy 
Autophagy, derived from the greek words ‘auto’ and ‘phagy’ meaning to eat one’s self, refers 
to the lysosomal mediated catabolic process for the degradation and re cycling of cellular 
debris (Boya et al., 2013). Activated in times of nutrient/oxidative stress or starvation, 
autophagy participates in many normal physiological processes to maintain cellular energy 
and homeostasis including its pivotal role in cellular differentiation, innate and adaptive 
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immunity and aging (Lum et al., 2005; Martinez-Vicente and Cuervo, 2007; Beth Levine and 
Kroemer., 2008; Deretic and Levine, 2009). 
Autophagy levels within cells are under tight control by signalling pathways that work in 
concert with environmental cues (Levine and Kroemer, 2008). Key signalling regulators of 
autophagy include AKT/mTOR and class I and class III phosphoinositide 3-kinase (PI3K) (Jung 
et al., 2010), and more than 20 evolutionarily conserved genes known as autophagy regulatory 
genes (ATG) that code for Atg proteins (autophagy related proteins). 
 
Figure 1.20 The Process of Autophagy 
Autophagy involves 5 component steps, including, initiation, nucleation/elongation, maturation, fusion 
and finally degradation. An ULK complex including ULK1/2, Atg13, FIP200 and Atg101 is key to the 
initiation phase of autophagy forming the pre-autophagosomal structure (PAS). Next, during the 
nucleation phase a complex of Beclin1, Vsp34, Atg14L and p150 is recruited to the PAS for 
autophagosomal construction. The subsequent elongation phase then enables the formation of a 
double membrane vesicle in which cytoplasmic contents are sequestered, the closing of which results 
in the completed autophagosome. The autophagosome then fuses with a lysosome where cytoplasmic 
contents are degraded by lysosomal hydrolase to generate free amino acids, fatty acids and  
unconjugated LC3-I, that can be recycled in a cell-autonomous fashion back to the cytoplasm by 
lysosomal permease, or delivered to distinct sites to sustain cellular energy and homeostasis. Taken 
from (Sun et al., 2013). 
 
The process of autophagy consists of five essential component steps (Figure 1.20) the first of 
which is called the ‘initiation phase’. During autophagy initiation, a stable complex consisting 
of ULK1, Atg13, and FIP200 integrates stress signals and initiates the autophagy process. mTOR 
next, disassociates from ULK1 allowing it to phosphorylate Atg13 and FIP200 which results in 
the localisation of ATG proteins and active ULK1 complex to a specialised site termed the pre-
autophagosomal structure (PAS) (Mizushima, 2010; Mizushima et al., 2011).The second 
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‘nucleation’ event recruits Atg proteins, in particular Beclin1, Vps34, Ambra1 and UVRAG as 
well as lipids to the PAS for autophagosome construction (Mizushima et al., 2011). This 
process is followed by the ‘elongation’ phase when the autophagosome forms de novo, in 
which cytoplasmic contents are sequestered. This process requires two unique protein 
conjugation systems, the first resulting in the formation of an Atg5–Atg12 conjugate, in a 
noncovalent complex with Atg16 (Orsi et al., 2010; Roy and Debnath, 2010), and the second, 
in which the C-terminally lipid-conjugated LC3 (Atg8) is conjugated to phosphatidyl-
ethanolamine (PE), recruiting cytosolic proteins and organelles to the phagopore (Fujita et al., 
2008; Simonsen and Tooze, 2009; Roy S and Debnath J, 2010). Additionally, LC3 binds cargo 
adaptor proteins such as p62 which bind ubiquinated cargo from the cytoplasm (Ichimura and 
Komatsu, 2010), enabling the fusion of the autophagosome with the lysosome to form an 
autolysosome marking ‘maturation’. The cytosolic contents along with p62 are finally 
degraded by lysosomal hydrolases, and the resulting products recycled and released back into 
the cytosol through permeases completing the process (Orsi et al., 2010). 
1.7.1 Autophagy Deregulation and Influence in Melanoma Therapy 
Although principally a cellular survival process, autophagy in cancer is complex, with both 
tumour suppressing and tumour promoting roles often referred to as the ‘autophagy paradox’ 
(Figure 1.21). While the maintenance of autophagy prevents the build-up of cytotoxic waste, 
suppressing tumourigenesis (Degenhardt K et al., 2006; Mathew et al., 2007), its re activation 
in later stages of tumourigenesis promotes tumour growth and survival in a nutrient deprived 
hypoxic environment, such as that of melanoma (Sivridis et al., 2011). 
As with many cancers autophagy is thus deregulated in melanoma (Corazzari et al., 2013). 
Immunohistochemical studies of Beclin1 expression in cutaneous melanoma, have reported 
its down regulation, with strong expression being evident in benign naevi, while expression is 
decreased as melanoma develops, suggesting a reduction of autophagy in early stage disease 
(Miracco et al., 2010). Electron microscopy studies have also demonstrated the increased 
presence of double membraned autophagosomes in advanced stage melanomas within 
hypoxic regions, that correlate with early disease mortality (Sivridis et al., 2011). Further, 
Immunohistochemical studies of endogenous LC3-II have demonstrated weak expression in 
normal melanocytes and naevi compared to cutaneous malignant melanomas supporting the 
reinstatement of autophagy in more advanced tumour stages (Lazova et al., 2010; Miracco et 
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al., 2010), and further supported by recent studies of p62 expression, revealing biphasic 
expression, reflecting the paradoxical role of autophagy in cancer (Ellis et al., 2014a) (Figure 
1.21). Further, in cutaneous melanoma autophagy maybe influenced by B-RAF mutational 
status, as basal autophagy is enhanced in B-RAF V600E melanomas as a consequence of chronic 
induction of ER stress, promoting chemo resistance (Armstrong et al., 2011; Corazzari et al., 
2015). 
Dysregulation of autophagy in uveal melanomas is only an emerging concept, with few 
publications dedicated to the expression of markers of autophagy in primary tumours. 
However consistent with studies in cutaneous melanoma, a immunohistochemical study of 99 
primary uveal melanomas, demonstrated endogenous LC3 and beclin1 expression in 50% of 
patients was associated with intense pigmentation and tumour hypoxia, consistent with 
autophagy activation as a survival response to low oxygenation (Giatromanolaki et al., 2011). 
In contrast, loss of Beclin1 expression by uveal melanomas has also been associated with 
worse prognosis (Ho and Ganesan, 2011). 
 
Figure 1.21 The Autophagy Paradox 
In early stage disease autophagy may be lost or deregulated detected by loss of Beclin1 expression and 
a concomitant increase in p62 expression. However, in advanced melanoma autophagy maybe 
regained detected by an increase in autophagosomes and LC3-II expression and a decrease in p62, 
promoting the tumour survival and chemo resistance. Taken from (Corazzari et al., 2013). 
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In addition to its deregulation in melanoma, autophagy may also play a detrimental role in the 
response to cytotoxic therapy, with many examples, not only in melanoma therapy, whereby 
autophagy is induced by traditional chemotherapeutics as well as by novel targeted agents to 
counteract apoptotic signalling, and as such is key to the development of the process of 
acquired drug resistance (Apel et al., 2008; Vazquez-Martin et al., 2009; Claerhout et al., 2010; 
Marino et al., 2010; Ren et al., 2010; Guo et al., 2012). Supporting this concept in a phase III 
clinical trial of temozolomide and sorafenib, the development of secondary tumours in 12 
AJCC stage IV melanoma patients, was associated with the increased presence of 
autophagosomes suggestive of high autophagy levels (Ma et al., 2011b). Further, in B-RAF 
inhibitor resistant xenograft models of cutaneous melanoma, combined B-RAF V600E and 
autophagy inhibition promotes tumour regression (Ma et al., 2014). Similarly, it has been 
recently demonstrated, that MEK and autophagy inhibition increases cell death of B-RAF 
inhibitor-induced resistant metastatic melanoma cell lines, identifying autophagy as a key 
promoter of B-RAF inhibitor resistance (Martin et al., 2015). 
Given other observations of drug-induced autophagy in melanoma therapy (Mariño et al., 
2007; Hammerová et al., 2012; Xie et al., 2013), clinical trials have now been initiated 
incorporating the lysosomal inhibitor hydroxychloroquine as monotherapy (NCT01273805) or 
in combination with current treatment regimens (NCT01128296), (NCT00909831) and 
(NCT00714181). Nevertheless, given blockade of autophagy may drive secondary 
tumourigeneis, other strategies to counteract the pro-survival effects of autophagy in 
advanced stage melanoma are under investigation, including the use of specific cannabinoids 
to drive its exacerbation and promote autophagic cell death (Armstrong et al., 2015). 
Modulation of autophagy in  uveal melanoma for therapeutic benefit has largely remained 
unexplored, however one study of uveal melanoma cell lines harbouring GNAQ mutations 
revealed the induction of autophagy, in response to combined MEK and AKT inhibition, but 
which resulted in enhanced cell apoptosis, and inhibition of tumour growth in a xenograft 
mouse model (Ambrosini et al., 2013b). Debate therefore remains as to whether autophagy 
modulation in uveal melanoma is a viable therapeutic approach together with the optimal 
means though which to harness modulation for optimal therapeutic benefit. 
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1.8 Aims and Objectives 
Chemotaxis, MAPK and VEGF signalling are key to melanoma development, migration and 
metastasis but their interplay remains largely undefined in the context of both cutaneous and 
uveal melanomas. Understanding the role and cross talk between key mediators of these 3 
signalling pathways, namely CXCR4, CXCL12 and VEGFR2 will inform on the development of 
more efficacious strategies to prevent melanoma migration and metastasis, the central aim 
to the current thesis. 
To this the specific objectives were to:  
 To define the prognostic significance of CXCR4, CXCR7 and CXCL12 expression in uveal 
and cutaneous melanoma, and the potential for autocrine signalling and impact on 
MAPK activation.  
 To investigate the potential crosstalk between CXCR4-CXCL12 mediated chemotaxis 
and MAPK signalling and other pro-survival signalling mechanisms (e.g. autophagy) in 
cutaneous and uveal melanoma.  
 To define the prognostic significance of VEGFR2 expression in relation to CXCR4 
expression in cutaneous and uveal melanoma, and the potential efficacy of VEGFR2 
blockade to inhibit cell viability and CXCR4-CXCL12-mediated-chemotaxis. 
 To explore the potential cross talk between VEGFR2 and CXCR4-CXCL12 signalling in 
both cutaneous and uveal melanoma and the potential for the combined inhibition of 
both pathways as a strategy to inhibit tumour migration and promote cell death.  
Derived results will thus inform on novel combinational and more efficacious targeted 
approaches through which to prevent melanoma, survival, migration and metastasis. 
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2.1 Growth and Maintenance of Human Cutaneous and Uveal 
Metastatic Melanoma, Hela, EA.hy.926, CXCR7 Overexpressing 
Chinese Hamster Ovary and Human Umbilical Vein Cell (HUVEC) 
Lines 
Human metastatic cutaneous cell lines CHL-1 (B-RAF wild-type), A375, WM-164 (B-RAF V600E 
mutated), WM-1361 (N-Ras mutated), human endothelial cell line EA.hy926 or CXCR7 
overexpressing Chinese hamster ovary (CHO) cells (a kind gift from Professor Simi Ali, 
Newcastle University) were grown and maintained in Dulbecco’s modified Eagles Medium 
(DMEM, Lonza, Vervies, Belgium) supplemented with 10% fetal calf serum (FCS, Sigma, St 
Louis, U.S.A) and 5% penicillin streptomycin (P/S, Lonza, Vervies, Belgium). All cell lines were 
obtained from American Type Culture Collection (ATCC, LGC Standards, Middlesex, U.K) with 
authenticity validated by commercial single nucleotide polymorphism (SNP) genotyping 
assays for the presence or absence of mutant B-RAF V600E, B-RAF V600D, N-Ras G61L or N-
Ras G61A as previously described (Hiscutt et al., 2010). 
Human metastatic uveal melanoma cell lines OM413, MEL290, C918 (GNAQ/GNA11 wild-
type), 92.1, MEL270, OMM2.3 (GNAQ mutated) and OMM1 (GNA11 mutated), (all a kind gift 
from Professor Richard Marais, Manchester CRUK) were grown and maintained in RPMI-1640 
medium (Sigma, St Louis, USA) supplemented with 10% FCS (Sigma) and 5% P/S (Lonza). 
UPMM1, UPMM3 (GNAQ mutated), UPMD1 and UPMD2 (GNA11 mutated), human metastatic 
melanoma cell lines (also kindly supplied by Professor Marais) were grown and maintained in 
Nutrient Mixture F-12 Ham (Sigma, St Louis, USA) supplemented with 10% FCS (Sigma) and 5% 
P/S (Lonza). Validation of common GNAQ and GNA11 mutations (GNAQ Q209, GNAQ R183, 
GNA11 Q209, GNA11 R183) of all uveal melanoma cells was performed by sequencing of PCR 
amplified DNA as detailed in section 2.8 (Appendix 1). Melanocytic lineage of all uveal 
melanoma cells was confirmed by detection of melan-A by reverse transcription PCR or 
immunofluorescence as detailed in section 2.7 and 2.11 (Appendix 1). 
Human Umbilical Vein Endothelial (HUVEC, PCS100010, ATCC) cells were grown and 
maintained in 0.2% gelatin (Sigma) coated tissue culture flasks with endothelial cell basal 
medium (Lonza, Vervies, Belgium) supplemented with Endothelial Growth Medium Bullet 
Supplement (Lonza, Vervies, Belgium), 10% FCS (Sigma), 1µg/ml hydrocortisone acetate 
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(Sigma), and 50nM N-6,2’-O-dibutyryl-adenosine 3’, 5’-cyclic monophosphate (Sigma) and 5% 
P/S (Lonza). 
All cell lines were stored long term as early passage numbers in 90% FCS (Sigma) and 10% 
Dimethyl sulfoxide (DMSO) (Fisher Scientific, Leicestershire, UK) in liquid nitrogen. Cells were 
grown to 70% confluence before passaging, by washing in sterile PBS (Lonza) and detaching 
cells using trypsin EDTA (Lonza, Vervies, Belgium). Once cells were detached, complete 
medium containing FCS was added to stop cell surface protein cleavage, and the cells were 
transferred to a new culture flask (Corning, New York, U.S.A). All cell lines were maintained at 
37 ᴼC in a humidified atmosphere of 5% C02 in air, up to a maximum of 50 passages and used 
for all experiments at approximately 70% confluence. 
2.2 Growth and Maintenance of Human Primary Dermal Fibroblasts, 
Keratinocytes, and Melanocytes 
Primary human epidermal keratinocytes, dermal fibroblasts and melanocytes were isolated 
from redundant foreskin, breast or abdominal skin as previously described (Todd and 
Reynolds, 1998). Full ethical permission was obtained for the use of redundant normally 
disposed tissue, (NRES reference 08/H0906/95+5) with all studies performed in accordance 
with the Declaration of Helsinki Principles. 
Isolated primary keratinocytes were expanded in human keratinocyte growth supplement 
MCDB medium (Sigma, St Louis, U.S.A), supplemented with histidine 37.3 mg/L, Isoleucine 
98.4 mg/L, methionine 13.4 mg/L, phenylalanine 14.4 mg/L, tryptophan 9.2 mg/L, tyrosine 
19.55 mg/L, ethanolamine 6.1µg/L, phosporylethanolamine 14.1 mg/L, Calcium 70µM, 
sodium bicarbonate 1.76 mg/L adjusted to pH 7.4 (all supplementary chemicals obtained from 
Sigma, St Louis, U.S.A). Dermal fibroblasts were expanded and maintained in Dulbecco’s 
Modified Eagles Medium (Lonza), supplemented with 10% FCS (Sigma) and 5% P/S (Lonza). 
Primary melanocytes were expanded and maintained in melanocyte 254 medium (Life 
Technologies, Paisley, U.K), supplemented with human melanocyte growth supplement (Life 
Technologies, Paisley, U.K) comprising of bovine pituitary extract (BPE) (0.2% v/v), fetal bovine 
serum (0.5% v/v), recombinant human insulin-like growth factor-I (1 µg/ml), bovine transferrin 
(5 µg/ml) basic fibroblast growth factor (3 ng/ml), Hydrocortisone (0.18 µg/ml), Heparin (3 
µg/ml) Phorbol 12-myristate 13-acetate (PMA) (10 ng/ml). 
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2.3 Primary Cohorts of Cutaneous and Uveal Melanomas, and 
Cutaneous Melanoma Lymph Node Metastases 
Formalin-fixed paraffin-embedded (FFPE) tissue was obtained from a retrospective cohort of 
77 primary melanomas comprising 13 benign melanocytic naevi and 64 primary American 
Joint Committee on Cancer (AJCC) stage I, II or III melanomas at the time of diagnosis, 
following excision at the Royal Victoria Infirmary, Newcastle-Upon-Tyne between January 
2003 and May 2005.  
For studies in primary uveal melanoma, a cohort of 13 formalin-fixed paraffin-embedded 
(FFPE) primary uveal melanomas (comprising of 5 with disomy and 8 monosomy of 
chromosome 3, with variable spindle, epithelial, or mixed tumour cell morphology) was 
obtained from Dr Lucianne Irion, (Department of Hisopathology, Clinical Sciences, Central 
Manchester and Manchester Children’s University Hospitals NHS Trust, Manchester). 
An additional cohort of 9 formalin-fixed paraffin-embedded (FFPE) primary cutaneous 
melanomas and patient matched FFPE metastatic lymph nodes (14 in total, 5 un-matched with 
primary cutaneous melanoma), or 2 normal lymph nodes (as controls) was obtained from Mr 
Jing Kim, and Dr Paul Barrett (Plastic Surgery and Department of Pathology, Durham 
University, Durham, Newcastle upon Tyne). 
Full ethical permission for all studies with primary cutaneous, uveal melanomas, or metastatic 
lymph nodes was obtained, NRES (Ref; 08/H0906/95+5). 
2.4 Chemical and Drug Treatment of Cells in Vitro 
Trametinib (GSK 112021B) a specific ATP allosteric inhibitor of MEK 1 and MEK 2, was dissolved 
in DMSO at a concentration of 10mM and stored in aliquots at -80°C, and added to cell culture 
medium at final concentrations of 0.1, 0.5, 1, 2.5, 5,10, and 32nM. 
Pazopanib (GSK GW786034), a selective multi-targeted tyrosine kinase inhibitor with primary 
targets of VEGFR2, VEGFR1 and VEGFR3 receptor tyrosine kinases (lesser biological action on 
Fibroblast growth factor receptor-1, Platelet derive growth factor receptor beta, KIT proto-
oncogene tyrosine kinase receptor and Colony stimulating factor 1) was dissolved in DMSO at 
a concentration of 10mM, and after gentle warming in a 37°C water bath, aliquots were stored 
at -80°C, and added to cell culture medium at final concentrations of 0.1, 0.17, 0.5, 0.85, 1, 
1.71, 4.28, 5, 8.56, 10, 17.12, 25µM. 
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Chloroquine (CQ, Sigma-Aldrich) a lysosomal inhibitor, was dissolved in sterile nanopure water 
at a concentration of 10mM, and stored at room temperature, protected from light, with final 
concentrations of 10µM added to cell cultures for 72 hours continuously or the final 2 hours 
of experiments if assaying LC3 I-II autophagic flux by western blotting. 
Temozolomide (Sigma, T2577) an alkylating chemotherapeutic agent, was dissolved in DMSO 
at a concentration of 100mM, aliquoted and stored at -20°C, before addition to cell cultures 
at a final concentration of 50µM for 4 or 72 hours. 
Recombinant CXCL12 (SDF-1α, CN-11, Almac, Craigavon, UK) was reconstituted in sterile PBS 
(LONZA) containing 0.1% bovine serum albumin (BSA, Alpha Diagnostics, San Antonio, U.S.A) 
at a concentration of 10µM, aliquoted and stored at -20°C, before addition to cell cultures at 
a final concentration of 10nM for 16 hours. 
Recombinant human VEGF 165 protein (293-VE, R&D systems, Abingdon, U.K) was 
reconstituted in 0.1% BSA in PBS at a concentration of 100µg/ml, aliquoted and stored at -
20°C, before addition to cell cultures at final concentrations of 10ng/ml for 16 hours. 
2.5 Transient Transfection of B-RAFWT and B-RAFV600E in Human 
Metastatic Melanoma Cells and Analysis of CXCR4 Subcellular 
Localisation 
CHL-1 wild-type metastatic melanoma cells were seeded in 6 well tissue culture plates 
(Corning Incorporated, New York, U.S.A) at a density of 4x105cells/well in a volume of 3ml 
complete culture medium and allowed to adhere overnight.  
Pre-transfection mixtures (per well) were prepared containing 100µl OPTIMEM transfection 
medium (Life Technologies; Invitrogen) to which 1µg of pEFm-B-RAFWT or pEFm-B-RAFV600E 
(Davies et al., 2002b; Flockhart et al., 2009) (a kind gift from Professor Richard Marais, Cancer 
Research UK Manchester Institute, The University of Manchester) and lipofectamine 2000 was 
added at a ratio of 1:3 DNA to Lipofectamine 2000 (DNA:Lipofectamine 2000). pEFm-B-RAFWT 
or pEFm-B-RAFV600E pre-mixtures are then added to lipofectamine mixtures and left at room 
temperature for 20 minutes before being added to cells dropwise, and incubation for 24 
hours. Cells are then re-seeded at a density of 2x105 cells/well for a further 48 hours. Cells 
subjected to Lipofectamine treatment in absence of cDNA were used as a control. 
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B-RAF over-expression and downstream activation of ERK was verified by western blot analysis 
of P-ERK, total ERK and GAPDH loading control, at 72 hours post transfection as described in 
section 2.14. 
CXCR4 subcellular localisation was determined either by immunofluorescence (as described 
section 2.11) or by western blot analysis for CXCR4 expression (section 2.14), following cell 
subcellular fractionation into cytoplasmic and nuclear fractions (Pierce, Thermo Fisher 
Scientific, Illinois, U.S.A) performed in accordance to manufacturer’s instructions. Successful 
cell fractionation was confirmed by western blotting for loading controls MEK 1/2 (cytoplasmic 
fraction) or Lamin A/C (nuclear fraction) as described section 2.14. 
2.6 siRNA Knockdown of VEGFR2 in Human Metastatic Melanoma 
Cell Lines 
CHL-1 or WM-164 cells were seeded at a density of 1.5x105 cells/well, in 6 well culture plates 
in 3ml of complete culture medium and allowed to attach overnight by incubation at 37oC. For 
the transient transfection of a single well, 2.5µl of lipofectamine RNAiMax reagent (Invitrogen, 
Carlsbad, California, U.S.A) was added to 125µl Opti-MEM1x reduced serum medium (life 
technologies, New York, U.S.A) before addition to respective pre-siRNA mixtures consisting of 
2.5µl (for CHL-1 transfection) or 5µl (for WM-164 transfection) of ON-TARGET plus KDR 
(VEGFR2) siRNA (SMART pool siRNA, Dharmacon, GE lifesciences, Lafayette, Colorado, U.S.A), 
or Stealth RNAi™ siRNA Negative Control (none target) (Invitrogen, Carlsbad, California, U.S.A) 
in 125µl Opti-MEM 1x reduced serum medium (Life technologies, U.S.A), and incubated at 
room temperature for 15 minutes. Cells were then washed in PBS before addition of 1ml Opti-
MEM 1x reduced serum medium (Life technologies, U.S.A) and the subsequent addition of 
250µl of each siRNA and lipofectamine mixture dropwise and corresponding to final 
concentrations of 40nM or 80nM siRNA. After continued culture for 6 hours, the transfection 
solution was removed from cells and replaced with complete culture medium containing FCS. 
To assess the effect of VEGFR2 knockdown on cell chemotaxis and the effect of pazopanib, 
cells were used in chemotaxis assays as described in section 2.16, 24 hours following 
transfection completion with the experiment ending 72 hours post transfection. mRNA levels 
of VEGFR2 were determined by qPCR as described in section 2.9. 
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2.7 Reverse Transcription Polymerase Chain Reaction (RT-PCR) for 
Melan-A Expression in Uveal Melanoma Cell Lines 
To detect the presence of Melan-A mRNA in uveal melanoma cell lines, RNA was extracted 
from C918, OM413, MEL290, 92.1, MEL270, OMM2.3, UPMM1, UPMM3, UPMD1, UPMD2 and 
OMM1 uveal melanoma cell lines using an RNeasy Mini Kit (Qiagen, Hilden, Germany) as per 
manufacturer’s instructions. The integrity of isolated RNA was revealed by electrophoresis 
through 1% agarose gels and for each sample, with isolated RNA reverse transcribed to cDNA 
using a High Capacity cDNA reverse transcription kit (Applied Biosystems, Vilnius, Lithuania), 
and amplified by PCR using a GeneAmp RNA PCR kit (Applied Biosystems, Roche, New Jersey, 
USA), again according to the manufactures instructions. PCR of cDNA was performed with 
specific primers to Melan-A and GAPDH loading control (Invitrogen, Life Technologies, 
California, USA, and designed in collaboration with Dr Asif Tulah, ICM, Newcastle University) 
using oligonucleotides as described in Table 2.1. For each sample, a 20μl PCR reaction 
consisted of 2μl DNA templates mixed with AmpliTaq PCR master mix (Applied Biosystems, 
California, U.S.A) for each primer as detailed in Tables 2.2. 
 Primer Oligonucleotides 5’to 3’ 
PCR Product 
Molecular Weight 
(base pairs) 
Melan-A 
Forward – ACT CTT ACA CCA CGG CTG AA 
254 
Reverse – GTG AAT AAG GTG GTG GTG ACT G 
GAPDH 
Forward – GGT GAA GGT CGG AGT CAA CGG A 
496 
Reverse – GAG GGA TCT CGC TCC TGG AAG A 
Table 2.1 Oligonucleotides for Determination of Melan-A and GAPDH Expression in Uveal 
Melanoma Cell Lines 
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PCR for Determination of Melan-A or GAPDH Expression 
Master mix 2µl 
De-ionised water 11.08µl 
Gold Buffer 2µl 
Magnesium (1.5mM) 1.2µl 
dNTP 0.8µl 
AmpliTaq Gold DNA Polymerase 0.12µl 
Forward and Reverse Primers (10mM) 0.4µl each 
DNA 2µl 
Table 2.2 Constituents of 20µl PCR Reactions for Determination of Melan-A or GAPDH 
Expression 
 
PCR conditions were: initial denaturation at 95°C for 10 minutes, followed by 28 cycles of 
denaturation of 4°C for 30 seconds, annealing at 57°C for Melan-A or 55°C for GAPDH for 30 
seconds, extension at 72°C for 1 minute, and a final extension at 72°C for 7 minutes, using a 
Gene Amp PCR system 9700 thermocycler (Applied Biosystems, California, USA). PCR products 
were then separated by electrophoresis through 2% agarose electrophoresis gels before 
bands were visualising using a FlourChem UV imager (Alpha Innotech, California, USA), to 
confirm the presence of Melan-A mRNA expression. 
2.8 Reverse Transcription Polymerase Chain Reaction (RT-PCR) and 
Sequence Analysis to Verify Activating Mutations in Uveal 
Melanoma Cell Lines 
To confirm the GNAQ/GNA11 mutational status of uveal melanoma cell lines, DNA was 
extracted from C918, OM413, MEL290, 92.1, MEL270, OMM2.3, UPMM1, UPMM3, UPMD1, 
UPMD2 and OMM1 uveal melanoma cell lines using a QIAmp DNA mini Kit (Qiagen, Hilden, 
Germany) as per manufacturer’s instructions. PCR was performed with specific primers 
(Invitrogen, Life Technologies, California, USA) to amplify areas of commonly mutated genes 
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GNAQ Q209, GNAQ R183, GNA11 Q209 and GNA11 R183 obtained from published literature 
(Van Raamsdonk et al., 2010; Laviv Y et al., 2012), and using oligonucleotides as described in 
Table 2.3. A 20μl PCR reaction for each replicate sample analysed comprised 2 or 4μl DNA 
templates mixed with AmpliTaq PCR master mix (Applied Biosystems, California, U.S.A) for 
each primer as detailed in Table 2.4. 
Mutation Primer Oligonucleotides 5’to 3’ 
PCR Product 
Molecular 
Weight (base 
pairs) 
GNAQ 
Q209 
Forward  - TTT TCC CTA AGT TTG TAA GTA GTG C 
222 
Reverse - CCT CAT TGT CTG ACT CCA CG 
GNAQ 
R183 
Forward  - TGG TGT GAT GGT GTC ACT GAC ATT CTC AT 
183 
Reverse - AGC TGG GAA ATA GGT TTC ATG GAC TCA GT 
GNA11 
Q209 
Forward  - CGC TGT GTC CTT TCA GGA TG 
150 
Reverse - CCA CCT CGT TGT CCG ACT 
GNA11 
R183 
Forward  - GTG CTG TGT CCC TGT CCT G 
249 
Reverse  - GGC AAA TGA GCC TCT CAG TG 
Table 2.3 Primer Oligonucleotides for Determination of GNAQ/GNA11 Mutations in Uveal 
Melanoma Cell Lines 
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PCR Reaction Mixture for Determination of Uveal Melanoma Mutations 
Master mix 2µl 
De-ionised water 11.08µl or 13.08µl 
Gold Buffer 2µl 
Magnesium (1.5mM) 1.2µl 
dNTP 0.8µl 
AmpliTaq Gold DNA Polymerase 0.12µl 
Forward and Reverse Primers (10mM) 0.4µl each 
DNA 2µl or 4µl 
Table 2.4 Constituents of 20µl PCR Reactions for Determination of Uveal Melanoma 
Mutations 
 
PCR conditions were: initial denaturation at 95°C for 10 minutes, followed by 28 cycles of 
denaturation of 4°C for 30 seconds, annealing at 55°C for 30 seconds, extension at 72°C for 1 
minute, a final extension at 72°C for 7 minutes. Each complete PCR cycle was repeated twice 
using a Gene Amp PCR system 9700 thermocycler (Applied Biosystems, California, USA). PCR 
products were then subjected to electrophoresis through 2% agarose gel, visualised using a 
FlourChem UV imager (Alpha Innotech, California, USA) and the correct molecular weight DNA 
product cut out from the gel and purified using a GeneJET Gel Extraction Kit (Thermo Scientific, 
Lithuania). Products were then sequenced by Source BioScience (Nottingham, UK) with 
sequencing chromatograms analysed using Chromas 2.4 soft-wear (Technelysium Pty Ltd, 
South Brisbane, Australia). 
2.9 Real Time Reverse Transcriptase Polymerase Chain Reaction 
(qPCR) 
qPCR was used to quantify VEGFR2 mRNA expression in HUVEC cells, human metastatic 
cutaneous melanoma cell lines CHL-1, WM-164, WM-1361, or human metastatic uveal 
melanoma cells OM413, MEL270, OMM2.3 and UPMD2. qPCR was also used to verify siRNA 
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knockdown of VEGFR2 in CHL-1 and WM-164 human metastatic cutaneous melanoma cell 
lines. All cell lines were seeded at 2x105 cells/well in a volume of 3ml/well of their respective 
cell culture medium, in 6 well flat bottom cell culture plates (Corning Inc) for 24 hours, prior 
to washing with ice cold PBS, and the extraction of RNA using a ReliaPrep™ RNA Cell Miniprep 
System (Promega, Madison, Wisconsin, U.S.A) including DNase digestion as per 
manufacturer’s instructions. RNA was stored at -80oC, prior to conversion to single-stranded 
cDNA using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Vilnius, 
Lithuania) as per manufacturer’s instructions. 20µl PCR reverse transcription reactions were 
prepared for each sample as detailed in Table 2.5 and with subsequent PCR performed using 
a Gene Amp PCR system 9700 thermocycler (Applied Biosystems, California, USA) with 
thermocycler conditions of 10 minutes 25 oC, 120 minutes 37 oC, 5 minutes 85 oC then 4 oC ∞. 
cDNA was stored at 4 oC, or -20 oC for long term storage. 
High Capacity Reverse Transcription 
10X RT Buffer 2µl 
25X dNTP Mix (100mM) 0.8 µl 
10X RT Random Primers 2 µl 
Multiscribe Reverse Transcriptase 0.5 µl 
RNase Inhibitor 0.2 µl 
Nuclease-free Water 4.5 µl 
RNA (same concentration in every reaction) 10 µl 
Table 2.5 Constituents of a Single Reverse Transcription Reaction 
 
qPCR was subsequently used to determine the relative expression levels of VEGFR2 mRNA, 
relative to the house keeping control of 18s mRNA. Master reaction mixes were prepared for 
each gene probe as described in Tables 2.7 and 2.8, using TaqMan Universal PCR Master Mix 
(Applied Biosystems, Warrington, UK), and pre-designed Gene Expression Assays for VEGFR2 
(KDR human Hs00911700_m1, Applied Biosystems, California, U.S.A) or 18s as a housekeeping 
gene (Integrated DNA Technologies, Leuven, Belgium), (Table 2.6). 8µl of master mix and 2µl 
Materials and Methods 
73 
 
cDNA were combined in each well of a 96 well MicroAmp Fast Optical Reaction Plate (Applied 
Biosystems, California, U.S.A). Duplicate samples for each gene samples were prepared 
incorporating both a non-template control (H2O only) and positive control of HUVEC cell cDNA, 
before plates were sealed with optical film, briefly centrifuged at 1200 RPM for 30 seconds 
and samples subjected to qPCR analysis using a StepOne Plus Real-Time PCR instrument 
(Applied Biosytems, California U.S.A), with 40 cycles of: 2 minutes at 50oC hold, 10 minutes at 
95oC hold, 15 seconds at 95oC denature, and 1 minute 60oC anneal/extend. Real-time mRNA 
expression analysis was determined using StepOne Soft wear V2.3 (Applied Biosystems, 
California, U.S.A). An average of VEGFR2 Cycle threashold (Ct) values for each sample was 
normalised to 18s and the fold change in VEGFR2 gene expression calculated using the 
comparative 2–[delta][delta]Ct method, where [delta][delta]Ct = [delta]Ct,VEGFR2 - 
[delta]Ct,18s, as previously described (Livak and Schmittgen, 2001). 
18s TaqMan® Gene Expression (FAM 
reporter -TAMRA quencher) Probe 5’-3’ 
FAM TCCT TTG GTC GCT CGC TCC TCT 
18s Forward Primer Oligonucleotides 5’-3’ CGA ATG CCT CAT TAA ATC AGT TAT GG 
18s Reverse Primer Oligonucleotides 5’-3’ TAT TAG CTC TAG AAT TAC CAC AGT TAT 
Table 2.6 Probe and Oligonucleotides for 18s Housekeeper Gene 
 
KDR (VEGFR2) TaqMan® Gene Expression 
Master mix (x2) 5µl 
Nuclease free Water 2.5µl 
KDR TaqMan® Gene Expression Assay (FAM 
reporter-NFQ quencher probe) 
0.5µl 
cDNA 2µl 
Table 2.7 Constituents of a Single PCR Reaction using KDR (VEGFR2) TaqMan Gene 
Expression Assay 
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18s TaqMan® Gene Expression 
Master mix (x2) 5µl 
Nuclease free Water 2.35µl 
18s Forward  & Reverse Primers 0.2µl 
18s FAM-TAMRA Probe 0.25 µl 
cDNA 2µl 
Table 2.8 Constituents of a Single PCR Reaction Using 18s Primer and Probe 
2.10 Cell Viability Assay 
Melanoma cells were seeded at 5x103 (A375, WM-1361, WM-164, OM413, MEL-270, UPMD2) 
or 2.5x103 (CHL-1) in 100μl/well of 96 flat well tissue culture plates (Corning Incorporated, 
New York, U.S.A). After 16, or 72 hours the cell culture medium was replaced with 100µl of 
fresh media or media in the presence or absence of a dose range of pazopanib or trametinib 
ranging from 0.5-75µM and 0.1-50nM respectively or with a fixed dose of both drugs at a ratio 
of 1: 1712.5 trametinib : pazopanib (nM). Cell viability was determined by addition of 20µl of 
Aqueous Non-Radioactive Cell Proliferation Assay (CellTitre-96, Promega, Southampton, UK) 
to each well (including blank wells containing just media) for 4 hours and absorbance 
measured at 490 nm using a Spectra Max 250 plate reader (Molecular Devices). 
Cell viability data were normalized to control cells and expressed as a mean of individual 
experiments. Variation in cell viability between treatment conditions was analyzed by One-
Way analysis of variance (ANOVA) with Dunnett’s post hoc correction test or using Kruskal-
Wallis analysis with Dunn’s post hoc test. 
2.11 Immunofluorescence for the Detection and Quantification of 
CXCR4, CXCR7, CXCL12, Melan-A and VEGFR2 in Human 
Melanoma or Endothelial Cell Lines 
Human metastatic uveal and cutaneous melanoma cells, HUVEC cells (positive control for 
VEGFR2), EA.hy926 or CXCR7 overexpressing Chinese hamster ovary (CHO) cells (positive 
control for CXCR7) primary dermal fibroblasts, keratinocytes or melanocytes, were seeded on 
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to cover slips at a density of 2.5x105 cells /well in 3mls of respective culture medium in 6 well 
tissue culture plates (TPP, Sigma, Poole, U.K) for 24 hours. 
For detection of CXCR4 expression, cells were serum starved in 0.2% BSA in DMEM (Lonza), 
RPMI-1640 (Sigma) or Nutrient Mixture F-12 Ham (Sigma) for 16 hours prior to cell fixation. 
For all analyses, cell culture medium was removed and cells washed with PBS before fixing in 
ice cold 4% paraformaldehyde (Sigma, Saint Louis, U.S.A) in PBS for 15 minutes at room 
temperature. After a further 3 washes with PBS, cells were permeabilized in 0.2% Triton X-100 
(Thermo Fisher Scientific, Illinois, U.S.A) in PBS for 10 minutes at room temperature. A blocking 
step was performed to block non-specific primary antibody binding, by incubating slides in 
20% swine serum (Serotec, Oxford, UK) in PBS for 30 minutes at room temperature. 
Coverslips were then transferred to glass slides, with the coverslip/cell area marked around 
with a  hydrophobic pen, before incubation with 100ul of primary antibody; anti-human CXCR4 
monoclonal antibody (Clone 44716) (R&D systems, Abingdon, U.K) at a concentration of 2.5 
ug/ml, anti-human CXCR7 monoclonal antibody (11G8, R&D systems, Abingdon, U.K) at a 
concentration of 10µg/ml, anti-human CXCL12 (ab9797, Abcam, Cambridge, UK) diluted 
1:500, anti-human Melan-A monoclonal antibody diluted 1:250 (ab731-500 Abcam, 
Cambridge, UK), Mel-5 (Anti-TRP1 antibody, Abcam, Cambridge, UK) diluted 1:250, anti-
human VEGFR2 (FLK-1 SC-6251, Santa Cruz, Heidelberg, Germany) diluted 1:50 in 20% swine 
serum (Serotec, Kidlington, U.K) or 20% FCS (Sigma) in PBS ,or as a negative control, 20% swine 
serum (Serotec) or 20% FCS (Sigma) in PBS, overnight at 4oC.  
Cells were then washed in PBS thrice before incubation with a secondary fluorescent antibody, 
Alexa Fluor® 488 Goat Anti-Mouse IgG (Life Technologies, Eugene, Oregon USA) or Alexa 
Fluor® 488 Goat Anti-Rabbit IgG (Life Technologies, Eugene, Oregon USA) diluted 1:250 with 
diamidino-2-phenylindole dye (DAPI, Thermo Fisher Scientific, Illinois, U.S.A) diluted 1:1000 in 
20% swine serum (Serotec) or FCS (Sigma) in PBS for 1 hour at room temperature. After final 
washing 3 times in PBS for 5 minutes, cover slips were mounted onto fresh glass slides using 
hardest fluorescence mounting medium (Vector labs, Burlingame, California, U.S.A) and 
stored at room temperature prior to analysis. Fluorescence was visualised and images 
captured with a Leica TCS SP2 UV confocal microscope and analysed using LC2 2.61 software 
(Leica Microsystems GmbH Heidelberg). 
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CXCL12, CXCR7 or VEGFR2 fluorescence per cell (relative to DAPI) was quantified above 
background fluorescence from 4 representative images per cell line respectively using ImageJ 
software (Rasband, W.S., ImageJ, Maryland, USA). 
2.12 Immunofluorescence for the Detection and Quantification of 
CXCR4, CXCL12 and Melan-A in Formalin Fixed Paraffin 
Embedded (FFPE) Primary Cutaneous and Uveal Melanomas 
5µm FFPE tissue sections derived from benign naevi or primary melanomas or human tonsil 
as a positive control (for CXCR4) were de-paraffinised in xylene (Thermo Fisher Scientific, 
Illinois, U.S.A) for 10 minutes at room temperature then dehydrated in 100% and 95% ethanol, 
each for 5 minutes (Barbro Ehlin-Henriksson et al., 2006). Sections were rinsed in de-ionised 
water and washed in Tris buffered saline pH 7.6 (TBS) for 1 minute before antigen retrieval 
was performed by heating slides in 10mM Tris hydrochloric acid (pH 7.4) for CXCR4 or in 10mM 
Sodium Citrate (pH 6) to reveal Melan-A and CXCL12, for 1 minute in a pressure cooker. 
Sections were rapidly cooled in cold de-ionised water and washed for 20 minutes in TBS. Cells 
were permeabilised in 0.2% Triton X-100 (Thermo Fisher Scientific, Illinois, U.S.A) in TBS for 10 
minutes at room temperature. After blocking for non-specific primary antibody binding with 
20% (v/v) swine serum (Serotec) or 20% FCS (Sigma) in TBS for 1 hour at room temperature, 
sections were marked with a hydrophobic pen, and incubated with primary mouse anti-human 
CXCR4 monoclonal antibody (Clone 44716) (R&D systems, Abingdon,UK), diluted to a final 
concentration of 10µg/ml in TBS containing 20% (v/v) FCS, primary rabbit anti-human melan-
A (ab731-500 Abcam, Cambridge, UK) diluted 1/250 or primary mouse anti-human CXCL12 
(ab9797, Abcam, Cambridge, UK) 1/500 in TBS containing 20% (v/v) FCS, at 4°C overnight. An 
additional slide of each section was used as a negative control, omitting incubation with 
primary anti-CXCR4, melan-A or CXCL12 antibody or with the addition of an isotype control 
primary antibody anti-Rabbit IgG polyclonal Isotype control antibody (ab171870, Abcam, 
Cambridge, UK) or anti-mouse IgG polyclonal Isotype control antibody (ab37355, Abcam, 
Cambridge, UK) at the same concentrations as respective primary antibodies in TBS containing 
20% (v/v) FCS. Sections were subsequently washed thrice for 5 minutes each in TBS, before 
incubation with secondary antibody tetramethylrhodamine isothiocyanate (TRITC) conjugated 
anti-Mouse IgG (Sigma-Aldrich, Gillingham, United Kingdom), Alexa fluor Goat anti-rabbit IgG 
568 (a11036, Thermo Fisher Scientific, Illinois, U.S.A), or Alexa fluor Goat anti-mouse IgG 488 
(a11001, Thermo Fisher Scientific, Illinois, U.S.A) diluted 1:250 in TBS containing 20% (v/v) FCS 
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for 1 hour at room temperature. All subsequent procedures were performed shielding the 
sections from light to prevent degradation of the secondary antibody fluorophore. Following 
incubation with diamidino-2-phenylindole dye (DAPI, Thermo Fisher Scientific, Illinois, U.S.A) 
diluted 1:1000 in TBS, for 10 minutes to reveal nuclear staining, sections were mounted using 
fluorescence mounting medium (DAKO, California, U.S.A). Auto fluorescence was blocked 
using Sudan Black (Sigma-Aldrich, Gillingham, United Kingdom) 0.3% (w v−1) in 100% ethanol 
for 20 minutes, and slides finally stored at 4°C prior to image analysis. Images were captured 
with a Leica TCS SP2 UV confocal microscope and analysed using LC2 2.61 software (Leica 
Microsystems GmbH Heidelberg). CXCL12 fluorescence per tumour cell (relative to melan A) 
or within the epidermis of melanoma tissue sections (relative to DAPI) was quantified above 
background fluorescence from 4 or 2 representative images per tumour respectively using 
ImageJ soft wear (Rasband, W.S., ImageJ, Maryland, USA). 
2.13 Immunohistochemistry for the Detection and Quantification of 
CXCR4, CXCR7, VEGFR2, Melan-A, Beclin-1 and P62 in Formalin 
Fixed Paraffin Embedded Primary Uveal Melanomas or Primary 
Cutaneous Melanomas and Patient Matched Metastatic Lymph 
Nodes 
5µm formalin fixed and paraffin embedded tissue sections derived from benign naevi or 
primary melanomas, tonsil (CXCR4 positive control), HUVEC cells (VEGFR2 positive control), or 
CHL-1 and A375 metastatic melanoma cells with known p62 and Beclin-1 expression (both 
markers of autophagy and used as positive controls) were de-paraffinised through immersion 
in xylene (Thermo Fisher Scientific, Illinois, U.S.A) for 10 minutes at room temperature before 
being dehydrated in 100%, followed by 95% ethanol each for 5 minutes (Barbro Ehlin-
Henriksson et al., 2006). Sections were then rinsed in de-ionised water before heating in 
antigen retrieval buffer; 10mM Tris hydrochloric acid (pH 7.4) for CXCR4, Melan-A and p62 
detection, 10mM Tris hydrochloric acid (pH 9) for CXCR7 detection, or 10mM Sodium Citrate 
(pH6) for Beclin-1 and VEGFR2, for 1 minute in a pressure cooker to unmask antigenic sites. 
Sections were then rapidly cooled in cold de-ionised water and washed for 20 minutes in TBS 
before sections were marked with a hydrophobic pen and then cells permeabilised in 0.2% 
Triton X-100 (Thermo Fisher Scientific, Illinois, U.S.A) in TBS for 10 minutes at room 
temperature. Endogenous peroxides were then blocked by incubation in 3% hydrogen 
peroxide (Sigma, Poole, U.K) in water for 10 minutes at room temperature. Sections were then 
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washed 3 times in TBS prior to incubation with avidin solution (Avidin/Biotin blocking kit, 
Vector laboratories, Burlingane, USA) for 15 minutes to block avidin binding sites. Sections 
were then again washed with TBS and subsequently incubated for a further 15 minutes with 
biotin solution (Avidin/Biotin blocking kit, Vector laboratories, Burlingane, USA) to block 
endogenous biotin receptors. Sections were then washed in TBS prior to a protein blocking 
step by incubation in 20% swine serum (AbD Serotec, Oxford, UK) in TBS or 20% FCS (Sigma) 
in TBS, for 1 hour at room temperature, washing in TBS and incubation with primary anti-
human CXCR4 monoclonal antibody (Clone 44716) (R&D systems) at a concentration of 2.5 
µg/ml, anti-human Melan-A monoclonal antibody (ab731-500 Abcam, Cambridge, UK) diluted 
1:500, anti-beclin-1 monoclonal antibody (Beclin-1 612113, BD Biosciences, UK) diluted 1:100 
or anti-p62 monoclonal antibody (SQSTM1 Sc28359, Santa Cruz Biotechnology, Heidelberg, 
Germany) diluted 1:50, anti-human CXCR7 monoclonal antibody (11G8, R&D systems, 
Abingdon, U.K) at a concentration of 5µg/ml, or anti-human VEGFR2 (FLK-1 SC-6251, Santa 
Cruz, Heidelberg, Germany) diluted 1:500 in 20% swine serum (AbD Serotec) in TBS overnight 
at 4°C, or for 1 hour at room temperature in the case of Beclin-1, p62 and Melan-A. An 
additional slide of each section was also included as a negative control, omitting incubation 
with primary antibody. After 3 washes with TBS, primary antibody binding was detected with 
biotinylated horse anti-mouse IgG secondary antibody (Vectastain Elite ABC Kit (Mouse IgG) 
or anti-rabbit IgG secondary antibody (Vectastain Elite ABC Kit (Rabbit IgG), Vector 
laboratories, Burlingane, U.S.A) diluted 1:200 in 20% swine serum (AbD Serotec) in TBS or 20% 
FCS (Sigma) in TBS for 30 minutes at room temperature. Sections were further washed thrice 
in TBS before staining with ABC Reagent from a Vectastain Elite kit (Vector laboratories) for 
30 minutes at room temperature. Following 3 more washes in TBS sections were incubated 
with VIP solution (Vector VIP Peroxidase Substrate Kit, Vector laboratories, Burlingane, USA), 
for 10 minutes according to the manufacturers specifications. Slides were next rinsed in tap 
water for 5 minutes and sections counterstained with hematoxylin solution (Harris Modified, 
Sigma Aldrich diagnostics, St Louis, U.S.A) for 2 minutes. Following washing in tap water with 
multiple changes for 10 minutes, sections were dehydrated through 75% and 100% ethanol 
for 5 seconds each, cleared in histoclear (Sigma, Poole, UK) for 2 minutes before being left to 
air dry. Finally, sections were mounted with a cover using DPX mountant (Thermo Fisher 
Scientific, UK) and visualised by light microscopy. Images were captured using the Zeiss Axio 
Imager microscope (Carl Zeiss Microscopy New York, U.S.A). 
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2.14 Western Blotting 
Human metastatic cutaneous melanoma cell lines CHL-1, WM-164, WM-1361, or human 
metastatic uveal melanoma cells OM413, MEL270, OMM2.3 and UPMD2 were seeded at 
2x105 cells/well in a volume of 3ml/well of their respective cell culture medium, in 6 well flat 
bottom cell culture plates (Corning Incorporated, New York, U.S.A) and allowed to attach 
overnight. For experiments analysing cells viability and autophagic flux in response to 
trametinib treatment, the medium in each well was replaced with 3mls of fresh media or 
media containing trametinib (2.5, 5, 32nM) or temozolomide (50µM) for 4 or 72 hours in the 
presence or absence of Chloroquine (10μM) for the duration of the experiment or the final 2 
hours of incubation before cells were subsequently harvested for western blot analysis. 
Experiments investigating the potential for autocrine CXCR4-CXCL12 cell signalling in WM-164 
metastatic melanoma cell line, cells were seeded at 1.5x105 cells/well in 6 well tissue culture 
plates 24 hours prior to the addition of 1µg/ml anti-CXCL12 neutralising antibody (Abcam 
Cambridge, UK, clone 9797) or IgG isotype control antibody (Abcam Cambridge, UK, clone 
171870) for 5-30 minutes before harvesting cell lysates for western blotting. 
Protein from human metastatic cutaneous and uveal melanoma cells in the presence or 
absence of treatment with Trametinib, Chloroquine or temozolomide was obtained after 
washing cells with PBS, and lysis on ice with 50μl of cell lysis buffer (0.1 M Tris-HCl pH 7.4, 
25mM NaF, 0.1M NaCl, 2mM EDTA (pH 8), 1mM benzamidine, 0.1mM sodium orthovanadate, 
0.1% Triton-X100) containing 150 µl/ml protease inhibitor cocktail (Promega, Southampton, 
UK). The adherent cells were then scraped in lysis buffer from 6 well plates into eppendorf 
micro centrifuge tubes. 
Protein was extracted by sonication, using a probe sonicator (Soniprep 150, MSE, UK) with 2 
pulses for 5 seconds at an amplitude of 7 microns and protein concentration determined by 
Bradford protein quantification assays (Pierce Biotech, Rockford, USA) according to the 
manufacturer’s specifications, with protein absorbance measured using SpectraMAX 250 
plate reader (Molecular Devices Ltd. UK). 10 µg of protein lysates were diluted 1:3 in 4x sample 
buffer (250 mM Tris HCL (pH 8), 8% sodium dodecyl sulphate (SDS), 40% glycerol, 10% β-
mercaptoethanol and bromophenol blue) prior to denaturation at 95oC for 5 minutes on a 
heat block. Proteins were separated by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) including a Bench MarkTM Prestained Protein Ladder (Invitrogen, 
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Paisley, UK; 10748-010), through 4-20% tris-glycine gels (Bio-Rad, UK) immersed in a SDS 
running buffer (25 mM Tris base, 190 mM glycine 0.1% SDS). Proteins were subsequently 
transferred from the gel onto a Trans-Blot Turbo PVDF membrane (Bio-rad, UK) using a Bio-
rad Turbo-blotter (1.3A, 25V; Bio-Rad, UK) for 7 minutes before membranes were blocked for 
non-specific primary antibody binding with 5% non-fat milk (OXOID ltd, Basingstoke, UK) 
diluted in TBS for 1 hour at room temperature. Membranes were then incubated over night 
at 4oC with primary antibodies; anti-human MEK1/2 (Rabbit monoclonal antibody, diluted 
1:8000, #9122 Cell Signalling, Life Technologies, Thermo Fisher Scientific, USA), anti-human 
ERK1/2 (Rabbit monoclonal antibody, diluted 1:5000, p44/p42 MAPK, #9102, Cell Signalling, 
Life Technologies, Thermo Fisher Scientific, USA ), anti-human Phospho–ERK1/2 (Rabbit 
monoclonal antibody, diluted 1:5000, Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 
(197G2) #4377, Cell Signalling, Life Technologies, Thermo Fisher Scientific, USA) anti-human 
LC3 I-II (Rabbit monoclonal antibody, diluted 1:2000, #2775, Cell Signalling, Life Technologies, 
Thermo Fisher Scientific, USA), anti-human CXCR4 (Rabbit polyclonal antibody, diluted to 
0.1ug/ml, (ab2074), Abcam, Cambridge, UK), anti-human Cleaved Caspase 3 (Monoclonal 
rabbit antibody, diluted 1:1000, #9664, Cell Signalling, Life Technologies, Thermo Fisher 
Scientific, USA ), anti-human B-RAF (Mouse monoclonal antibody, diluted 1:40,000 (sc-5284, 
Santa Cruz, Heidelberg, Germany), anti-human Lamin A/C (Mouse monoclonal antibody, 
diluted 1:1000, (4C11) # 4777, Cell Signalling, Life Technologies, Thermo Fisher Scientific, USA) 
or for 1 hour at room temperature in the case of anti-human GAPDH loading control (Rabbit 
monoclonal antibody, diluted 1:5000, #2118s, Cell signalling, Life Technologies, Thermo Fisher 
Scientific, USA ) diluted in 5% Bovine Serum Albumin (Alpha Diagnostics, Texas, USA) 0.2% 
Tween, Tris Buffered saline (TBS/T). Membranes were then washed thrice for 15 minutes in 
TBS/T before 1 hour incubation with peroxidase labelled anti-rabbit IgG or anti-mouse IgG 
secondary antibodies (at dilutions of 1:2000 (for the detection of Cleaved Caspase 3), 1:5000 
or 1:10,000 (for detection of GAPDH), Vector Laboratories, Burlingame, USA) diluted in TBS/T 
containing 5% non-fat milk. Membranes were then washed again thrice for 15 minutes in 
TBS/T, before proteins were visualised using ECL-plus system (Clarity Western ECL-Substrate, 
Bio-Rad, USA) according to the manufacturer’s specifications. Band density quantification was 
determined using Image J soft-wear (Rasband, W.S., ImageJ, U. S. National Institutes of Health, 
Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-2015) or Odyssey FC Image studio 
software (Li-cor Biosciences, Lincoln, Nebraska, U.S.A). 
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2.15 Enzyme-Linked Immunosorbent Assay for the Detection of 
CXCL12 
Cutaneous and uveal metastatic melanoma cell lines, EA.hy.926 endothelial cells, primary 
keratinocytes, dermal fibroblasts or melanocytes were seeded in 1ml culture medium at 5x104 
cells/well in 24 well tissue culture plates (TPP, Sigma, Poole, U.K) and incubated overnight at 
37oC. Media was replaced with 300μl of DMEM/10% FCS (Sigma Chemical Co), 5% P/S (Lonza) 
and incubation continued for 72 hours before supernatant was removed, centrifuged and 
stored at -20ᴼC. Human biliary epithelial cell supernatants were provided by Dr Isabella 
Swidenbank, (Newcastle University) and also stored at -20ᴼC. A commercial sandwich enzyme-
linked immunosorbent assay (ELISA), Human CXCL12/SDF-1 alpha Quantikine ELISA Kit (R&D, 
Minneapolis, Minnesota, U.S.A) was used to detect CXCL12 secretion as per manufacturer’s 
specifications. Absorbance was measured at 492 nm using a Spectra Max 250 plate reader 
(Molecular Devices, Workingham, UK). CXCL12 concentration in pg/ml was determined 
relative to a standard curve of known concentrations of CXCL12. 
In vitro CXCL12 secretion by cell lines and primary cells was expressed as a mean of individual 
experiments for cell lines or 4 independent tissue donors for primary cells, and analysed by 
Mann-Whitney U test.  
2.16 Transwell Chemotaxis Assays 
24 hours prior to assay, the cell culture media of each cutaneous or uveal melanoma cell line 
was replaced with serum free DMEM (CHL-1 and WM-164 cells), or RPMI (OM413 cells) media 
supplemented with 0.2% BSA and 5% P/S. The undersides of inserts (8µm pore size, BD Falcon, 
Oxford, UK) were coated with 30µl of 2.5µg/ml fibronectin (Sigma Aldrich, St Louis, U.S.A) 
diluted in DMEM, or RPMI media supplemented with 0.2% BSA 5% P/S for 1 hour at room 
temperature. Excess fibronectin was removed and inserts air dried for 1 hour. The 24 well 
companion plate (Falcon, Becton Dickinson Labwear, Franklin Lakes, New Jersey, U.S.A) was 
blocked with 1ml PBS +1% BSA for an hour, before addition of 800µl/well of human CXCL12, 
Stromal Cell Derived Factor 1 chemokine (Almac, Edinburgh, U.K) at concentrations of 1, 10 or 
50nM diluted in DMEM, or RPMI media +0.1% BSA, or supernatant derived from primary 
dermal fibroblasts, to wells with their respective tissue culture media as a control. For 
experiments evaluating the migratory effect of recombinant CXCL12, rabbit anti-human 
CXCL12 (ab9797, Abcam, Cambridge, UK) or rabbit anti-IgG isotype control (ab171870, Abcam, 
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Cambridge, UK) antibodies, were added to the well media or dermal fibroblast supernatants 
at a concentration of 1µg/ml. Melanoma cells were applied to the top of inserts at a 
concentration of 2x105 cells in 500µl of DMEM, or RPMI media + 0.2% BSA after detachment 
with 2mM Ethylenediamine tetra-acetic acid (VWR, Leicestershire, UK) in PBS. For 
experiments evaluating the potential inhibitory effects of trametinib or pazopanib alone or in 
combination, cells were treated for the duration of the experiment in the presence of 2.5, 5 
or 32nM trametinib or 1, 5 or 25μM pazopanib alone or in combination at a fixed dose ratio 
of 1:1712.5 (trametinib nM: pazopanib nM). For experiments evaluating the effect of 
knockdown of VEGFR2 on cell chemotaxis, wild-type or B-RAF mutated melanoma cell lines 
subjected to transfection with a control scrambled oligonucleotide (none target siRNA) or 
following transient knockdown with a pool of siRNA targeting VEGFR2 were applied to the 
insert in the presence or absence of 10ng/ml recombinant human VEGF 165 protein (293-VE, 
R&D, Minneapolis, Minnesota, U.S.A) for the duration of the experiment. After incubation at 
37oC for 16 hours, un-migrated cells were gently swabbed from within the insert, before 
migrated cells were fixed in ice cold methanol overnight, and before immersion in Mayer’s 
haematoxylin solution (Sigma, Aldrich, St Louis, Missouri, U.S.A) for 20 minutes, Scott’s tap 
water for 10 minutes, and dehydration with 50, 75, 90 and 100% ethanol and final mounting 
on coverslips with DPX (Raymond A Lamb, Life Technologies, Thermo Fisher Scientific, USA). 
Total numbers of migrated cells were recorded in 9 representative fields of vision (as shown 
in figure 2.1) of each filter, with 3 filters used per treatment condition. 
Cell migration/chemotaxis data were recorded as cell migration per high powered field (HPF), 
and normalised to control cells, and expressed as mean of individual experiments. Data were 
analysed using one-way ANOVA with Dunnett’s post hoc correction or by Kruskal-Wallis with 
Dunn’s post hoc test. The effect of individual drug treatments and combined drug treatments 
on cell chemotaxis was assessed using a one-way analysis of variance with Bonferroni’s post 
hoc correction. 
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Figure 2.1 Chemotaxis Filter and Areas of High Powered Field of Vision Analysed 
Example of a chemotaxis filter, the areas to be analysed for migrated cells are depicted by the red cross. 
2.17 Biomarker Analysis 
The mean percentage of CXCR4 or VEGFR2 positively stained cells in each tumour section was 
derived as a mean of 10 representative images per tumour section (example selection of areas 
to image Figure 2.2), captured using Zeiss Axio Imager microscope (Carl Zeiss Microscopy New 
York, U.S.A) and expressed as a mean percentage of cells expressing total CXCR4 (nuclear and 
cytoplasmic expression) or VEGFR2 using Leica QWin V3 software (Leica Microsystems, 
Newcastle upon Tyne). Nuclear and cytoplasmic CXCR4 staining were graded in each image by 
eye using the following criteria: 1= no staining, 2= under 50% of cells positively stained, 3= 50-
75% of cells positively stained, 4= over 75% of cells positively stained. Inter-assay variability 
was assessed by repeated staining of the same strongly positive or negative tumour sections 
in each assay with reproducible percentage staining positivity confirmed. 
Mean CXCL12 fluorescence per tumour cell (relative to melan-A) or within the epidermis of 
melanoma tissue sections (relative to DAPI) was quantified above background fluorescence 
from 4 or 2 representative images per tumour respectively, using ImageJ soft wear. 
 
Materials and Methods 
84 
 
 
Figure 2.2 Example Image of VEGFR2 Expression in a Primary Cutaneous Melanoma, with 
Areas Highlighted for Expression Analysis 
Example image of VEGFR2 expression in AJCC stage II primary cutaneous melanoma. The square boxes 
represent areas selected for 20x magnification high powered field examination. Image taken at 2.5x 
magnification. Scale bar -1mm. 
For biomarker studies of CXCR4, CXCL12 or VEGFR2 data were correlated with clinical outcome 
after a minimum of seven years’ follow-up, allowing the correlation of CXCR4, CXCL12 and 
VEGFR2 expression in the primary tissue sample with the time to development of first 
metastasis (disease free survival; DFS). Disease recurrence was defined by the time to first 
radiological or tissue diagnosis of metastatic disease (nodal or systemic) from the point of 
initial primary tumour excision, or time to death from melanoma (melanoma specific 
mortality; MSM). Reporting of the data was performed in line with the REMARK guidelines for 
tumour marker prognostic studies (McShane et al., 2005). 
Mean percentage total CXCR4 expression or mean nuclear CXCR4 staining score was 
compared with AJCC disease stage by One-way Analysis of Variance (ANOVA). Independent 
group analysis between localised and metastatic disease (eventual AJCC stage I/II versus 
eventual AJCC stage III/IV disease) was determined by Mann-Whitney U. The Difference 
between “high” and “low” CXCR4 expression levels for survival curve analysis was analysed by 
Wilcoxon Signed Rank Test, highlighting that 50% CXCR4 expression as an appropriate cut off 
point, as this expression level differed significantly in both localised and metastatic disease. 
Univariate and subsequent Log-rank (Mantel-Cox) survival analysis was undertaken using R 
2.15.0 (R Foundation for Statistical Computing). Comparison of nuclear CXCR4 expression in 
localised and metastatic tumours (eventual AJCC stage I/II versus eventual AJCC stage III/IV 
disease), and comparison between wild-type and B-RAF/N-Ras mutated tumours was 
performed using an Unpaired T test. 
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In vivo tumoural CXCL12 Immunofluorescence data were expressed as mean fluorescence per 
cell and comparison made between AJCC disease stage by Kruskal-Wallis test with post hoc 
Dunn’s multiple comparison test. Mann-Whitney U was used for analysis of CXCL12 
fluorescence between localised and metastatic disease (eventual AJCC stage I/II versus 
eventual AJCC stage III/IV disease) or B-RAF mutated and wild-type melanomas, while 
Spearman’s Rank Correlation was used to correlate CXCL12 expression with time to metastasis 
and CXCR4 expression. Pearson Product Moment Correlation analysis was used to correlate 
CXCL12 expression with nuclear CXCR4 expression. 
In vivo CXCL12 Immunofluorescence within the epidermis beside the tumour bulk or epidermis 
overlying the tumour, was expressed as the mean expression per cell and comparison 
analysed using the Wilcoxon Signed Rank test. Correlation of CXCL12 expression in the 
epidermis beside the tumour with time to metastasis or tumoural cytoplasmic CXCR4 
expression was analysed using Pearson product moment correlation. 
In vivo uveal melanoma CXCL12 immunofluorescence data were expressed as the total mean 
fluorescence per cell. Mann-Whitney U was used for comparison of cutaneous and uveal 
melanomas, and unpaired T- test for analysis of uveal melanomas and differing chromosome 
3 status. 
Mean percentage VEGFR2 tumoural expression and mean percentage epidermis VEGFR2 
expression was compared with AJCC disease stage by Kruskal Wallis analysis. Independent 
group analysis of VEGFR2 expression % (tumour) between localised and metastatic disease 
(eventual AJCC stage I/II versus eventual AJCC stage III/IV disease) was determined by Mann-
Whitney U. Comparison between wild-type and B-RAF/N-Ras mutated tumours was 
performed using Mann-Whitney U. Correlation between Mean percentage VEGFR2 expression 
and mean percentage total CXCR4 expression was determined by Spearman’s r correlation. 
Comparison between mean percentage tumour and epidermis VEGFR2 expression was 
assessed by Kruskal-Wallis test, and correlation determined by Spearman’s r correlation. 
2.18 Statistics 
Throughout this thesis statistical analyses were performed using IMB SPSS statistic Soft-wear 
(version 22 for windows, IBM soft-wear Group, Chicago, Illinois, U.S.A) and GraphPad Prism 
(version 5.00 for windows, GraphPad Software, San Diego California USA). For all experiments 
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throughout data were assessed for normality by Shapiro-Wilk Test. Where there was not 
enough data point to analyse data by Shapiro-Wilk Test, normality was not assumed and non-
parametric tests were applied. Normally distributed data were further assessed for 
homogeneity of variance by Levene Test, or sphericity by Mauchly’s Test, before using the 
appropriate statistical test having satisfied statistical assumptions. Statistical significance is 
indicated by P values of P< 0.05 *, P< 0.01 **, P< 0.001 ***, throughout the thesis with values 
P > 0.05 deemed non-significant (ns). 
In vitro basal VEGFR2 mRNA expression in cell lines and primary cells was determined by qPCR 
with an average of VEGFR2 Cycle threshold (Ct) values for each sample normalised to 18s 
mRNA Ct values. Normalised VEGFR2 mRNA expression between all cell lines and primary cells 
was analysed by Kruskal-Wallis test with Dunn’s post hoc correction. Normalised VEGFR2 
mRNA expression between VEGFR2 siRNA and non-target siRNA was compared by Students 
T-Test. 
In vitro immunofluorescent expression of CXCR7 fluorescence per cell in EA.hy.926 and CXCR7 
overexpressing Chinese Hamster Ovary cells was compared to null primary control cells by 
Students-T test. CXCL12 or VEGFR2 immunofluorescent expression by cell lines and primary 
cells was expressed as mean fluorescence per cell (relative to DAPI) and compared using 
Mann-Whitney U test. 
ImageJ or Odyssey FC Image studio soft-wear (Li-cor) was used to determine band intensity of 
western blots. For each experiment protein intensity was normalised to GAPDH (loading 
control) intensity for each treatment condition and expressed relative to control of each 
individual experiment. Differing protein expression was analysed by One-way analysis of 
variance (ANOVA) with Dunnett’s post hoc correction.  
Analysis of the effect of drug combinations of trametinib and pazopanib on cell viability or cell 
chemotaxis compared with either drug given alone, was assessed using a one-way analysis of 
variance with Bonferroni’s post hoc correction.
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3.1 Introduction 
The growing interest in the important role of the tumour microenvironment in cancer has 
accelerated the understanding of cancer biology. The CXCR4-CXCL12 chemokine axis provides 
the crosstalk between cancer cells and their microenvironment and hence is the target of 
much research and therapeutic interventions. 
The CXCR4-CXCL12 chemokine axis plays a diverse role in directing cellular migration, as early 
as embryogenesis in humans where it regulates the migration and positioning of embryonic 
stem cells (Domanska et al., 2013). The de novo synthesis of the chemokine CXCL12 
throughout our body allows establishment of chemokine gradients where cells expressing the 
cognate receptor CXCR4 can be directed to locations in the body of high chemokine 
concentration, down ‘cellular highways’ (Zlotnik et al., 2011). In adults the CXCR4-CXCL12 axis 
also has an important role in immune responses directing CXCR4 expressing leukocytes along 
gradients of CXCL12 present at the site of inflammation, and in neovascularisation, recruiting 
progenitor cells from the bone marrow to the site of new vessel formation (Loetscher P et al., 
2000; Roeliene C. Kruizinga et al., 2009). Unsurprisingly in line with the Darwinian evolution 
of cancer, cancer cells may hijack the chemokine axis, upregulate chemokine receptors or 
secrete chemokine ligands which have diverse effects on cancer cell behaviour, the tumour 
microenvironment and establishment of metastasis. 
Over a decade ago Muller and colleagues in a seminal paper, demonstrated the 
overexpression of CXCR4 in primary and metastatic breast tumours (Muller et al., 2001b). We 
now know CXCR4 is the most widely over expressed chemokine receptor on malignant cells 
including melanoma, where aberrant expression results from oncogenic mutations, 
inactivation of tumour suppressor genes and hypoxia (Schioppa et al., 2003; Guerra et al., 
2007; Pivarcsi et al., 2007). The gain of CXCR4 expression in the context of melanoma 
determines destination, allowing tumour cells to behave like leukocytes and home towards 
the source of CXCL12 secreted at common sites of metastasis (Cardones et al., 2003). The 
expression of chemokine receptors by tumour cells not only permits melanoma metastasis, 
but also promotes tumour cell survival and proliferation by activation of the MAP/ERK 
pathway (Robledo et al., 2001). The significance of CXCR4 protein expression has also been 
demonstrated in both cutaneous and uveal melanomas. In uveal melanoma Scala et al 
correlated CXCR4 tumour expression with an epithelioid cell phenotype, conferring a worse 
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prognosis, while subsequent studies have shown increased CXCR4 expression correlates with 
the increased likelihood of hepatic metastasis (Scala et al., 2007; Dobner et al., 2012). In terms 
of cutaneous melanoma, elevated levels of CXCR4 expression have been linked to tumour 
ulceration, thickness as well as the development of metastasis (Longo-Imedio et al., 2005; 
Scala et al., 2005; Tucci et al., 2007; Toyozawa et al., 2012). However, to date, the significance 
of CXCR4 as a prognostic biomarker in melanoma has remained undefined. 
Strikingly, the mechanisms mediating the regulation and expression of CXCL12 within primary 
tumours, and the microenvironment is also lacking. CXCL12 is widely expressed by many 
different tumour types and commonly induced by hypoxia or as a result of hormone triggered 
pathways where it exerts a wide variety of effects including, promoting tumour cell 
proliferation via the activation of AKT or ERK cell signalling or survival through induction of 
NFκB signalling (Wang CY et al., 1996; Sonoda et al., 2001; Bachelder et al., 2002; Kryczek et 
al., 2005). CXCL12 also has potent angiogenic activity and through synergistic action with VEGF 
induces endothelial cell proliferation, and recruitment of pro-angiogenic plasmacytoid 
dendritic cells (Curiel, 2004; Kryczek et al., 2005). In metastasis, CXCL12 aids tumour 
dissemination by the induction of metalloproteinases that break down the extracellular 
matrix, and through up regulation of integrins that can promote tumour cell adhesion (Burger 
et al., 2003; Singh et al., 2004). The appropriate trafficking of immune cells and their retention 
in a tumour is important for immune detection and eradication, however CXCL12 can generate 
an immunosuppressive tumour microenvironment through recruitment of CD4+ T regulatory 
cells and plasmacytoid dendritic cells that induce immunosuppressive IL-10 secretion from T 
cells (Zou et al., 2001; Zou et al., 2004a). However, although many in vivo studies describe the 
diverse effects of CXCL12 in the tumour microenvironment, studies in melanoma are limited 
mainly to in vitro studies demonstrating the migration of tumour cells towards recombinant 
CXCL12 or enriched supernatants derived from liver cell types (O'Boyle et al., 2013). Only one 
in vivo study in cutaneous melanoma, correlated absence of CXCL12 expression with poor 
prognosis (Robledo et al., 2001; Di Cesare et al., 2007a; Mitchell et al., 2014). The role of 
CXCL12 in tumour progression particularly in primary melanoma is hence largely undefined.  
To add complexity to the CXCR4-CXCL12 signalling axis, recent studies have identified CXCR7 
as a chemokine receptor that binds to CXCL12 with 10 times the affinity of CXCR4 (Balabanian 
et al., 2005). However, despite its classical features as a chemokine receptor, CXCR7 is in 
general, regarded as a ‘decoy’ receptor that ‘scavenges’ and hence removes monomeric 
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CXCL12 to dampen or inhibit CXCR4-CXCL12 signalling (Naumann et al., 2010). Supporting 
these observations, studies in CXCR7 knockout mice or in the presence of CXCR7 inhibitors in 
vivo, have been shown to increase CXCL12 levels by up to 5 fold (Berahovich et al., 2014). The 
scavenging of CXCL12 allows CXCR7 the ability to modulate circulating chemokine levels 
possibly priming a chemokine gradient for effective cell chemotaxis. Furthermore, the 
modulation of circulating CXCL12 levels by CXCR7 has also been shown to effect leucocyte 
CXCL12 homing, and hence may indirectly modulate tumour infiltration (Berahovich et al., 
2014). CXCR7 also has the ability to heterodimerise with CXCR4, which is thought to affect 
CXCR4 G-protein signalling, therefore CXCR7 has the potential to modulate CXCR4 
downstream signalling including proliferation, survival and cell migration (Décaillot et al., 
2011b). Indeed the up regulation of CXCR7 has been shown to promote proliferation in breast 
cancer, tumour growth in lung cancer and migration in colon cancer (Décaillot et al., 2011b; 
Hernandez et al., 2011; Xu et al., 2011). However, to date there have been no reports of CXCR7 
expression on melanoma tumour cells, although notably one study demonstrates high 
expression by tumour associated blood vessels (Sánchez-Martín et al., 2011b). The possibility 
of a role for CXCR7 in tumour angiogenesis is also postulated given it’s known up regulation 
by hypoxia and VEGF, and ability to compromise vascular permeability when expressed on 
endothelial cells (Maksym et al., 2009a; Totonchy et al., 2014). 
There is strong evidence of the importance of the CXCR4-CXCL12 axis in the migration of 
cancer cells to metastatic sites however the role of CXCR4, and CXCL12 within the primary 
tumour and microenvironment remains poorly defined. The possible interplay with CXCR7 in 
CXCR4-CXCL12 exclusive events and the urgent need for novel prognostic biomarkers in 
melanoma therefore leads to the aims of the current chapter; to define the expression of 
CXCR4, CXCR7 and CXCL12 in uveal and cutaneous metastatic melanoma cell lines and in vivo 
in a cohort of primary tumours as well as to define the interplay between components of the 
CXCR4/CXCR7-CXCL12 axis. 
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3.2 Results 
3.2.1 CXCR4 is a Putative Prognostic Biomarker for AJCC Stage II Cutaneous 
Melanomas 
A pre-optimised immunohistochemical assay (A.McConnell Mres 2013) was used to quantify 
CXCR4 expression in a cohort of 64 melanocytic naevi and primary mealnomas of differeing 
AJCC stage. The mean percentage positively stained cells was calculated from 10 
representative 20X high powered fields using Leica QWin software. Results demonstrated 
variable CXCR4 expression in both the cytoplasm and the nucleus of both benign naevi and all 
AJCC stage primary melanomas (Figure 3.1). 
 
 
Figure 3.1 Cytoplasmic and Nuclear CXCR4 Epression in Primary Cutaneous Melanomas 
Example pictomicrographs of Cytoplasmic CXCR4 expression A.) or Nuclear CXCR4 expresion B.) in 
primary cutanous melanomas. Images were acquired at x20 magnification. Scale bar represents 50 µm. 
Correlation of total CXCR4 expression with eventual AJCC disease stage revealed a general 
decrease in total CXCR4 expression from naevi to AJCC stage II melanomas with a significant 
increase in CXCR4 expression from stage II melanomas to stage III/IV melanomas (One-way 
ANOVA, *P=0.0296, Figure 3.2 A). Furthermore, correlation of total CXCR4 expression in 
localised and metastatic disease revealed a significant increase in mean percentage CXCR4 
expression from 37.48% in localised melanomas to 56.08% in tumours which metastasised 
(Mann-Whitney U, *P=0.0369, Figure 3.2 B). These results thus highlight up regulation of 
CXCR4 expression associated with the development of metastatic disease, consistent with the 
reported role of CXCR4 in cancer cell migration (Kim et al., 2006). 
The significant difference in CXCR4 expression between localised and metastatic tumours 
allowed a differential cut off point of 50% CXCR4 expression that differed significantly 
between localised and metastatic tumours, calculated using a Wilcoxon signed-rank test. 
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Therefore 50% CXCR4 expression was considered an appropriate cut off point, for further 
analysis. Univariate analysis of mean percentage total CXCR4 expression in all AJCC stage 
melanomas revealed a non-significant decrease in disease free survival from 65.5% for 
individuals expressing low CXCR4 (<50%), to 47.6% in individuals expressing high CXCR4 
(>50%) over seven years (Log-rank (Mantel-Cox) test HR = 1.99 (95% CI 0.81 – 4.91) P=0.13, 
Figure 3.2 C). However, stratification according to AJCC stage II melanomas at diagnosis, 
revealed high CXCR4 expression (>50%) was associated with significantly decreased disease 
free survival to 30.77%, compared to 73.68% of individuals with low CXCR4 expression (<50%) 
and who remained disease free over 7 years (Log-rank (Mantel-Cox) test HR = 3.24 (95% CI 
1.08 – 9.73) *P=0.036) (Figure 3.2 D). Collectively, these results therefore highlight a 3-fold 
risk of disease reoccurrence for individuals with high total CXCR4 expression (>50%), further 
suggesting high CXCR4 expression (>50%) may be a useful prognostic biomarker for disease 
progression in AJCC stage II melanomas. 
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Figure 3.2 CXCR4 Expression in Primary Melanomas.  
A.) Scatter graph representing the mean (mean of 10 HPF) % positive  cells for CXCR4 expression in 
eventual stage melanocytic naevi or AJCC stage I, II or III melanomas. The horizontal bar represents the 
median % staining for each group. B.) Scatter graph representing the mean % positive CXCR4 staining 
cells in localised (eventual AJCC stage of disease I/II) and metastatic melanomas (eventual AJCC stage 
III/IV) after 7 years follow up. Horizontal bars represent median staining percentage, (Mann-Whitney 
U P *= 0.0369) C.) Kaplan-Meier survival curve showing univariate analysis of % CXCR4 expression and 
disease free survival (7 years) in all stage melanomas. Vertical lines represent individual patients 
developing a metastasis. Log-rank (Mantel-Cox) test HR = 1.99 (95% CI 0.81 – 4.91) P = 0.13.D.) Kaplan-
Meier survival curve showing Univariate analysis of % CXCR4 expression and disease free survival (7 
years) in stage II melanomas. Vertical lines represent individual patients developing a metastasis. Log-
rank (Mantel-Cox) test HR = 3.24 (95% CI 1.08 – 9.73) *P = 0.036. 
Studies in breast, renal and lung cancer demonstrate the expression of nuclear CXCR4 
correlates with the increased risk of metastasis, however in cutaneous melanoma this has 
remained undefined (Na et al., 2008; Woo et al., 2008; Linhui Wang et al., 2009). Further 
analysis of nuclear CXCR4 expression in all AJCC stage melanomas revealed a stepwise but 
non-significant increase in nuclear CXCR4 expression with disease progression (One-way 
ANOVA, P=0.78, Figure 3.3 A). However, when comparing nuclear CXCR4 expression in 
localised and metastatic disease, results revealed a significant increase in nuclear CXCR4 
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expression in metastatic disease (Unpaired t-test *P=0.027, Figure 3.3 B). In addition, 
correlation of nuclear CXCR4 expression in all AJCC stage wild-type with B-RAF/N-Ras mutated 
melanomas, revealed a significant increase in nuclear CXCR4 expression in those tumours 
bearing an activating mutation in either B-RAF or N-Ras (Unpaired t-test ***P = 0.0004, Figure 
3.3 C). Collectively these data suggest an association of nuclear CXCR4 expression with 
oncogenic N-Ras/B-RAF signalling and the evolution of a more aggressive tumour phenotype. 
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Figure 3.3 Nuclear CXCR4 Expression in Primary Melanomas 
A.)Scatter graph representing the mean (mean of 10 HPF)  nuclear CXCR4 score in eventual stage 
melanocytic naevi or AJCC stage I, II or III melanomas. B.) Scatter graph representing the mean nuclear 
CXCR4 score in localised (eventual AJCC stage of disease I/II) and metastatic melanomas (AJCC stage 
III/IV) after 7 years follow up (Unpaired t-test *P = 0.027) C.)  Scatter graph representing the mean 
nuclear CXCR4 score in B-RAF/N-Ras wild-type and B-RAF/N-Ras mutated melanomas all AJCC stages 
(Unpaired t-test *** P = 0.0004). The horizontal bar represents the mean nuclear CXCR4 staining score 
for each group. 
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3.2.2 CXCR4 is Strongly Expressed by Primary Uveal Melanomas 
Using the same optimised immunohistochemistry protocol as performed in Section 3.2.1, 
CXCR4 expression was determined in a small cohort of 12 primary uveal melanoma tumours. 
Results demonstrated CXCR4 expression in 83% of tumours, where expression, be it nuclear 
or cytoplasmic, was observed in all tumour cells (Figure 3.4), consistent with results obtained 
from a study of 70 uveal melanomas which demonstrated total CXCR4 expression in 98.6% of 
tumours, with expression levels of 75-100% (Dobner et al., 2012). In the current primary uveal 
melanoma cohort however, both nuclear and cytoplasmic CXCR4 expression were observed, 
although in general results revealed expression as either cytoplasmic or nuclear, with dual 
CXCR4 expression observed in 2 tumours (Figure 3.4) and with no apparent correlation 
between subcellular localisation or monosomy or disomy of chromosome 3 (Figure 3.4 B). 
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Figure 3.4 Immunohistochemistry of CXCR4 Expression in Primary Uveal melanomas 
A.) Representative images of CXCR4 immunohistochemical expression in a cohort of primary uveal 
melanomas. Images were acquired at x20 magnification. Scale bar represents 50µm. B.) Summary table 
of cohort features and CXCR4 immunohistochemical expression. 
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3.2.3 CXCR4 is Expressed by Cutaneous and Uveal Metastatic Melanoma Cell 
Lines and Primary Melanocytes 
To further explore any impact of hyper-activating mutations in MAPK signalling on nuclear and 
cytoplasmic expression of CXCR4, both total and nuclear/cytoplasmic CXCR4 expression were 
evaluated in a panel of B-RAF/N-Ras wild-type or mutated cutaneous or wild-type and 
GNAQ/GNA11 mutant uveal melanoma cell lines, and compared with expression in normal 
cutaneous melanocytes. 
Western blot analysis of total CXCR4 expression revealed variable but consistent expression 
of CXCR4 in primary melanocytes as well as in cutaneous CHL-1 (B-RAF/N-Ras wild-type), WM-
164 (B-RAFV600E mutated) and WM-1361 (N-Ras mutated) metastatic melanoma cell lines, and 
in OM413 (GNAQ/GNA11 wild-type), MEL270, OMM2.3 (GNAQ mutated) and UPMD2 (GNA11 
mutated) uveal melanoma cell lines, which in all melanoma cell lines was enhanced compared 
to expression in primary melanocytes (Figure 3.5). 
 
Figure 3.5 Total CXCR4 Expression in Human Uveal Melanoma Cell Lines.  
Representative western blot of CXCR4 and GAPDH (loading control) expression in A.) CHL-1 (wild-type) 
WM-164 (V600E B-RAF mutated), or WM-1361 (N-Ras mutated) human metastatic cutaneous 
melanoma cells or OM413 (GNAQ/GNA11 wild-type), MEL270, OMM2.3, (GNAQ mutated) and UPMD2 
(GNA11 mutated) human uveal melanoma cell lines. B.) Each bar represents the mean of 4 replicates 
of CXCR4 band intensity normalised to GAPDH band intensity (CXCR4/GAPDH) for each cell line, and 
expressed relative to the mean of each individual experiment (mean ± SD, N = 4). 
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Immunofluorescence analysis for subcellular localisation of CXCR4 revealed expression mainly 
in the cytoplasm of primary melanocytes, (Figure 3.6), whereas in a select panel of both 
cutaneous and uveal metastatic melanoma cell lines (Figure 3.7) consistent expression of both 
nuclear and cytoplasmic CXCR4 was observed. Interestingly and consistent with findings of 
increased nuclear CXCR4 in primary cutaneous metastatic melanomas (Figure 3.3 B), results 
demonstrated increased nuclear CXCR4 expression in metastatic OMM2.3 uveal melanoma 
cells compared to expression in MEL270, the primary uveal melanoma cell line derived from 
the same patient (derived from the liver metastasis). 
 
Figure 3.6 Immunofluorescent Analysis of CXCR4 Expression in Primary Melanocytes. 
Representative image of CXCR4 or null primary antibody control expression in primary melanocytes. 
Green depicts CXCR4 positivity and blue DAPI nuclear staining.  Images taken by confocal microscopy 
with a magnification 20x scale bar = 50μm. 
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Figure 3.7 Immunofluorescence for the Expression of CXCR4 in Cutaneous and Uveal 
Metastatic Melanoma Cell Lines. 
Representative images from 3 replicate experiments for the immunofluorescent expression of 
cutaneous metastatic melanoma cell lines CHL-1, A375, WM-164 and WM-1361 or null primary control 
or uveal melanoma cell lines OM413, MEL270, OMM2.3 and UPMD2 or null primary. Green depicts 
CXCR4 positivity and blue DAPI nuclear staining. Images were acquired by confocal microscopy with a 
magnification 20x scale bar = 50μm or Z stacks of cells taken and the middle cross section of the cell 
shown, with a magnification of 40x, scale bar 20μm. 
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3.2.4 Oncogenic B-RAF Does Not Enhance Nuclear Localisation of CXCR4 
To test the hypothesis that activated MAPK in cutaneous melanoma cells signalling mediated 
by B-RAF/N-Ras (or GNAQ/GNA11) mutation may result in the translocation of CXCR4 
expression to the nucleus as suggested by in vivo data demonstrating the significant increase 
in nuclear CXCR4 expression in tumours bearing an activating mutation in either B-RAF or N-
Ras (Unpaired T-test ***P=0.0004, Figure 3.3 C), B-RAFWT or B-RAFV600E were transiently 
transfected into B-RAFWT CHL-1 cells prior to determining CXCR4 subcellular localisation by 
western blotting and immunofluorescence. Expression of B-RAFWT or B-RAFV600E was 
confirmed by a significant increase in total B-RAF expression in cells transfected with both B-
RAFWT or B-RAFV600E compared to un transfected cells (One way Analysis of variance with 
Dunnett’s Post Hoc correction *P<0.05, **P<0.005 for B-RAFWT or B-RAFV600E transfected cell 
respectively , Figure 3.8 A and B), with activation of oncogenic B-RAF signalling confirmed by 
a significant increase in the phosphorylation of ERK (One way analysis of variance with 
Dunnett’s Post Hoc correction ***P<0.001) (Figure 3.8 A and C). Western blotting of 
cytoplasmic and nuclear cell components following cell fractionation revealed consistently 
and significantly lower expression of CXCR4 in the cytoplasm compared to nuclear subcellular 
location in all conditions (Paired T test ***P<0.0001). However, there was no significant 
change in CXCR4 expression observed in either subcellular locations of cells overexpressing B-
RAFWT or B-RAFV600E compared to un transfected cells (One-way analysis of variance P>0.05 
ns) (Figure 3.8 D and E). Immunofluorescence analysis of CXCR4 expression in both 
cytoplasmic and nuclear fractions of CHL-1 cells over expressing B-RAFWT or B-RAFV600E also 
revealed no significant changes in the subcellular CXCR4 location compared to un-transfected 
cells, (Figure 3.9), collectively suggesting that, at least, in vitro oncogenic B-RAFV600E does not 
confer enhanced nuclear localisation of CXCR4. 
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Figure 3.8 Oncogenic B-RAF Does Not Enhance Nuclear Localisation of CXCR4 
A.) Western blot for the expression of total B-RAF, Phospho-ERK, ERK and GAPDH loading control in 
CHL-1 cells (lipofectamine only) or in CHL-1 cells transiently transfected for 72 hours with B-RAFWT (WT 
B-RAF) or B-RAFV600E (V600E B-RAF) B and C) Relative expression of B-RAF or pERK in CHL-1 cells 
(lipofectamine) or CHL-1 cells transiently transfected for 72 hours with WT B-RAF or V600E B-RAF. Each 
bar is the mean of 3 replicate experiments normalised to GAPDH band intensity, and expressed relative 
to the mean of each individual experiment (mean ± SD N=3), statistics acquired by One-way analysis of 
variance, P=0.0143 with Dunnett post- hoc test, *P<0.05, **P<0.01. ***P<0.0001. D.) Western blot for 
the expression of CXCR4, Lamin A/C (Nuclear loading control) and MEK (Cytoplasmic loading control) 
in cytoplasmic and nuclear subcellular fractions of CHL-1 cells (lipofectamine only) or CHL-1 cells 
transiently transfected for 72 hours with WT B-RAF or V600E B-RAF. E.) Relative expression of CXCR4 in 
CHL-1 cells (lipofectamine) or CHL-1 cells transiently transfected for 72 hours with WT B-RAF or V600E 
B-RAF Each bar represents the mean of 3 replicate experiments expressed relative to the mean of each 
individual experiment (mean ± SD N=3), statistics acquired by One-way analysis of variance with 
Dunnett’s post-hoc test, P>0.05 ns. 
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Figure 3.9 Oncogenic B-RAF Does Not Enhance Nuclear Localisation of CXCR4 
Representative images for the immunofluorescent expression of CXCR4 in 3 replicate experiments of 
CHL-1 cells (lipofectamine only) or CHL-1 cells transiently transfected for 72 hours with B-RAFWT (WT B-
RAF) or B-RAFV600E (V600E B-RAF) or null primary antibody control. Green depicts CXCR4 positivity and 
blue DAPI nuclear staining.  Images taken by confocal microscopy with a magnification 20x scale bar = 
50μm, 40x scale bar = 20μm or Z stacks of cells taken and the middle cross section of the cell shown, 
with a magnification of 40x, scale bar 20 μm (N=3). 
3.2.5 CXCR7 is Not Expressed by Cutaneous and Uveal Metastatic Melanoma 
Cell Lines 
CXCR7 has recently been described as an additional binding partner to CXCL12 and although 
originally thought to ‘scavenge’ CXCL12 to dampen, inhibit or regulate CXCR4-CXCL12 
signalling, CXCR7 has also been shown to induce cell proliferation and migration in some 
cancer cell types (Naumann et al., 2010; Décaillot et al., 2011b; Singh and Lokeshwar, 2011; 
Xu et al., 2011; Yates et al., 2013). Furthermore, its reported expression on tumour associated 
endothelial cells suggests a contribution to tumour angiogenesis (Wang et al., 2008b). Given 
the unclear role of CXCR7 in melanoma, its potential contribution to the CXCL12-CXCR7 axis 
and to processes that were previously thought to be monogamously CXCL12-CXCR4 driven, 
the expression and role of CXCR7 in melanomas was therefore further evaluated. 
Immunofluorescence analysis for the expression of CXCR7 was performed in primary 
cutaneous metastatic CHL-1, WM-164, metastatic uveal melanoma cell lines OM413 and 
UPMD2 (Figure 3.10) or primary melanocytes (Figure 3.11) and compared with expression in 
known control expressing cell lines; HeLa, EA.hy926 or Chinese hamster Ovary (CHO) cells 
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stably over expressing CXCR7 (a kind gift from Professor Simi Ali, Newcastle University, Figure 
3.10). 
 
Figure 3.10 Immunofluorescence for the Expression of CXCR7 in Cutaneous and Uveal 
Metastatic Melanoma Cell Lines. 
Representative images from 3 replicate experiments for the immunofluorescent expression of CXCR7 in 
Hela, Chinese Ovary cells stably expressing CXCR7 (CHO), EA.hy926 cells (positive controls), or 
cutaneous metastatic melanoma cell lines CHL-1, and WM-164 or metastatic uveal melanoma cell lines 
OM413 and UPMD2 or  null primary antibody control. Green depicts CXCR7 positivity and blue DAPI 
nuclear staining. Images taken by confocal microscopy with a magnification 20x scale bar = 50μm. 
CXCR4, CXCR7 and CXCL12 Expression and Signalling in Cutaneous and Uveal Melanoma 
106 
 
Results demonstrated cytoplasmic CXCR7 was expressed by Hela cells, EA.hy926 and CHO cell 
stably expressing CXCR7 (Figure 3.10). However, there was no apparent expression of CXCR7 
by either the cutaneous or uveal melanoma cell lines (Figure 3.10) or in primary melanocytes 
(Figure 3.11). 
Further quantification of CXCR7 expression also confirmed the significant expression of CXCR7 
on EA.hy926 endothelial cells as well as a positive control CHO cells over expressing CXCR7 
(Unpaired T test **P= 0.0016 and **P=0.0018 respectively, Figure 3.12). 
 
Figure 3.11 CXCR7 is not Expressed by Primary Melanocytes 
Representative images for the immunofluorescent expression of CXCR7 in primary melanocytes. Green 
depicts CXCR7 positivity and blue DAPI nuclear staining. Images taken by confocal microscopy with a 
magnification 20x scale bar = 50μm (N=3). 
Collectively these data therefore suggest CXCR7 expression is negligible on cutaneous and 
uveal melanoma cells but is expressed by endothelial cell types, consistent with previous 
studies in vivo demonstrating expression of CXCR7 within the tumour microenvironment of 
cutaneous melanoma and specifically expression by the endothelial cells of tumour associated 
blood vessels (Sánchez-Martín et al., 2011b). 
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Figure 3.12 Immunofluorescence for the Expression of CXCR7 in Chinese Hamster Ovary Cells 
Overexpressing CXCR7 and EA.hy926 Umbilical Vein Endothelial Cells 
A.) Representative images from 3 replicate experiments of CXCR7 expression in Chinese hamster ovary 
cells (CHO-CXCR7, positive control), or EA.hy926 endothelial cells or following staining with a null 
primary antibody control. Green fluorescence represents CXCR7 expression and cell nuclei are 
represented by blue DAPI staining. Images were acquired by confocal microscopy with a magnification 
20x scale bar = 50μm (N=3). B) Relative CXCR7 fluorescence/expression in CHO-CXCR7 or EA.hy.926 
cells compared to expression in corresponding cells stained with null primary antibody control. Statistics 
acquired by unpaired T test **P<0.01. Each bar is the mean +/- SEM (N=3). 
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3.2.6 CXCR7 is Not Expressed by Melanocytic Naevi or Primary Cutaneous 
Melanomas but is Expressed Within the Tumour Microenvironment 
To confirm previous reports of CXCR7 expression within the tumour microenvironment of 
cutaneous melanoma in vivo and to further assess any potential expression by melanocytes 
or melanoma cells, the expression of CXCR7 was determined in cohort of 24 primary FFPE 
cutaneous melanomas of differing disease stage or melanocytic naevi using a previously 
optimised immunohistochemistry assay (optimised in collaboration with Barnaby Pathy, 
undergraduate 2015), and optimised using Hela FFPE cell pellets (Figure 3.13) (Sánchez-Martín 
et al., 2011b). 
Results confirmed in vitro studies, with no apparent expression of CXCR7 expression detected 
in any of the 24 analysed cutaneous melanomas or benign nevi. However, notably, in 7 
tumours (30%) expression of CXCR7 was clearly detectable within the tumour 
microenvironment of the dermis seemingly on cells lining the inner lumen of blood vessels 
and capillaries, postulated to be endothelial cells (Figure 3.13). In 1 advanced stage melanoma 
there was also strong CXCR7 expression in the immune infiltrate of the tumour, possibly on T 
or B lymphocytes, tumour associated macrophages or dendritic cells known to express CXCR7 
(Sánchez-Martín et al., 2013). Nevertheless, the expression of CXCR7 within the tumour 
microenvironment was varied and could not be correlated to any particular disease stage or 
with B-RAF/N-Ras mutational status. Thus, data confirm the absence of CXCR7 on melanoma 
tumour cells, but with expression evident within the tumour microenvironment of a 
proportion of melanomas. 
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Figure 3.13 Immunohistochemical Expression of CXCR7 in Primary Cutaneous Melanomas.  
Representative images of CXCR7 immunohistochemical expression in FFPE Hela cells (positive control) 
or a cohort of primary cutaneous melanomas or following staining with a null primary antibody control. 
Images were acquired at x20 magnification. Arrow depicts positive CXCR7 staining in capillaries, blood 
vessels and immune cells.Scale bar = 50µM. 
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3.2.7 CXCR7 is Not Expressed by Primary Uveal Melanomas 
The immunohistochemical expression of CXCR7 was also determined within a small cohort of 
7 FFPE primary uveal melanomas (Figure 3.14) with results again confirming in vitro studies in 
uveal melanoma cell lines (section 3.2.5), with no detectable expression of CXCR7 on primary 
uveal melanoma tumour cells (Figure 3.14 iii), or cells within the normal retina or choroid of 
the eye (Figure 3.14 iv). 
 
Figure 3.14 Immunohistochemical Expression of CXCR7 in Primary Uveal Melanomas 
Representative images of CXCR7 expression on Hela cells (positive control, (i) or Primary Uveal 
melanomas (ii- vi) or following staining with null primary antibody control. Images depict Primary Uveal 
Melanoma tumour cells (iii), the choroid and retina of the eye (iv) or capillaries within primary uveal 
melanomas (v and vi) Black arrow depicts positive CXCR7 expression. Images were acquired at x40 
magnification. Scale bar = 50µm. 
Similarly, to observations in cutaneous melanoma (section 3.2.6), CXCR7 expression was 
detected on cells lining capillaries within the bulk of 3 tumours (42%) (Figure 3.14 v and vi), 
suggesting as with cutaneous melanoma, CXCR7 expression is present within the 
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microenvironment of some primary uveal melanomas and specifically expressed by 
endothelial cell types. 
3.2.8 Autocrine CXCR4-CXCL12 Cell Signalling Activates the Pro-survival MAPK 
Signalling in Cutaneous Metastatic Melanoma Cell Lines 
In melanoma, the CXCR4-CXCL12 axis is well known to promote the specific homing of CXCR4 
positive tumour cells to regions with high levels of CXCL12 found at the secondary sites of 
metastasis. In addition to promoting organ specific migration, CXCL12 can also promote cell 
proliferation, survival, angiogenesis and immunosuppression, all factors that can have a pro-
tumorigenic effect on the primary tumour and its microenvironment. However, the effect of 
CXCL12 and its presence in the primary melanoma tumour microenvironment remains poorly 
understood, with the few studies performed, reporting non-significant and contradictory 
results. To assess the role of CXCL12 in the primary tumour environment of both cutaneous 
and uveal melanomas, initial immunofluorescence studies for expression of CXCL12 were 
therefore performed in cutaneous and uveal metastatic melanoma cell lines, as well as in 
EAhy.926 endothelial cells and primary cells known to be present within the local tumour 
microenvironment including, primary melanocytes, primary keratinocytes, and primary 
dermal fibroblasts. CXCL12 fluorescence was quantified using ImageJ software, where 
thresholds were applied to limit fluorescence intensity for green (CXCL12) and blue (cell 
nuclei) with a standardised threshold limit of 8 and 11 respectively. CXCL12 fluorescence per 
cell was determined by division of total CXCL12 fluorescence per image by number of DAPI 
pixels per image (Figure 3.15). 
Interestingly results revealed variable expression of cytoplasmic CXCL12 by all cell lines and 
primary cells, indicating that under normal and unstimulated cell culture conditions, CXCL12 
is likely produced in situ (Figure 3.15 A and B). Results also revealed increased CXCL12 
expression in primary melanocytes compared to expression in primary keratinocytes or 
dermal fibroblasts and moreover, compared to expression in all melanoma cell lines, 
suggesting a trend for CXCL12 down regulation by melanomas (Figure 3.15 C). Expression of 
CXCL12 between differing cutaneous and uveal melanoma cell lines however, did not 
significantly vary (Figure 3.15 C). Quantitative and statistical analysis of CXCL12 expression in 
primary melanocytes, keratinocytes and dermal fibroblasts also revealed significantly less 
expression in primary keratinocytes compared to both primary dermal fibroblasts and 
melanocytes ( Man Whitney U * P=0.0117 and **P= 0.0047 respectively, Figure 3.15 C).  
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To investigate whether CXCL12 is secreted from each cell type, CXCL12 was quantified in cell 
culture supernatants derived from confluent cutaneous and uveal melanoma cells, primary 
melanocytes, keratinocytes and fibroblasts, the control medium of each cell type as well as in 
supernatants derived from primary biliary epithelial cells obtained from a liver resection using 
a commercial ELISA assay (Figure 3.16). 
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Figure 3.15 Immunofluorescence Analysis of the Expression of CXCL12 in Cutaneous and 
Uveal Metastatic Melanoma Cell Lines and Cells within the Tumour Microenvironment 
A.) Representative image from 3 replicate experiments for the  immunofluorescent expression of 
CXCL12 or following staining with null primary antibody negative control in cutaneous metastatic 
melanoma cell lines CHL-1, A375, WM-164, WM-1361 or metastatic uveal melanoma cell lines OM413, 
MEL270 and UPMD2 or B.) in known primary cells in the tumour microenvironment; primary 
melanocytes, primary keratinocytes, primary dermal fibroblasts (all primary cells are representative 
images of 4 individual donors) or in the endothelial cell line EAhy.926. Green depicts CXCL12 positivity 
and blue, DAPI nuclear staining.  Images taken by confocal microscopy, magnification 40x. Scale bar = 
20μm. C. Mean CXCL12 fluorescence per cell within cutaneous and uveal metastatic melanoma cell 
lines, primary dermal fibroblasts, keratinocytes, or EAhy926 cells. Each bar is the mean CXCL12 
fluorescence per cell of >3 replicates (mean ± SD N=3, n=6). Statistics acquired by Mann Whitney U 
*P<0.05, **P<0.01. 
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Figure 3.16 Secretion of CXCL12 by Cutaneous Metastatic Cell Lines, Cells within the Tumour 
Microenvironment and Billary Epithelial Cells. 
CXCL12 (pg/ml) secretion by human metastatic cutaneous melanoma cell lines CHL-1, WM-164, A375, 
WM-1361, human metastatic uveal melanoma cell lines OM413, MEL270, OMM2.3, UPMD2, Primary 
(1o) melanocytes, dermal fibroblasts, keratinocytes and primary biliary epithelial cells (BEC), or control 
DMEM, RPMI, F12 Hams, melanocyte, BEC or keratinocyte specific growth medias. Each bar represents 
the mean of 3 independent experiments of cell lines or 4 separate donors for primary cells +/- SD. 
Statistics acquired by Mann Whitney U *P=>0.01 (N>3). 
Surprisingly although all cells tested previously displayed cytoplasmic expression of CXCL12, 
only CHL-1 (B-RAF/N-Ras wild-type) and WM-164 (B-RAFV600E mutated) cutaneous metastatic 
melanoma cell lines, primary biliary epithelial cells and dermal fibroblasts secreted detectable 
levels of CXCL12 (Figure 3.16). Significantly higher secretion of CXCL12 was detected in B-
RAF/N-Ras wild-type cutaneous metastatic melanoma cells CHL-1 compared to WM-164 B-
RAFV600E mutated cells (Mann Whitney U *P=0.0286) with no observed secretion by B-RAF/N-
Ras mutated A375 and WM-1361 suggesting that CXCL12 secretion maybe down regulated as 
a result of hyper activating mutations in MAPK signalling. The observed secretion of CXCL12 
from cutaneous metastatic melanoma cell lines, previously shown to express CXCR4 (section 
3.2.3) thus uncovers the interesting possibility that these cell lines may display autocrine 
CXCL12 signalling, as previously reported in head and neck cancer cells (Wang et al., 2008a). 
However, there was no detectable secretion of CXCL12 in either wild-type, or GNAQ/GNA11 
mutant metastatic uveal melanoma cell lines, suggesting in line with previous reports in the 
literature that uveal melanoma cell lines do not secrete CXCL12 (Di Cesare et al., 2007b). 
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Although CXCL12 expression was evident within the cytoplasm of primary melanocytes, there 
was however, no detectable secretion of CXCL12. 
The observed consistently high levels of CXCL12 secreted by primary dermal fibroblasts also 
suggests that these cells may act as the main secretory source of CXCL12 in normal skin or 
within the local primary tumour microenvironment while the observed lower secretion of 
CXCL12 from primary biliary epithelial cells further confirmed the liver as a CXCL12 secreting 
source with the potential to attract CXCR4 positive melanoma cells as widely described (Wald 
et al., 2004; Hong et al., 2009; Saiman et al., 2015). 
 
Figure 3.17 Autocrine CXCR4-CXCL12 Cell Signalling in Cutaneous Melanoma 
A.) Representative Western blot of Phospho-CXCR4 (P-CXCR4), Phospho-ERK (P-ERK), total ERK and 
GAPDH loading control expression in WM-164 (B-RAFV600E mutated) metastatic melanoma cells treated 
with Anti-CXCL12 neutralising antibody or IgG isotype control for 5, 10, 20, 30 minutes. N=3. B.) 
Densitometric analysis of P-CXCR4 relative to GAPDH expression. Each bar represents the mean of 3 
replicates of P-CXCR4 band intensity normalised to GAPDH band intensity (P-CXCR4/GAPDH), and 
expressed relative to the mean of each individual experiment (mean ± SD, N = 3). Statistics acquired by 
one-way ANOVA with Dunnett’s post hoc correction **P= 0.01. C.) Densitometric analysis of P-ERK 
relative to GAPDH expression. Each bar represents the mean of 3 replicates of P-ERK band intensity 
normalised to GAPDH band intensity (P-ERK/GAPDH), and expressed relative to the mean of each 
individual experiment (mean ± SD, N = 3). Statistics acquired by one-way ANOVA with Dunnett’s post 
hoc correction **P= 0.003. 
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To investigate the possibility of CXCR4-CXCL12 autocrine cell signalling and its impact on MAPK 
cell signalling, a neutralising antibody to CXCL12 or isotype control antibody was incubated 
with B-RAF mutated WM-164 metastatic melanoma cells that secrete CXCL12. Western 
blotting revealed a significant reduction of phospho-CXCR4 expression after treatment with 
CXCL12 neutralising antibody for 10 or 20 minutes (one-way ANOVA with Dunnett’s post hoc 
correction **P= 0.001, Figure 3.17 A). This was accompanied by concurrent significant 
inhibition of MAPK cell signalling and a concomitant reduction in phospho-ERK expression 
(one-way ANOVA with Dunnett’s post hoc correction **P=0.003, Figure 3.17 B and C). 
Together these data suggest that endogenous CXCL12 secreted form metastatic melanoma 
cells may act in an autocrine manner activating CXCR4 receptors on melanoma cells to 
promote pro-survival MAPK cell signalling. 
3.2.9 Epidermal CXCL12 Expression Prevents Melanoma Metastasis 
To investigate further the possibility of CXCL12 autocrine signalling in cutaneous melanomas 
at the primary site and determine the expression of CXCL12 in the tumour microenvironment, 
immunofluorescence for the expression of CXCL12 was performed in a FFPE cohort of 24 
melanocytic naevi or primary melanomas of differeing AJCC stage as well as in 2 FFPE samples 
of normal human skin, with double staining for Melan-A, as a melanocytic marker. CXCL12 
fluorescence intensity was quantified using ImageJ softwear, with thresholds applied to limit 
fluorescence intensity for green (Melan-A) and red (CXCL12) at a standardised threshold limit 
of 8 and 6 respectively. CXCL12 fluorescence per cell was acquired by division of total CXCL12 
fluorescence per image by the number of Melan-A pixels per image. 
Results demonstrated the expression of Melan-A by melanocytes at the stratum basale of the 
epidermis in normal skin as expected (Figure 3.18) with CXCL12 expression detected, as 
previously documented in both the sweat glands and capillaries (Pablos et al., 1999; Avniel et 
al., 2005; Mitchell et al., 2014). In line with in vitro observations (section 3.2.8) and previous 
literature, CXCL12 expression was also observed within the dermis, located around dermal 
fibroblasts (Figure 3.18 A. B) (Pablos et al., 1999; Avniel et al., 2005; Mitchell et al., 2014). 
However, contradictory to findings from the present in vitro studies (section 3.2.8) and 
previous reports, CXCL12 expression was also observed in the epidermis located around 
keratinocytes, with increased intensity towards the stratum corneum, and suggesting the 
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possibility that CXCL12 expression in the epidermis increases in line with increasing epidermal 
differentiation (Figure 3.18) (Avniel et al., 2005). 
Studies in all AJCC stage primary cutaneous melanomas, confirmed Melan-A expression by all 
tumour cells which co-localised to varying degrees with tumoural CXCL12 expression (Figure 
3.19 Ai, Bi). Interestingly in all primary melanomas studied, CXCL12 was also expressed in the 
same pattern as that observed in normal skin, with expression observed within the epidermis 
adjacent to the tumours (Figure 3.19 A iii, B ii). However, CXCL12 expression in the epidermis 
overlying primary melanomas appeared to be reduced (Figure 3.19 A iv). 
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Figure 3.18 Immunofluorescence analysis of Melan-A and CXCL12 in Normal Skin 
A.) Representative images of Melan-A (green), CXCL12 (red) expression or DAPI nuclear staining (blue) 
in FFPE sections in the epidermis, capillaries or sweat glands of normal human skin. White box 
highlights dermal fibroblasts. Images were acquired by confocal microscopy with a magnification 20x. 
Scale bar = 150 or 50μm. 
Analysis of CXCL12 within primary melanomas revealed consistent expression of CXCL12 by 
tumour cells albeit it at low levels, which did not vary significantly between AJCC disease stage 
(Figure 3.20 A) (Kruskal-Wallis test P=0.2488 ns) or between localised or metastatic 
melanomas (Figure 3.20 B.) (Mann Whitney U P=0.1138 ns). Furthermore, there was no 
significant correlation between CXCL12 expression and time to metastasis in advanced 
tumours (Spearman’s rank correlation P=0.3680 ns), collectively suggesting that although 
CXCL12 is present or possibly secreted by tumour cells in an autocrine manner; this does not 
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apparently influence disease progression. Remarkably, however, comparison of CXCL12 
expression with B-RAF/N-Ras mutational status revealed significantly reduced CXCL12 
expression in B-RAF/N-Ras mutant tumours compared to expression in wild-type tumours 
(Figure 3.20 D.) (Students T test *P=0.0323), consistent with the observations seen in vitro 
(section 3.2.8) showing B-RAF mutated cell lines secrete significantly less CXCL12 compared to 
B-RAF wild-type melanoma cell lines, and further supporting the hypothesis that the down-
regulation of CXCL12 secretion is mediated by activation of MAPK signalling. 
Given the association between high nuclear CXCR4 expression and the presence of a B-RAF/N-
Ras mutation in primary melanomas observed in section 3.2.1, the expression of CXCL12 with 
either total, nuclear or cytoplasmic CXCR4 was therefore compared in the same combined 
cohort of melanocytic nevi and primary melanomas of varying AJCC disease stage (Figure 3.20 
E and F). Results however, demonstrated there was no apparent correlation between total 
CXCR4 and CXCL12 expression (Spearman’s rank correlation P=0.5301, Figure 3.20 E) or indeed 
between cytoplasmic CXCR4 and CXCL12 expression (data not shown), supporting data from 
a previous study in cutaneous melanoma where similarly no relationship between CXCR4 and 
CXCL12 expression was observed (Toyozawa et al., 2012). Nevertheless, the comparison of 
nuclear CXCR4 with mean CXCL12 expression across the whole cohort revealed a trend, albeit 
insignificant in the current cohort size, for high nuclear CXCR4 expression with low CXCL12 
expression (Spearman’s rank correlation P=0.057 ns). 
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Figure 3.19 Immunofluorescence for the Expression of CXCL12 in Primary Cutaneous 
Melanomas 
A.i) Representative image of Melan-A (green), CXCL12 (red) expression or nuclear DAPI (blue) staining 
in a primary cutaneous melanoma AJCC stage III. ii.) Nuclear DAPI staining only following treatment 
with null primary antibody control. iii) CXCL12 expression depicted in the epidermis beside or iii) above 
the primary tumour. B.) Representative images of blue DAPI staining or Melan-A (green) and CXCL12 
(red) expression in a primary melanoma AJCC stage III depicted i.) in the tumour bulk, including co-
localisation plot of Melan-A and CXCL12 expression or ii.) in the epidermis beside or iii) above the 
tumour. Images taken by confocal microscopy with a magnification 20x scale bar = 150μm. 
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Figure 3.20 Expression of CXCL12 and Comparison with CXCR4 expression in a Cohort of 
Melanocytic Naevi and Primary Melanomas of Differeing AJCC Stage 
A.) Scatter graph representing the mean (mean of 4 high powered fields of view (HPF) +/-  SD) CXCL12 
fluorescence/expression per cell in eventual stage melanocytic naevi or AJCC stage I, II or III melanomas. 
B.) Scatter graph representing mean CXCL12 fluorescence/expression per melanoma cell in localised 
(eventual AJCC stage of disease I/II) or metastatic melanomas (eventual AJCC stage III/IV) after 7 years 
follow up. Horizontal bars represent mean CXCL12 fluorescence per cell (mean of 4 HPF +/-  SD). C.) 
Scatter graph representing mean CXCL12 fluorescence/expression per cell (mean of 4 HPF +/-  SD) in 
metastatic melanomas (eventual AJCC stage III/IV) in relation with time to metastasis (months) after a 
7 year follow up. D.) Scatter graph representing the mean CXCL12 fluorescence per cell in all AJCC stage 
B-RAF/N-Ras wild-type or mutant melanomas. Horizontal bars represent mean CXCL12 fluorescence 
per cell (mean of 4 HPF +/- SD). Statistics acquired by students T test *P<0.05. E.) Scatter graph 
representing mean CXCL12 fluorescence per cell (mean of 4 HPF in eventual stage melanocytic naevi or 
AJCC stage I, II or III melanomas in relation to mean total % CXCR4 expression (mean of 10 HPF). F.) 
Scatter graph representing mean CXCL12 fluorescence per cell (mean of 4 HPF) in eventual stage 
melanocytic naevi or AJCC stage I, II or III melanomas in relation to mean total % nuclear CXCR4 (mean 
of 10 HPF). 
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To further explore observations of CXCL12 expression in normal and peri-tumoural epidermis, 
CXCL12 fluorescence was additionally quantified in 2 samples of normal skin, and the peri-
tumoural or epidermis overlying primary melanomas within the same patient cohort. 
Threshold limits for CXCL12 and Melan-A fluorescence of 11 and 6 were applied respectively, 
with mean CXCL12 fluorescence derived by the division of total CXCL12 fluorescence per 
image by the number of DAPI pixels. Results revealed a trend for increased CXCL12 expression 
in the epidermis of normal skin compared to the epidermis adjacent or overlying primary 
melanomas (Figure 3.21 A), although a comparison of CXCL12 levels in the adjacent epidermis 
or the epidermis overlying primary melanomas demonstrated this effect was insignificant 
(Wilcoxon signed-rank test P=0.0710 ns, Figure 3.21 B). Comparative analysis of CXCL12 
expression in the adjacent epidermis of all AJCC stage melanomas with tumour progression 
however, revealed increased CXCL12 expression correlated significantly with increased time 
to metastasis (Figure 3.21 C) (Pearson’s correlation *P=0.0136), suggesting CXCL12 in the 
immediate tumour microenvironment may limit disease progression. Furthermore, a 
significant correlation of adjacent epidermal CXCL12 expression with tumoural expression of 
cytoplasmic CXCR4 expression was also observed (Pearson’s correlation **P=0.0098, Figure 
3.21 B.), highlighting the possible relationship of CXCL12 expression in the microenvironment 
with chemokine receptor localisation in the tumour, and proposing a previously un-described 
intimate relationship between micro environmental CXCL12, melanoma phenotype and 
patient outcome. 
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Figure 3.21 Immunofluorescence for the Expression of CXCL12 in the Epidermis of Normal 
Skin, Tumoural Epidermis and Epidermis in the Melanoma Microenvironment. 
A.) Scatter plot representing CXCL12 fluorescence per cell in each high powered view (HPV) in the 
epidermis of normal skin, adjacent (beside) or overlying (above) all AJCC stage melanomas. Horizontal 
bars represent mean CXCL12 fluorescence per cell +/- SD. B.) Scatter plot representing mean CXCL12 
fluorescence per cell (Mean of 2 HPV) in the epidermis beside and above all AJCC stage melanomas. 
Statistics acquired by Wilcoxon signed-rank test, P>0.05 ns. C.) Scatter graph representing mean 
CXCL12 fluorescence per cell (mean of  2 HPF) in the epidermis beside eventual AJCC stage III/IV 
melanomas in relation to time to metastasis (months) after 7 year follow up. Statistics acquired by 
Pearson’s correlation *P<0.05. D.) Scatter graph representing mean CXCL12 fluorescence per cell (mean 
of  2 HPF) in the epidermis beside all AJCC stage melanomas in relation to relative tumoural cytoplasmic 
CXCR4 expression. Statistics acquired by Pearson’s correlation **P<0.01. 
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3.2.10 Downregulation of CXCL12 is Associated with Monosomy of 
Chromosome 3 in Primary Uveal Melanomas 
CXCL12 has been defined as a mediator of choroidal neovascularisation and vasculogenesis, 
recruiting bone marrow derived vascular progenitors and endothelial precursors to the 
developing or injured eye, likely regulated by hypoxia and VEGF (Sengupta et al., 2005; Jin et 
al., 2006; Ruiz de Almodovar et al., 2006). However, the expression of CXCL12 in the normal 
eye and in uveal melanoma is currently poorly defined. Given the observations of strongly 
positive CXCR4 expression observed in primary uveal melanomas (section 3.2.2) and the 
unknown role of CXCL12 at the primary tumour site, expression of CXCL12 and Melan-A were 
evaluated by immunofluorescence under the same experimental and analysis conditions 
described in section 3.2.9 in a cohort of 7 primary uveal melanomas (Figures 3.22 and 3.23). 
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Figure 3.22 Immunofluorescence for the Expression of CXCL12 and Melan-A in the Normal 
Choroid and Retina of Primary Uveal Melanomas 
Representative images of CXCL12 (red) or Melan-A (green) expression, or DAPI nuclear staining (Blue) 
or merged expression in the normal choroid and retina of primary uveal melanomas. Images taken by 
confocal microscopy with a magnification 20x, scale bar = 75μm. M= Melanocytes, C= choroid, BM= 
Bruch’s membrane, PC= pigmented cells, RC= rods and cones, RCN=rods and cones nuclei, BCN=bipolar 
cell nuclei, GCN= ganglion cell nuclei, BV= blood vessels. 
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In the normal choroid and retina of all primary uveal melanomas (area far from tumour site), 
results demonstrated strong melan-A expression in melanocytes of the choroid, and 
pigmented cells of Bruch’s membrane and outward protrusions of rods and cones of the 
retina, with weak expression in ganglion cells facing the posterior cavity of the eye (Figure 
3.22). CXCL12 immunoreactivity was generally intense, strongest in the retina of the eye, with 
particular expression seen in the retinal pigment epithelium, ganglion cells and within blood 
vessels of the choroid co-localised with Melan-A and consistent with previous reports, 
proposing the retina and choroid as CXCL12 rich sources within the eye (Crane et al., 2000; 
Hasegawa et al., 2008; Otsuka et al., 2010). 
 
Figure 3.23 Immunofluorescence for the Expression of CXCL12 in Primary Uveal Melanomas 
A.) i,ii,iii,iv Representative images of melan-A (green) and CXCL12 (red) expression in primary uveal 
melanomas tumour cells with melan-A/ CXCL12 co-localisation plot, blue depicts nuclear staining. 
BV=blood vessel. Images taken by confocal microscopy with a magnification 20x scale bar = 75μm. 
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CXCL12 expression also varied between primary uveal melanoma tumours but co-localised 
with Melan-A, suggesting the potential for autocrine CXCL12 secretion (Figure 3.23 i). Notably, 
high levels of CXCL12 immunoreactivity were observed within and around blood vessels inside 
the tumour bulk, although this observation was not apparent in all tumours (Figure 3.23 ii, iv). 
Nevertheless, these observations suggest blood vessels may serve as another source of 
CXCL12 in primary uveal tumours if the tumour is vascularised. A comparison of CXCL12 
fluorescence levels in uveal compared to levels expressed by primary cutaneous melanomas, 
further revealed significantly increased CXCL12 fluorescence per cell in primary uveal 
melanomas (Mann Whitney U **P=0.0274, Figure 3.24 Aii), indicating a reliance on CXCL12 
signalling at the primary site. Interestingly similar to the observed lower levels of CXCL12 
expression seen in B-RAF/N-Ras mutated cutaneous melanomas (section 3.2.9), uveal 
melanomas with monosomy of chromosome 3 (strongest prognostic indicator of metastasis) 
also displayed significantly lower CXCL12 expression compared to those tumours with disomy 
of chromosome 3 (Students T test **P=0.0099, Figure 3.23 A iii). Collectively these data thus 
suggest the down regulation of CXCL12 at the primary site, is associated with the metastatic 
potential of uveal melanoma and that reduced CXCL12 expression by both cutaneous and 
uveal melanomas is associated with tumour progression, while conversely, higher CXCL12 
levels in the local tumour environment may limit disease spread. 
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Figure 3.24 CXCL12 Expression in Primary Uveal and Cutaneous Melanoma Tumours 
A.) i Scatter plot representing CXCL12 fluorescence per cell for each high powered view (HPV) of primary 
uveal melanomas. Horizontal bar represents mean CXCL12 fluorescence per cell +/- SD. ii.) Scatter plot 
representing CXCL12 fluorescence per cell for each HPV in primary cutaneous melanomas and primary 
uveal melanomas. Horizontal bar represents mean CXCL12 fluorescence per cell +/- SD. Statistics 
acquired by Mann Whitney U *P<0.05. iii.) Scatter plot representing CXCL12 fluorescence per cell for 
each HPV in primary uveal melanomas with disomy or monosomy of chromosome 3. Horizontal bar 
represents mean CXCL12 fluorescence per cell +/- SD. Statistics acquired by student’s T test **P<0.01. 
N=7, n=28. 
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3.3 Discussion 
3.3.1 CXCR4 Expression in Cutaneous and Uveal Melanoma 
Tumour thickness and ulceration are currently the two components of the AJCC melanoma 
staging system that provide the most important prognostic information for patients diagnosed 
with primary cutaneous melanomas (Balch et al., 1980; Balch et al., 2009a). However, neither 
tumour thickness or ulceration or any other prognostic indicators are able to reliably identify 
‘high risk’ patients, whose tumours will eventually progress, hence emphasising the acute 
demand for novel biomarkers with predictive accuracy of metastatic progression. Current 
evidence suggests chemokines and their receptors play a critical role in melanoma metastasis 
with the CXCR4–CXCL12 axis involved in many key aspects of tumour progression, including 
cell proliferation, survival, immune evasion, invasion, angiogenesis and cell chemotaxis 
(Bachelder et al., 2002; Hall and Korach, 2003; Murakami et al., 2003; Balkwill, 2004; O'Boyle 
et al., 2013). CXCR4 expression is frequently up regulated in both cutaneous and uveal 
melanomas, where in cutaneous melanoma increased expression has been linked with 
increased Breslow thickness, ulceration, metastasis as well as poor patient outcome (Longo-
Imedio et al., 2005; Scala et al., 2005; Tucci et al., 2007; Li et al., 2009; Toyozawa et al., 2012). 
High CXCR4 expression in uveal melanoma on the other hand is associated with the increased 
likelihood of liver metastasis (Li et al., 2009). Results from the present study, highlight the 
reduction in total CXCR4 expression in AJCC stage I/II cutaneous melanomas relative to 
expression detected in benign naevi, a pattern which may reflect the importance of CXCR4-
CXCL12 autocrine signalling in early stage disease which in turn may promote cell survival and 
proliferation through activation of MAPK and PI3K signalling, downstream of CXCR4 
(Murakami et al., 2003; Balkwill, 2004; Balkwill, 2012). Conversely, the significant increase in 
total CXCR4 expression demonstrated in metastatic compared to localised melanomas as well 
as the significant increase in CXCR4 expression from AJCC stage II to III/VI disease reinforces 
the pivotal role of CXCR4 expression in metastatic spread. In this respect the up regulation of 
CXCR4 expression in locally invasive melanomas likely enables tumour exit from the primary 
site, migration down chemokine gradients and subsequent metastasis to organ specific 
locations that secrete CXCL12 including the liver, lungs, bone and brain, hence providing the 
rationale for CXCR4 as a therapeutic target (O'Boyle et al., 2013). Consistent with the 
association of high CXCR4 expression and the increased risk of metastasis, results from the 
present study also showed individuals bearing AJCC stage II cutaneous melanomas with high 
CXCR4, CXCR7 and CXCL12 Expression and Signalling in Cutaneous and Uveal Melanoma 
130 
 
CXCR4 expression (>50%) were over 3 times more likely to develop metastasis compared to 
individuals with lower CXCR4 expression (<50%). Collectively these data thus show, in addition 
to being a potential therapeutic target, CXCR4 expression defines a high risk melanoma AJCC 
stage II sub group, and hence may be a valuable putative clinical prognostic biomarker. 
In uveal melanoma the strongest prognostic indicators for poor outcome are monosomy of 
chromosome 3, cell phenotype (epithelioid) and tumour diameter (>1.5cm). However, these 
factors again do not allow for the reliable identification of high risk patients. Current data 
supports previous observations of increased expression of CXCR4 in primary uveal melanomas 
with CXCR4 expression detected in 100% of tumour cells within 83% of primary uveal 
melanomas evaluated (Scala et al., 2007; Li et al., 2009; Franco et al., 2010; Dobner et al., 
2012). However, the lack of any expression in the remaining uveal melanoma cohort suggests 
CXCR4 expression may be an ‘all or nothing’ scenario. Previous studies have correlated CXCR4 
expression within an epithelioid tumour cell type demonstrating expression in this context 
increases the risk of metastasis with reduced time to disease progression (Scala et al., 2007; 
Franco et al., 2010). Although the cohort of uveal melanomas in the present study was of too 
small to demonstrate any association with tumour phenotype or chromosome 3 status, the 
increased expression of CXCR4 observed nevertheless suggests an important role for this 
chemokine receptor in uveal melanoma pathogenesis.  
Interestingly immunohistochemical analysis demonstrated differential expression of nuclear 
and cytoplasmic CXCR4 expression in primary cutaneous and uveal melanomas. Previous 
studies have reported CXCR4 cytoplasmic expression in both cutaneous and uveal melanoma, 
while in many other cancers, nuclear CXCR4 expression is well documented, and commonly 
associated with the development of metastasis and a worse prognosis (Oda et al., 2007; Akashi 
et al., 2008; Na et al., 2008; Woo et al., 2008; Yoshitake et al., 2008; Frank M. Speetjens et al., 
2009; Linhui Wang et al., 2009; Dobner et al., 2012; Toyozawa et al., 2012). CXCR4 is a G-
protein coupled cell receptor which unstimulated exists on the cell cytoplasmic membrane 
(Nguyen and Taub, 2002; Wang et al., 2006). Stimulation of the receptor with its cognate 
ligand CXCL12 causes receptor dimerisation and internalisation to augment cell signalling 
before being recycled back to the cell surface by endocytosis or degradation by lysosomes. 
However, recent reports describe the identification of a latent receptor response where long 
term stimulation of CXCR4 with ligand results in its nuclear translocation (Linhui Wang et al., 
2009). Nuclear CXCR4 expression detected in the current cohort of cutaneous melanomas may 
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therefore reflect long term receptor stimulation, and may explain the observed trend of 
increased nuclear CXCR4 expression with disease progression. Interestingly results from the 
present study also demonstrated significantly increased nuclear CXCR4 expression in 
metastatic compared to localised disease, suggesting a possible role of nuclear CXCR4 in the 
evolution of an aggressive phenotype in cutaneous melanoma. Moreover, this observation 
was also reflected by studies of CXCR4 subcellular localisation in vitro, where both nuclear and 
cytoplasmic CXCR4 expression were detected in all cutaneous and uveal metastatic melanoma 
cell lines with the exception of studies in the primary uveal melanoma cell line, MEL270 (all 
other cell lines were derived from a tumour metastasis) in which nuclear CXCR4 expression 
was undetectable. In further support of the association of nuclear CXCR4 expression with 
metastasis, functional and ligand responsive CXCR4 in the nucleus of metastatic cells, has also 
been shown to promote tumour invasion (Linhui Wang et al., 2009; Don-Salu-Hewage et al., 
2013). Although a mechanism by which nuclear CXCR4 promotes tumourigenesis has yet to 
be defined, the fact that CXCR4 is not recycled back to the cell membrane or degraded, steps 
important for signal termination, and is able to participate in intra-nuclear signalling, suggests 
that nuclear CXCR4 may ensure or intensify cell signalling, promoting the evolution of a 
metastatic phenotype (Pelchen-Matthews A et al., 1999; Don-Salu-Hewage et al., 2013). 
Strikingly, the immunohistochemical analysis of the present cutaneous melanoma cohort 
revealed significantly increased nuclear CXCR4 expression in B-RAF mutant compared to wild-
type tumours. Although a study in papillary thyroid carcinoma demonstrated CXCR4 up 
regulation by B-RAF activation, and total CXCR4 up regulation has been described in cutaneous 
melanoma, there have been no previous reports of any specific association of CXCR4 
expression and B-RAF/N-Ras mutational status in cutaneous melanoma (Castellone et al., 
2004; Borrello et al., 2005; Torregrossa et al., 2012; Mitchell et al., 2014). Since B-RAF is a 
bonafide oncogene in cutaneous melanoma and oncogenic signalling may up regulate CXCR4, 
this may account for the increased expression of nuclear CXCR4 seen in the present cohort of 
B-RAF mutant tumours, collectively suggesting that oncogenic B-RAF signalling and nuclear 
CXCR4 cooperatively commit the cell to an aggressive phenotype (Castellone et al., 2004; 
Toyozawa et al., 2012). However, although CXCR4 was observed in the cytoplasm and to a 
greater extent in the nucleus of B-RAF wild-type CHL-1 cells, transfection of wild-type or B-
RAFV600E did not significantly alter total CXCR4 levels or subcellular localisation. Discordance in 
results with in vivo observations may thus reflect the myriad of other unknown influences on 
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CXCR4 expression in an in vivo setting, including for example exposure to CXCL12. Given that 
nuclear CXCR4 expression increases with disease progression, results from the present study 
suggest perhaps that the acquisition of nuclear expression may occur over a prolonged time 
period, and thus explain the lack of such observation by transient transfection mutant B-RAF 
over 72 hours. 
3.3.2 CXCR7: A Likely Scavenger of CXCL12 in the Cutaneous and Uveal 
Microenvironment 
CXCL12 engages with both chemokine receptors CXCR4 and CXCR7 to regulate homeostatic 
and pathological processes. While expressed on immune cells, endothelial cells and some 
tumour cell types, the presence of CXCR7 on melanoma cells or any association with tumour 
progression remains undefined. Contrary to reports of CXCR7 in breast cancer , results from 
the present study however, clearly showed there was no expression of CXCR7 on melanoma 
cells in vitro or in vivo, reaffirming CXCR4 as the predominantly expressed chemokine 
receptor, and the likely primary driver of CXCL12 chemotaxis (Salazar et al., 2014). 
Nevertheless, and consistent with previous reports of CXCR7 expression within the cancer 
microenvironment and specifically on endothelial cells of tumour associated vasculature, 
results confirmed the expression of CXCR7 on EA.hy926 and Hela endothelial cells in vitro as 
well as on endothelial cell types of capillaries and blood vessels within the microenvironment 
of 30-40% of primary cutaneous and uveal melanomas (Sánchez-Martín et al., 2011b). 
CXCR7 expression on endothelial cells is often associated with periods of accelerated growth 
and vascularisation, and given the known up regulation of CXCR7 in hypoxic regions of a 
tumour and by pro-angiogenic secreted factors such as VEGF and CXCL8, CXCR7 maybe a 
surrogate marker of tumour angiogenesis (Hattermann and Mentlein; Maksym et al., 2009a). 
Although there were no obvious associations of CXCR7 expression with prognostic features in 
the current cutaneous and uveal melanoma cohort, CXCR7 may be playing some pro-
tumorigenic role. CXCR7 has enhanced affinity over CXCR4 for CXCL12, and its ability to 
scavenge CXCL12, means that CXCR7 has the ability to modulate circulating chemokine levels. 
When CXCR7 is absent or inhibited, serum CXCL12 levels can increase 5 fold, demonstrating 
the potentially large modulatory role of CXCR7 (Jin et al., 2013). The scavenging of CXCL12 by 
CXCR7 receptors on vascular endothelium sharpens the extracellular chemokine gradient of 
CXCL12 facilitating the chemotaxis of cells in and out the blood vessels. This could be 
particularly important within the tumour microenvironment as it may provide a precise 
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chemokine gradient assisting melanoma intravasation from CXCL12 present in the tumour into 
the blood. Conversely the sharpened chemokine gradient may also facilitate the extravasation 
of cells from the blood into tissues, which would allow CXCR7 to modulate leukocyte CXCL12 
homing and may affect tumour infiltration (Jin et al., 2013). While not as clear as the role for 
CXCR4 in melanoma pathogenesis, CXCR7 may nevertheless therefore support melanoma 
progression by fine tuning chemotactic gradients thereby providing optimal migratory 
conditions for tumour chemotaxis. 
3.3.3 CXCL12: Implications of Expression and Signalling in Cutaneous and Uveal 
Melanoma  
CXCL12 plays a critical role in driving melanomas chemotaxis, organ specific metastasis, cell 
proliferation and survival, as well as influencing angiogenesis and tumour immune infiltration 
demonstrating a regulatory capacity in both temporal and spatial cancer pathogenesis 
(Balkwill, 2004). However, studies of CXCL12 expression and distribution with the melanoma 
microenvironment are less well defined. In the present study the skin and retina of the eye 
were identified as rich sources of CXCL12 expression in vivo. In vitro studies also highlighted 
primary dermal fibroblasts and biliary epithelial cells as prominent secretors of CXCL12 
suggesting these may be the dominant sources of CXCL12 chemokine gradients for CXCR4 
expressing melanomas in vivo. Data from the present study in both the skin and eye suggests 
the establishment of a CXCL12 chemokine gradient whereby melanocytes at the 
epidermal/dermal junction sit above strong sources of chemokine secretors within the dermis 
of the skin or the retina of the eye, making it unsurprising that melanoma cells evolve to take 
advantage of such a chemokine source to invade and metastasise.  
Studies of CXCL12 expression identified widespread cytoplasmic expression of CXCL12 by all 
cutaneous and uveal melanoma cell lines. Of note primary melanocytes expressed CXCL12 
most strongly suggesting CXCL12 expression may be down regulated by melanoma cells. 
CXCL12 was also detected within the supernatants of CXCR4 positive cutaneous metastatic 
melanoma cell lines CHL-1 and WM-164 suggesting that CXCL12 is secreted from melanoma 
cells potentially resulting in autocrine chemokine signalling. The ability of a cancer cell to 
secrete chemokines together with the expression of the cognate receptor allows the cell to 
self-perpetuate advantageous cell signalling indefinitely. Autocrine chemokine-receptor loops 
are thought to give cancer cells a survival advantage and in glioma and head and neck cancer 
have been shown to promote cell survival and resistance to chemotherapy (Wang et al., 
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2008a; Hattermann et al., 2010). Probably the best example of such signalling in melanoma is 
the CXCR2-CXCL8 chemokine axis where by CXCL8 acts as an autocrine growth factor, where 
blocking its interaction with CXCR2 inhibits melanoma cell growth in vitro (Norgauer J et al., 
1996; Homey et al., 2002). Neutralisation of CXCL12 caused deactivation of CXCR4 and 
downregulation of MAPK cell signalling in WM-164 metastatic melanoma cell line, defining an 
autocrine signalling mechanism whereby tumoural secretion of CXCL12 is able to promote 
activation of pro-survival MAPK cell signalling. Previous studies have illustrated CXCL12-
induced activation of MAPK signalling and melanoma cell growth, suggesting CXCL12 may 
contribute to melanomagenesis (Robledo et al., 2001; Murakami et al., 2002); however the 
present study is the first to demonstrate that endogenous CXCL12 drives MAPK cell signalling 
in melanoma. However, given that none of the other melanoma cell lines or primary 
melanocytes secreted CXCL12, it may be that CXCL12 secretion is cell line specific. 
Nevertheless, as CXCL12 was expressed within the cytoplasm of all melanoma cell lines to 
some extent, these data question whether there may be a mechanism of chemokine retention 
in play. Supporting this hypothesis, studies have demonstrated that chemokines may possess 
a endoplasmic reticulum retention signal that may prevent receptor cell surface expression 
(Yang et al., 1997; X Baia et al., 1998). Collectively these data therefore suggest early 
interaction of chemokines and chemokine receptors within the cell cytoplasm may prevent 
normal chemokine receptor trafficking to the cell surface which may account for accumulation 
of CXCL12 and CXCR4 within the cytoplasm of melanoma in absence of any CXCL12 secretion. 
Expression of CXCL12 was detected in the current cohort of primary cutaneous melanomas at 
low levels, however, whether or not it is secreted in an autocrine manner or if perhaps 
originated from an alternative source within the tumour microenvironment could not be 
differentiated. As CXCL12 expression did not differ significantly between naevi and all AJCC 
stage melanomas, localised and metastatic tumours or correlate with time to metastasis, this 
suggests that although present, CXCL12 does not play a prominent role in disease progression 
or metastasis, results that are corroborated by previous studies (Toyozawa et al., 2012). 
However, given its expression in all disease stages including naevi, and the fact that in vitro 
experiments suggest a mechanism of CXCR4-CXCL12 autocrine cell signalling, a general role 
for CXCL12 in primary tumours is postulated, where the tumour cells uptake endogenously 
derived CXCL12, driving pro-survival MAPK cell signalling allowing sustained tumour 
maintenance and survival. The low levels of CXCL12 expressed within the primary tumour and 
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lack of association with disease progression are perhaps not surprising given that abundant 
endogenous CXCL12 within the primary site would logically act to retain CXCR4 positive 
tumour cells, rather than facilitate their migration towards CXCL12 at distant sites. In support 
of this hypothesis, studies have shown trends for increased CXCR4 expression with the 
absence of CXCL12 expression in melanomas as well as the enhanced metastatic potential of 
CXCR4 positive cancer cells following the epigenetic silencing of CXCL12 (Wendt et al., 2006; 
Mitchell et al., 2014). Alternatively, secreted CXCL12 may be degraded by tumour proteases 
including MMPs, cathepsin G and elastase known to be upregulated in the tumour 
microenvironment of nearly all cancer types (Delgado et al., 2001; McQuibban et al., 2001; 
Valenzuela-Fernández et al., 2002). Although significantly higher than that detected in primary 
cutaneous melanomas, CXCL12 was also detected albeit again at low levels in all primary uveal 
melanomas. The role of CXCL12 in uveal melanoma is uncertain with only 2 studies 
documenting expression of CXCL12 in 27% and 41% of primary uveal tumours respectively 
(Franco et al., 2010; Dobner et al., 2012). In one study CXCL12 was associated with increased 
tumour diameter and an epithelioid cell type, implying that unlike in cutaneous melanoma, 
CXCL12 within primary uveal melanomas may exert a pro-tumourigenic effect (Franco et al., 
2010; Dobner et al., 2012). In both these studies CXCL12 expression was also reported to 
display low immunoreactivity, much lower than other chemokines such as CCL19 and CCL21, 
alluding to the possibility that CXCL12 is not of paramount importance within primary tumours 
and that its effects are more likely relevant once tumour cells have evaded the primary site. 
To date only one study has evaluated the relationship between CXCL12 expression and B-
RAF/N-Ras mutational status in primary cutaneous melanomas, however researchers were 
unable to find any association (Mitchell et al., 2014). An interesting outcome from the present 
study was the observation of significantly reduced CXCL12 expression in B-RAF/N-Ras mutated 
compared to wild-type cutaneous melanomas, indicating for the first time, that oncogenic B-
RAF signalling may promote down regulation of CXCL12 expression, or CXCL12 secretion from 
primary tumour cells. This trend was also recognised in primary uveal melanoma where down 
regulation of CXCL12 was associated with monosomy of chromosome 3, the strongest 
prognostic indicator of metastasis. Together these data thus support a pattern of CXCL12 
down regulation in the primary tumour which one could hypothesise, may assist the 
emergence of an aggressive phenotype enabling CXCR4 positive tumour cells to escape from 
the primary site and encouraging metastasis towards a distant CXCL12 secreting site. This 
CXCR4, CXCR7 and CXCL12 Expression and Signalling in Cutaneous and Uveal Melanoma 
136 
 
trend is further supported by literature reporting the increased ratio of CXCL12:CXCR4 mRNA 
in thin compared to thick cutaneous melanomas (Monteagudo et al., 2012). Given the fact B-
RAFV600E mutated melanoma cell lines express higher levels of cytokines including MMP-1 
compared to wild-type cutaneous melanoma cell lines this raises the possibility that CXCL12 
down regulation is a reflection of enhanced degradation by MMP-1 secreted by B-RAF 
mutated melanomas (Whipple and Brinckerhoff, 2014). Nevertheless, in general, low CXCL12 
expression in primary tumours appears to be an advantageous quality although the 
mechanism and impact of this observation remains to be determined. 
Similarly to other reports, studies of CXCR4 and CXCL12 expression in the present cohort of 
primary cutaneous revealed no significant correlation between total CXCR4 and CXCL12 
expression, perhaps surprising given the close relationship between CXCR4 and CXCL12 but 
which may reflect the low expression levels of CXCL12 observed, or the unimportance of 
CXCR4-CXCL12 signalling in the primary tumour (Toyozawa et al., 2012; Mitchell et al., 2014). 
Nevertheless, data from the current study demonstrated the association of B-RAF/N-Ras 
mutant cutaneous melanomas expressing increased levels of nuclear CXCR4 expression with 
low levels of CXCL12 expression leading to the hypothesis that oncogenic B-RAF signalling 
promotes both nuclear CXCR4 translocation and down regulation of CXCL12 expression which 
may be key to the emergence of an aggressive cutaneous melanoma phenotype. 
Specific studies of CXCL12 in cancer have focused mainly on tumour expression, with very little 
research into the function of CXCL12 within the tumour microenvironment or its interaction 
with the primary tumour, and even less so in the context of studies of melanoma. The 
observation of increased epidermal CXCL12 expression adjacent to some primary cutaneous 
melanomas compared to expression in the epidermis overlying the tumour prompted further 
investigation. Although epidermal CXCL12 expression did not significantly differ between the 
adjacent and overlying tumoural epidermis, the presence of increased levels of CXCL12 in the 
adjacent epidermis did however, correlate with a reduced time to tumour metastasis, there 
by suggesting the presence of CXCL12 in the adjacent epidermis limits tumour progression. 
Although the precise mechanisms mediating this affect are unclear it is possible that the high 
CXCL12 gradient within the adjacent epidermis may act to retain CXCR4 positive tumour cells 
at the epidermal/dermal junction thereby promoting radial growth and delaying melanoma 
vertical invasion into the dermis with subsequent metastasis. Adjacent epidermal CXCL12 
expression was also associated with cytoplasmic CXCR4 expression by melanoma cells. These 
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data are coherent since they suggest tumoural CXCR4 is chronically activated by 
microenvironmental CXCL12 and therefore internalised from the melanoma cell membrane. 
Importantly, chronic CXCR4 signalling by melanoma is supported by our in vitro observation 
of basal pCXCR4 levels; phosphorylation of CXCR4 being characterised by ligand occupancy 
and a pre-requisite of receptor internalisation (Marchese, 2014). Given the association 
between CXCR4 nuclear expression with B-RAF/N-Ras mutated tumours and the increased 
likelihood of the development of metastatic disease, it may be postulated that B-RAF/N-Ras 
wild-type cutaneous melanomas expressing increased levels cytoplasmic CXCR4 with 
relatively low levels of nuclear CXCR4 expression are more likely to remain localised. 
Therefore, the association of epidermal CXCL12 expression adjacent to the primary tumour 
with tumoural cytoplasmic CXCR4 expression may thus reflect a subset of tumours more likely 
to remain localised, in contrast cutaneous B-RAF/N-Ras mutated tumours with high levels of 
nuclear CXCR4 expression which unresponsive to epidermal CXCL12 are more likely to 
metastasise.  
In conclusion, increased CXCR4 expression within primary cutaneous and uveal melanoma is 
highlighted as a putative biomarker for metastasis and disease progression. The pro-
tumourigenic role of CXCR4 is likely further aided by CXCL12 autocrine signalling promoting 
enhanced MAPK activation within tumour cells, and when secreted from distant sites 
promoting tumour cell mobilisation and migration from the primary tumour. Although present 
within primary melanomas, the most influential role played by CXCL12 maybe within the 
primary tumour microenvironment where CXCL12 chemokine gradients are in part modulated 
by CXCR7 sequestration, may promote retention of CXCR4 positive cells within the primary 
location. Data thus reinforces the intricate and intercalating roles of the CXCR4/CXCR7-CXCL12 
chemokine axis within primary melanomas, the immediate tumour microenvironment and 
sites of distant metastasis, including the liver. 
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3.4 Summary 
 High CXCR4 expression (>50%) is a prognostic biomarker for AJCC stage II cutaneous 
melanoma  
 Nuclear CXCR4 expression is associated with B-RAF/N-Ras mutant cutaneous 
melanomas and an aggressive metastatic phenotype. 
 CXCR4 is strongly expressed by primary uveal melanomas 
 CXCR7 is not expressed by cutaneous or uveal melanomas in vitro or in vivo but is 
present on vascular endothelium within the tumour microenvironment in vivo. 
 CXCL12 is expressed by primary melanocytes, keratinocytes, and dermal fibroblasts 
within normal skin 
 CXCL12 is expressed by both cutaneous and uveal melanoma cell lines and primary 
cutaneous and uveal melanomas 
 CXCL12 is secreted by primary dermal fibroblasts and biliary epithelial cells, and 
select cutaneous melanoma cell lines. 
 Secretion of CXCL12 by WM-164 cutaneous melanoma cell line acts in an autocrine 
manor activating CXCR4 receptors and MAPK cell signalling. 
 Activating mutations in B-RAF/N-Ras in cutaneous melanoma or monosomy of 
chromosome 3 in uveal melanoma are associated with decreased tumoural 
expression of CXCL12  
 High levels of CXCL12 expression in the adjacent epidermis to cutaneous melanomas 
are associated with tumoural cytoplasmic expression of CXCR4 and increased time to 
disease progression 
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4.1 Introduction 
In cancer, chemokines maybe present within tumours themselves, within the stroma of the 
tumour microenvironment or enriched at specific metastatic sites. It is often the balance of 
chemokines within the tumour or microenvironment and summation of their divergent 
functions that impacts tumour growth and metastasis. The CXCR4-CXCL12 chemokine axis has 
an important regulatory role in many aspects of tumorigenic processes including shaping 
leukocyte recruitment or tumour stromal content, angiogenesis, tumour cell proliferation, 
invasion and survival (as previously discussed section 1.5.). However, the overriding 
detrimental role of the CXCR4-CXCL12 axis in malignant processes is the promotion of tumour 
cell migration, that leads to enhanced invasive capabilities and eventual organ specific 
metastasis of tumour cells.  
A number of studies in different cancers have correlated CXCR4 and CXCL12 expression with 
tumour metastasis and worse prognosis (Li et al., 2004; Kang et al., 2005; Scala et al., 2005; 
Toyozawa et al., 2012), with additional evidence demonstrating the inhibition of this axis 
reduces metastatic ability with improved patient outcome (Liang et al., 2004b; Mori et al., 
2004; Sun et al., 2005). Indeed results from chapter 3 demonstrate the upregulation of CXCR4 
in AJCC stage II primary cutaneous melanomas, is predictive of metastasis and worse 
prognosis, emphasising the potential for targeting CXCR4 to prevent melanoma metastasis 
(O'Boyle et al., 2013). 
It has long been recognised that cancer cells metastasise to their own favoured sites in the 
body (Paget, 1889); favoured sites that naturally express chemokine ligands, and with cancer 
cells expressing the cognate chemokine receptor, circulating passively within our vasculature 
sensing a local chemokine source, then extravasating into the secreting tissue. Further, it is 
well established that in melanoma the CXCR4-CXCL12 chemokine axis promotes tumour cell 
dissemination to high CXCL12 secreting distant sites such as the lymph nodes, liver, and lungs 
(Ben-Baruch, 2008; O'Boyle et al., 2013). The source of CXCL12 at these sites is generally 
assumed to be secreted primarily from stromal fibroblasts (Micke and Östman, 2005; Orimo 
et al., 2005), with results derived from chapter 3 additionally highlighting CXCL12 expression 
by keratinocytes within the epidermis as protective of tumour metastasis, the 
chemoattractant stimulus for which is postulated to be mediated by a haptotaxic mechanism. 
However, findings from the present study also suggest that CXCL12 downregulation in 
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melanomas is associated with more aggressive B-RAF/N-Ras mutant cutaneous melanomas or 
uveal melanomas with monosomy of chromosome 3. Collectively, these data suggest that 
tumoural secretion of CXCL12 may be reduced to provide a localised decline in CXCL12 
chemokine concentration, an effect that CXCR7 expression by skin vasculature could also 
potentiate, allowing melanoma cell migration towards higher CXCL12 concentrations. Given 
that 36% of melanoma patients develop recurrence, with local recurrence seen in 63-87% of 
these patients (Balch et al., 2009a), the noted potent secretion of CXCL12 by primary dermal 
fibroblasts and their location, it is logical to question whether melanoma cells, firstly migrate 
towards primary dermal fibroblasts, and secondly if this is mediated by CXCL12-specific 
secretion. 
Given the important role that CXCR4-CXCL12 cell signalling has in cancer metastasis, it is 
perhaps unsurprising that this axis has been exploited therapeutically. Targeting has mainly 
focused on CXCR4 where small molecule inhibitors, peptide inhibitors and antibodies have 
been trialled (Tamamura et al., 2003; Cashen AF, 2009; Kuhne et al., 2013). Although many of 
the agents are currently in clinical trials, only one agent has been approved for clinical use; 
Plerixafor (Genzyme, previously called AMD3100), for use pre-bone marrow transplantation 
as an immune-stimulant in lymphoma and myeloma. Plerixafor has shown some promise in 
melanoma, inhibiting CXCL12 induced chemotaxis in vitro and reducing lung metastases in vivo 
(D’Alterio et al., 2012). Other CXCR4 inhibitors have shown similar blockade of CXCR4-CXCL12 
chemotaxis in melanoma in vitro (Liang et al., 2012; O'Boyle et al., 2013). Although the concept 
of inhibiting CXCR4-CXCL12 cell signalling to prevent metastasis has been proven there are 
however, some potential pit falls in targeting chemokine receptors in this manner. Firstly, 
rarely do cancer cells only express one chemokine receptor. Blocking one chemokine axis may 
mediate cancer metastasis to differing sites under the influence of a different chemokine axis. 
Secondly, chemokine axes are involved in many aspects of immunity and developmental 
processes (Mithal et al., 2012), and hence their inhibition may impair potential anti-tumour 
chemokine immune responses, or establish other unwanted side effects related to immune 
system dysfunction (Weitzenfeld and Ben-Baruch, 2014). In particular CXCR4-CXCL12 is crucial 
for haematopoiesis, and blocking this axis may result in cytopenia and mobilization of 
haematopoietic stem cells to blood (Weitzenfeld and Ben-Baruch, 2014). 
Such potential serious implications of targeting the chemokine system specifically, thus 
questions whether there may be a better way to target melanoma migration and metastasis. 
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In the context of CXCR4-CXCL12 mediated chemotaxis, migration is mitigated through CXCL12 
binding and activating CXCR4, a heterotrimeric G protein coupled receptor. Activation of the 
receptor leads to a cascade of downstream signalling pathways including the PKC, PI3K and 
MAPK pathways that enable intracellular calcium mobilisation and cell migration (Robledo et 
al., 2001). Previous studies have illustrated an association between CXCR4-CXCL12 activation 
and MAPK cell signalling (Robledo et al., 2001; Murakami et al., 2002). Furthermore, recent 
studies from the Lovat lab have demonstrated a link between hyper-activation of MAPK and 
melanoma cell migration, illustrated by transfection of CHL-1 wild-type melanoma cells with 
mutant B-RAF and subsequent increased CXCR4-CXCL12 cell migration (O'Boyle et al., 2013). 
Results from the previous chapter further illustrated autocrine secretion of CXCL12 can 
promote activation of pro-survival MAPK cell signalling in the cutaneous melanoma cell line 
WM-164. Collectively these data provide a potential rational for preventing CXCR4-CXCL12 
mediated cell migration by inhibiting the MAPK pathway, and leads to the initial aim of the 
current chapter to test whether MEK inhibition with the MEK 1/2 specific clinical inhibitor 
trametinib prevents melanoma CXCR4-CXCL12 chemotaxis. 
Although targeted therapies such as B-RAF/MEK inhibition have revolutionised melanoma 
treatment in recent years, researchers are now faced with the almost inevitable emergence 
of drug resistance and the task of identifying strategies to overcome drug-induced resistance. 
Autophagy has been identified as a key player in the acquisition of drug resistance to many 
different chemotherapeutic regimens (Amaravadi RK and Thompson CB, 2007). This self-
cannibalisation process, primarily activated as a housekeeping stress response to adverse 
cellular challenges including hypoxia and nutrient deprivation, is also activated by many anti-
cancer therapies to counter act drug-induced cytotoxicity (Degenhardt K et al., 2006). 
Targeting autophagy however, has become somewhat of a controversial issue within the 
literature, stemming from autophagy’s contradictory roles in tumour progression deemed the 
‘autophagy paradox’, where defective autophagy can drive neoplastic formation, whereas 
efficient autophagy may promote tumour survival (Mathew et al., 2009; Roy S and Debnath J, 
2010; Ellis et al., 2014b). There is evidence that targeting cyto-protective autophagy maybe 
beneficial and sensitise cells to many different anti-cancer regimes, including traditional 
chemotherapies and radiotherapy, hormonal treatments and newer targeted agents such as 
B-RAF and MEK inhibitors (Carew JS et al., 2007; Apel et al., 2008; Qadir et al., 2008; Del Bello 
et al., 2013; Yao et al., 2015; Goulielmaki et al., 2016). Conversely exacerbation of autophagy 
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may lead to cell death (type II) or ‘autophagic cell death’, mediated by large scale autophagic 
vacuolization and extensive degradation of intracellular contents that leads to cell death (Liu 
and Levine, 2015). Therefore the induction of autophagy to promote autophagic cell death in 
some cancers has emerged as a therapeutic strategy including melanoma (Ambrosini et al., 
2013b; Xie et al., 2013; Amirouchene-Angelozzi et al., 2014). It is clear that both inhibiting and 
inducing autophagy can harness this process for therapeutic benefit, however in which cancer, 
what drug, regime, or timeframe, remains enigmatic. Hence, in the current chapter the 
specific effect of trametinib-induced MEK inhibition on autophagy in uveal and cutaneous 
melanoma was investigated, together with potential strategies through which to harness 
autophagy to enhance the efficacy of MEK specific targeted therapy. 
Collectively the specific aims of this chapter were to investigate whether CXCR4-CXCL12 
mediated chemotaxis of cutaneous melanoma cell lines (both B-RAF/N-Ras mutant and wild-
type) within the cutaneous microenvironment may be mediated by CXCL12 secreted by 
dermal fibroblasts, and to question if this and CXCR4-CXCL12 mediated chemotaxis of uveal 
melanomas may additionally be prevented by treatment with the MEK specific inhibitor, 
trametinib and any potential impact of this strategy on autophagy.  
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4.2 Results 
4.2.1 CXCR4 Expressing Cutaneous and Uveal Metastatic Melanoma Cells 
Migrate Towards Human Recombinant CXCL12 and CXCL12 Rich Supernatant 
Derived from Primary Cutaneous Dermal Fibroblasts 
Studies in chapter 3 demonstrate CXCL12 in the immediate melanoma microenvironment of 
the adjacent epidermis is protective of metastasis, however high levels of CXCR4 expression 
correlate with the increased risk of metastasis in AJCC stage II melanomas, suggesting the 
CXCR4-CXCL12 axis likely influences primary tumour escape to distant sites. This coupled with 
the downregulation of CXCL12 by more aggressive B-RAF/N-Ras mutant melanomas suggests 
directional migration sensing, leading to the hypothesis that an alternative CXCL12 source, 
likely derived from primary cutaneous dermal fibroblasts may influence CXCR4 positive 
tumour cell escape, and provide a chemotactic gradient to potentiate deeper invasion within 
the dermis and subsequent migration to distant sites. To investigate this possibility a series of 
conventional transwell CXCR4-CXCL12 chemotaxis experiments were performed to confirm 
the migration of CXCR4 expressing melanoma cells towards both human recombinant CXCL12 
(rCXCL12) and supernatants derived from primary dermal fibroblasts as well as the potential 
to inhibit such chemotaxis within the cutaneous environment by MEK inhibition with 
trametinib. 
Results demonstarted both CXCR4 expressing cutaneous CHL-1 (B-RAF/N-Ras wild-type) and 
B-RAF mutant WM-164 cells as well as OM413 (GNAQ/GNA11 wild-type) uveal melanoma cells 
significantly migrated towards 10nM rCXCL12 compared to no chemokine control (One-way 
ANOVA, with Bonferroni’s multiple comparison post hoc correction, or Kruskal-Wallis test with 
Dunn’s multiple comparison post hoc correction, P***< 0.001), (Figure 4.1). However, this 
effect was significantly abrogated by co-treatment with a neutralising anti-CXCL12 antibody 
(One-way ANOVA with Bonferroni’s multiple comparison post hoc correction, or Kruskal-
Wallis test with Dunn’s multiple comparison post hoc correction, P***<0.001), while there 
was no observed migration in the presence of an isotype control antibody, (One-way ANOVA, 
with Bonferroni’s multiple comparison post hoc correction, or Kruskal-Wallis test with Dunn’s 
multiple comparison post hoc correction, ns P>0.05) (Figure 4.1). 
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Figure 4.1 Cutaneous and Uveal Metastatic Melanoma Cell Lines Migrate Towards Human 
Recombinant CXCL12 
Relative cell migration per high field vision (HPF) of A.) CHL-1 or B.) WM-164 cutaneous metastatic 
melanoma cells or C.) OM413 metastatic uveal melanoma cells over 16 hrs towards 10nM human 
recombinant CXCL12 (CXCL12) in the presence or absence of anti-CXCL12 neutralising antibody, or 
Isotype control anti-IgG antibody, expressed relative to migration towards control media without 
chemokine. Each bar represents the mean of 9 replicate filters from 3 independent experiments + SD. 
Statistics were acquired by one-way analysis of variance, with Bonferroni’s multiple comparison post 
hoc correction, or Kruskal-Wallis test with Dunn’s multiple comparison post hoc correction, where ns = 
P>0.05, ***P<0.001. D.) Representative photomicrographs from one high powered field (HPF) of 
migrated CHL-1, WM-164 or OM413 metastatic melanoma cells in the presence or absence of CXCL12, 
anti-CXCL12 or anti-IgG. Images were acquired at X20 magnification; scale bar represents 100µm. 
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4.2.2 CXCR4 Expressing Cutaneous Metastatic Melanoma Cells Migrate 
Towards CXCL12 in Supernatants Derived from Primary Dermal Fibroblasts 
To question whether cutaneous melanoma cells also migrate towards CXCL12 secreted from 
primary dermal fibroblasts, supernatants collected from primary dermal fibroblasts following 
72 hours of culture were incorporated as the chemoattractant in transwell chemotaxis assays 
with CHL-1 or WM-164 cutaneous melanoma cells, in the presence or absence of CXCL12 
neutralising antibody. Results demonstrated a significant increase in cell migration of both 
metastatic melanoma cell lines towards primary dermal fibroblast supernatant compared to 
control (DMEM +10% FCS) (Kruskal-Wallis test with Dunn’s multiple comparison post hoc 
correction, ***P< 0.001, Figure 4.2), an effect that was particularly evident in WM-164 cells 
(Figure 4.2 B). The migration of melanoma cells was significantly blocked by the CXCL12 
neutralising antibody (Kruskal-Wallis test with Dunn’s multiple comparison post hoc 
correction ***P< 0.001, Figure 4.2), however no significant effect was seen with the isotype 
control antibody (Kruskal-Wallis test with Dunn’s multiple comparison post hoc correction, ns 
P>0.05, Figure 4.2).  
Collectively these data therefore confirmed CXCR4-CXCL12 chemotaxis of CXCR4 expressing 
cutaneous and uveal metastatic melanoma cell lines towards rCXCL12, with no apparent effect 
of the presence of an activating MAPK mutation, as well as CXCR4-CXCL12-mediated 
chemotaxis of cutaneous melanoma cells towards dermal fibroblasts. 
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Figure 4.2 Cutaneous Melanoma Cell Lines Migrate Towards CXCL12 Secreted by Primary 
Dermal Fibroblasts  
Relative cell migration per high field vision (HPF) of A.) CHL-1 or B.) WM-164 cutaneous metastatic 
melanoma cells towards CXCL12 rich supernatants derived from primary dermal fibroblasts over 16hs, 
in the presence or absence of anti-CXCL12 neutralising antibody, or Isotype control anti-IgG antibody, 
expressed relative to migration towards control complete culture media. Each bar represents the mean 
of 9 replicate filters from 3 independent experiments each with a different donor of primary dermal 
fibroblast supernatants + SD. Statistics were acquired by Kruskal-Wallis test with Dunn’s multiple 
comparison post hoc correction, where ns = P>0.05, ***P<0.001. D.) Representative photomicrographs 
from one high powered field (HPF) of migrated CHL-1, or WM-164 metastatic melanoma cells in the 
presence or absence of dermal fibroblast supernatants, anti-CXCL12 antibody or anti-IgG antibody. 
Images were acquired at X20 magnification; scale bar represents 100µm. 
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4.2.3 MEK Inhibition Prevents CXCR4-CXCL12 Chemotaxis of Cutaneous and 
Uveal Melanoma Cells towards Human Recombinant CXCL12 
To determine if MEK inhibition could inhibit CXCR4-CXCL12 melanoma chemotaxis, additional 
chemotaxis assays of cutaneous and uveal melanoma cells towards recombinant CXCL12 were 
performed in the presence of trametinib. Initial dose response assays of trametinib-induced 
inhibition of cell viability were first performed in order to optimise assay time frames and to 
rule out any effects of inhibited cell migration due to reduction of cell viability. MTS cell 
viability assays were performed with cutaneous and uveal melanoma cell lines after 16 hours’ 
incubation with a dose escalating range of trametinib around the clinically achievable dose of 
32nM.  
Results revealed a dose dependant decrease in cell viability in all cell lines with the exception 
of uveal OM413 cells in which there was no significant inhibition of cell viability at any dose of 
trametinib at this time point (One-way analysis of variance with Dunnett’s multiple 
comparison post hoc correction P=0.4215 Figure 4.3 C). As expected B-RAF mutant cutaneous 
WM-164 or GNA11 mutated uveal UPMD2 cells (Figure 4.3 B and D) were more sensitive to 
trametinib than wild-type cell lines CHL-1 and OM413 (Figure 4.3 A and C), with significant 
inhibition of cell viability observed even with 5nM trametinib (Kruskal Wallis test with Dunn’s 
multiple comparison post hoc correction, **P<0.01, ***P<0.001, Figure 4.3 B and D). 
Trametinib concentrations of 2.5nM, 5nM and the maximum clinically achievable 
concentration of 32nM trametinib were therefore selected for use in all subsequent 
chemotaxis assays. UPMD2 GNA11 mutated metastatic uveal melanoma cell line, although 
migrated towards rCXCL12, the basal level of migration was particularly low and hence once 
inhibitors were added to chemotaxis assays it was impossible to determine a dose response, 
so this cell line was omitted from assays. 
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Figure 4.3 Trametinib-induced Inhibition of Cell Viability of Cutaneous and Uveal Metastatic 
Melanoma Cell Lines 
Cell viability of A.) CHL-1, B.) WM-164 cutaneous metastatic melanoma cell lines or C.) OM413 or, D.) 
UPMD2 uveal metastatic melanoma cell lines in the presence of 0.1-50nM trametinib for 16 hours, 
relative to control untreated cells. Each bar represents mean cell viability of 12 replicates from 3 
independent experiments + SD. Statistics acquired by one-way analysis of variance with Dunnett’s 
multiple comparison post hoc correction or Kruskal-Wallis test with Dunn’s multiple comparison post 
hoc correction, where *P<0.05, **P<0.01, ***P<0.001. 
To confirm the ability of trametinib to inhibit MAPK signalling in cutaneous and uveal 
melanoma cells CHL-1, WM-164, OM413 and UPMD2 cells were treated in the presence of 
2.5, 5 or 32nM trametinib for 16 hours prior to western blot analysis of phospho-ERK, total 
ERK and GAPDH (loading control) expression. Results revealed increased basal phospho-ERK 
expression in B-RAF mutant WM-164, compared to B-RAF/N-Ras wild-type CHL-1 cells (Figure 
4.4 A), however increased expression of phospho-ERK was also apparent in both OM413 
GNAQ/II wild-type and GNA11 mutated UPMD2 cells (Figure 4.4 B). Although OM413 cells do 
not harbour a GNAQ or GNA11 activating mutation, literature reports the presence of a B-RAF 
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mutation in these cells which therefore likely contributes to the observed increase in phospho-
ERK expression (Griewank et al., 2012). Nevertheless, trametinib induced the dose dependent 
inhibition of phospho-ERK expression in all cell lines, collectively indicating its potent activity 
as a MAPK signalling inhibitor at all employed concentrations. 
 
Figure 4.4 The Effect of Trametinib on MAPK Signalling in Cutaneous and Uveal Metastatic 
Melanoma Cell Lines  
Representative western blots of, Phospho-ERK (42 kDa), total ERK (42 kDa), and GAPHD (loading 
control, 37 kDa) expression in A.) CHL-1 or WM-164 cutaneous metastatic melanoma cells or B.) OM413 
or UPMD2 uveal metastatic melanoma cells after treatment with 2.5, 5 and 32nM trametinib (TRA) for 
16 hours. 
Having optimised trametinib doses, the potential for this MEK inhibitor to prevent CXCR4-
CXCL12 chemotaxis was evaluated by co-treating CXCR4 positive CHL-1, WM-164 or OM413 
cells for 16 hrs with 2.5, 5 or 32 nM trametinib when incorporated into transwell chemotaxis 
assays towards rCXCL12 (Figure 4.5). 
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Results demonstrated that trametinib at all concentrations induced the significant dose 
dependent inhibition of chemotaxis of all cells towards rCXCL12 compared to control, and 
importantly at concentrations of 2.5nM in WM-164 cells and 2.5 or 5nM in CHL-1 and OM413, 
doses at which there was no significant effect on cell viability (Kruskal-Wallis test with Dunn’s 
post hoc multiple comparison test, *P<0.05, ***P<0.001, Figure 4.5). 
Collectively these data therefore demonstrate the potent ability of the MEK specific inhibitor 
trametinib to inhibit CXCR4-CXCL12 mediated chemotaxis of both B-RAF mutant and wild-type 
cutaneous or GNAQ/GNA11 wild-type metastatic uveal melanoma cells. 
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Figure 4.5 Trametinib Inhibits Cutaneous and Uveal Metastatic Melanoma Cell Line 
Migration towards Human Recombinant CXCL12 
Relative cell migration per high powered field of vision (HPF) of A.) CHL-1 or B.) WM-164 cutaneous 
metastatic melanoma cells or C.) OM413 metastatic uveal melanoma cells towards 10nM human 
recombinant CXCL12 following treatment for 16 hrs in the presence or absence of 2.5, 5 or 32nM 
trametinib and expressed relative to cell migration towards recombinant CXCL12 of untreated cells. 
Each bar represents the mean of 9 replicate filters from 3 independent experiments + SD. Statistics were 
acquired by Kruskal-Wallis test with Dunn’s multiple comparison post hoc correction, where *P<0.05, 
***P<0.001. D.) Representative photomicrographs from one high powered field (HPF) of migrated CHL-
1, WM-164 or OM413 metastatic melanoma cells in the presence or absence of 2.5, 5, 32nM trametinib. 
Images were acquired at X20 magnification; scale bar represents 100µm. 
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4.2.4 Trametinib Prevents CHL-1 Melanoma Cell Migration towards 
Supernatants Derived from Primary Dermal Fibroblasts  
Next to determine the potential of trametinib to inhibit CXCR4-CXCL12 mediated chemotaxis 
of CXCR4 positive cutaneous melanoma cells towards CXCL12 rich dermal fibroblast 
supernatants, trametinib was titrated into chemotaxis assays for 16 hours with dermal 
fibroblast supernatants as the chemoattractant stimulus. As with experiments using 
recombinant CXCL12, results clearly demonstrated the dose dependent ability of trametinib 
to significantly inhibit CHL-1 cell migration towards primary dermal fibroblast supernatant 
(Kruskal-Wallis test with Dunn’s multiple comparison post hoc correction, ***P<0.001) (Figure 
4.6 A). 
 
Figure 4.6 Trametinib Inhibits Cutaneous Melanoma Cell Line Migration towards Dermal 
Fibroblast Supernatants 
Relative cell migration per high powered field of vision (HPF) of A.) CHL-1 cutaneous metastatic 
melanoma cells towards supernatant derived from primary dermal fibroblasts in the presence of 2.5, 5 
or 32nM trametinib, expressed relative to cell migration towards untreated cells. Each bar represents 
the mean of 9 replicate filters from 3 independent experiments each with a different donor of primary 
dermal fibroblast supernatants + SD. Statistics were acquired by Kruskal-Wallis test with Dunn’s 
multiple comparison post hoc correction, where ***P<0.001. B.) Representative photomicrographs 
from one high powered field (HPF) of migrated CHL-1 metastatic melanoma cells towards primary 
dermal fibroblast supernatant in the presence or absence of 2.5, 5, 32nM trametinib. Images were 
acquired at X20 magnification; scale bar represents 100µm. 
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4.2.5 Increased Basal Autophagy in Uveal Melanomas in vivo is Associated with 
Monosomy of Chromosome 3 
In line with the paradoxical role of autophagy in cancer, studies have documented increased 
autophagic activity in metastatic cutaneous melanomas raising the possibility that active 
autophagy may serve to protect tumour cells from the cytotoxic effects of trametinib (Ma et 
al., 2011a). Furthermore, several biomarker studies have confirmed the autophagy status of 
cutaneous melanomas with differing markers (Hersey and Zhang, 2008; Lazova et al., 2012; 
Ellis et al., 2014b), but to date only one study has reported the autophagy status of uveal 
melanomas (Giatromanolaki et al., 2011). Specifically Giatromanolaki et al report increased 
Beclin-1 expression in uveal melanomas is associated with hypoxia and pigmentation and a 
poor clinical outcome, leading to their conclusion that increased autophagic activity in uveal 
melanomas is associated with a more aggressive phenotype (Giatromanolaki et al., 2011). 
Given Beclin-1 expression alone is not a reliable marker of autophagy (Grishchuk et al., 2011) 
pre-optimised immunohistochemical assays for p62 as well as Beclin-1 expression and the 
expression of Melan-A as a melanocyte marker were therefore adopted in order to further 
confirm the potential status of autophagy in a cohort of 13 primary uveal melanomas with 
primary cutaneous melanomas of known Beclin-1 and p62 expression included as 
positive/negative controls (Table 4.1).  
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Primary Uveal 
Tumours 
Chromosome 3 
Status 
Melan-A Beclin-1 P62 
M13705/12 Monosomy ++ 
Variable 
expression 
Variable expression ++/+ 
M7871/13 Monosomy ++ 
Weak 
expression 
++ 
M12068 Monosomy + 
Strong 
expression 
++ 
M8375 Monosomy + 
Variable 
expression 
Variable expression ++/+ 
M7214 Monosomy + 
Variable 
expression 
Variable expression ++/+ 
M1529 Monosomy + 
Variable 
expression 
Weak expression in tumour centre +, 
strong expression +++ around edges 
M11052(A6) Monosomy ++ 
Variable 
expression 
Weak expression in tumour centre +, 
strong expression +++ around edges 
M11052(A7) Monosomy ++ 
Variable 
expression 
Weak expression in tumour centre +, 
strong expression +++ around edges 
M07885/12 Disomy + 
Weak 
expression 
+++ 
M9219/12 Disomy + 
Weak 
expression 
+++ 
M1135 Disomy 
No 
staining 
No staining No staining 
M13759 Disomy 
No 
staining 
No staining No staining 
M16827 Disomy +++ 
Weak 
expression 
Weak expression in tumour centre +, 
strong expression +++ around edges 
Table 4.1 Immunohistochemical Expression Melan-A, Beclin-1 and P62 in Primary Uveal 
Melanomas 
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Visual analysis revealed differential expression of Melan-A, Beclin-1 and p62 among all 
tumours with no expression of any marker detected in 2 primary tumours with disomy for 
chromosome 3 (Table 4.1). Notably however, p62 expression in 4 tumours was weaker in the 
centre of the tumour compared with much stronger staining observed at the tumour edge, 
which was also associated with the maintained expression of beclin-1 (Table 4.1, Figure 4.7). 
In addition, reduced expression of p62 in the tumour core centre was also associated, in 
general, with tumours with monosomy of chromosome 3 (Table 4.1, Figure 4.8). Collectively, 
these data thereby suggest the presence of increased autophagic activity within the hypoxic 
environment of the tumour core of primary uveal melanomas bearing monosomy of 
chromosome 3, and association with a more aggressive phenotype. Studies in a larger cohort 
however, are required to verify these findings, and any correlation with GNAQ/GNA11 
mutational status. 
.
 
Figure 4.7 Autophagy is Increased within the Hypoxic Core of Metastatic Uveal Melanomas 
Representative images for the immunohistochemical expression of p62 (or null primary negative) 
control in 3 primary uveal melanomas (M11052A6, M1529, M16827). Images represent p62 expression 
at the tumour edge or centre of the tumour bulk acquired by confocal microscopy with a magnification 
20x scale bar = 50μm. 
Crosstalk Between CXCR4-CXCL12 and MAPK Cell Signalling 
158 
 
 
 
 
Figure 4.8 Increased Basal Autophagic Activity is Associated with Monosomy of 
Chromosome 3 in Metastatic Uveal Melanomas.  
Representative images for the immunohistochemical expression of for Melan-A, Beclin1 and p62 (or 
null primary negative control) in two uveal melanomas; M07 with disomy of chromosome 3 and M13 
monosomic for chromosome 3. Images were acquired by confocal microscopy with a magnification of 
20X, scale bar = 50μm. 
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4.2.6 Combined Treatment with Trametinib and Chloroquine Potentiates 
Apoptosis of Uveal Melanoma in Vitro 
Since studies in vivo confirmed an apparent increase in basal autophagy in metastatic uveal 
melanomas with an aggressive phenotype, western blotting for LC3 conversion in the 
presence or absence of the lysosomal inhibitor chloroquine was used to establish basal 
autophagy levels in metastatic uveal melanoma cell lines. Furthermore, it is also well 
documented that the efficacy of drug-induced apoptosis can be hindered by the capacity of 
many drugs, including MEK inhibitors, to induce pro-survival autophagy to counter act 
apoptotic effects (Martin et al., 2015; Yao et al., 2015). The potential for clinically achievable 
concentrations of trametinib to induce autophagy in uveal melanoma cell lines was also 
evaluated in comparison to the effects of treatment with the clinically approved 
chemotherapeutic agent temozolomide. Specifically, OM413 (GNAQ/GNA11 wild-type), 
MEL270 (GNAQ mutated), or UPMD2 (GNA11 mutated) uveal melanoma cell lines were 
treated with clinically achievable concentrations of trametinib or temozolomide, for 4 hours 
in the presence or absence chloroquine prior to western blotting for the expression of total or 
phosphorylated/active ERK 1/2 or LC3 I-II. 
As shown by figure 4.9, trametinib induced the significant inhibition of pERK1/2 relative to 
total ERK1/2 in all cell lines, while no effect was observed in response to treatment with 
temozolomide or chloroquine alone (One-way ANOVA with Dunnett’s post-hoc test 
***P<0.001). However, treatment of all uveal melanoma cell lines resulted in increased basal 
autophagy as evidenced by the small but nevertheless increased expression of LC3-II (Figure 
4.10). Furthermore, the co-treatment of all cell lines with either trametinib or temozomide 
and chloroquine blocked LC3 flux (Figure 4.10), as evidenced by maintained/increased levels 
of LC3-II expression. Collectively these data demonstrate trametinib induces potent inhibition 
of MAPK signalling in uveal melanoma cells, but is accompanied by a concomitant increase in 
autophagic activity. 
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Figure 4.9 The Effect of MEK Inhibition on MAPK Signalling in Human Uveal Melanoma Cell 
Lines. 
Representative western blots for the expression of phospho- ERK1/2 (p-ERK) 44/42 kDa, total ERK1/2 
44/42 kDa, and GAPDH (loading control) 37 kDa expression in Ai.) OM413 (GNAQ/GNA11 wild-type) 
Bi.) Mel270 (GNAQ mutated) and Ci.) UPMD2 (GNA11 mutated) uveal melanoma cells in the presence 
or absence or combined treatment for 4 hrs with of trametinib (32nM), temozolomide (50µM), alone 
or in combination with treatment with chloroquine (CQ, 10µM) for the final 2 hours’ incubation. A, B, C 
ii.) Respective densitometric analysis representing p-ERK expression relative to GAPDH loading control, 
following the aforementioned treatment conditions. Each bar represents 3 replicates of p-ERK band 
intensity normalised to GAPDH band intensity (p-ERK/GAPDH) for each treatment condition, and 
expressed relative to control of each individual experiment (mean ± SD, N = 3). Statistics were acquired 
using one-way ANOVA with Dunnett’s post-hoc test (***P<0.001). 
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Figure 4.10 The Effect of MEK Inhibition on the Induction of Autophagy in Human Uveal 
Melanoma Cell Lines. 
Representative western blots for the expression of LC3 I/II 19/17 kDa, and GAPHD (loading control) 37 
kDa expression in Ai.) OM413 (GNAQ/GNA11 wild-type) Bi.) Mel270 (GNAQ mutated) and Ci.) UPMD2 
(GNA11 mutated) uveal melanoma cell lines in the presence or absence or combined treatment for 4 
hrs with trametinib (32nM), temozolomide (50µM), alone or in combination with treatment with 
chloroquine (CQ, 10µM) for the final 2 hours’ incubation. A, B, C ii.)  Respective densitometric analysis 
representing LC3 II expression relative to GAPDH loading control. Each bar represents 3 replicates of 
LC3 II band intensity normalised to GAPDH band intensity (LC3 II/GAPDH) for each treatment condition, 
and expressed relative to control of each individual experiment (mean ± SD, N = 3). 
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To test the hypothesis that trametinib-induced LC3 II is indicative of the induction of pro-
survival autophagy, OM413, MEL270, and UPMD2 cells were subsequently treated with 
combined 32nM trametinib and 10µM chloroquine, for 72 hrs prior to analysing the effect on 
cell viability or apoptosis (as determined by western blotting for caspase 3 cleavage), in 
comparison with the effects derived by treatment of each cell line with combined 
temozolomide (50µM) and chloroquine. Results revealed no significant effect on the viability 
of any uveal melanoma cell line following treatment with chloroquine or temozolomide alone, 
however treatment of each cell line with trametinib resulted in a significant reduction in cell 
viability, particularly apparent in MEL270 and UPMD2 cells harbouring hyper-activating 
mutations in GNAQ/11 compared to effects observed in OM413 wild-type cell (One-way 
ANOVA with Dunnett’s Post hoc correction, *P<0.05, **P<0.01, *** P<0.001, Figure 4.11 A-C 
i). Furthermore, co treatment of all cell lines with chloroquine and trametinib resulted in a 
trend for enhanced inhibition of cell viability compared to trametinib treatment alone (Figure 
4.11, A-C, i). In contrast any effect of temozolomide on the inhibition of cell viability was only 
minimally potentiated by co-treatment with chloroquine and was insignificant when 
compared to control MEL270 and UPMD2 cells (Kruskal-Wallis test with Dunn’s Multiple 
comparison post hoc test, ns P>0.05, Figure 4.11 B-Ci). Supporting these data, results also 
revealed little or no effect of treatment with temozolomide or chloroquine alone on the 
induction of cleaved caspase 3, while clear induction was observed in all cell lines under all 
trametinib treatment conditions (alone or in combination with chloroquine or temozolomide) 
(Figure 4.11 A-C ii, iii). Interestingly the most significant induction of cleaved caspase 3 was 
observed in OM413 and MEL270 cells following combined treatment with temozolomide, 
trametinib and chloroquine suggesting the combined treatment of trametinib and 
chloroquine may also increase the efficacy of temozolomide-induced apoptosis in some uveal 
melanomas. 
Collectively these data suggest trametinib induces pro-survival autophagy in uveal melanoma 
cell lines and that the combined treatment with chloroquine may potentiate the efficacy of 
trametinib to induce apoptosis, thereby presenting a novel therapeutic strategy to enhance 
targeted MEK inhibition in vivo. 
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Figure 4.11 The Effect of MEK Inhibition on Survival in Human Uveal Melanoma Cell Lines. 
Relative cell viability of human uveal Ai.) OM413 (GNAQ/GNA11 wild-type), Bi.) Mel270 (GNAQ mutated) and Ci.) UPMD2 (GNA11 mutated) melanoma cell lines 
treated for 72 hrs with trametinib (32nM), temozolomide (50µM) or vehicle control, in the presence or absence chloroquine (CQ, 10µM). Each bar represents the 
mean of 12 replicates +/- SD from 3 independent experiments. Statistics acquired by One-way ANOVA with Dunnett’s post hoc correction (*P<0.05, **P<0.01, 
***P<0.001). Representative western blots for the expression of cleaved caspase 3 17/19 kDa, and GAPHD (loading control) 37 kDa in A ii.) OM413 B ii.) Mel270 and 
C ii.) UPMD2 uveal melanoma cells under the same experimental conditions or A, B, C iii.) Respective densitometric analysis representing caspase 3 cleavage 
expression relative to GAPDH loading control. Each bar represents 3 replicates of cleaved caspase 3 band intensity normalised to GAPDH band intensity (cleaved 
caspase 3/GAPDH) for each treatment condition, and expressed relative to vehicle control of each individual experiment (mean ± SD, N = 3). Statistics were acquired 
using one-way ANOVA with Dunnett’s post-hoc test (*P<0.05, **P<0.01). 
4.2.7 Combined Treatment of Trametinib and Chloroquine Potentiates 
Apoptosis of Cutaneous Melanoma In Vitro 
In line with the observed results in uveal melanoma cells (section 4.2.6) and data indicating 
MEK inhibition with trametinib results in concomitant up regulation of autophagy, similar 
studies were conducted in cutaneous melanoma cell lines to confirm increased basal 
autophagy (Armstrong et al., 2011), the potential for trametinib-induced autophagy and to 
test the hypothesis that dual inhibition of MEK and autophagy may drive the efficacy of 
trametinib-induced cell death/apoptosis. To this aim, CHL-1 (wild-type), WM-164 (B-RAF 
mutated) and WM-1361 (N-Ras mutated) cutaneous melanoma cell lines were treated with 
clinically achievable concentrations of trametinib or temozolomide, for 4 hours in the 
presence or absence of chloroquine, before the effects on inhibition of MAPK signalling and 
induction of autophagic flux were determined by western blotting for phospho-ERK1/2 (p-
ERK1/2), total ERK1/2 or LC3 I-II (Figures 4.12 and 4.13). As shown by figure 4.12, trametinib 
induced the significant inhibition of pERK1/2 relative to total ERK1/2 in all cell lines, while no 
effect was observed in response to treatment with temozolomide or chloroquine alone (One-
way ANOVA with Dunnett post-hoc test, ***P<0.001). However, as in studies with uveal 
melanoma cell lines, trametinib appeared to increase basal autophagy in all cutaneous 
melanoma cell lines as evidenced by a small increase in expression of LC3-II (Figure 4.13), an 
effect also observed, albeit to a less extent, by treatment of all cell lines with temozolomide. 
As predicted, this effect was further potentiated by the blockade of autophagic flux with the 
addition of chloroquine, resulting in maintained accumulation of LC3-II expression. 
Collectively these data suggest similarly to observations in uveal melanoma that potent 
inhibition of MAPK signalling in cutaneous melanoma cells, by treatment with trametinib also 
results in a concomitant increase in autophagy. 
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Figure 4.12 The Effect of MEK Inhibition on MAPK Signalling in Human Cutaneous Melanoma 
Cell Lines. 
Representative western blots for the expression of phospho-ERK1/2 (p-ERK) 44/42 kDa, total ERK1/2 
44/42 kDa, and GAPDH (loading control) 37 kDa expression in Ai.) CHL-1(B-RAF/N-Ras wild-type) Bi.) 
WM-164 (B-RAF mutated) and Ci.) WM-1361 (N-Ras mutated) cutaneous melanoma cell lines in the 
presence or absence or combined treatment for 4 hrs with of trametinib (32nM), temozolomide (50µM), 
alone or in combination with treatment with chloroquine (CQ, 10µM) for the final 2 hour’s incubation. 
A, B, C ii.) Densitometric analysis of p-ERK expression relative to GAPDH loading control, following 
treatments as outlined in A-C. Each bar represents 3 replicates of p-ERK band intensity normalised to 
GAPDH band intensity (p-ERK/GAPDH) for each treatment condition, and expressed relative to control 
of each individual experiment (mean ± SD, N = 3). Statistics were acquired using one-way ANOVA with 
Dunnett’s post-hoc test (***P<0.001). 
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Figure 4.13 The Effect of MEK Inhibition on the Induction of Autophagy in Human Cutaneous 
Melanoma Cell Lines. 
Representative western blots for the expression of LC3 I/II 19/17 kDa, and GAPDH (loading control) 37 
kDa expression in Ai.) CHL-1 (B-RAF/N-Ras wild-type) Bi.) WM-164 (B-RAF mutated) and Ci.) WM-1361 
(N-Ras mutated) cutaneous melanoma cell lines in the presence or absence or combined treatment for 
4 hrs with of trametinib (32nM), temozolomide (50µM), alone or in combination with treatment with 
chloroquine (CQ 10µM) for the final 2 hours’ incubation. A, B, C ii.) Densitometric analysis of LC3 II 
expression relative to GAPDH loading control. Each bar represents 3 replicates of LC3 II band intensity 
normalised to GAPDH band intensity (LC3 II/GAPDH) for each treatment condition, and expressed 
relative to control of each individual experiment (mean ± SD, N= 3). 
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Similarly, to studies in uveal melanoma cell lines, the effect of MEK inhibition with trametinib 
on cutaneous melanoma cell survival was then determined in the presence or absence of 
chloroquine. Results again revealed no significant effect on the inhibition of CHL-1, WM-1361 
or WM-164 cell viability in the presence of chloroquine or temozolomide alone, however, 
trametinib induced a significant reduction in cell viability of WM-164 and WM-1361 cell lines 
bearing hyper-activating mutations in MAPK signalling compared to CHL-1 B-RAF/N-Ras wild-
type cells (Kruskal-Wallis with Dunn’s multiple comparison post hoc test, **P<0.01 and 
***P<0.001, Figure 4.14 A-Ci). Furthermore, combined treatment of chloroquine and 
trametinib potentiated the effects of trametinib-induced cell death alone, (Kruskal-Wallis with 
Dunn’s multiple comparison post hoc test, **P<0.01 and ***P<0.001, Figure 4.14 A-Bi), 
although this effect was not observed in WM-164 cells (Figure 4.14 Ci). Again, although clearly 
potentiating the effects of trametinib-induced cell death, the effect of chloroquine on the 
enhancement of temozolomide-induced inhibition of cell viability of all cutaneous melanoma 
cell lines, although evident, was less potent with only a significant effect seen in WM-164 cells 
(*P<0.05, Kruskal-Wallis with Dunn’s multiple comparison post hoc test, Figure 4.14 Ci). 
Supporting the enhanced inhibitory effects of combined treatment with trametinib and 
chloroquine on cell viability, western blotting for caspase 3 cleavage in WM-164 cells 
confirmed the mode of cell death as apoptosis as evidenced by the induction of cleaved 
caspase 3 following treatment of cells for 72 hours with trametinib +/- temozolomide +/- 
chloroquine treatment, with the greatest induction of apoptosis seen with a combination of 
all 3 drugs (Figure 4.14 C ii, iii). Collectively these results suggest as in studies in uveal 
melanoma cell lines, that trametinib treatment results in the induction of pro-survival 
autophagy to counter act apoptotic effects thereby providing further rationale for the dual 
inhibition of MEK and autophagy as a therapeutic strategy for cutaneous as well as metastatic 
uveal melanoma. 
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Figure 4.14 The Effect of MEK Inhibition on Survival in Human Cutaneous Melanoma Cell 
Lines. 
Relative cell viability of human cutaneous melanoma cells A.) CHL-1 (B-RAF/N-Ras wild-type) B.) WM-
164 (B-RAF mutated) and C.) WM-1361 (N-Ras mutated) treated in the presence trametinib (32nM) or 
temozolomide (50µM), or vehicle control in the presence or absence chloroquine (CQ, 10µM) for 72 
hours. Each bar represents the mean of a minimum of 12 replicates +/- SD from 3 independent 
experiments. Statistics acquired by One way ANOVA with Dunnetts post hoc correction (*P<0.05, 
**P<0.01,***P<0.001 C.ii) Representative western blots and iii) densitometric analysis for the 
expression of cleaved caspase-3 17/19 kDa, and GAPDH (loading control) 37 kDa, expression in WM-
164 (B-RAF mutated) cutaneous melanoma cells under the same experimental conditions where each 
bar represents 3 replicates of cleaved caspase 3 band intensity normalised to GAPDH band intensity 
(cleaved caspase 3/GAPDH) for each treatment condition, and expressed relative to vehicle control of 
each individual experiment (mean ± SD, N = 3).  
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4.3 Discussion  
4.3.1 MEK Inhibition as a Strategy to Inhibit of CXCR4-CXCL12 Chemotaxis in 
Cutaneous and Uveal Melanoma 
Results derived from this chapter reiterate the important role of CXCR4-CXCL12 cell signalling 
in melanoma cell migration and its possible role within the primary tumour 
microenvironment. Studies demonstrating the significant migration of CXCR4 positive 
cutaneous and uveal metastatic melanoma cells towards recombinant CXCL12, with reduced 
cell migration to an unstimulated level observed by inclusion of a neutralising CXCL12 
antibody, underpin the potency of CXCL12 as a chemoattractant for melanoma cells. Although 
cutaneous melanoma cell migration towards recombinant CXCL12 has been explored 
comprehensively (O'Boyle et al., 2013), the role of CXCR4-CXCL12 chemotaxis in uveal 
melanoma is an emerging topic of investigation in which the present results corroborate two 
previous studies reporting uveal melanoma migration towards recombinant CXCL12. 
However, unlike results derived from the present study, neither of these published studies 
were able to confirm migration was specifically mediated by CXCR4-CXCL12 chemotaxis, since 
in both cases the use of a neutralising CXCL12 blocking antibody was not included (Di Cesare 
et al., 2007a; Chattopadhyay et al., 2014). 
CXCL12 in humans exists in 6 isoforms α, β, y, ε, δ, and φ, generated from differential gene 
splicing events. Data from the present study report the effects of chemotaxis towards alpha 
recombinant CXCL12 ligand (CXCL12-α) and therefore can only be considered as CXCL12-α 
specific. Nevertheless, CXCL12-α and β are thought to be ubiquitously expressed, including 
within the skin (Cipriani et al., 2006), while the -y isoform is highly expressed within the brain 
and heart but only has low affinity for CXCR4. Other isoforms of CXCL12 are somewhat 
uncharacterised (Rueda et al., 2008). Furthermore, it is likely that functional differences 
between differing CXCL12 isoforms exist, supported by studies demonstrating CXCL12-β but 
not CXCL12-α is able to modulate leukocyte infiltration in brain ischemia (Stumm et al., 2002). 
Collectively these data further emphasise that the reported findings in the present study 
cannot be extrapolated to all CXCL12 isoforms and that future studies are required to 
specifically determine the potential contribution of other isoforms of CXCL12, and in particular 
CXCL12-β, to CXCR4-CXCL12 mediated chemotaxis of uveal or cutaneous melanoma. 
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The effect of MEK inhibition on uveal melanoma cell migration has also previously been 
explored, however, in contrast to results derived from the present study, results derived from 
a recent study by Chattopadhyay et al demonstrated MEK inhibition with MK-8033 had no 
effect on cell migration of wild-type or GNAQ/11 mutated cell lines, (Chattopadhyay et al., 
2014). Such discrepancy in results may reflect however, the lack of chemoattractant stimulus 
in the migration assay studies by Chattopadhyay et al, therefore only able to measure basal 
unstimulated migration, with cells presumably displaying lower levels of MAPK activation in 
the absence of a CXCL12 chemoattractant stimulus. In this context, results from the present 
study are the first to demonstrate the potential of MEK inhibition as a means to specifically 
prevent CXCR4-CXCL12 mediated chemotaxis in melanoma and the rationale for the use of 
trametinib to prevent CXCR4-CXCL12 mediated chemotaxis even in B-RAF/N-Ras or GNAQ/11 
wild-type cutaneous or uveal metastatic melanomas. Since patients harbouring B-RAF/N-Ras 
wild-type cutaneous melanomas account for up to 26 % of all melanoma patients, and there 
are still no specific targeted therapies for this sub group, resulting in continued dismal survival 
rates (Dummer et al., 2012; Hodis et al., 2012a), the use of MEK specific inhibitors may 
therefore offer a novel targeted treatment approach. The confirmation of CXCR4 expression 
may be a companion predictive biomarker; an approach supported by results from the present 
and other studies demonstrating B-RAF/N-Ras wild-type cutaneous melanoma cell lines are as 
sensitive to MEK inhibition as mutated cell lines (Stones et al., 2013; Ranzani et al., 2015), and 
clinical trials demonstrating partial responses to trametinib in patients with B-RAF/N-Ras wild-
type advanced melanomas (Falchook et al., 2012).  
Early stage melanomas classified as in radial growth phase have good prognosis following 
surgical excision, however melanomas that have transitioned to vertical growth phase with 
the presence of invasion into the dermis, display a much worse prognosis. The mechanism 
that promotes the transition from radial to vertical growth phase is unclear but is thought to 
involve the bidirectional interplay of tumour and stromal cells within the microenvironment 
(Villanueva J and Herlyn M, 2008). Supporting this hypothesis, results derived from studies in 
chapter 3, highlight the influence of epidermal CXCL12 expression on tumour progression. An 
interesting study by Whipple et al demonstrated cytokines secreted from melanoma cells (IL-
1β, IL-6 and IL-8, and MMP-1) upregulate the secretion of CXCL12 from dermal fibroblasts 
facilitating tumorigenic behaviour (Whipple and Brinckerhoff, 2014). Having demonstrated 
the potent secretion of CXCL12-α from primary dermal fibroblasts, it was therefore 
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hypothesised that this may provide the chemoattractant gradient to facilitate the invasion and 
migration of tumour cells. In support of this concept, the present chemotaxis studies of both 
B-RAF/N-Ras mutated and wild-type metastatic cutaneous melanoma cell lines demonstrated 
significant tumour migration towards supernatants derived from primary dermal fibroblasts, 
and that CXCL12 within these supernatants specifically facilitates this migration. Furthermore, 
data from the present study demonstrate CXCR4-CXCL12 mediated chemotaxis of cutaneous 
melanoma cells (B-RAF/N-Ras wild-type or mutant) towards dermal fibroblast supernatant is 
inhibitable by treatment with trametinib, suggesting MEK inhibition may present a viable 
strategy through which inhibits vertical growth phase migration and cutaneous invasion. 
Nevertheless, it should be noted that the level trametinib inhibited chemotaxis of melanoma 
cells towards dermal fibroblast supernatant was less than the level of inhibition achieved 
towards rCXCL12, suggesting that although CXCL12 is clearly a chemoattractant secreted by 
dermal fibroblasts the concentration of CXCL12 in the supernatants is likely less than 10nM 
used in experiments employing recombinant CXCL12, or that other factors secreted by dermal 
fibroblasts may counteract the inhibitory effects of trametinib on chemotaxis. In this respect, 
the validation of results derived in vitro, should be further explored in an in vivo setting, since 
there is potential for CXCL12 to be attained within the primary melanoma microenvironment 
from sources other than dermal fibroblasts, with endothelial cells, immune cells (monocytic 
phagocytes) to name but a few potential sources, as well as CXCL12 within the circulation or 
bone marrow, likely to influence the CXCR4-CXCL12 chemotactic gradient at the primary 
tumour site (Sun et al., 2010; Sánchez-Martín et al., 2011a). Although dermal fibroblasts are 
likely a major secretor of CXCL12 within skin in vivo, extrapolation of in vitro results to a 
primary tumour setting are further complicated by the multitude of factors that may affect 
tumour cell migration, including the secretion of CXCL12 by the tumour itself, modulation of 
CXCL12 levels by CXCR7-mediated sequestration, CXCL12 cleavage by metalloproteinase, or 
the presence of other chemoattractant cytokines which may have a greater effect on cell 
migration. In addition, chemotaxis experiments in the present study were performed over a 
relatively short time period of 16 hours, in a controlled experimental setting, whereas in vivo, 
chronic chemokine stimulation and fluctuations in chemotactic gradients from several 
potential sources are likely to influence CXCR4-CXCL12 chemotactic responses. Moreover, 
although the transwell chemotaxis assay adopted in the present study is the most commonly 
used assay to assess cell migration in vitro, and allows great flexibility in the screening of 
multiple experimental conditions, it is nevertheless a 2D endpoint assay and as such more 
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complex assays may reveal greater insight. Such assays could include the use of the ACEA 
biosciences xCELLigence system, that integrates a traditional boyden chamber with 
electrodes, to provide a real-time assay of chemotaxis and cell kinetics, or the Ibidi µ Slide 
Chemotaxis assay, where chemotaxis can be observed using time lapse microscopy, allowing 
both efficiency of cell migration and directionality to be assessed. Limitations in the use of 
such assays still remain however, since neither mimics in vivo cell chemotaxis, as cells would 
have to migrate through the skins extracellular matrix. In this context the incorporation of a 
matrix (collagen/fibronectin) into 2D assays may be pertinent or the use of 3D chemotaxis 
assays, such as a spheroid migration assay, to assess single cell or collective cell movement in 
a physiologically relevant environment, with flexibility to incorporate other cell types into the 
assay and the assessment of the effect of cell-cell interactions on cell migration (Kramer et al., 
2013; Leight et al., 2015). 
4.3.2 Harnessing Autophagy Modulation to Promote the Cytotoxic Effects of 
MEK Inhibition 
Although present results demonstrated effective dose-dependent inhibition of CXCR4-CXCL12 
chemotaxis in B-RAF/N-Ras and GNAQ/11 mutated as well as wild-type cutaneous/uveal 
melanoma cells by trametinib, the effect of trametinib on the inhibition of cell viability, 
particularly in wild-type cell lines, was modest. Given the fact that many chemotherapeutic 
drugs activate autophagy as a compensatory survival mechanism to counteract pro-apoptotic 
signals (Wright et al., 2013) and the inevitable emerging resistance of melanoma to MEK 
inhibition (Welsh et al., 2016), this raises the possibility that the presence of a B-RAF or 
GNAQ/GNA11 activating mutations and/or treatment with trametinib leads to increased 
activation of pro-survival autophagy. Supporting previous studies, have highlighted the 
presence of increased autophagy in advanced cutaneous melanomas (Ellis et al., 2014b), as 
well as a single study in primary uveal melanomas where increased autophagy was associated 
with earlier metastasis and worse prognosis (Giatromanolaki et al., 2011). Results from this 
present study confirmed increased autophagic activity in primary uveal melanomas with an 
associated metastatic phenotype as evidenced in general, by the maintained presence of 
Beclin-1 and decreased p62 expression within the hypoxic core of poorly vascularised tumours 
with monosomy of chromosome 3 (Degenhardt K et al., 2006; Giatromanolaki et al., 2011). 
Interestingly, Giatromanolaki et al (Giatromanolaki et al., 2011) found that depleted/reduced 
expression of Beclin-1 in primary uveal melanomas was associated with a better prognosis, 
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which may partially explain present observations in 2 uveal melanoma tumours with disomy 
of chromosome 3, which did not express any marker of autophagy including Beclin-1 and 
suggests that these tumours may display defective autophagy. Together these data thus 
highlight the potential for increased basal autophagy in advanced cutaneous or uveal 
melanoma (in vivo) regardless of the B-RAF or GNAQ/GNA11 mutational status. 
Studies of basal autophagy in metastatic melanoma cell lines confirmed previous observations 
of increased basal LC3 II expression in cutaneous B-RAF mutant compared to B-RAF/N-Ras 
wild-type cells (Armstrong et al., 2011), additionally revealing increased basal LC3 II expression 
in GNAQ/GNA11 mutant metastatic uveal melanoma cell lines as well as GNAQ/GNA11 wild-
type OM413 cells, although in the latter case this was not surprising since OM413 cells bear 
an activating B-RAF mutation (Refaian et al., 2015). Collectively therefore, increased basal 
autophagy in cutaneous and uveal melanoma appears to be associated with a metastatic 
phenotype with, in particular, the additional presence of an activating B-RAF or GNAQ/GNA11 
mutation, which may explain in part, the inherent relative resistance of such tumours to the 
cytotoxic effects of trametinib. Results demonstrating further induction of LC3 II by trametinib 
in both cutaneous and uveal melanoma cells further supported the hypothesis of additionally 
increased drug-induced pro-survival autophagy and led to the question of whether dual 
inhibition of MEK and autophagy may offer a potential means through which to increase the 
efficacy and cytotoxic effects of trametinib in both uveal and cutaneous melanomas. Indeed, 
results demonstrated the co-treatment of all uveal melanoma, and cutaneous melanoma cell 
lines CHL-1 and WM-1361 with trametinib and chloroquine, led to increased inhibition of cell 
viability as well as increased expression of cleaved caspase 3, compared to cells treated with 
trametinib alone, collectively suggesting inhibiting basal/drug-induced autophagy with 
chloroquine enhances the pro-apoptotic effects of trametinib. Interestingly this effect was not 
B-RAF/N-Ras or GNAQ/11 mutation dependant as the response of cutaneous/uveal wild-type 
CHL-1 and OM413 cells to dual MEK and autophagy inhibition also resulted in increased 
apoptosis. 
Hydroxychloroquine (HCQ, the clinically used formulation of Chloroquine), has been shown to 
improve the efficacy of many anti-cancer agents and in pre-clinical models augments cell 
death (Amaravadi et al., 2007; Degtyarev et al., 2008; Maclean et al., 2008; Qadir et al., 2008; 
Carew et al., 2010; Fan and Weiss, 2011; Guo et al., 2011b; Tang et al., 2011; Yang et al., 2011; 
Xie et al., 2013). Furthermore Phase I studies of cutaneous metastatic melanoma (and 
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including other solid tumours) demonstrate in addition to its favourable safety profile, HCQ 
combined with temsirolimus or temozolomide, results in favourable anti-tumour activity and 
reduced autophagic activity (Rangwala et al., 2014a; Rangwala et al., 2014b). Coupled with 
the current use of HCQ in over 50 trials for various cancer types, including 4 specifically in 
melanoma (ClinicalTrials.Gov), and an open phase I/II trial of HCQ and trametinib for advanced 
B-RAF melanoma (NCT02257424), results from the present study may also support the use of 
HCQ to increase the efficacy and cytotoxic effects of MEK inhibition as a therapeutic strategy 
for metastatic uveal melanoma. In this context, it will be important to evaluate the efficacy of 
trametinib and HCQ in pre-clinical models of uveal melanoma and to address this potential I 
have successfully obtained additional supplementary funding from the MRC to initiate these 
studies in collaboration with Professor Marais, Cancer Research UK. 
Nevertheless, although autophagy inhibition by HCQ at high micro-molar concentrations has 
a favourable safety profile, it is not a specific autophagy inhibitor but rather an inhibitor of 
lysosomal function, specifically blocking autophagosome lysosome fusion by increasing 
lysosomal PH and leading to cell cycle arrest. The use of more specific autophagy inhibitors 
such as SBI-0206965, a selective inhibitor of the serine/threonine autophagy-initiating kinase 
ULK1, or Spautin-1 that promotes the degradation of the Vps34-PI3 kinase complex, maybe 
thus a more beneficial approach to autophagy inhibition (Solomon and Lee, 2009; Jiang et al., 
2010). An additional caveat to the use of such selective inhibitors or HCQ is their capacity to 
inhibit autophagy not only in tumour cells but also their potential to inhibit autophagy in 
normal cells where autophagy plays a homeostatic role. The kidneys are particularly sensitive 
to chemotherapy, and recent studies have shown autophagy to be protective of acute renal 
injury in response to cisplatin treatment (Takahashi et al., 2012). Further, chronic use of HCQ 
has been linked with increased risk of retinopathies (Leung et al., 2015). Moreover, the 
inhibition of autophagy maybe detrimental to immune responses, as autophagy promotes T 
cell survival (Kovacs et al., 2012), dendritic cell MHC class II antigen presentation (Hayward 
and Dinesh-Kumar, 2010) and is a regulator of dendritic cell and T-cell immunological synapse 
formation important for adaptive immune responses (Wildenberg et al., 2012). Additionally 
inhibition of autophagy may also affect immunogenic cell death mechanisms induced by 
chemotherapeutics, as autophagy is required for the immunogenic release of ATP from dying 
cancer cells, essential for immune effector cell recruitment to tumours (Michaud et al., 2011; 
Martins et al., 2012). With most pre-clinical models of autophagy inhibition performed in 
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xenograft models of immunocompromised animals, the effect of autophagy inhibition on the 
immune system has also not been fully considered. 
Further, although inhibiting drug-induced autophagy or activated autophagy in advanced 
tumours seems attractive, autophagy nevertheless plays a paradoxical role in tumourigenesis; 
blocked or deregulated autophagy in early stages promotes genomic instability driving 
tumorigenesis while reactivation in response to increased metabolic stress in advanced 
tumours promotes tumour survival (Mathew et al., 2009; White et al., 2010). Inhibition of 
autophagy in advanced melanomas in this context may promote the emergence of secondary 
tumour development and hence driving autophagy exacerbation may be a more viable 
approach, further discussed below.  
The role of autophagy in cell migration is controversial and remains relatively undefined. 
Three studies have indicated that autophagy inhibition (mediated by knock down of 
autophagy dependant regulatory Atg genes) increases cell migration of mouse embryonic 
fibroblasts (Tuloup-Minguez et al., 2013; Qiang et al., 2014; Yoshida et al., 2016). Supporting 
these observations overexpression beclin-1 in tongue squamous cell carcinoma also inhibits 
cell migration (Weng et al., 2014). Conversely however, one study in lung cancer 
demonstrated chemical inhibition of autophagy with 3-MA or knock down of atg5 inhibited 
TLR dependent migration suggesting TLR-induced autophagy is required for cancer cell 
migration (Zhan et al., 2014). Although controversial, these studies thus pose a further 
interesting caveat to results derived from the present study in that although dual MEK and 
autophagy inhibition promoted cutaneous and uveal melanoma cell death, the inhibition of 
autophagy in MEK resistant subpopulations may perhaps increase tumour migration and 
subsequent metastasis. It would therefore be interesting to incorporate trametinib and 
chloroquine into chemotaxis assays to assess the potential effect of autophagy inhibition on 
cell migration. 
Taken on balance, although autophagy inhibition may potentiate the cytotoxic effects of 
trametinib, the possible role of autophagy inhibition in secondary tumour development, and 
implications on immune function and cell migration, may question whether in this context 
exacerbating autophagy induced by trametinib with drugs that use autophagy to exert their 
cytotoxic effects to promote autopahgic cell death may be more applicable. Metformin, 
terfenadine and Δ9-Tetrahydrocannabinol (THC) have demonstrated in melanoma to drive cell 
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death by induction of autophagy (Nicolau-Galmés et al., 2011; Tomic et al., 2011; Armstrong 
et al., 2015). Interestingly in uveal melanoma Ambrosini et al also demonstrated the use of 
the MEK inhibitor selumetinib (AZD6244) combined with AKT inhibition (MK2206) induced 
synergistic cell death via the exacerbation of autophagy (Ambrosini et al., 2013a). Therefore, 
strategies which alternatively harness autophagy induction by trametinib to promote 
apoptosis would be an interesting line of further investigation to pursue in uveal and 
cutaneous melanoma. 
Collectively results derived from the present chapter highlight the ability of MEK inhibition 
with trametinib to prevent cutaneous/uveal CXCR4-CXCL12 chemotaxis, but reveal the 
induction of compensatory mechanisms in that trametinib-induced autophagy may limit the 
cytotoxic efficacy of this drug. Dual inhibition of MEK and autophagy may represent a novel 
therapeutic strategy through which to limit CXCR4-CXCL12 mediated chemotaxis as well as 
potentiate apoptosis of uveal and cutaneous melanomas. 
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4.4 Summary 
 
 CXCR4 expressing cutaneous and uveal metastatic melanoma cells migrate towards 
human recombinant CXCL12 in vitro  
 CXCR4 expressing cutaneous metastatic melanoma cells migrate towards CXCL12 rich 
supernatants derived from primary dermal fibroblasts in vitro 
 MEK inhibition with trametinib inhibits CXCR4-CXCL12 chemotaxis of cutaneous and 
uveal melanoma cells towards human recombinant CXCL12 in vitro 
 MEK inhibition with trametinib prevents the chemotaxis of cutaneous metastatic 
melanoma cells migration towards CXCL12 rich dermal fibroblast supernatant 
 Increased autophagy in primary uveal melanomas in vivo is associated with an 
aggressive metastatic phenotype and monosomy of chromosome 3  
 Increased basal autophagy in metastatic uveal or cutaneous melanoma cell lines in 
vitro is associated with the presence of an activating B-RAF or GNAQ/GNA11 mutation 
 MEK inhibition with trametinib in uveal or cutaneous metastatic melanoma cell lines 
is associated with an increase in basal autophagy  
 Concomitant inhibition of MEK (with trametinib) and autophagy (with chloroquine) 
increases apoptosis of uveal and cutaneous melanoma cell lines   
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5.1 Introduction 
Angiogenesis and lymphangiogenesis are hallmarks of cancer, where the ‘angiogenic switch’ 
represents a rate limiting step in carcinogenesis (Hanahan and Folkman, 1996). The angiogenic 
switch is controlled by the balance between pro- and anti-angiogenic factors, expressed by 
tumour cells or within the tumour microenvironment. Of most importance in cancer is the 
principal pro-angiogenic factor, vascular endothelial growth factor A (VEGF-A) that binds to 
vascular endothelial growth factor receptor 2 (VEGFR2) on endothelial cells, inducing vascular 
permeability, disruption of adherent junctions, cell proliferation and migration required for 
new blood vessel formation. Lymphangiogenesis the formation of new lymphatic vessels, on 
the other hand is regulated by VEGF-C and VEGF-D that bind to VEGFR3 of lymphatic 
endothelial cells. However, proteolytic cleavage of VEGF-C, and VEGF-D can result in their 
enhanced binding to VEGFR2 on both lymphatic and blood vessel endothelium, making 
VEGFR2 an attractive target for both anti-angiogenesis and anti-lymphangiogenesis therapy 
(Hong et al., 2004a; Hirakawa et al., 2007). 
Cutaneous melanoma is one of the most highly vascularised tumours, with tumour vascularity 
often surpassing Breslow depth as a determinant of patient survival (Ilmonen S et al., 1999; 
Kashani-Sabet et al., 2002). VEGF although absent from normal melanocytes, is often secreted 
by melanoma cells, correlating with angiogenesis and metastatic potential in tumour 
xenografts (Pötgens et al., 1995; Claffey et al., 1996). In cutaneous melanoma, increased VEGF 
expression has been associated with the transition from radial to vertical growth phase, and 
melanoma metastasis (Marcoval et al., 1997; Vlaykova T et al., 1999; Osella-Abate et al., 
2002). Similarly in uveal melanoma, increased aqueous concentrations of VEGF-A or tumoural 
expression is associated with larger tumours and correlated with distant metastasis 
particularly to the liver (Missotten et al., 2006; Sahin et al., 2007; Crosby et al., 2011b). 
Although VEGF secretion from melanomas is thought to signal in a paracrine manner affecting 
local endothelial cells, identification of VEGF receptors on half of all melanoma cell lines, 
suggests that VEGF may also exert autocrine effects on tumour cells (Molhoek et al., 2008). 
The presence of VEGF-VEGFR autocrine cell signalling loops has been demonstrated in many 
solid tumours and haematological malignancies, with disruption of the autocrine loop, 
reducing tumour growth, survival and migration (Kim et al., 2005; Schoeffner et al., 2005; Wey 
et al., 2005; O'Donnell et al., 2016). Autocrine VEGF cell signalling is particularly favourable to 
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cancer cells, as in some circumstances it may promote epithelial-mesenchymal transition 
leading to enhanced tumour invasion and survival (Goel and Mercurio, 2013). A probable 
reason for this phenotypic change is that VEGF receptors activate an abundance of 
downstream cell signalling pathways including phospholipase C, the MAP-kinase and 
phosphoinositide 3–Kinase/Akt, that results in calcium release, cell proliferation, migration 
and survival (Xia et al.; Wang et al., 2008c). The expression of VEGF receptors has also been 
investigated in cutaneous melanomas, with evidence of all 3 receptors present to varying 
degrees in primary disease, however, VEGFR2 and VEGFR3 are thought to be most abundant, 
with VEGFR3 promoting tumour-associated lymphangiogenesis and VEGFR2 associated with 
angiogenesis and promotion of cell survival and migration (Mandriota et al., 2001a; Straume 
and Akslen, 2001; Pisacane and Risio, 2005; Mehnert et al., 2010). Specific studies of VEGFR2 
in cutaneous melanomas reported VEGFR2 expression in 78%-89% of metastatic tumours, 
compared to expression in only 9% of primary melanocytic naevi, highlighting the potential 
therapeutic benefit of VEGF receptor targeted therapy (Mehnert et al., 2010). Conversely, 
conflicting studies report, absence of VEGFR2 expression or only very low expression present 
in a mere 7% of metastatic melanomas (Molhoek et al., 2011; Miettinen et al., 2012). Such 
variable VEGFR2 expression may be attributable to the use of antibodies with differing epitope 
specificity, but caution the rationale for VEGFR2 specific targeted therapy. In uveal melanoma 
while, some VEGFR2 expression has been detected on uveal melanoma cell lines (Koch et al., 
2014a), there are to date, no documented studies of expression by primary uveal melanoma 
tumours. 
Despite the assumed benefits of inhibiting angiogenesis in melanoma, no anti-angiogenic 
therapy has improved significantly overall patient survival, or has been approved for use in 
metastatic melanoma. With inconsistent data for VEGF receptor expression, the recent clinical 
approach to inhibiting angiogenesis in melanoma has been focussed towards inhibiting the 
ligand, with Bevacizumab (Avastin), a humanised monoclonal antibody against VEGF, 
preventing the interaction of VEGF ligand with cognate VEGF receptors. Bevacizumab has the 
additional potential to inhibit both paracrine and autocrine VEGF signalling in cutaneous 
melanoma. As a single agent, however, bevacizumab has displayed disappointing clinical 
activity in cutaneous melanoma (Varker et al., 2007a), although in combination with other 
chemotherapies has been shown to improve the clinical outcome for various other cancers 
including breast and colon cancer (Miller et al., 2007; Saltz et al., 2008). In addition the clinical 
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efficacy of bevacizumab may limited, by inability to inhibit the interaction of VEGF with 
neuropilin receptors, known to promote growth, survival, invasion and tumour migration of 
cancer cells (Fukasawa M et al., 2007). Nevertheless encouraging results with bevacizumab 
have been derived in pre-clinical models of uveal melanoma, where intraperitoneal injection 
of bevacizumab in an orthotopic model supressed primary tumour growth and the 
development of hepatic metastasis, suggesting this anti-angiogenic therapy may offer clinical 
benefit in uveal melanoma (Yang et al., 2010). Over all, bevacizumab has had no effect on 
improved overall patient survival for melanoma (Corrie et al., 2014), and hence clinical 
approaches to anti-angiogenic therapy have more recently turned to new generation tyrosine 
kinase inhibitors, with broader antiangiogenic profiles, able to target multiple signalling 
pathways and which through inhibition of intracrine VEGF signalling may offer improved anti-
angiogenic therapy. 
Pazopanib currently approved for treatment of advanced soft tissue sarcoma and advanced 
renal cell carcinoma (Sonpavde G and Hutson TE, 2007), is a multi-target tyrosine kinase 
inhibitor of vascular endothelial growth factor receptor-1, 2, and 3, platelet-derived growth 
factor alpha and beta, and cytokine receptor inhibitor (c-kit). The additional activity against c-
kit may be of particular benefit, as up to 28% of melanomas harbour activating mutations or 
amplification of the receptor tyrosine kinase KIT (Becker et al., 2007). Initial phase I trials have 
noted partial responses and disease stabilisation in advanced solid tumours including 
melanoma (Hurwitz et al., 2009; Tan et al., 2010; Burris et al., 2012), and an interim analysis 
of a phase II trial demonstrated encouraging disease control rates of 80% with some complete 
and partial responses reported with combined use of pazopanib and paclitaxel as a first line 
therapy in unresectable melanoma (Fruehauf JP, 2012). 
Cell migration is an important pre-requisite for angiogenesis and metastasis, highlighting 
possible crosstalk between CXCR4-CXCL12 and VEGF cell signalling in promotion of tumour 
progression. The crosstalk between these 2 important pathways has been eloquently 
demonstrated, in colon cancer where CXCR4-CXCL12 pathway activation induces VEGF 
production, an effect abrogated by the use of a CXCR4 inhibitor (Ottaiano et al., 2006). In 
addition, breast cancer, osteosarcoma, glioma as well as renal cell carcinoma, VEGF signalling 
has been shown to upregulate CXCR4 expression, resulting in increased cell migration 
(Bachelder et al., 2002; Zagzag et al., 2005; Hong et al., 2006; Oda et al., 2006). Furthermore, 
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a correlation between CXCR4 and VEGF expression has recently been reported in a cohort of 
53 patients with uveal melanoma (Franco et al., 2010). CXCR4 and VEGFR2 expression as well 
as CXCL12 and VEGF secretion by tumour and endothelial cells, may be promoted by hypoxia-
induced activation of the common regulator hypoxia inducible factor-1 (HIF-1), highlighting 
further potential crosstalk between VEGF and CXCR4-CXCL12 signalling (Ceradini et al., 2004; 
Schutyser et al., 2007; Adamcic et al., 2012; Hu et al., 2016). In addition recent studies of 
bevacizumab in a lung cancer model report the promotion of tumoural secretion of CXCL12 
and the recruitment of CXCR4 positive fibrocyte cells, as a mechanism mediating drug 
resistance (Mitsuhashi et al., 2015). Taken together these studies suggest that inhibition of 
both CXCR4-CXCL12 and VEGF-VEGFR2 signalling may be beneficial to prevent overlapping 
downstream migratory pathway activation but also resistance to anti-angiogenic therapy. 
Results from the previous chapter (4), demonstrated MEK inhibition provides a potential 
therapeutic strategy through which to prevent CXCR4-CXCL12 chemotaxis of melanoma cells. 
Given the know role of VEGF-VEGFR2 cell signalling in also mediating cell migration, dual 
inhibition of MEK and VEGFR2 cell signalling may hence represent a more potent means 
through which to prevent tumour migration and metastasis. In support of this hypothesis, dual 
inhibition of RAF (upstream of MEK) and VEGFR2 in a pre-clinical model of pancreatic cancer 
has been shown to result in reduced tumour growth and metastasis (Lang et al., 2008). 
Further, the combination of a VEGFR2 inhibitor (cediranib) and a B-RAF inhibitor (PLX4720) 
has also been shown to promote the induction of apoptosis in melanoma cell lines and 
promote tumour regression in xenograft models, with the combination of these agents 
yielding greater effects than either drug alone (Friedman et al., 2015). 
To explore the potential cross talk between VEGFR2 and CXCR4-CXCL12 signalling in both 
cutaneous and uveal melanoma and the potential for the combined inhibition of both 
pathways as a strategy to inhibit tumour migration and promote cell death. The present 
chapter aimed to further characterise VEGFR2 expression in primary cutaneous and uveal 
melanomas in relation to CXCR4 expression and determine the potential efficacy of pazopanib 
alone and in combination with trametinib to inhibit cell viability and CXCR4-CXCL12-mediated-
chemotaxis.  
5.2 Results 
5.2.1 VEGFR2 is Expressed at Low Levels in Melanocytic Naevi and Primary 
Cutaneous Melanomas 
To date there has been wide disparity with respect to melanoma expression of VEGFR2 
(Mehnert et al., 2010; Molhoek et al., 2011). To further explore, the potential contribution of 
VEGFR2 to tumour progression, and possible correlation with CXCR4 expression and crosstalk 
with CXCR4-CXCL12 signalling, VEGFR2 expression was evaluated by semi quantitative 
immunohistochemical analysis in a FFPE cohort of 1 melanocytic naevi or 26 primary 
melanomas of differeing AJCC stage, with known CXCR4 expression. Immunohistochemical 
analysis was optimised using FFPE HUVEC endothelial cell pellets, well documented to express 
VEGFR2 (Zhang et al., 2011), and used as a positive control in all subsequent 
immuohistochemistry experiments (Figure 5.1). 
 
Figure 5.1 HUVEC Cells Express VEGFR2 Strongly 
Representative images of VEGFR2 immunohistochemical expression in HUVEC cells, where A.) 
represents a null primary and B.) positive VEGFR2 staining. Images were acquired at x20 magnification. 
Scale bar represents 50µm. 
A threshold for positive and negative tumoural VEGFR2 staining was set using images 
representative of strong VEGFR2 staining, the lowest threshold of positive staining and no 
VEGFR2 statining (Figure 5.2). Using Leica QWin software the mean percentage positively 
stained tumour cells, was derived from the analysis of up to 10 representative 20X high-
powered fields. 
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Figure 5.2 Threshold for Positive and Negative Tumoural VEGFR2 Staining 
A.) Representative image of VEGFR2 immunohistochemical expression in an AJCC stage II primary 
cutaneous melanoma used to set thresholds of VEGFR2 expression detection where I.) Represents, 
positive VEGFR2 expression, II.) Lowest threshold of VEGFR2 positivity, or III.) Negative VEGFR2 
expression. Images were acquired at x20 magnification. Scale bar represents 50µM. 
Results revealed VEGFR2 was strongly expressed by endothelial cells within tumoural and 
dermal capillaries, sweat glands, sebaceous glands and hair follicles in all sections, and served 
as internal positive controls in each case (Figure 5.3 A-E). In addition the epidermal 
keratinocytes in some tumour sections displayed notable VEGFR2 expression (Figure 5.3 A, 5.4 
E-F), so an additional representative images of epidermal VEGFR2 expression for each tumour 
was also acquired, with semi quantitative analysis perfomed by applying the same threshold 
as applied to quantify tumoural VEGFR2 expression. 
Visual analysis of tumoural VEGFR2, revealed cytoplasmic expression, generally weak and 
heterogeneously expressed within melanomas (Figure 5.4). Semi quantitative analysis 
however, revealed 73% of all cutaneous melanomas across all AJCC disease stages displayed 
less than 1% mean VEGFR2 expression, with only one AJCC stage III melanoma expressing a 
mere 4.18% expression. Statistical analyses also confirmed a lack of any significant differences 
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in VEGFR2 expression between any AJCC disease stage, (Kruskal-Wallis test, P= 0.6726, Figure 
5.5 A), localised and metastatic tumours (Mann Whitney U, P=0.5878, Figure 5.5 B), or 
between B-RAF/N-Ras wild-type or mutated tumours (Mann Whitney U, P= 0.2059, Figure 5.5 
C). 
Although the analysed cohort contained a broad range of mean % CXCR4 expressing 
melanomas, however results revealed there was no significant correlation between tumour 
VEGFR2 expression and CXCR4 expression (Spearman’s r correlation, P=0.3248, Figure 5.5 D), 
or CXCL12 expression (Spearman’s r correlation, P= 0.9892, data not shown). Collectively 
these data suggest that VEGFR2 is expressed heterogeneously at low levels within tumours 
and there is no association between CXCR4 and VEGFR2 expression by primary cutaneous 
melanomas. 
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Figure 5.3 Immunohistochemical Expression of VEGFR2 in Skin. 
A.) Representative image of VEGFR2 immunohistochemical expression in skin of a benign melanocytic 
naevus tumour. Images were acquired at x10 magnification. Scale bar represents 200µm. 
Representative images of VEGFR2 immunohistochemical expression in B.) Capillaries, C.) Sweat glands, 
D.) Sebaceous glands and E.) Hair follicles of a benign naevi tumour serving as internal positive control 
in each section. Images were acquired at x20 magnification. Scale bar represents 50µm. 
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Figure 5.4 VEGFR2 is Expressed by Primary Cutaneous Melanomas at Low Levels 
Representative images of VEGFR2 immunohistochemical expression in AJCC stage II primary cutaneous 
melanomas where A.) Represents a null primary, or B, and C.) Positive VEGFR2 Staining, D.) Negative 
VEGFR2 staining, E.) Positive staining of the epidermis or F.) Negative staining of the epidermis. Images 
were acquired at x20 magnification. Scale bar represents 50µm. 
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Figure 5.5 Primary Cutaneous Melanomas Express Low Levels of VEGFR2, with no 
Association with AJCC Stage, Localised or Metastatic Disease or CXCR4 Expression 
A.) Scatter graph representing the mean VEGFR2 expression % in eventual stage melanocytic naevi or 
AJCC stage I, II or III melanomas or B.) localised (eventual AJCC stage of disease I/II) or metastatic 
melanomas (eventual AJCC stage III/IV) after 7 years follow up. C.) Scatter graph representing mean 
VEGFR2 expression % in all AJCC stage wild-type or B-RAF/N-Ras mutated primary melanomas. Each 
point is the mean of 10 high powered fields of view (HPF), horizontal bars represent median % VEGFR2 
expression D.) Scatter graph representing mean VEGFR2 expression % in relation to mean CXCR4 
expression % in all AJCC stage melanomas. 
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Similarly, to VEGFR2 expression within primary melanomas, mean VEGFR2 expression % 
within the overlying epidermis was also less than 1% in 80.7% of all tumours analysed, with 
levels of VEGFR2 expression >10% detected within the epidermis of just 3 tumours (2 AJCC 
stage II and 1 AJCC stage III) (Figure 5.6 A). There was no significant difference in epidermal 
VEGFR2 expression % between all AJCC stages (Kruskal-Wallis test, P=0.0935, Figure 5.6 A), or 
between tumour and epidermal VEGFR2 expression (P=0.2001 Mann Whitney U, Figure 5.6 
B). However, there was a moderate positive correlation found between tumour and epidermal 
VEGFR2 expression % (Spearman’s r= 0.4216, CI 95% 0.02-0.70, *P=0.0319, Figure 5.6 C). 
Collectively data suggests epidermal VEGFR2 expression is indicative of tumoural expression, 
and suggestive of a common upregulation of VEGFR2 within the skin as a whole. 
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Figure 5.6 Potential Association of VEGFR2 Expression in Primary Cutaneous Melanomas and 
the Overlying Epidermis 
A.) Scatter graph representing the mean epidermal VEGFR2 expression % (mean of 2 high powered 
fields HPF) in eventual stage melanocytic naevi or AJCC stage I, II or III melanomas or B.) mean VEGFR2 
expression % in all AJCC stage primary melanoma tumours or overlying epidermis C.) mean VEGFR2 
expression % in individual melanomas relative to mean VEGFR2 expression % in the corresponding 
epidermis. All horizontal bars represent median VEGFR2 expression %.  
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5.2.2 Association of VEGFR2 Expression in Primary Cuatneous Melanomas and 
Patient Matched Metastatic Lymph Nodes 
The role and importance of VEGFR2 in promoting lymphangiogenesis is unclear, however the 
ability of VEGFR2 to bind mature VEGF-C and VEGF-D the primary mediators of 
lymphangiogenesis, questions whether VEGFR2 expression by melanoma cells in lymph node 
metastases may be integral to tumour metastasis to sentinel lymph nodes. To investigate this 
possibility, pre-optimised immunohistochemistry for VEGFR2 expression was performed in a 
FFPE cohort of 9 primary cutaneous melanomas and patient matched metastatic lymph nodes 
(Durham Cohort) and 2 normal lymph nodes, with FFPE HUVEC cell pellets used as a positive 
control and a previously VEGFR2 negative primary cutaneous melanoma (Newcastle Cohort) 
as a negative control. 
Consistent with results derived above, HUVEC cells (positive control) stained strongly for 
VEGFR2 (data not shown), while little or no expression was detected in the primary cutaneous 
melanoma (negative control) derived from the Newcastle cohort (Figure 5.7 C). Visual analysis 
of VEGFR2 expression in the 2 normal lymph nodes (Figure 5.7 A and B) on the other hand 
revealed positive expression by immune cells. While analysis of 1 primary and patient matched 
metastatic lymph node metastases was not possible due to overwhelming melanin 
pigmentation. Interestingly, the immune infiltrate from lymph node metastases derived from 
some tumours also did not display any visual expression of VEGFR2 (Figure 5.7 G). Conversely, 
variable expression of VEGFR2 was detected in tumour cells in both primary cutaneous 
melanomas and patient matched metastatic lymph nodes, in general, revealing strong 
cytoplasmic expression throughout the tumour bulk (Figure 5.7 E-H).   
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Figure 5.7 Immunohistochemistry for the Expression of VEGFR2 in a Cohort of Primary 
Cutaneous Melanomas with Patient Matched Metastatic Lymph Nodes  
Immunohistochemistry for VEGFR2 expression in a cohort of primary cutaneous melanomas or patient 
matched metastatic lymph nodes, or normal lymph nodes derived from the Durham patient cohort 
where A.) Represents null primary antibody control staining in a normal lymph node, B.) Positive 
VEGFR2 staining in a normal lymph node C.) Negative VEGFR2 expression in a primary cutaneous 
melanoma from the Newcastle Cohort (negative control), D.) Null Primary antibody control staining in 
a primary cutaneous melanoma, E.) Positive VEGFR2 expression in a primary cutaneous melanoma, and 
F.) Weak VEGFR2 expression in a matched metastatic lymph node. G.) VEGFR2 expression in a 
metastatic lymph node with negative expression in the immune cells or H.) VEGFR2 expression in a 
metastatic lymph node with positive expression in the immune cells. Black arrows depict immune cells.  
Images were acquired at x20 magnification. Scale bar represents 50µm. 
Crosstalk between VEGFR2 Cell Signalling and CXCR4-CXCL12 Chemotaxis in Cutaneous and 
Uveal Melanoma 
194 
 
In comparison, there was no significant difference between VEGFR2 expression in primary 
cutaneous melanomas and expression in patient matched metastatic lymph nodes, suggesting 
if VEGFR2 expression is present in the primary tumour then expression is maintained within 
in the lymph node metastases (Paired T test, ns P=0.2086, Figure 5.8). 
 
Figure 5.8 Association of VEGFR2 Expression in a Cohort of Primary Cutaneous Melanomas 
and Patient Matched Metastatic Lymph Nodes 
A.) Scatter graph representing the mean (mean of 10 high powered fields of view (HPF)) VEGFR2 
expression % in a cohort of primary cutaenous melanomas or secondary metastatic lymph nodes 
(Durham Cohort). Statistics Acquired by Paired T Test. Horizontal bars represent mean VEGFR2 
expression % +/- SD. 
Although the cohort of primary cutaneous melanomas and patient matched metastatic lymph 
nodes comprised patients with just eventual AJCC stage III/IV disease, and hence did not 
comprise a range of differing AJCC stage melanomas, when VEGFR2 expression was compared 
in tumours that remained localised (eventual AJCC stage I/II melanomas derived from the 
Newcastle cohort), with those that went on to develop metastases (eventual AJCC stage III/IV 
from the Durham and Newcastle patient cohort), a significant increase in VEGFR2 expression 
was observed in those tumours that subsequently developed metastasis (Mann Whitney U, 
***P= 0.0004, Figure 5.9). Collectively these results imply VEGFR2 upregulation in primary 
cutaneous melanomas may be indicative of metastasis, in particular to lymph nodes, although 
a larger patient cohort would be required to validate this hypothesis.  
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Figure 5.9 VEGFR2 Expression is Increased in Primary Tumours That Develop Metastatic 
Disease 
Scatter graph representing mean % (mean of 10 high powered fields of view (HPF)) VEGFR2 expression 
in localised (eventual AJCC stage I/II disease) or metastatic melanomas (eventual AJCC stage III/IV) after 
7 years follow up in two primary melanoma patient cohorts derived from Newcastle or Durham. 
Horizontal bars represent median VEGFR2 expression %. Statistics acquired by Mann Whitney U 
***P=0.0004. 
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5.2.3 VEGFR2 Expression is Increased in Primary Uveal Melanomas 
Using the same pre-optimised immunohistochemical assay used for the analysis of VEGFR2 in 
cutaneous melanoma, VEGFR2 expression was analysed in a cohort of 9 primary uveal 
melanomas with or without monosomy for chromosome 3 (Figure 5.10). Results revealed 
heterogeneous cytoplasmic expression of VEGFR2 in all uveal melanomas with the exception 
of one tumour with disomy of chromosome 3 (Figure 5.11 A). VEGFR2 was also detected within 
the retina and choroid of the eye, to varying degrees in all samples, and was most strongly 
expressed within micro vessels of the ganglion cell layer as well as rods and cones, as 
previously reported in normal eyes (Stitt et al., 1998; Kim et al., 1999). 
However, there was no significant difference in VEGFR2 % expression between tumours 
bearing monosomy or disomy of chromosome 3 (Mann Whitney U, P=0.2619, Figure 5.11 B), 
although it should be noted that statistical analysis is limited in such a small sample size. 
Results demonstrate that on average 30% of uveal melanoma tumour cells express VEGFR2, 
however we detected expression up to 61.72% in a tumour with monosomy of chromosome 
3. Together data suggests that VEGFR2 is a potential therapeutic target for uveal melanomas, 
in particular tumours with adverse prognostic features. 
Furthermore, statistically, there was significantly greater VEGFR2 expression in uveal 
compared to cutaneous melanomas, (Mann Whitney U, ***P=0.0004, Figure 5.11 C) while 
interestingly, there was no significant correlation between VEGFR2 expression and the 
expression of either CXCR4, or CXCL12, (data not shown), perhaps also reflected by the small 
total cohort size of uveal melanomas employed by the present study. 
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Figure 5.10 Immunohistochemistry for Expression of VEGFR2 in a Cohort of Primary Uveal 
Melanomas. 
Immunohistochemistry for VEGFR2 expression in a cohort of primary uveal melanomas where A.) 
Represents a null primary control, B.) Positive VEGFR2 staining in a tumour with disomy of chromosome 
3, C.) Positive VEGFR2 staining in a tumour with monosomy of chromosome 3, D.) Null Primary control 
of the retina and choroid of the eye E.) Positive VEGFR2 expression in the retina and choroid of the eye 
F.) Weak VEGFR2 expression in the retina and choroid of the eye. Images were acquired at x20 
magnification. Scale bar represents 50µm. 
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Figure 5.11 Quantification of Immunohistochemistry for the Expression of VEGFR2 in a 
Cohort of Primary Uveal Melanomas 
A.) Scatter graph representing the mean (mean of 10 high powered fields of view (HPF)) VEGFR2 
expression % in a cohort of primary uveal melanomas. B.) Scatter graph representing mean VEGFR2 
expression % in tumours that have disomy or monosomy of chromosome 3 C.) Scatter graph 
representing mean VEGFR2 expression % in primary cutaneous or uveal melanomas. Statistics acquired 
by Mann Whitney U Test ***P<0.001. All horizontal bars represent median VEGFR2 expression %. 
  
Crosstalk between VEGFR2 Cell Signalling and CXCR4-CXCL12 Chemotaxis in Cutaneous and 
Uveal Melanoma 
199 
 
5.2.4 VEGFR2 is Expressed by Cutaneous and Uveal Melanoma In Vitro 
Given the seemingly low expression of VEGFR2 in primary cutaneous melanomas, but which 
increased in tumours which subsequently metastasised to regional lymph nodes as well as 
seemingly increased expression by primary uveal melanomas, the immunofluorescent 
expression of VEGFR2 was also determined in a panel of cutaneous and uveal melanoma cell 
lines (Figure 5.12) as well as in keratinocytes and melanocytes (Figure 5.13) using HUVEC cells 
as a positive control (Slongo et al., 2007). In addition the immunofluorescent subcellular 
localistaion of VEGFR2 was determined by the acquisition of Z stacks of the middle section of 
fixed cells, since it has been suggested that a nuclear expression pattern is associated with 
benign naevi and microinvasive melanomas whereas a cytoplasmic and nuclear expression 
pattern are associated with a worse prognosis and advancement towards invasive melanomas 
(Figure 5.12 and 5.13) (Pisacane and Risio, 2005). 
Results revealed differential expression of VEGFR2 among all cutaneous and uveal melanoma 
cell lines (Figure 5.12), with all cell lines expressing VEGFR2 but with weak expression 
displayed by the uveal metastatic melanoma cell line OM413. VEGFR2 expression was also 
evident in primary keratinocytes and melanocytes, (Figure 5.13). Intrestingly the subcellular 
localisation of VEGFR2 varied between cell lines with most displaying nuclear and cytoplasmic 
expression (CHL-1, A375, WM-1361, OM413, HUVEC, Figure. 5.12, and primary melanocyte 
cells Figure 5.13). Strikingly WM-164, OMM2.3 and primary keratinocytes expressed much 
greater nuclear VEGFR2 expression while in contrast, UPMD2 cells expressed VEGFR2 
predominantly within the cytoplasm with only weak levels of VEGFR2 expression within the 
nucleus (Figure 5.12 and 5.13). 
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Figure 5.12 Immunofluorescent Expression of VEGFR2 in Cutaneous and Uveal Metastatic 
Melanoma Cell Lines 
Representative images from 3 replicate experiments for the immunofluorescent expression of HUVEC 
cells (positive control), cutaneous metastatic melanoma cell lines CHL-1, A375, WM-164 and WM-1361, 
or uveal melanoma cell lines OM413, MEL270, OMM2.3 and UPMD2, or null primary control. Green 
depicts VEGFR2 positivity and blue DAPI nuclear staining. Images were acquired by confocal microscopy 
at 20x magnification, scale bar = 50μm or Z stacks of cells taken and the middle cross section of the cell 
shown, with magnification of 20x, scale bar 50μm. 
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Figure 5.13 Immunofluorescent Expression of VEGFR2 in HUVEC cells, Primary Keratinocytes 
and Melanocytes 
Representative images from 3 replicate experiments for the immunofluorescent expression of VEGFR2 
in HUVEC cells, primary keratinocytes and primary melanocytes, or null primary control. Green depicts 
VEGFR2 positivity and blue DAPI nuclear staining. Images were acquired by confocal microscopy with 
magnification of 20x, scale bar = 50μm or Z stacks of cells taken and the middle cross section of the cell 
shown, with magnification of 20x, scale bar 50μm. 
Given the large intra-variability of VEGFR2 expression detected by immunofluorescence 
(Figure 5.14 A), mRNA expression of VEGFR2 expression was also quantified in all cell lines and 
primary cells (Figure 5.14 B). Similarly, to immunofluorescent protein expression analysis, 
VEGFR2 mRNA expression was detectable in primary keratinocytes and melanocytes as well 
as in all cutaneous and uveal melanoma cell lines, with again very low level of expression in 
uveal OM413 cells (Figure 5.14 B). Interestingly while WM-164 cutaneous melanoma cells 
expressed high levels of VEGFR2 protein, these cells displayed very low expression of VEGFR2 
mRNA (Figure 5.14). Differences in mRNA and protein expression are perhaps unsurprising 
given the myriad of post-transcriptional mechanisms, differences in protein half-life and 
experimental error or noise generated in both mRNA and immunofluorescent experiments. 
However overall, using mRNA and protein expression analysis results confirmed the 
expression of VEGFR2 by all cutaneous and uveal melanoma cell lines as well as in primary 
keratinocytes and melanocytes (Greenbaum et al., 2003). 
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Figure 5.14 Differential Expression of VEGFR2 Protein and mRNA by Cutaneous and Uveal 
Metastatic Melanoma Cell Lines, HUVEC cells and Primary Keratinocytes and Melanocytes 
A.) Mean VEGFR2 fluorescence per cell, within cutaneous and uveal metastatic melanoma cell lines, 
HUVEC cells (positive control) and primary melanocytes or keratinocytes. Each bar is the mean VEGFR2 
fluorescence per cell derived from 4 representative images from 3 independent experiments (mean + 
SD, N=3). B.) Mean mRNA expression of VEGFR2 in cutaneous and uveal metastatic melanoma cell lines, 
HUVEC cells, and primary melanocytes or keratinocytes. Each bar is mean of VEGFR2 Cycle threshold 
for each sample normalised to 18s cycle threshold from 3 independent experiments (mean +SD N=3). 
Results further revealed enhanced immunofluorescent expression of VEGFR2 by cutaneous 
and uveal melanoma cells grown in close proximity compared to cells cultured in monolayer 
at a lower density. The subcellular localisation of VEGFR2 also appeared to be more 
cytoplasmic within cells that had grown to larger cell clusters. The presence of a variable 
cluster size of cells with positive VEGFR2 expression led to the hypothesis that seeding density 
may affect expression and subcellular localisation. To test this hypothesis A375, WM-164 and 
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WM-1361 cells were seeded at variable densities for 24 hours, or CHL-1, WM-164 and WM-
1361 cells were seeded at 1x104 cells/well for 24-96 hours, prior to the analysis of the 
immunofluorescent/mRNA expression of VEGFR2 (Appendix 2). Results demonstrated that 
seeding density increased VEGFR2 expression and that VEGFR2 translocated from the nucleus 
to the cell cytoplasm at higher seeding density, which may therefore account for the variability 
in VEGFR2 expression and subcellular localisation observed in uveal/cutaneous melanoma cell 
lines (Appendix Figures 2.1-2.8). However, whether such an effect may be influenced by the 
secretion of VEGF from uveal or melanoma cell lines requires further evaluation. 
5.2.5 Pazopanib Inhibits Cell Viability and CXCR4-CXCL12 Chemotaxis of 
Cutaneous and Uveal Melanoma Cell Lines 
Given the expression of VEGFR2 by cutaneous and uveal melanoma cell lines in vitro (Section 
5.2.4) as well as by primary cutaneous and uveal melanomas, and patient matched metastatic 
lymph nodes in vivo (Section, 5.2.1, 5.2.2 and 5.2.3), this provides a rationale for targeting 
VEGFR2 to prevent melanoma migration and metastasis especially in uveal melanoma. 
Previous clinical trials targeting the VEGF signalling pathways with the VEGF ligand trapping 
monoclonal antibody bevacizumab, have provided the proof of concept for use of 
angiogenesis inhibitors in cancer therapy (Varker et al., 2007b). Furthermore bevacizumab 
prevents uveal melanoma cell migration in vitro, highlighting the role of VEGF signalling in 
melanoma cell migration (Logan et al., 2013). Given that CXCR4-CXCL12 chemokine axis is the 
major mediator of melanoma cell migration, to investigate the potential of inhibiting VEGF cell 
signalling and CXCR4-CXCL12 mediated migration/chemotaxis by targeting the VEGFR2 
receptor, experiments were initiated to test the efficacy of the pan VEGFR2 tyrosine kinase 
inhibitor, pazopanib in this capacity. Initially the effect of pazopanib on melanoma cell viability 
over a clinically achievable dose range was evaluated in both B-RAF/N-Ras wild-type and 
mutant cutaneous melanoma as well as GNAQ/GNA11 wild-type and mutant uveal melanoma 
cell lines (Figure 5.15). 
Pazopanib induced a dose dependant decrease in cell viability of both cutaneous and uveal 
melanoma cell lines (Figure 5.15). WM-164 cutaneous melanoma cells were least sensitive to 
treatment with significant inhibition of cell viability seen only at the highest dose of 25µM 
pazopanib (Kruskal-Wallis test with Dunn’s multiple comparison post hoc test, ***P<0.001, 
Figure 5.15 B). As there was no significant effect on cell viability with pazopanib in any cell line 
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at 1µM or in WM-164 and OM413 at 5µM, concentrations of 1, 5 and 25µM were selected to 
titrate in subsequent chemotaxis assays. 
 
Figure 5.15 Pazopanib-induced Inhibition of Cell Viability of Cutaneous and Uveal Metastatic 
Melanoma Cell Lines 
Cell viability of A.) CHL-1, B.) WM-164, cutaneous metastatic melanoma cell lines or C.) OM413 or, D.) 
UPMD2 uveal metastatic melanoma cell lines in the presence or absence of 0.1-25µM pazopanib for 16 
hours, relative to control untreated cells. Each bar represents mean cell viability of 12 replicates from 
3 independent experiments +SD N=3. Statistics acquired by one-way analysis of variance with Dunnett’s 
multiple comparison post hoc correction or Kruskal Wallis test with Dunn’s multiple comparison post 
hoc correction, where *P<0.05, ***P<0.001. 
To determine the effect of pazopanib on CXCR4-CXCL12 cell chemotaxis of cutaneous and 
uveal metastatic melanoma cells, cells were treated with 1, 5, 25µM pazopanib prior to 
incorporation into transwell chemotaxis assays. Analysis of chemotaxis of CHL-1, WM-164 or 
OM413 cells revealed pazopanib (at all utilized concentrations) induced significant dose-
dependent inhibition of chemotaxis towards rCXCL12 compared to control untreated cells 
(Kruskal-Wallis test with Dunn’s multiple comparison post hoc test, *P<0.05, **P<0.01, 
***P<0.001, Figure 5.16). However, although pazopanib induced a significant inhibition of 
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chemotaxis of CHL-1 cells at a concentration of 1µM pazopanib and for WM-164 and OM413 
cells at concentrations of 5µM pazopanib (Kruskal-Wallis test with Dunn’s multiple 
comparison post hoc test, ***p<0.001, Figure 5.16), there was no significant inhibition of cell 
viability observed at these concentrations (Figure 5.15). Collectively, these data suggest both 
trametinib and pazopanib display a more potent ability to inhibit cutaneous and uveal 
metastatic melanoma CXCR4-CXCL12 mediated chemotaxis compared to their effects on 
inhibition of cell viability, additionally further highlighting the apparent crosstalk between 
CXCR4-CXCL12 driven chemotaxis, MAPK and VEGFR2 cell signalling. 
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Figure 5.16 Pazopanib Inhibits Chemotaxis of Cutaneous and Uveal Metastatic Melanoma 
Cell Lines Towards rCXCL12 
Relative Migration (per high powered field) of A.) CHL-1, B.) WM-164 cutaneous metastatic melanoma 
cells or C.) OM413 metastatic uveal melanoma cells, towards 10nM recombinant CXCL12 in the 
presence of 1, 5 or 25µM pazopanib, expressed relative to migration towards recombinant CXCL12 of 
untreated cells. Each bar represents the mean of 9 replicate filters from 3 independent experiments + 
SD. Statistic acquired by Kruskal-Wallis test with Dunn’s multiple comparison post hoc correction, 
where *P<0.05 and ***P<0.001. D.) Representative photomicrographs from one high powered field 
(HPF) of migrated CHL-1, WM-164 or OM413 metastatic melanoma cells towards rCXCL12 in the 
presence or absence of 1, 5, or 25µM pazopanib. Images acquired at X20 magnification, scale bar 
represents 100µm. 
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Although clearly able to potently inhibit cutaneous and uveal melanoma cell chemotaxis, 
pazopanib is a multi-targeted tyrosine kinase inhibitor that primarily targets VEGFR2, but also 
has biological affinity for VEGFR1, VEGFR3 and to a lesser extent on fibroblast growth factor 
receptor-1, platelet derive growth factor receptor beta, KIT proto-oncogene tyrosine kinase 
receptor and colony stimulating factor receptor. It therefore remained unclear whether 
pazopanib-induced inhibition of CXCR4-CXCL12 melanoma chemotaxis was due to the specific 
inhibition of VEGFR2. To address this, a siRNA pool was used to specifically knock down 
VEGFR2 in CHL-1 and WM-164 metastatic melanoma cell lines and the effect on melanoma 
cell migration determined in the presence or absence of treatment with recombinant VEGF 
and pazopanib. 
Knockdown of VEGFR2 in both CHL-1 and WM-164 metastatic melanoma cell lines was 
confirmed by the significant reduction in VEGFR2 mRNA by, on average 40% in CHL-1 and 32% 
in WM-164 cells compared to expression following transfection of cells with control non-
targeting siRNA (Students T test, **P=0.090, and ***P=0.008, Figure 5.17 A). 
Preliminary experiments in WM-164 B-RAF mutated metastatic melanoma cells additionally 
confirmed treatment with VEGF resulted in the significant increase in migration of 
untransfected cells in the absence of chemotactic stimulant (One-way ANOVA with Bonferroni 
post hoc correction, ***P<0.001, Figure 5.17 B). Interestingly, results also confirmed that the 
effects of transfection alone appeared to reduced WM-164 cell migration, with a significant 
reduction in migration of non-targeting control and VEGFR2 siRNA transfected cells compared 
to untransfected cells (One-way ANOVA with Bonferroni post hoc correction, ***P<0.001, 
Figure 5.17B). Pazopanib also significantly inhibited cell migration of WM-164 cells transfected 
with non-targeting siRNA in the presence or absence of treatment with VEGF (One-way 
ANOVA with Bonferroni post hoc correction, *P<0.05, Figure 5.17B), conversely, there was no 
reduction in WM-164 cell migration following transfection with VEGFR2 siRNA suggesting that 
pazopanib-induced inhibition of cell migration is mediated via VEGFR2 inhibition (One-way 
ANOVA, with Bonferroni post hoc correction, ns P>0.05, Figure 5.17B). Furthermore, a 
significant reduction in WM-164 cell migration was also observed following VEGFR2 mediated 
knockdown compared to that observed following transfection of cells with non-targeting 
siRNA, collectively suggesting VEGFR2 signalling is required for cell migration (One-way 
ANOVA with Bonferroni post hoc correction, *P<0.05, Figure 5.17B). 
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Migration studies were then repeated in CHL-1 and WM-164 cells cutaneous metastatic 
melanoma cells transfected with non-targeting or VEGFR2 siRNA in the presence or absence 
of VEGF and pazopanib. In both cell lines treatment of un-transfected cells with recombinant 
VEGF significantly increased melanoma cell chemotaxis (Kruskal-Wallis test with Dunn’s 
multiple comparison post hoc correction, **P<0.01 and ***P<0.001 for CHL-1 and WM-164 
respectively, Figure 5.17 C), thereby confirming the involvement of VEGF cell signalling in 
melanoma cell migration. Transfection of both cell lines with either non-targeting or VEGFR2 
siRNA also significantly reduced VEGF-induced cell migratory ability, confirming again that 
transfection alone is able to inhibit melanoma cell migration (Kruskal-Wallis test with Dunn’s 
multiple comparison post hoc correction, ***P<0.001, Figure 5.17 C). While in CHL-1 cells 
there was a non-significant trend for a reduction in cell migration following VEGFR2 siRNA 
transfection compared to non-targeting siRNA transfection (Kruskal-Wallis test with Dunn’s 
multiple comparison post hoc correction, ns P>0.05), in WM-164 cells, knockdown of VEGFR2 
resulted in a significant reduction in cell migration compared to cells transfected with non-
targeting siRNA, (Kruskal-Wallis test with Dunn’s multiple comparison post hoc correction, 
***P<0.001, Figure 5.17B), suggestive of a role for VEGFR2 cell signalling in WM-164 cell 
migration, at least. Nevertheless, treatment of both cell lines with pazopanib following non-
targeting siRNA transfection resulted in significant reduction of cell migration (Kruskal-Wallis 
test with Dunn’s multiple comparison post hoc correction, ***P<0.0001, Figure 5.17 C), while 
there was no significant reduction in cell migration of either cell lines following knockdown of 
VEGFR2 (Kruskal-Wallis test with Dunn’s multiple comparison post hoc correction, ns P>0.05, 
Figure 5.17 C), collectively indicating VEGFR2 is required for pazopanib induced-inhibition of 
melanoma migration. 
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Figure 5.17 Knockdown of VEGFR2 Impairs Pazopanib-Induced Inhibition of Melanoma Cell 
Migration  
A.) Mean VEGFR2 mRNA expression in CHL-1 or WM164 metastatic melanoma cutaneous cell lines, 72 
hours post transfection with VEGFR2 siRNA or non-target (NT) control siRNA. Each bar is mean VEGFR2 
Cycle threshold normalised to 18s cycle threshold from 3 independent experiments (mean +SD N=3). 
Statistics acquired by Students T test (**P<0.01, **P<0.001). B.) Relative migration (Per high powered 
field, HPF) of WM164 cutaneous metastatic melanoma cells in the presence or absence of transfection 
with VEGFR2 siRNA or non-targeting (NT) siRNA, in the presence or absence of treatment with 
recombinant VEGF (10ng/ml) and pazopanib (1µM), for 16 hours. Each bar represents the mean HPF of 
9 replicate filters +SD. Statistics acquired by One-way analysis of variance with Bonferroni post hoc 
correction (*P<0.05, ***P<0.001) C.) Relative migration per HPF of CHL-1 or WM164 cutaneous 
metastatic melanoma cells, in the presence or absence of transfection with VEGFR2 siRNA or non-
targeting (NT) siRNA, in the presence or absence of treatment with recombinant VEGF (10ng/ml) and 
pazopanib (1µM), for 16 hours. Each bar represents the mean HPF derived from 9 replicate filters from 
3 independent experiments + SD. Statistics acquired by Kruskal-Wallis test with Dunn’s multiple 
comparison post hoc correction (ns P>0.05, **P<0.01, ***P<0.001). 
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5.2.6 Combined MEK and VEGFR2 Inhibition Potentiates Inhibition of 
Cutaneous and Uveal Melanoma Cell Viability and CXCR4-CXCL12 
Chemotaxis 
Results revealed both MEK and VEGFR2 inhibition impairs melanoma cell viability and 
chemotaxis when trametinib and pazopanib are used as single agents (Section 4.2.3 and 5.2.5), 
however monotherapy targeting the MAPK pathway or angiogenesis has historically lead to a 
plethora of resistant mechanisms and reactivation of pro-survival downstream signalling 
pathways (Ellis and Hicklin, 2008a; Welsh et al., 2016). Consequently attempts have been 
made to target the same pathways simultaneously or by combining drugs that target 
alternative pathways, resulting in increased efficacy and the reduced emergence of drug 
resistance (Lang et al., 2008; Dankort et al., 2009; Meng et al., 2010; Flaherty et al., 2012a; 
Carlino et al., 2014). Experiments were therefore initiated, to investigate the potential for the 
increased efficacy of combined MEK and VEGFR2 inhibition on uveal or cutaneous melanoma 
CXCR4-CXCL12 chemotaxis. 
Initially, the effect of combined trametinib and pazopanib on CHL-1 or WM-164 cutaneous or 
OM413 or UPMD2 uveal melanoma cell viability was assessed over 16 hours, in response to 
treatment with a clinically achievable dose range of both drugs and at a fixed dose ratio of 1: 
1712.5 trametinib:pazopanib (nM), calculated from the cMax of both drugs. Results 
demonstrated there was no significant effect of single agent trametinib at any concentration 
on the inhibition of CHL-1 or OM413 cell viability (One-way ANOVA, P=0.2762 and P=0.6850 
respectively, Figure 5.18 A and 5.20 A). Conversely, concentrations of trametinib at 2.5-10nM 
in WM-164 and 0.5-10nM in UPMD2 induced significant inhibition of cell viability (One-way 
analysis of variance with Dunnett’s multiple comparison post hoc test, or Kruskal-Wallis test 
with Dunn’s multiple comparison post hoc test, *p<0.05, **P<0.01, ***P<0.001, Figures 5.19 
A and 5.21 A), highlighting the relative increased sensitivity of cutaneous and uveal melanoma 
cells bearing activating MAPK mutations to trametinib compared to B-RAF/N-Ras or GNAQ/11 
wild-type cell lines. 
Studies of single agent pazopanib-induced inhibition of melanoma cell viability, revealed dose 
dependant significant inhibition of CHL-1 and UPMD2 cells from 4.28 – 17.13µM (One-way 
ANOVA with Dunnett’s post hoc correction, *P<0.05 and ***P<0.001 respectively, Figure 
5.18B and 5.21B) and in WM-164 (Figure 5.19B) and OM413 (Figure 5. 20B) cells at doses 8.56-
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17.12µM (One-way ANOVA with Dunnett’s post hoc correction, **P<0.01 and ***P<0.001 
respectively), collectively suggesting pazopanib-induced inhibition of melanoma cell viability 
is independent of B-RAF/N-Ras or GNAQ/GNA11 mutational status. 
Next, the effects of combined trametinib and pazopanib were compared in which results 
demonstrated the significant inhibition of CHL-1, OM413 and UPMD2 cell viability in response 
to combined treatment over a fixed dose ratios of 2.5nM:4.28µM to 10nM:17.12µM  
(trametinib:pazopanib) (One-way ANOVA with Dunnett’s post hoc correction, *P<0.05, 
**P<0.01, ***P<0.001,  Figure 5.18 C, 5.20 C and 5.21 C), and in response to fixed dose ratio 
trametinib:pazopanib in WM-164 cells from 5nM:8.56µM to 10nM:17.12µM (One-way 
ANOVA with Dunnett’s post hoc correction, ***P<0.001, Figure 5.10 C). Collectively these 
results demonstrate a dose-dependent inhibition of melanoma cell viability in vitro by dual 
MEK and VEGFR2 blockade with combined trametinib and pazopanib treatment. 
To determine the significance of the effect of combined trametinib and pazopanib on the 
inhibition of cell viability with that derived by single agent treatment, one-way analysis of 
variance was performed with Bonferroni post hoc correction at each dose ratio comparing 
results derived using each drug alone (Figures 5.18-21 D and Appendix 3, Appendix Table 3.1-
3.4). Results confirmed the dose dependant inhibition of cell viability in CHL-1, WM-164, 
OM413 and UPMD2 cell lines by single agent treatment (Figures 5.18-21D). Inhibition of CHL-
1, WM-164 and OM413 cell viability was significantly potentiated by combined trametinib and 
pazopanib at the fixed dose ratios of 5nM:8.56µM and 10nM:17.12µM (trametinib:pazopanib) 
compared to single agents trametinib and pazopanib at the same concentrations (One-way 
ANOVA with Bonferroni post hoc correction, *P<0.05, **P<0.01,***P<0.001, Figures 5.18-20 
D, and Appendix Table 3.1-3.3). However, in UPMD2 cells although combined 
trametinib:pazopanib potentiated trametinib-induced inhibition of cell viability at fixed doses 
of 5nM:8.56µM to 10nM:17.12µM (One-way ANOVA with Bonferroni post hoc correction, 
*P<0.05, **P<0.01,***P<0.001, Figure 5.21 D and Appendix Table 3.4), combined 
trametinib:pazopanib only potentiated pazopanib-induced inhibition of cell viability at a fixed 
dose ratio of 5nM:8.56µM (One-way ANOVA with Bonferroni post hoc correction, *P<0.001 
Figure 5.21 D and Appendix Table 3.4) Collectively these data highlight the potentiation of the 
inhibition of melanoma cell viability by combined trametinib and pazopanib. 
Crosstalk between VEGFR2 Cell Signalling and CXCR4-CXCL12 Chemotaxis in Cutaneous and 
Uveal Melanoma 
212 
 
Since, there was no significant inhibition of cell viability by either single agent or combined at 
fixed dose ratios of 0.5nM:0.85µM, and 1nM:1.71µM trametinib:pazopanib, these drug 
combination ratios were therefore selected to evaluate the effects of combined MEK and 
VEGFR2 blockade on CHL-1, WM-164 and OM413 CXCR4-CXCL12 mediated chemotaxis. 
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Figure 5.18 Combined Trametinib and Pazopanib Potentiates the Inhibition of CHL-1 
Cutaneous Melanoma Cell Viability 
A.) Relative cell viability of CHL-1 cutaneous metastatic melanoma cells following treatment of 0.10-
10nM trametinib or B.) following treatment of 0.17-17.12 µM pazopanib or C.) following combined 
treatment of trametinib and pazopanib at a fixed dose ratio of 1:1712 (relative to control untreated 
cells) for 16 hours. Each bar represents mean cell viability of 12 replicates from 3 independent 
experiments + SD. Statistics acquired by one-way ANOVA with Dunnett’s post hoc correction *P<0.05 
and ***P<0.001. D.) Relative cell viability of CHL-1 cutaneous metastatic melanoma cells following 
treatment for 16 hours with single agent trametinib (0.1-10nM), or pazopanib (0.17-17.12µM) or with 
both agents at a fixed dose ratio of 1:1712 (relative to untreated control) for 16 hours. Each point 
represents mean cell viability of 12 replicates from 3 independent experiments. 
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Figure 5.19 Combined Trametinib and Pazopanib Potentiates the Inhibition of WM-164 
Cutaneous Melanoma Cell Viability 
A.) Relative cell viability of WM-164 cutaneous metastatic melanoma cells following treatment of 0.10-
10nM trametinib or B.) following treatment of 0.17-17.12 µM pazopanib or C.) following combined 
treatment of trametinib and pazopanib at a fixed dose ratio of 1:1712 (relative to control untreated 
cells) for 16 hours. Each bar represents mean cell viability of 12 replicates from 3 independent 
experiments + SD. Statistics acquired by one-way ANOVA with Dunnett’s post hoc correction **P<0.05, 
**P<0.01 and ***P<0.001. D.) Relative cell viability of WM-164 cutaneous metastatic melanoma cells 
following treatment for 16 hours with single agent trametinib (0.1-10nM), or pazopanib (0.17-
17.12µM) or with both agents at a fixed dose ratio of 1:1712 (relative to untreated control) for 16 hours. 
Each point represents mean cell viability of 12 replicates from 3 independent experiments. 
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Figure 5.20 Combined Trametinib and Pazopanib Potentiates the Inhibition of OM413 Uveal 
Melanoma Cell Viability 
A.) Relative cell viability of OM413 uveal metastatic melanoma cells following treatment of 0.10-10nM 
trametinib or B.) following treatment of 0.17-17.12 µM pazopanib or C.) following combined treatment 
of trametinib and pazopanib at a fixed dose ratio of 1:1712 (relative to control untreated cells) for 16 
hours. Each bar represents mean cell viability of 12 replicates from 3 independent experiments + SD. 
Statistics acquired by one-way ANOVA with Dunnett’s post hoc correction ***P<0.001. D.) Relative cell 
viability of OM413 uveal metastatic melanoma cells following treatment for 16 hours with single agent 
trametinib (0.1-10nM), or pazopanib (0.17-17.12µM) or with both agents at a fixed dose ratio of 1:1712 
(relative to untreated control) for 16 hours. Each point represents mean cell viability of 12 replicates 
from 3 independent experiments. 
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Figure 5.21 Combined Trametinib and Pazopanib Potentiates the Inhibition of UPMD2 Uveal 
Melanoma Cell Viability 
A.) Relative cell viability of UPMD2 uveal metastatic melanoma cells following treatment of 0.10-10nM 
trametinib or B.) following treatment of 0.17-17.12 µM pazopanib or C.) following combined treatment 
of trametinib and pazopanib at a fixed dose ratio of 1:1712 (relative to control untreated cells) for 16 
hours. Each bar represents mean cell viability of 12 replicates from 3 independent experiments + SD. 
Statistics acquired by one-way ANOVA with Dunnett’s post hoc correction *P<0.05, **P<0.01, and 
***P<0.001. D.) Relative cell viability of UPMD2 uveal metastatic melanoma cells following treatment 
for 16 hours with single agent trametinib (0.1-10nM), or pazopanib (0.17-17.12µM) or with both agents 
at a fixed dose ratio of 1:1712 (relative to untreated control) for 16 hours. Each point represents mean 
cell viability of 12 replicates from 3 independent experiments. 
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Studies of the effect of combined trametinib and pazopanib (at fixed dose ratios of 
0.5nM:0.85µM, or 1nM:1.71µM, and 5nM:8.56µM trametinib:pazopanib) on CHL-1, and 
OM413 CXCR4-CXCL12 mediated chemotaxis revealed firstly, the significant inhibition of 
migration towards 10nM recombinant CXCL12 by 5nM trametinib and 8.56µM pazopanib as 
single agents (Kruskal-Wallis test with Dunn’s multiple comparison post hoc test, *P<0.05 or 
***P<0.001, Figure 5.22 A-B and 5.24 A-B), and also by single agent trametinib at 1nM and 
5nM or single agent pazopanib at 1.71µM and 8.56µM in WM-164 cells (Kruskal-Wallis test 
with Dunn’s multiple comparison post hoc test, *P<0.05, Figure 5.23 A-B). Further, in response 
to combined trametinib and pazopanib at all fixed dose ratios in all cells lines there was a 
significant inhibition of CXCR4-CXCL12 chemotaxis, with the exception of 0.5nM:0.85µM 
trametinib:pazopanib in OM413 cells (Kruskal-Wallis test with Dunn’s multiple comparison 
post hoc test, **P<0.01, ***P<0.001, Figure 5.22C-5.24C). 
To determine the significance of combined trametinib and pazopanib on the inhibition of 
CXCR4-CXCL12 mediated chemotaxis with that derived by single agent treatment, one-way 
analysis of variation was performed with Bonferroni post hoc correction at each drug ratio, 
comparing results derived from either drug alone (Figures 5.22 D - 5.24 D, and Appendix Table 
3.5-3.7). Results demonstrated combined trametinib and pazopanib significantly potentiated 
the inhibition of CXCR4-CXCL12 mediated chemotaxis of CHL-1 and WM-164 cells over either 
drug alone at all fixed dose ratios (One-way ANOVA with Bonferroni post hoc correction, 
***P<0.001, Figure 5.22 D-5.23 D and Appendix Table 3.5 and 3.6). While, in OM413 cells 
significant potentiation of the inhibition of CXCR4-CXCL12 mediated chemotaxis, was only 
observed with combined trametinib:pazopanib at fixed dose ratios of 1nM:1.71µM (One-way 
ANOVA with Bonferroni post hoc correction, *P<0.05 and **P<0.01, Figure 5.24 D, Appendix 
Table 3.7). 
Collectively, these data demonstrate that in cutaneous and uveal metastatic melanoma cell 
lines the combination of trametinib and pazopanib significantly increases the inhibition of cell 
chemotaxis than either drug does alone, at concentrations that do not affect cell viability. 
Furthermore, these data additionally propose that dual inhibition of MEK and VEGFR2 maybe 
a more effective way of preventing cutaneous and uveal melanoma migration. 
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Figure 5.22 Combined Trametinib and Pazopanib Potentiates the Inhibition of CHL-1 
Cutaneous Melanoma CXCR4-CXCL12 Chemotaxis 
Relative CHL-1 metastatic cutaneous melanoma cells migration (per high powered field, HPF) towards 
10nM recombinant CXCL12 in the presence of A.) 0.50-5.00nM trametinib, or B.) 0.85-8.56µM 
pazopanib, or C.) in the presence of trametinib and pazopanib at a fixed dose ratio of 1:1712 for 16 
hours, expressed relative to cell migration towards recombinant CXCL12 of untreated cells. Each bar 
represents the mean HPF of 6 replicate filters from 2 independent experiments + SD. Statistic acquired 
by Kruskal-Wallis test with Dunn’s multiple comparison post hoc correction, where **P<0.01, 
***P<0.001. D.) Relative CHL-1 metastatic cutaneous melanoma cells migration (per HPF) towards 
10nM recombinant CXCL12 for 16 hours with single agent trametinib (0.5-5nM) or pazopanib (0.85-
8.56µM), or with both agents at a fixed dose ratio of 1:1712. 
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Figure 5.23 Combined Trametinib and Pazopanib Potentiates the Inhibition of WM-164 
Cutaneous Melanoma CXCR4-CXCL12 Chemotaxis 
Relative WM-164 metastatic cutaneous melanoma cells migration (per high powered field, HPF) 
towards 10nM recombinant CXCL12 in the presence of A.) 0.50-5.00nM trametinib, or B.) 0.85-8.56µM 
pazopanib, or C.) in the presence of trametinib and pazopanib at a fixed dose ratio of 1:1712 for 16 
hours, expressed relative to cell migration towards recombinant CXCL12 of untreated cells. Each bar 
represents the mean HPF of 6 replicate filters from 2 independent experiments + SD. Statistic acquired 
by Kruskal-Wallis test with Dunn’s multiple comparison post hoc correction, where *P<0.05, 
***P<0.001. D.) Relative WM-164 metastatic cutaneous melanoma cells migration (per HPF) towards 
10nM recombinant CXCL12 for 16 hours with single agent trametinib (0.5-5nM) or pazopanib (0.85-
8.56µM), or with both agents at a fixed dose ratio of 1:1712. 
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Figure 5.24 Combined Trametinib and Pazopanib Potentiates the Inhibition of OM413 Uveal 
Melanoma CXCR4-CXCL12 Chemotaxis 
Relative OM413 metastatic uveal melanoma cells migration (per high powered field, HPF) towards 
10nM recombinant CXCL12 in the presence of A.) 0.50-5.00nM trametinib, or B.) 0.85-8.56µM 
pazopanib, or C.) in the presence of trametinib and pazopanib at a fixed dose ratio of 1:1712 for 16 
hours, expressed relative to cell migration towards recombinant CXCL12 of untreated cells. Each bar 
represents the mean HPF of 6 replicate filters from 2 independent experiments + SD. Statistic acquired 
by Kruskal-Wallis test with Dunn’s multiple comparison post hoc correction, where **P<0.01, 
***P<0.001. D.) Relative OM413 metastatic uveal melanoma cells migration (per HPF) towards 10nM 
recombinant CXCL12 for 16 hours with single agent trametinib (0.5-5nM) or pazopanib (0.85-8.56µM), 
or with both agents at a fixed dose ratio of 1:1712. 
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5.3 Discussion  
Angiogenesis is an important step for melanoma progression, hence therapeutic attempts 
have been made to target VEGF ligand with bevacizumab the monoclonal antibody, however 
no improvement in overall survival of patients with cutaneous metastatic melanoma has been 
made (Corrie et al., 2014). Such finding has led to current clinical interest in specific VEGFR 
anti-angiogenic therapy with agents such as pazopanib a new generation small molecule 
inhibitor, with particular efficacy to VEGFR2. In this context the analysis of VEGFR2 expression 
in primary melanoma tissues, may allow for biomarker identification and stratification of 
patients most likely to benefit from treatment with pazopanib. In cutaneous melanoma, the 
validity of targeting VEGFR2 expression by tumour cells is debatable since there is 
contradictory evidence for its expression. Although previous data report increased expression 
of VEGFR2 in cutaneous melanomas compared to benign naevi, supporting the emergence of 
an angiogenic phenotype facilitating tumour progression (Mehnert et al., 2010), data from the 
present study did not corroborate these findings. In fact, the present data demonstrated little, 
if any difference between VEGFR2 expression in any AJCC stage primary melanoma and 
cutaneous naevi, or between primary melanomas that remained localised and those which 
subsequently metastasised (Figure 5.5 A and B). Such lack of differential VEGFR2 expression 
may perhaps be explained by extremely low levels of expression observed overall. Three 
quarters of all analysed primary cutaneous melanomas expressed VEGFR2 in <1% tumour cells 
with weak immunoreactivity, and it could be argued that this may reflect experimental noise 
or irrelevant expression since previous studies report only VEGFR2 expression of >10% are 
considered as positive expression (Liu et al., 2008). Nevertheless the overall observed low 
levels of VEGFR2 expression aligns with results derived from a further large study cohort 
reporting detectable VEGFR2 expression in <10% of primary melanomas and thereby 
suggesting only a few patients would benefit from the anti-proliferative effects of anti-
angiogenic therapies that target VEGFR2 (Molhoek et al., 2011). 
A common paradigm held for over 40 years is that angiogenesis is required for tumours to 
exceed a volume of 1-2mm3 (Gimbrone et al., 1972) however, there is evidence that 
angiogenesis is actually required at a much earlier pre-malignant stage in most cancers 
including melanoma. In this context, studies of pre-malignant benign melanocytic naevi and 
dysplastic melanocytic naevi demonstrate an increase in microvascular density occurs, 
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suggesting angiogenesis is active at early stages of tumour development (Barnhill RL et al., 
1992). It may therefore be the case that VEGFR2 upregulation occurs at a pre-malignant stage 
and hence account for minimal changes in expression levels at later stages of melanoma 
progression. 
Data from the present study additionally demonstrated a lack of any association between 
VEGFR2 expression in primary cutaneous melanomas and B-RAF/N-Ras mutational status 
(Figure 5.5 C). Although there are no reports of any such association, the presence of a B-RAF 
mutation has been correlated with micro and lymphovascular density, suggesting some 
association of the presence of an activating B-RAF mutation with markers of angiogenesis in 
cutaneous melanoma (Aung et al., 2015). Furthermore, secretion of VEGF by melanoma cells 
is reported to be regulated, at least in part, by oncogene-mediated activation or tumour 
suppressor- mediated inactivation (Arbiser et al., 1997; Arbiser, 2004), with supporting studies 
demonstrating MAPK-induced activation in cutaneous melanocytes, leads to tumourigenesis, 
VEGF and MMP secretion and an angiogenic switch (Govindarajan et al., 2003). Collectively 
these reports thus further support a putative association between hyper-activation of MAPK 
signalling and angiogenesis, not corroborated by this study. 
Data from the present study were again unable to find any correlation between 
CXCR4/CXCL12 and VEGFR2 expression. It may be that the level of VEGF secretion by 
melanomas is more correlative than VEGF receptor expression, since most studies indicating 
crosstalk between CXCR4-CXCL12 and VEGF-VEGFR2 cell signalling support a role for VEGF 
ligand (Bachelder et al., 2002; Zagzag et al., 2005; Hong et al., 2006; Oda et al., 2006; Ottaiano 
et al., 2006; Franco et al., 2010). Observations of strong VEGFR2 expression in capillary 
endothelial cells within melanomas or within the dermis, nevertheless suggest anti-angiogenic 
therapies may display some degree of targeting ability at the primary site (Figure 5.3). 
Interestingly, keratinocytes within the surrounding epidermis of primary melanomas 
expressed low levels of VEGFR2, a result also confirmed by the immunofluorescent expression 
of VEGFR2 observed in primary keratinocytes in vitro. Keratinocytes are known to express both 
VEGFR2 and VEGFR1 and use VEGF cell signalling in an autocrine manner to maintain their 
proliferative and migratory capacity in normal skin homeostasis (Man et al., 2006). A 
significant positive correlation between VEGFR2 expression in the epidermis overlying 
melanomas and that expressed by tumour cells themselves was also observed (Figure 5.6 C), 
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suggesting that VEGFR2 expression maybe regulated by a global source within the tumour 
microenvironment. This could be the result of paracrine agents released by the tumour, 
including feasibly VEGF. 
In Cutaneous melanoma like many cancers, the lymphatic vessels represent the major route 
for metastatic dissemination, with sentinel lymph nodes, serving as an important prognostic 
indicator. Little is known about the mechanism by which melanoma cells enter the lymphatic 
system; however, several important factors including VEGF-C and VEGF-D have been identified 
as important facilitators of lymphangiogenesis, where tumoural expression correlates with 
increased lymphatic density and the likelihood of lymph node metastasis (Schietroma et al., 
2003; Dadras et al., 2005). The major receptor that binds VEGF-C and D is VEGFR3, and 
blocking this interaction negates the ability of VEGF-C and VEGF-D to promote 
lymphangiogenesis and metastasis to lymph nodes (Mandriota et al., 2001b; Veikkola et al., 
2001). However, the N–terminal and C-terminal pro-peptides of VEGF-C and VEGF-D can 
undergo proteolytic cleavage to a mature form that bind VEGFR2 that may induce 
circumferential lymphatic vessel growth but not sprouting (Nagy et al., 2002; Wirzenius et al., 
2007). Although the role of VEGFR3 on lymphatic endothelial cells is well established in the 
promotion of lymphangiogenesis, the role for VEGF receptors on tumour cells in this process 
is nevertheless ambiguous (Mehnert et al., 2010). To elute a possible role for VEGFR2 
expression by melanoma cells and lymph node metastasis, immunohistochemical expression 
was quantified in primary cutaneous melanomas and patient matched metastatic lymph 
nodes. Results revealed no significant difference between VEGFR2 expression in primary 
tumours and metastatic lymph nodes, suggesting that VEGFR2 expression in metastasised 
tumours within the lymph nodes is preserved at a similar level to that in primary tumours and 
thereby proposing a potential role for VEGFR2 in the maintenance of a metastatic phenotype 
(Figure 5.8). Interestingly levels of VEGFR2 expression in primary tumours varied between 
tumour cohorts, being greater in the Durham compared to the Newcastle cohort. However, it 
should be noted that the Durham cohort of primary cutaneous melanomas contained only 
eventual AJCC stage III tumours that subsequently metastasized to a regional lymph nodes 
and hence was not representative of a complete tumour cohort containing a range of differing 
AJCC stage tumours and tumours which remained localised. While the inclusion of eventual 
AJCC stage I/II tumours within the Durham melanoma cohort would be required to validate 
these findings, results from the analysis of this cohort nevertheless suggest VEGFR2 maybe 
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upregulated in the primary cutaneous tumours of patients who subsequently develop 
metastatic disease (Figure 5.9), and supports the notion that VEGFR2 promotes tumour 
progression and metastatic potential (Streit and Detmar, 2003). 
Unlike skin, the choroid of the eye is a highly oxygenated microenvironment making the role 
of angiogenesis in uveal melanoma likely distinct from cutaneous melanoma (Stitt and 
Gardiner, 2002). Although the presence of VEGF in uveal melanoma tumours has been 
reported to correlated with poor prognostic indicators such as necrosis, scleral invasion, larger 
tumours, mixed and epithelioid cell type, suggestive of some clinicopathological value, there 
are however no reports of any association of VEGF expression by tumours with metastasis or 
patient survival (Sheidow et al., 2000; Boyd et al., 2002b; Yang et al., 2014). Most uveal 
melanoma cell lines secrete abundant amounts of VEGF-A, that acts on VEGFR1 or VEGFR2 
receptors to sustain autocrine proliferation and migration (Notting et al., 2006; Logan et al., 
2013; Koch et al., 2014b). However, the expression of VEGF receptors by primary tumours has 
only been identified in one study in which Stitt et al reported the expression of VEGFR1 and 2 
as well as VEGF-A in enucleated eyes derived from both retinoblastoma and uveal melanomas, 
and with elevated expression also noted in the choroid, retina and iris compared to expression 
in normal eyes (Stitt et al., 1998). Although Stitt et al did not quantify the level of VEGFR2 
expression or relate expression to any clinicopathological features; this study nevertheless 
identified the potential for VEGFR2 upregulation in uveal melanomas and autocrine VEGF cell 
signalling. In the present study, although VEGFR2 expression was clearly and significantly 
increased in primary uveal melanomas (in albeit a small cohort) compared to expression by 
cutaneous melanomas, there was however, no apparent association with chromosome 3 
status. Collectively these data thus suggest rational for anti-angiogenic therapy in uveal 
melanoma to prevent both neovascularisation as well as autocrine cell signalling. 
In the present study, immunohistochemical expression of VEGFR2 in melanomas was detected 
in the cytoplasmic compartment, suggesting the receptor has been activated and is 
internalised upon ligand binding. However, the subcellular localisation of immunofluorescent 
VEGFR2 expression differed between melanoma cell lines, with most having equivocal 
cytoplasmic and nuclear expression, but in which WM-164 cutaneous and OMM2.3 uveal 
metastatic melanoma cell lines showed predominant nuclear expression. In contrast, VEGFR2 
expression in the metastatic uveal melanoma cell line UPMD2 was predominantly 
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cytoplasmic. While not a primary aim, the diverse staining patterns for VEGFR2 expression in 
cutaneous or uveal melanoma cell lines warranted more investigation (Figure 5.12). The stark 
contrast in subcellular localisation of VEGFR2 between melanoma cell lines could represent 
receptor activation. Previous studies in both endothelial and cancer cells have demonstrated 
the translocation of VEGFR2 upon stimulation, to the cell nucleus where it may activate its 
own promoter in vivo (Blazquez et al., 2006; Constantino Rosa Santos et al., 2007; Domingues 
et al., 2011), which would account for nuclear localisation of VEGFR2. Future studies to 
confirm this hypothesis could include ELISA assays to determine VEGF secretion by melanoma 
cell lines, or the treatment of cells with recombinant VEGF to determine any correlation with 
receptor activation and subcellular localisation. 
Increasing the seeding density of melanoma cell lines incorporated in the present study also 
resulted in the increased immunofluorescent expression of VEGFR2 (Appendix 2). This may be 
mediated by increased VEGF availability secreted from a greater number of cells that may 
promote the nuclear localisation of VEGFR2 and constitutional transcriptional activation of the 
VEGFR2 promoter by the receptor itself (Domingues et al., 2011). Remarkably, over time, 
however, even though the overall expression of VEGFR2 increased, nuclear subcellular 
localisation was lost and receptor expression became enhanced within the cytoplasm or most 
obviously at areas of cell-cell contact as culture confluence was reached. Studies have shown 
that VEGFR2 in endothelial cells accumulates at cell–cell contacts forming complexes with VE-
cadherin/β-catenin, blocking the proliferative effect of VEGF, as a mechanism of cell contact 
inhibition (Hendrix et al., 2001; Lampugnani et al., 2006). This may therefore explain the 
accumulation of VEGFR2 expression at cell-cell contacts in cultures of confluent melanoma 
cells, although further studies are required to confirm this hypothesis (Hendrix et al., 2001; 
Lampugnani et al., 2006). 
Collectively the immunohistochemical and immunofluorescent analysis of VEGFR2 expression 
in cutaneous and uveal melanoma in the present study, supported the rational for targeting 
VEGFR2 to prevent paracrine and possible autocrine VEGF signalling and led to subsequent 
studies with pazopanib. Treatment of both cutaneous and uveal melanoma cells with 
pazopanib resulted in dose dependent inhibition of cell viability, supporting studies of other 
VEGF receptor tyrosine kinase inhibitors (Eustace et al., 2008; Li et al., 2016). In addition, 
pazopanib potently inhibited cutaneous and uveal melanoma cell CXCR4-CXCL12 mediated 
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cell chemotaxis, at concentrations that did not affect cell viability, emphasising the capability 
for VEGFR2 inhibition to prevent melanoma migration, but also highlighting the crosstalk 
between these two signalling pathways. Interestingly the chemotaxis of the metastatic uveal 
melanoma cell line OM413 was most sensitive to pazopanib-induced inhibition, yet this cell 
line demonstrated the lowest levels of VEGFR2 expression, at both protein and mRNA level. 
This may indicate that the mechanism of action of pazopanib in this cell line, maybe through 
the targeting of a different tyrosine kinase receptor to VEGFR2. To explore further the 
mechanism of action by which pazopanib inhibits CXCR4-CXCL12 chemotaxis, siRNA was used 
to prevent translation of VEGFR2 in CHL-1 and WM-164 cutaneous melanoma cell lines. 
Results from these studies indicated VEGF treatment of these melanoma cell lines increased 
basal cell migration, confirming the ability of VEGF signalling to promote cell migration not 
only of endothelial cells but also of melanoma cells themselves (Erhard H et al., 1997; Bougatef 
et al., 2010). On the other hand, knockdown of VEGFR2 in WM-164 cells resulted in 
significantly reduced cell migration, suggesting that VEGFR2 cell signalling is also involved in 
WM-164 cell migration. However, this effect was not significant in B-RAF/N-Ras wild-type CHL-
1 cells suggesting that VEGFR2 activation may not be the dominant migratory pathway for this 
cell line. Nevertheless, pazopanib only reduced cell migration of cells transfected with non-
targeting control siRNA, confirming that pazopanib-mediated inhibition of cell migration is due 
to its effective VEGFR2 inhibition. 
Both MEK inhibition and VEGFR2 inhibition reduced melanoma cell viability and chemotaxis 
as single agents (Section 5.2.6), however monotherapy targeting the MAPK signalling or 
angiogenesis has historically lead to a plethora of resistant mechanisms and reactivation of 
downstream signalling (Ellis and Hicklin, 2008a; Welsh et al., 2016). It is frequently evidenced 
that a combination of drugs targeting the same pathways simultaneously or combining drugs 
that target alternative pathways is more efficacious with the reduced emergence of drug-
induced resistance (Lang et al., 2008; Dankort et al., 2009; Meng et al., 2010; Flaherty et al., 
2012a; Carlino et al., 2014). Interestingly a recent paper by Friedman et al demonstrated that 
cediranib (a pan VEGF tyrosine kinase receptor inhibitor) was able to re-sensitise B-RAF 
inhibitor resistant melanoma cell lines, to the cytotoxic effect of PLX4720 (Friedman et al., 
2015). Furthermore Friedman et al demonstrated the synergistic effects of combined VEGFR 
antagonists and B-RAF inhibitors in a large panel of melanoma cell lines (Friedman et al., 
2015), supporting a potential rationale for combined MEK and VEGFR2 inhibition as a more 
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efficacious therapeutic strategy for metastatic melanoma compared to single agent therapy. 
Results from the present study additionally demonstrated the potentiation of combined 
trametinib and pazopanib on the inhibition of cutaneous and uveal melanoma cell viability, as 
well as the inhibition of CXCR4-CXCL12-mediated chemotaxis (Section 5.2.6). Whether or not 
these effects were synergistic or additive requires further analysis. In addition, it remains to 
be determined whether pazopanib has the capacity like trametinib to induce pro-survival 
autophagy to counteract its apoptotic capacity. Nevertheless, results derived from the present 
study of combined trametinib and pazopanib highlight the potential added benefits of dual 
MEK and VEGFR2 inhibition as an effective strategy to prevent melanoma migration and 
metastasis. 
In summary, this chapter highlights VEGFR2 as not only an anti-angiogenic therapeutic target 
for endothelial cells but also as a target for cutaneous and uveal melanoma cells that promotes 
cell migration and which may be a feature of the metastatic melanoma phenotype. 
Furthermore, data highlight the capacity of pazopanib to inhibit CXCR4-CXCL12-mediated 
chemotaxis of melanoma cells through the inhibition of VEGFR2, an effect that can be 
enhanced by dual inhibition of MEK by trametinib. 
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5.4 Summary 
 
 Primary cutaneous melanomas and cutaneous metastatic melanoma cell lines 
express VEGFR2. 
 VEGFR2 expression is increased in primary cutaneous melanomas that 
subsequently metastasise to regional lymph nodes compared to expression in 
primary melanomas that remain localised. 
 There is no correlation between VEGFR2 expression by cutaneous 
melanomas/melanoma cell lines and B-RAF/N-Ras mutational status. 
 Metastatic uveal melanomas and uveal melanoma cell lines express VEGFR2. 
 There is no correlation between VEGFR2 expression by uveal 
melanomas/melanoma cell lines and monosomy/disomy of chromosome 3  
 Pazopanib inhibits cutaneous and uveal melanoma cell viability. 
 Pazopanib inhibits CXCR4-CXCL12-mediated chemotaxis of cutaneous and 
uveal melanoma cells. 
 Pazopanib targets VEGFR2 to prevent melanoma cell migration. 
 Combined trametinib and pazopanib potentiate trametinib-induced inhibition 
of cutaneous and uveal melanoma cell viability. 
 Combined trametinib and pazopanib significantly potentiates the inhibition of 
cutaneous melanoma CXCR4-CXCL12-mediated chemotaxis over and above 
either drug alone. 
 Combined trametinib and pazopanib significantly potentiates the inhibition of 
uveal melanoma CXCR4-CXCL12-mediated chemotaxis compared to tametinib 
alone. 
 Dual inhibition of MEK and VEGFR2 may be an effective strategy to limit 
melanoma migration and metastasis.
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80-90% of cutaneous and uveal melanomas bear genetic mutations in B-RAF/N-Ras or 
GNAQ/11 respectively, that occur early in melanoma pathogenesis and lead to hyper-
activation of MAPK signalling pathway, driving cell cycle progression and autonomous cell 
proliferation of melanocytes (Davies et al., 2002a; Van Raamsdonk et al., 2010). The MAPK 
pathway is activated by signalling from several receptor tyrosine kinases including 
epidermal/platelet derived and fibroblast growth factor receptors, as well as the CXCR4-
CXCL12 chemokine axis and VEGF-VEGFR receptor axis that provide melanomas with 
increased metastatic capabilities (Xia et al.; Robledo et al., 2001; Wang et al., 2008c). As a 
result, the MAPK pathway has become an attractive therapeutic target for both metastatic 
uveal and cutaneous melanoma, with MEK inhibition a corner stone to treatment of these 
tumours bearing activating mutations. However, although initially successful, the 
development of acquired resistance to MAPK inhibition in inevitable and with no clinically 
efficacious targeted treatments for B-RAF/N-Ras/GNAQ/GNA11 wild-type melanomas, 
metastatic disease is unvaryingly fatal and currently untreatable in both disease settings 
(Altekruse S.F et al., 2010). Prognosis for patients with melanomas that progress from the 
primary site falls sharply, with tumours rapidly acquiring the ability to migrate, a key factor in 
driving tumour escape (Balch et al., 2009a; S.B. Edge et al., 2010). The ability to inhibit 
melanoma migration would not only provide a means to prevent tumour invasion within the 
primary tumour microenvironment, thereby reducing the likelihood of metastasis, but would 
also prevent metastatic spread itself. Defining novel strategies to impair melanoma migration 
is hence, an attractive therapeutic prospect. 
The biggest player governing melanoma migration is the CXCR4-CXCL12 chemotaxis axis, with 
CXCR4 upregulated by melanomas and CXCL12 secreted from metastatic sites promoting 
organ specific metastasis (Muller et al., 2001b; Murakami et al., 2002; Toyozawa et al., 2012). 
Yet, melanomas acquire other vital capabilities to facilitate tumour migration and the 
emergence of metastatic disease. Such capabilities include the process of angiogenesis, 
whereby the angiogenic mitogen, VEGF is secreted by tumour cells, and on binding to VEGF 
receptors on tumour associated endothelial cells promotes their migration, vital for new 
vessel development. However, it has been documented that melanomas themselves are able 
to upregulate the expression of VEGF receptors including VEGFR2, therefore enabling VEGF to 
drive tumour cell migration via an autocrine signalling mechanism (Mehnert et al., 2010). Such 
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observations thus suggest both CXCR4-CXCL12 and VEGF-VEGFR2 signalling pathways are 
viable targets to inhibit melanoma migration. Given that components of both CXCR4-CXCL12 
and VEGF-VEGFR2 pathways are upregulated in response to hypoxia, and correlations 
between CXCR4 and VEGF expression have been noted in melanoma, crosstalk between both 
pathways is anticipated, and perhaps unsurprising since the MAPK pathway is a common 
downstream signalling path to both axes (Bachelder et al., 2002; Ceradini et al., 2004; Zagzag 
et al., 2005; Hong et al., 2006; Oda et al., 2006; Ottaiano et al., 2006; Franco R et al., 2010; 
Adamcic et al., 2012). Understanding the role of the CXCR4-CXCL12 chemokine axis and 
VEGFR2 within primary melanomas, and the effect that these pathways and MAPK cell 
signalling have on melanoma migration, is the key aim of the present thesis, and will therefore 
inform on more efficacious combinational therapeutic approaches to limit primary tumour 
dissemination and the prevention of melanoma metastasis. 
To endeavour to understand the currently undefined influence of CXCR4-CXCR7-CXCL12 and 
VEGFR2 signalling within primary melanomas and the tumour microenvironment, the 
expression of components of these axes and prognostic significance was first determined. 
CXCR4 was strongly expressed by the majority of primary uveal melanomas with differential 
expression seen by cutaneous melanomas as well as cutaneous and uveal melanoma cell lines, 
seemingly independent of mutational status, thereby confirming CXCR4 as a viable 
therapeutic target in all melanomas. Consistent with the association of high CXCR4 expression 
and the increased risk of metastasis in primary cutaneous melanomas, high CXCR4 expression 
(>50%) was found to be a putative prognostic biomarker for AJCC stage II cutaneous 
melanoma. This not only demonstrates the pivotal role that the CXCR4-CXCL12 axis plays in 
enabling the metastatic ability of locally invasive melanomas to exit from the primary site but 
also defines a ‘high risk’ melanoma AJCC stage II sub group, identifying those tumours that will 
eventually progress and allowing more predictive accuracy of metastatic progression at the 
time of excision. Contrasting to the role of CXCR4 in melanoma progression, CXCL12 
expression by primary cutaneous and uveal melanomas was particularly low and did not 
influence disease progression from the primary site. However, this low expression of CXCL12 
within the primary tumour seems logical given that abundant endogenous CXCL12 within the 
tumour would logically act to retain CXCR4 positive tumour cells, rather than facilitate their 
migration towards CXCL12 at distant sites. Studies do however suggest an important role for 
this low basal level of CXCL12 within primary tumours in driving pro-survival MAPK cell 
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signalling, allowing sustained tumour maintenance and survival, evidenced by the presence of 
autocrine CXCR4-CXCL12 cell signalling in cutaneous melanoma cell line WM-164. Together 
data from the present study suggest that targeting the CXCR4-CXCL12 chemokine axis within 
the primary tumour would not only prevent tumour cell migration but inhibit the activation of 
autocrine pro-survival MAPK cell signalling. Coupled with the role of the CXCR4-CXCL12 axis in 
primary tumours, the bidirectional interplay of this chemokine axis within the primary tumour 
and its microenvironment, likely influences tumour progression, but remains largely 
unexplored. CXCL12 was found to be abundantly expressed within both cutaneous and uveal 
melanoma tumour microenvironments, present within the epidermis and dermis of skin as 
well as within the retina and choroid of the eye. Interestingly the presence of increased levels 
of CXCL12 in the adjacent epidermis of primary cutaneous melanomas correlated with a 
increased time to tumour metastasis and cytoplasmic CXCR4 expression by tumour cells. Such 
findings suggest that high adjacent levels of CXCL12 are protective of metastasis with chronic 
activation of CXCR4 receptors within the primary tumour. It is hypothesised that the high 
CXCL12 gradient within the adjacent epidermis may act to retain CXCR4 positive tumour cells 
at the epidermal/dermal junction thereby promoting radial growth and delaying melanoma 
vertical invasion into the dermis and subsequent metastasis. For effective chemotaxis a 
gradient of CXCL12 stronger than that produced by the tumour or epidermis is required for 
the directional vertical migration of melanomas into the dermis. Given the potent secretion 
of CXCL12 from primary dermal fibroblasts and the presence of CXCR7 decoy receptor on 
dermal microvascular, suggests that these maybe key in modulating local CXCL12 
concentrations within the tumour microenvironment and the promotion of directional 
melanoma migration. Transwell chemotaxis assays illustrated the ability of cutaneous 
metastatic melanoma cells to migrate towards supernatants derived from primary dermal 
fibroblasts. The use of an anti-CXCL12 neutralising antibody revealed that chemotaxis is 
specific to CXCL12 secreted within the primary dermal fibroblast supernatants. The scavenging 
of CXCL12 by CXCR7 decoy receptors on vascular endothelium has the ability to sharpen the 
extracellular chemokine gradient generated by dermal fibroblasts, possibly facilitating the 
chemotaxis of tumour cells in and out the blood vessels via modulation of local chemokine 
levels (Berahovich et al., 2014). The detection of CXCR7 present on vessel endothelium within 
primary uveal melanoma tumours, hints that local chemokine levels may also be modulated 
in a similar fashion by CXCR7 expression within uveal melanomas. Taken together the role of 
the CXCR4-CXCR7-CXCL12 chemokine axis in primary melanomas highlights an intricate 
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relationship; intercalating variable expression of CXCR4 receptors by tumour cells with the 
secretion and modulation of CXCL12 within the tumour microenvironment, the summation of 
which may promote or hinder tumour progression. 
The role of VEGFR2 in cutaneous and uveal melanoma primary tumours is far from 
understood. Although there is abundant evidence illustrating the role of VEGFR2 expressed by 
tumour associated endothelial cells promoting angiogenesis and lymphangiogenesis (Nagy et 
al., 2002; Hong et al., 2004b; Shibuya and Claesson-Welsh, 2006), as well as markers of 
angiogenesis or lymphangiogenesis linked with worse prognosis in both cutaneous and uveal 
melanoma (Foss et al., 1996; Ilmonen S et al., 1999; Mäkitie et al., 1999; Kashani-Sabet et al., 
2002; Dadras et al., 2005; Ly et al., 2010), there is however little evidence specifically linking 
VEGFR2 expression by melanomas with disease progression. VEGFR2 expression by tumour 
cells is thought to provide autocrine VEGF-VEGFR2 cell signalling with subsequent 
enhancement of proliferation, survival and epithelial to mesenchymal transition (Adamcic et 
al., 2012; Ji et al., 2015; Scherbakov et al., 2016; Szabo et al., 2016). VEGFR2 was expressed by 
cutaneous and uveal melanoma cell lines at both the protein and mRNA level, with 
significantly higher expression detected in primary uveal melanomas compared to cutaneous 
primary melanomas of all AJCC stages. Although the level of expression of VEGFR2 in all 
primary cutaneous melanomas was extremely low, this was however, significantly increased 
in tumours that subsequently metastasised, particularly to lymph nodes, compared to those 
that remained localised (combined cohorts). This proposes that VEGFR2 expression may aid 
the emergence of a metastatic phenotype likely due to autocrine/endogenous VEGF-VEGFR2 
cell signalling promoting cell survival and cell migration to lymph nodes, suggesting a role of 
VEGFR2 in lymphatic metastasis. In support of this hypothesis, chemotaxis assays using B-
RAF/N-Ras mutated or wild-type cutaneous metastatic melanoma cell lines, demonstrated 
that stimulation with recombinant VEGF, increased cell migration, providing evidence for 
VEGF-VEGFR2-mediated promotion of melanoma migration. In addition to the expression of 
VEGFR2 on tumour cells, VEGFR2 was also strongly and consistently expressed by endothelial 
vasculature within skin and uveal melanomas. Taken together these data suggests that 
targeting VEGFR2 will not only inhibit angiogenesis of tumour associated vasculature but also 
may inhibit tumour autocrine VEGF-VEGFR2 cell signalling if present, and importantly prevent 
melanoma migration and subsequent metastasis. 
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While data from the present study demonstrated the contribution of CXCR4-CXCL12 and 
VEGFR2 signalling to tumour progression and the associations with a worse prognosis, there 
is a clear rationale to target both the CXCR4-CXCL12 chemokine axis and VEGFR2 to inhibit 
melanoma cell survival and migration, however the optimal means by which to approach this 
strategy must be carefully considered. While targeting the ligands of these pathways has 
provided proof of concept, positive clinical results haven’t transpired (Liang et al., 2004a; 
Corrie et al., 2014). Worries over the effect of reduced CXCL12 and VEGF availability and 
immune regulation, as well as normal homeostatic processes and possible serious side effects 
with CXCR4 inhibition, suggests caution should be taken. Further, given that results derived 
from the present studies suggest higher epidermal expression of CXCL12 is actually 
preventative of cutaneous melanoma metastasis, directly targeting the CXCR4-CXCL12 axis 
may have undesired consequences. Results from the present studies also revealed increased 
nuclear CXCR4 expression and the down regulation of tumoural CXCL12 was associated with 
the presence of activating B-RAF/N-Ras mutations in cutaneous melanoma. Likewise, in uveal 
melanoma monosomy of chromosome 3, the strongest prognostic indicator of metastasis, 
was also associated with downregulation of CXCL12. Both increased tumoural CXCR4 and the 
downregulation of tumoural CXCL12 would aid tumour migration, indicating that hyper-
activation of MAPK cell signalling in both cutaneous and uveal melanoma is associated with a 
more aggressive melanoma phenotype. These observations coupled with the presence of 
CXCR4-CXCL12 autocrine signalling also activating the MAPK pathway in cutaneous 
melanoma, suggests that inhibition of MAPK cell signalling maybe a novel way to inhibit the 
effects of CXCR4-CXCL12 cell signalling. The MEK inhibitor trametinib is currently used in 
clinical trials for advanced melanomas and unlike B-RAF inhibitors that are mutation specific 
inhibitors, trametinib is applicable for treatment of both B-RAF/N-Ras mutant cutaneous and 
GNAQ/GNA11 mutant uveal melanomas. In the present study trametinib at clinically 
achievable concentrations was able to significantly inhibit both B-RAF/N-Ras mutated and 
wild-type cutaneous melanoma chemotaxis towards recombinant CXCL12 and primary dermal 
fibroblast supernatants at concentrations in which there was no effect on the inhibition of cell 
viability. Likewise, OM413 (the GNAQ/11 wild-type uveal melanoma cell line) chemotaxis 
towards recombinant CXCL12 was also significantly inhibited by trametinib at concentrations 
that did not affect cell viability. Results thus indicate that MEK inhibition is a novel and 
efficacious means to prevent melanoma chemotaxis further highlighting the potential benefit 
of this strategy for both B-RAF/N-Ras mutant and wild-type cutaneous melanoma as well as 
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both GNAQ/GNA11 wild-type and mutant uveal melanoma, with MEK inhibition additionally 
preventing local invasion towards the dermis in the case of cutaneous melanoma, and further 
metastatic spread. 
Results demonstrating VEGFR2 expression in primary cutaneous and uveal melanomas, and 
association of elevated VEGFR2 expression with metastasis of primary cutaneous melanomas, 
as well as the ability of VEGF to stimulate melanoma cell migration, advocates the use of 
VEGFR2 inhibition as a strategy to also prevent tumour migration. Data from the present study 
demonstrated the potent ability of pazopanib, a pan VEGFR2 tyrosine kinase inhibitor to 
inhibit the cell viability of both B-RAF/N-Ras or GNAQ/11 mutated or wild-type metastatic 
cutaneous and uveal melanoma cell lines, as well as inhibiting CXCR4-CXCL12 chemotaxis, at 
concentrations which had no effect on the inhibition of viability. Knockdown of VEGFR2 also 
confirmed VEGFR2 specific inhibition of melanoma migration by pazopanib, however the 
mechanistic effects of pazopanib on the inhibition of cell viability are unclear and maybe 
mediated by the inhibition of other tyrosine kinase receptors. Nevertheless, these 
investigations highlight the crosstalk between CXCR4-CXCL12 and VEGFR2 cell signalling, 
demonstrating both pathways promote melanoma cell migration, and that inhibition of just 
one of these pathways alone reduces migration. However, inhibiting only one pathway leaves 
an open opportunity for cell migration and MAPK cell signalling to be stimulated by the 
untargeted pathway. Given that there is potential to improve the efficacy of inhibition of cell 
viability and CXCR4-CXCL12 chemotaxis by use of both trametinib and pazopanib, studies were 
therefore undertaken to assess the potential efficacy of a combinational approach. In general, 
the combination of trametinib and pazopanib, potentiated the inhibition of cell viability 
induced by either drug alone, but notably resulted in significantly enhanced inhibition of 
CXCR4-CXCL12 chemotaxis, even at drug concentrations that had no effect on cell viability. 
Collectively, these data thus suggest dual MEK and VEGFR2 inhibition may be a more 
efficacious approach to inhibiting cutaneous and uveal melanoma cell viability and CXCR4-
CXCL12 chemotaxis regardless of B-RAF/N-Ras or GNAQ/GNA11 mutational status. 
Most targeted therapeutic approaches for melanoma, however powerful, ultimately given the 
heterogeneous nature of melanoma and ability to resist pro-apoptotic cell signalling lead to 
intrinsic or acquired drug resistance. In addition to defining more effective drug targets and 
more efficacious drug combinations, overcoming drug resistance is of equal importance in 
improving long term survival for patients with metastatic melanoma. Given the association of 
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activated autophagy in advanced cutaneous melanomas with a poorer prognosis (Ellis et al., 
2014b), its paradoxical role in tumour progression as well as in counteracting the pro apoptotic 
effects of chemotherapy (Mariño et al., 2007; Hammerová et al., 2012; Xie et al., 2013) it was 
perhaps not surprising that autophagy was induced in cutaneous and uveal melanoma cell 
lines in response to treatment with trametinib. How to harness autophagy for the greatest 
therapeutic benefit is an area of much debate with evidence for both autophagy inhibition 
and exacerbation revealing beneficial effects in melanoma treatment (Mariño et al., 2007; 
Hammerová et al., 2012; Ambrosini et al., 2013b; Xie et al., 2013). Results from the present 
study however, revealed a clear sensitization of both uveal and cutaneous melanoma cells to 
the cytotoxic effects of trametinib by dual treatment with the lysosomal inhibitor chloroquine, 
suggesting dual autophagy and MEK inhibition maybe a viable strategy to increase the efficacy 
of MEK inhibitors such as trametinib. Nevertheless, such strategies require confirmation in 
vivo, including exploring the potential efficacy of more specific inhibitors of autophagy, such 
as new generation inhibitors of Vsp34 (Marsh T and Debnath J, 2015 ) or the potential for 
agents such as the cannabinoid Tetrahydrocannabinol (THC) that require autophagy induction 
/exacerbation for their cytotoxic effect (Armstrong et al., 2015). 
In conclusion, while many aspects of cutaneous and uveal melanoma in terms of genetic 
background, pathogenesis, microenvironment and immune regulation contrast, the present 
study highlights great similarities between these two malignancies. Expression and 
dependence on key cell signalling pathways including CXCR4-CXCL12, VEGFR2 and MAPK 
signalling for melanoma cell survival, migration and disease progression, as well as similar 
responses to targeted pathway inhibition, suggests that many therapeutic interventions 
developed for cutaneous melanoma may be applicable to uveal melanoma. Uveal melanoma 
is generally thought to be the more aggressive form of melanoma with present data 
supporting this notion and specifically evidenced by the detection of higher CXCR4 and 
VEGFR2 expression levels in primary uveal tumours compared to cutaneous melanomas. With 
improved understanding of the melanoma microenvironment and how this interacts with 
tumour biology and disease progression, comes the opportunity to highlight critically required 
biomarkers to identify high risk patients and those most likely to benefit from novel 
stratified/precision based therapeutic interventions. Results from the present studies 
highlight CXCR4 expression as a biomarker to identify high risk AJCC stage II cutaneous 
melanomas, enabling earlier patient follow up. Inhibition of MAPK signalling is a likely 
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continued cornerstone for therapeutic intervention given its regulation in many aspects of 
melanoma tumorigenesis. However, single pathway targeted approaches are in the long term 
ineffective, emphasising the need for more tailored therapeutic approaches which take into 
account both the genetic and receptor profiles of individual tumours. In this context the 
present study highlights the potential benefits of novel combinational therapies for both B-
RAF/N-Ras or GNAQ/GNA11 mutant or wild-type cutaneous/uveal melanomas directed at 
targeting the cross talk and interplay between multiple signalling mechanisms key to tumour 
metastasis and specifically, CXCR4-CXCL12 chemotaxis, autophagy, MEK and VEGFR2 
signalling (Figure 6.1). 
 
 
Figure 6.1 Novel Therapeutic Strategies to Target the Cross-talk of CXCR4-CXCL12 
Chemotaxis, Autophagy, MAPK and VEGFR2 Cell Signalling in Cutaneous and Uveal 
Melanoma Metastasis 
Schematic illustration of key signalling pathways: CXCR4-CXCL12 chemotaxis, autophagy, MAPK and 
VEGFR2 signalling that contribute to cutaneous and uveal melanoma survival, proliferation and 
migration and potential targeted approaches through which to prevent the cross talk and interplay of 
these key signalling mechanisms with trametinib, pazopanib and chloroquine to limit tumour chemo-
resistance, progression and metastasis. 
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 Appendix 1 
Characterisation of Uveal Melanoma Cell Lines 
Although cutaneous melanoma cell lines are reportedly well characterised (Lovat et al., 2008; 
Armstrong et al., 2011), conflicting reports of misidentification highlighted the need to 
authenticate the selected uveal melanoma cell lines used in the present study (Folberg et al., 
2008). Metastatic uveal melanoma cell lines OM413, MEL270 and UPMD2 obtained from 
Professor R Marais (University of Manchester) were therefore characterised as being of 
melanocytic linage with the proposed mutations in GNAQ/GNA11. 
Immunofluorescence studies confirmed the expression of the melanocytic proteins Melan-A 
and Mel-5 in all GNAQ/GNA11 mutant cell lines (illustrated for MEL270 and UPMD2 in 
Appendix Figure 1.1 Aii). However, no expression of either Melan-A or Mel-5 was detected in 
the reportedly GNAQ/GNA11 wild-type cell line, OM413. The expression of Melan-A mRNA 
was therefore determined by PCR analysis, revealing again, Melan-A mRNA expression in all 
GNAQ/GNA11 mutated cells, as well as, albeit weak, expression in OM413 cells (GNAQ/GNA11 
wild-type) (in Appendix Figure 1.1 Ai and summarised in Appendix Figure 1.1 Bi). 
The GNAQ/GNA11 mutational status of all selected uveal melanoma cell lines was confirmed 
by PCR analysis and subsequent sequencing for single nucleotide polymorphisms in GNAQ or 
GNA11: GNAQ Q209, GNAQ R183, GNA11 Q209 and GNA11 R183, illustrated for 
GNAQ/GNA11 wild-type OM413, GNAQ mutant MEL270 harbouring a GNAQ Q209P mutation 
or UPMD2 with a GNA11 Q209L mutation. 
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Appendix Figure 0.1 Characterisation of Metastatic Uveal Melanoma Cell Lines 
A)i Representative image of gel electrophoresis of PCR products for MART-1 (Melan-A) mRNA or GAPDH 
(loading control) in OM413 (GNAQ/GNA 11 wild-type), MEL270 (GNAQ mutated) and UPMD2 (GNA11 
mutated) human uveal melanoma cell lines. A.) ii Representative immunofluorescent images for the 
expression of melanocyte markers Melan-A, Mel-5 or null primary control in OM413, MEL270, and 
UPMD2 human uveal melanoma cell lines. Green depicts positive Melan-A or Mel-5 staining, blue is 
DAPI nuclear staining.  Images taken by confocal microscopy with a magnification 20x scale bar = 50μm. 
B.)i Table of reported and determined uveal melanoma cell line characteristics and GNAQ/GNA11 
mutational status of OM413, MEL270 and UPMD2 cells. B.) ii Representative sequencing plots of wild-
type (OM413) or single nucleotide polymorphisms (SNP) at position 626 of GNAQ209 gene (MEL270) or 
position 626 of GNA11 Q209 gene (UPMD2) in human uveal melanoma cell lines. 
 
 
 
 Appendix 2 
Increasing the Seeding Density of Cutaneous Melanoma Cells Increases the 
Expression of VEGFR2 
Immunofluorescent analysis for the expression of VEGFR2 in cutaneous and uveal metastatic 
melanoma cell lines, revealed an apparent increase in expression in cells growing in large 
clusters compared to in cells growing as single cell colonies, implying VEGFR2 expression is 
modified by cell seeding density. To test this hypothesis A375, WM-164 and WM-1361 cells 
were seeded at increasing densities ranging from 1 X 104 to 7.5 X 105 /well of a 6 well plate, in 
a volume of 3mls normal cell culture media for 24 hours prior to the analysis and quantification 
of VEGFR2 fluorescence (Appendix Figure 2.1-2-2.4). Results revealed a significant increase in 
VEGFR2 expression in A375 and WM-1361 cells seeded at an original density of 7.5x105, and 
in WM-164 cells seeded at an original density of 2.5x105 compared to expression in cells 
seeded at the lowest seeding density of 1x104cells/well (One-way ANOVA with Dunnett’s post 
hoc correction, **P<0.01 and ***P<0.001, Appendix Figure 2.4), suggesting VEGFR2 
expression is enhanced with increasing cellular seeding density. To test whether increasing 
cellular seeding density impacted on VEGFR2 mRNA expression levels, qPCR analysis of 
VEGFR2 expression in WM-164 cells was also analysed following the seeding of cells for 24 
hours over the same differing density range. Although qPCR analysis did not reveal any 
statistically significant changes in VEGFR2 mRNA expression with increasing cell seeding 
density (One-way ANOVA, with Dunnett’s post hoc correction, P=0.1505, Appendix Figure 2.5), 
a similar trend for increased VEGFR2 expression with higher seeding densities was notable. 
Furthermore, the subcellular localisation of VEGFR2 in WM-164 and WM-1361 cells seemed 
to alter at higher seeding densities of 5x105 and 7.5x105cells/well where nuclear VEGFR2 
expression appeared to be reduced and cytoplasmic expression increased, particularly at cell-
cell junctions. 
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Appendix Figure 0.1 The Effect of Seeding Density on the Immunofluorescent Expression of 
VEGFR2 in A375 Cutaneous Metastatic Melanoma Cell Line 
Representative images from 3 replicate experiments for the immunofluorescent expression of VEGFR2 
or null primary control in cutaneous metastatic A375 melanoma cells seeded at 1 or 5x104, or 1-7.5x105 
cells/well in a 6 well plate for 24 hours. Green depicts VEGFR2 positivity and blue DAPI nuclear staining. 
Images were acquired by confocal microscopy with a magnification 20x scale bar = 20μM. 
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Appendix Figure 0.2 The Effect of Seeding Density on the Immunofluorescent Expression of 
VEGFR2 in WM-164 Cutaneous Metastatic Melanoma Cell Line 
Representative images from 3 replicate experiments for the immunofluorescent expression of VEGFR2 
or null primary control in cutaneous metastatic WM-164 melanoma cells seeded at 1 or 5x104, or 1-
7.5x105 cells/well in a 6 well plate for 24 hours. Green depicts VEGFR2 positivity and blue DAPI nuclear 
staining. Images were acquired by confocal microscopy with a magnification 20x scale bar = 20μM. 
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Appendix Figure 0.3 The Effect of Seeding Density on the Immunofluorescent Expression of 
VEGFR2 in WM-1361 Cutaneous Metastatic Melanoma Cell Line 
Representative images from 3 replicate experiments for the immunofluorescent expression of VEGFR2 
or null primary control in cutaneous metastatic WM-1361 melanoma cells seeded at 1 or 5x104, or 1-
7.5x105 cells/well in a 6 well plate for 24 hours. Green depicts VEGFR2 positivity and blue DAPI nuclear 
staining. Images were acquired by confocal microscopy with a magnification 20x scale bar = 20μM. 
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Appendix Figure 0.4 Quantification of VEGFR2 Immunofluorescent Expression by Cutaneous 
Metastatic Melanoma Cell Lines Seeded at Different Density 
Mean VEGFR2 fluorescence per cell within A.) A375, B.) WM-164, or C.) WM-1361 cutaneous metastatic 
melanoma cell lines seeded at 1x104, 5x104, 1x105, 2.5x105, 5x105 and 7.5x105 cells/well of a 6 well 
plate for 24 hours. Each bar is the mean VEGFR2 fluorescence per cell relative to DAPI, of 4 replicates 
from 2 independent experiments (mean +SD). Statistics acquired by One-way analysis of variance with 
Dunnett’s post hoc correction, **P<0.01 and ***P<0.001. 
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Appendix Figure 0.5 VEGFR2 mRNA Expression in WM-164 Metastatic Melanoma Cells 
According to Seeding Density 
VEGFR2 mRNA expression in WM-164 cutaneous melanoma cell line seeded at 1x104, 5x104, 1x105, 
2.5x105, 5x105 and 7.5x105 cells/well of a 6 well plate for 24 hours. Each bar is mean of VEGFR2 Cycle 
threshold for each sample normalised to 18s cycle threshold from 2 independent experiments (mean 
+SD N=2). Statistics acquired one-way analysis of variance with Dunnett’s post hoc correction, all non-
significant.  
To determine if VEGFR2 expression also increased over time CHL-1, WM-164 and WM-1361 
cutaneous metastatic melanoma cell lines were seeded at a low seeding density of 
1x104cells/well for 24, 48, 72 or 96 hours prior to the analysis and quantification of VEGFR2 
immunofluorescent expression (Appendix Figure 2.6-2.8 A). Results revealed a significant 
increase in VEGFR2 expression in CHL-1, WM-164 and WM-1361 cells following culture for 96, 
72 or 96 hours respectively compared to 24 hours (Kruskal-Wallis test with Dunn’s multiple 
comparison post hoc correction, **P<0.01, *P<0.05, Appendix Figure 2.6-2.8 B). A similar 
although non-significant trend was also observed in WM-164 VEGFR2 mRNA expression levels 
(One-way ANOVA with Dunnett’s post hoc correction, P=0.4820, Appendix Figure 2.7 C). 
Although immunofluorescent VEGFR2 expression increases over time to 96 hours in CHL-1 and 
WM-1361 cell lines, there was an apparent but non-significant reduction in VEGFR2 expression 
in WM-164 cells at 96 hours compared to 72 hours (Appendix Figure 2.7 B). Interestingly in all 
cell lines there was a very obvious change in VEGFR2 subcellular localisation from 72 hours to 
96 hours, where the predominantly nuclear subcellular location of VEGFR2 at 72 hours 
appeared to be lost with strong accumulation of cytoplasmic VEGFR2, particularly seen at cell 
to cell contacts at 96 hours, a pattern mirrored with higher seeding densities of cells at 24 
hours as previously described (Appendix Figure 2.1-2.5). 
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Appendix Figure 0.6 The Effect of Culture Time on the Immunofluorescent Expression of 
VEGFR2 in the Cutaneous Metastatic Melanoma Cell Line CHL-1 
A.) Representative images from 2 replicate experiments for the immunofluorescent expression of 
VEGFR2 or null primary control in CHL-1 cutaneous melanoma cells seeded at a density of 1x104 
cells/well of a 6 well plate and incubated for 24, 48, 72, 96 hours. Green depicts VEGFR2 positivity and 
blue DAPI nuclear staining. Images were acquired by confocal microscopy with a magnification 20x 
scale bar = 20µm B.) Mean VEGFR2 fluorescence per cell at 24, 48, 72 or 96 hours’ incubation. Each bar 
is the mean VEGFR2 fluorescence per cell relative to DAPI, of 8 replicates from 2 independent 
experiments (mean +SD). Statistics acquired by Kruskal-Wallis test with Dunn’s multiple comparison 
post hoc correction, **P<0.01. 
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Appendix Figure 0.7 The Effect of Culture Time on the Immunofluorescent Expression of 
VEGFR2 in the Cutaneous Metastatic Melanoma Cell Line, WM-164 
A.) Representative images from 2 replicate experiments for the immunofluorescent expression of 
VEGFR2 or null primary antibody control in cutaneous WM-164 cells seeded at a density of 1x104 
cells/well in a 6 well plate for 24, 48, 72, 96 hours. Green depicts VEGFR2 positivity and blue DAPI 
nuclear staining. Images were acquired by confocal microscopy with a magnification 20x scale bar = 
20µm B.) Mean VEGFR2 fluorescence per cell at 24, 48, 72 or 96 hours’ incubation. Each bar is the mean 
VEGFR2 fluorescence per cell relative to DAPI, of 8 replicates from 2 independent experiments (mean 
+SD). Statistics acquired by Kruskal-Wallis test with Dunn’s multiple comparison post hoc correction, 
*P<0.05. C.) VEGFR2 mRNA expression WM-164 cells seeded at a density of 1x104 cells/well in a 6 well 
plate for 24, 48, 72 or 96 hours. Each bar is mean of VEGFR2 Cycle threshold for each sample normalised 
to 18s cycle threshold from 2 independent experiments (mean +SD N=2). Statistics acquired one-way 
analysis of variance with Dunnett’s post hoc correction, all non-significant. 
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Appendix Figure 0.8 The Effect of Culture Time on the Immunofluorescent Expression of 
VEGFR2 in the Cutaneous Metastatic Melanoma Cell Line, WM-1361 
A.) Representative images from 2 replicate experiments for the immunofluorescent expression of 
VEGFR2 or null primary antibody control in cutaneous WM-1361 cells seeded at a density of 1x104 
cells/well in a 6 well plate for 24, 48, 72, 96 hours. Green depicts VEGFR2 positivity and blue DAPI 
nuclear staining. Images were acquired by confocal microscopy with a magnification 20x scale bar = 
20µm B.) Mean VEGFR2 fluorescence per cell at 24, 48, 72 or 96 hours’ incubation. Each bar is the mean 
VEGFR2 fluorescence per cell relative to DAPI, of 8 replicates from 2 independent experiments (mean 
+SD). Statistics acquired by Kruskal-Wallis test with Dunn’s multiple comparison post hoc correction, 
*P<0.05.
 Appendix 3 
One-way Analysis of Variance of Combined MEK and VEGFR2 Inhibition on 
Cutaneous and Uveal Melanoma Cell Viability and CXCR4-CXCL12 Chemotaxis 
To assess if combined efficacy of trametinib and pazopanib on the inhibition of melanoma cell 
viability or CXCR4-CXCL12 chemotaxis compared to the efficacy of either drug alone, a one-
way analysis of variance was performed at each drug concentration, comparing trametinib, 
pazopanib or trametinib and pazopanib. The results of each individual ANOVA with 
significance values are tabulated below, all significant differences in cell viability (Appendix 
Table 3.1-3.4) or chemotaxis are highlighted in blue (Appendix Table 3.5-3.7). 
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CHL-1 Cell Viability 
Drug Concentrations Drug Combinations 
ANOVA 
(P value) 
Dunnett’s Post Hoc Correction 
(P value) 
0.10nM Trametinib (T) 
0.17µM Pazopanib (P) 
T vs P 
0.1063 (ns) 
0.4326 
T vs T+P 0.089 
P vs T+P 0.6237 
0.50nM Trametinib (T) 
0.85µM Pazopanib(P) 
T vs P 
0.1869 (ns) 
0.1622 
T vs T+P 0.5473 
P vs T+P 0.6950 
1.00nM Trametinib (T) 
1.71µM Pazopanib (P) 
T vs P 
0.4503 (ns) 
0.7268 
T vs T+P 0.8695 
P vs T+P 0.4219 
2.50nM Trametinib (T) 
4.28µM Pazopanib (P) 
T vs P 
0.2420 (ns) 
0.7052 
T vs T+P 0.2129 
P vs T+P 0.6320 
5.00nM Trametinib (T) 
8.56µM Pazopanib (P) 
T vs P 
***P<0.001 
***P<0.001 
T vs T+P ***P<0.001 
P vs T+P 0.0482 *P<0.05 
10.00nM Trametinib (T) 
17.12µM Pazopanib (P) 
T vs P 
***P<0.001 
***P<0.001 
T vs T+P ***P<0.001 
P vs T+P 0.0183 *P<0.05 
Appendix Table 0.1 One-way Analysis of variance of CHL-1 Cell Viability in Response to 
Trametinib and Pazopanib Alone or in Combination 
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WM-164 Cell Viability 
Drug Concentrations Drug Combinations 
ANOVA 
(P value) 
Dunnett’s Post Hoc Correction 
(P value) 
0.10nM Trametinib (T) 
0.17µM Pazopanib (P) 
T vs P 
0.2606 (ns) 
0.2393 
T vs T+P 0.9392 
P vs T+P 0.4987 
0.50nM Trametinib (T) 
0.85µM Pazopanib(P) 
T vs P 
0.993 (ns) 
0.0836 
T vs T+P 0.5489 
P vs T+P 0.5659 
1.00nM Trametinib (T) 
1.71µM Pazopanib (P) 
T vs P 
0.0201 (*P<0.05) 
0.0162 *P<0.05 
T vs T+P 0.7823 
P vs T+P 0.1265 
2.50nM Trametinib (T) 
4.28µM Pazopanib (P) 
T vs P 
0.0185 (*P<0.05) 
0.0145 *P<0.05 
T vs T+P 0.7488 
P vs T+P 0.1300 
5.00nM Trametinib (T) 
8.56µM Pazopanib (P) 
T vs P 
0.0001 (***P<0.0001) 
0.5022 
T vs T+P ***P<0.0001 
P vs T+P 0.0075 **P<0.01 
10.00nM Trametinib (T) 
17.12µM Pazopanib (P) 
T vs P 
<0.0001 (***P<0.0001) 
***P<0.0001 
T vs T+P ***P<0.0001 
P vs T+P 0.0093 **P<0.01 
Appendix Table 0.2 One-way Analysis of variance of WM-164 Cell Viability in Response to 
Trametinib and Pazopanib Alone or in Combination 
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OM413 Cell Viability 
Drug Concentrations Drug Combinations 
ANOVA 
(P value) 
Dunnett’s Post Hoc Correction 
(P value) 
0.10nM Trametinib (T) 
0.17µM Pazopanib (P) 
T vs P 
0.4764 (ns) 
0.4436 
T vs T+P 0.8338 
P vs T+P 0.8098 
0.50nM Trametinib (T) 
0.85µM Pazopanib(P) 
T vs P 
0.2298 (ns) 
0.2502 
T vs T+P 0.8098 
P vs T+P 0.9939 
1.00nM Trametinib (T) 
1.71µM Pazopanib (P) 
T vs P 
0.2146 (ns) 
0.3499 
T vs T+P 0.9984 
P vs T+P 0.2466 
2.50nM Trametinib (T) 
4.28µM Pazopanib (P) 
T vs P 
0.0441 (ns) 
0.3058 
T vs T+P 0.3520 
P vs T+P 0.4987 
5.00nM Trametinib (T) 
8.56µM Pazopanib (P) 
T vs P 
***P<0.001 
***P<0.001 
T vs T+P ***P<0.001 
P vs T+P 0.0426 *P<0.05 
10.00nM Trametinib (T) 
17.12µM Pazopanib (P) 
T vs P 
***P<0.001 
***P<0.001 
T vs T+P ***P<0.001 
P vs T+P 0.0069 **P<0.01 
Appendix Table 0.3 One-way Analysis of Variance of OM413 Cell Viability in Response to 
Trametinib and Pazopanib Alone or in Combination 
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UPMD2 Cell Viability 
Drug Concentrations Drug Combinations 
ANOVA 
(P value) 
Dunnett’s Post Hoc Correction 
(P value) 
0.10nM Trametinib (T) 
0.17µM Pazopanib (P) 
T vs P 
0.6416 (ns) 
0.9649 
T vs T+P 0.7859 
P vs T+P 0.6325 
0.50nM Trametinib (T) 
0.85µM Pazopanib(P) 
T vs P 
0.0013 (**P<0.01) 
0.0123 *P<0.05 
T vs T+P 0.0016 **P<0.01 
P vs T+P 0.7311 
1.00nM Trametinib (T) 
1.71µM Pazopanib (P) 
T vs P 
0.1031 (ns) 
0.0913 
T vs T+P 0.7406 
P vs T+P 0.3379 
2.50nM Trametinib (T) 
4.28µM Pazopanib (P) 
T vs P 
0.4277 (ns) 
0.8076 
T vs T+P 0.3943 
P vs T+P 0.7597 
5.00nM Trametinib (T) 
8.56µM Pazopanib (P) 
T vs P 
***P<0.0001 
***P<0.001 
T vs T+P ***P<0.001 
P vs T+P ***P<0.001 
10.00nM Trametinib (T) 
17.12µM Pazopanib (P) 
T vs P 
***P<0.0001 
***P<0.001 
T vs T+P ***P<0.001 
P vs T+P 0.9857 
Appendix Table 0.4 One-way Analysis of Variance of UPMD2 Cell Viability in Response to 
Trametinib and Pazopanib Alone or in Combination  
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CHL-1 Cell Chemotaxis 
Drug Concentrations Drug Combinations 
ANOVA 
(P value) 
Dunnett’s Post Hoc 
Correction 
(P value) 
0.50nM Trametinib (T) 
0.85µM Pazopanib(P) 
T vs P 
***P<0.001 
0.8457 
T vs T+P 0.0004 ***P<0.001 
P vs T+P 0.0038 **P<0.01 
1.00nM Trametinib (T) 
1.71µM Pazopanib (P) 
T vs P 
***P<0.001 
0.9742 
T vs T+P ***P<0.0001 
P vs T+P ***P<0.0001 
5.00nM Trametinib (T) 
8.56µM Pazopanib (P) 
T vs P 
***P<0.001 
***P<0.0001 
T vs T+P ***P<0.0001 
P vs T+P ***P<0.0001 
Appendix Table 0.5 One-way Analysis of Variance of CHL-1 Cell Chemotaxis in Response to 
Trametinib and Pazopanib Alone or in Combination 
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WM-164 Cell Chemotaxis 
Drug Concentrations Drug Combinations 
ANOVA 
(P value) 
Dunnett’s Post Hoc 
Correction 
(P value) 
0.50nM Trametinib (T) 
0.85µM Pazopanib(P) 
T vs P 
***P<0.001 
0.8457 
T vs T+P 0.0004 ***P<0.001 
P vs T+P 0.0038 **P<0.01 
1.00nM Trametinib (T) 
1.71µM Pazopanib (P) 
T vs P 
***P<0.001 
0.9742 
T vs T+P ***P<0.0001 
P vs T+P ***P<0.0001 
5.00nM Trametinib (T) 
8.56µM Pazopanib (P) 
T vs P 
***P<0.001 
0.9792 
T vs T+P ***P<0.0001 
P vs T+P ***P<0.0001 
Appendix Table 0.6 One-way Analysis of Variance of WM-164 Cell Chemotaxis in Response 
to Trametinib and Pazopanib Alone or in Combination 
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OM413 Cell Chemotaxis 
Drug Concentrations Drug Combinations 
ANOVA 
(P value) 
Dunnett’s Post Hoc 
Correction 
(P value) 
0.50nM Trametinib (T) 
0.85µM Pazopanib(P) 
T vs P 
0.008 **P<0.01 
0.7131 
T vs T+P 0.0990 
P vs T+P 0.0631 
1.00nM Trametinib (T) 
1.71µM Pazopanib (P) 
T vs P 
0.0003 ***P<0.001 
0.9992 
T vs T+P 0.0011 **P<0.01 
P vs T+P 0.0014 **P<0.01 
5.00nM Trametinib (T) 
8.56µM Pazopanib (P) 
T vs P 
P<0.0001 ***P<0.001 
***P<0.001 
T vs T+P ***P<0.001 
P vs T+P 0.9829 
Appendix Table 0.7 One-way Analysis of Variance of OM413 Cell Chemotaxis in Response to 
Trametinib and Pazopanib Alone or in Combination
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